<SEC-DOCUMENT>0001437749-22-006737.txt : 20220318
<SEC-HEADER>0001437749-22-006737.hdr.sgml : 20220318
<ACCEPTANCE-DATETIME>20220318162119
ACCESSION NUMBER:		0001437749-22-006737
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		62
CONFORMED PERIOD OF REPORT:	20211231
FILED AS OF DATE:		20220318
DATE AS OF CHANGE:		20220318

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Diffusion Pharmaceuticals Inc.
		CENTRAL INDEX KEY:			0001053691
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				300645032
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37942
		FILM NUMBER:		22752825

	BUSINESS ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902
		BUSINESS PHONE:		(434) 220-0718

	MAIL ADDRESS:	
		STREET 1:		300 EAST MAIN STREET
		STREET 2:		SUITE 201
		CITY:			CHARLOTTESVILLE
		STATE:			VA
		ZIP:			22902

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	RestorGenex Corp
		DATE OF NAME CHANGE:	20140307

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Stratus Media Group, Inc
		DATE OF NAME CHANGE:	20080722

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	FERIS INTERNATIONAL, INC.
		DATE OF NAME CHANGE:	20080228
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>dffn20211231_10k.htm
<DESCRIPTION>FORM 10-K
<TEXT>
<XBRL>
<html xmlns="http://www.w3.org/1999/xhtml" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldi="http://xbrl.org/2006/xbrldi" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:us-types="http://fasb.org/us-types/2017-01-31" xmlns:srt-types="http://fasb.org/srt-types/2017-01-31" xmlns:utreg="http://www.xbrl.org/2009/utr" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:us-roles="http://fasb.org/us-roles/2017-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:thunderdome="http://www.RDGFilings.com" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dffn="http://www.diffusionpharma.com/20211231" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:rr="http://xbrl.sec.gov/rr/2018-01-31" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21">
 <head>
  <title>dffn20211231_10k.htm</title>
  <!-- Generated by ThunderDome Portal - 3/18/2022 7:45:00 PM -->
  <meta http-equiv="Content-Type" content="text/html" /></head>
 <body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;"><div style="display: none;"><ix:header><ix:hidden>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityCentralIndexKey" id="thunderdome-EntityCentralIndexKey">0001053691</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:EntityRegistrantName" id="thunderdome-EntityRegistrantName">Diffusion Pharmaceuticals Inc.</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:AmendmentFlag" format="ixt:booleanfalse">false</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:CurrentFiscalYearEndDate">--12-31</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalPeriodFocus">FY</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dei:DocumentFiscalYearFocus">2021</ix:nonNumeric>
<ix:nonFraction id="c82208380" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c82208381" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommitmentsAndContingencies" scale="0" xsi:nil="true"></ix:nonFraction>
<ix:nonFraction id="c82208385" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c82208386" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.001</ix:nonFraction>
<ix:nonFraction id="c82208387" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000,000</ix:nonFraction>
<ix:nonFraction id="c82208388" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">1,000,000,000</ix:nonFraction>
<ix:nonFraction id="c82208389" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">101,914,280</ix:nonFraction>
<ix:nonFraction id="c82208391" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">101,914,280</ix:nonFraction>
<ix:nonFraction id="c82208390" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesIssued" scale="0" format="ixt:numdotdecimal" decimals="INF">64,015,441</ix:nonFraction>
<ix:nonFraction id="c82208392" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:CommonStockSharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">64,015,441</ix:nonFraction>
<ix:nonFraction id="c82208642" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction>
<ix:nonNumeric contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c82208672" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" name="us-gaap:WarrantsAndRightsOutstandingTerm" id="c82208679" format="ixt-sec:duryear">5</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" id="c82208765" format="ixt-sec:duryear">10</ix:nonNumeric>
<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c82208767" format="ixt-sec:duryear">3</ix:nonNumeric>
<ix:nonFraction id="c82208780" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction></ix:hidden>
<ix:references>
<link:schemaRef xlink:href="dffn-20211231.xsd" xlink:type="simple"></link:schemaRef></ix:references>
<ix:resources>
<xbrli:context id="d_2021-01-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="USD"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-06-30"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-06-30</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Share"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2022-03-14"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-03-14</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="NonApplicable"><xbrli:measure>thunderdome:item</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="USDPerShare"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit>
<xbrli:context id="d_2020-01-01_2020-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2019-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Year"><xbrli:measure>utr:Y</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-10-01_2021-12-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-10-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-11-08_2021-11-08"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-11-08</xbrli:startDate><xbrli:endDate>2021-11-08</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Pure"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:PublicOfferingInclusiveOfUnderwriterSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-02-01</xbrli:startDate><xbrli:endDate>2021-02-28</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:PublicOfferingInclusiveOfUnderwriterSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:unit id="Day"><xbrli:measure>utr:D</xbrli:measure></xbrli:unit>
<xbrli:context id="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-02-28</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:TheMay2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:TheMay2020OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PriorWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-05-01_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PriorWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:NewWarrantsIssuedMay82020Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-05-01_2020-05-31"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2020-05-01</xbrli:startDate><xbrli:endDate>2020-05-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020PAWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:HCWainwrightAndCoLLCMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-05-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsAttachedToSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2022-01-01_2022-01-01_PlanNameAxis-EquityIncentivePlan2015Member_SubsequentEventTypeAxis-SubsequentEventMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-01-01</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:unit id="Month"><xbrli:measure>utr:M</xbrli:measure></xbrli:unit>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context>
<xbrli:context id="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001053691</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context></ix:resources>
</ix:header></div>
  <div>
    &#xa0;
  </div>
  <div><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
<hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>UNITED STATES</b></p>
<p style="font-family:Times New Roman;font-size:12pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>SECURITIES AND EXCHANGE COMMISSION</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Washington, D.C. 20549</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>FORM</b>&#xa0;<b><ix:nonNumeric name="dei:DocumentType" contextRef="d_2021-01-01_2021-12-31">10-K</ix:nonNumeric></b></p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td colspan="2" style="vertical-align:top;width:100.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Mark one)</p> </td></tr>
</tbody></table>
<table style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="width: 15%; text-align: center;"><ix:nonNumeric name="dei:DocumentAnnualReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2612;</ix:nonNumeric></td><td style="width: 85%;"><b>ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></td></tr>
</tbody></table>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td colspan="2" style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the fiscal year ended </b><ix:nonNumeric name="dei:DocumentPeriodEndDate" format="ixt:datemonthdayyearen" contextRef="d_2021-01-01_2021-12-31"><b>December</b>&#xa0;<b>31, 2021</b></ix:nonNumeric><b></b></p> </td></tr>
<tr><td colspan="2" style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>OR</b></p> </td></tr>
<tr><td style="vertical-align: top; width: 15%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: center;"><ix:nonNumeric name="dei:DocumentTransitionReport" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align: top; width: 85%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934</b></p> </td></tr>
<tr><td colspan="2" style="vertical-align: top; width: 15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>For the transition period from</b>&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;<b>&#xa0;</b>&#xa0;<b>to</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Commission file number: <ix:nonNumeric name="dei:EntityFileNumber" contextRef="d_2021-01-01_2021-12-31">000-24477</ix:nonNumeric></b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div style="text-align: center;">
 <img alt="logo.jpg" src="logo.jpg" />
</div>
<p style="font-family:Times New Roman;font-size:24pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>Diffusion Pharmaceuticals Inc.</b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Exact Name of Registrant as specified in its Charter)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:50.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" contextRef="d_2021-01-01_2021-12-31">Delaware</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(State or Other Jurisdiction of Incorporation or Organization)</p> </td><td style="vertical-align:bottom;width:50.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityTaxIdentificationNumber" contextRef="d_2021-01-01_2021-12-31">30-0645032</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(I.R.S. Employer Identification No)</p> </td></tr>
<tr><td style="vertical-align:bottom;width:50.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressAddressLine1" contextRef="d_2021-01-01_2021-12-31">300 East Main Street, Suite 201</ix:nonNumeric></b><br /> <b><ix:nonNumeric name="dei:EntityAddressCityOrTown" contextRef="d_2021-01-01_2021-12-31">Charlottesville</ix:nonNumeric>, <ix:nonNumeric name="dei:EntityAddressStateOrProvince" contextRef="d_2021-01-01_2021-12-31">VA</ix:nonNumeric></b><br /> (Address of Principal Executive Offices)</p> </td><td style="vertical-align:bottom;width:50.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><ix:nonNumeric name="dei:EntityAddressPostalZipCode" contextRef="d_2021-01-01_2021-12-31">22902</ix:nonNumeric></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">(Zip Code)</p> </td></tr>
</tbody></table>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>(<ix:nonNumeric name="dei:CityAreaCode" contextRef="d_2021-01-01_2021-12-31">434</ix:nonNumeric>) <ix:nonNumeric name="dei:LocalPhoneNumber" contextRef="d_2021-01-01_2021-12-31">220-0718</ix:nonNumeric></b></p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">(Registrant's telephone number, including area code)</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">Securities registered pursuant to Section&#xa0;12(b) of the Act:</p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:37.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Title of Each Class</span></b></p> </td><td style="vertical-align:bottom;width:15.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Trading Symbol</span></b></p> </td><td style="vertical-align:bottom;width:47.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><span style="text-decoration: underline; ">Name of Each Exchange on Which Registered</span></b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:37.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:Security12bTitle" contextRef="d_2021-01-01_2021-12-31">Common Stock, par value $0.001 per share</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:15.7%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><ix:nonNumeric name="dei:TradingSymbol" contextRef="d_2021-01-01_2021-12-31">DFFN</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:47.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">The <ix:nonNumeric name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" contextRef="d_2021-01-01_2021-12-31">Nasdaq</ix:nonNumeric> Capital Market</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">Securities registered pursuant to Section&#xa0;12(g) of the Act:</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>None</b>&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Yes&#xa0;&#x2610; <ix:nonNumeric name="dei:EntityWellKnownSeasonedIssuer" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric> &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act. Yes&#xa0;&#x2610; <ix:nonNumeric name="dei:EntityVoluntaryFilers" contextRef="d_2021-01-01_2021-12-31">No</ix:nonNumeric> &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. <ix:nonNumeric name="dei:EntityCurrentReportingStatus" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric>&#xa0;&#x2612; No&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (&#xa7;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). <ix:nonNumeric name="dei:EntityInteractiveDataCurrent" contextRef="d_2021-01-01_2021-12-31">Yes</ix:nonNumeric>&#xa0;&#x2612; No&#xa0;&#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM">
    &#xa0;
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See definitions of &#x201c;large accelerated filer,&#x201d; &#x201c;accelerated filer,&#x201d; &#x201c;smaller reporting company,&#x201d; and &#x201c;emerging growth company&#x201d; in Rule 12b-2 of the Exchange Act.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:69.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Large accelerated filer &#x2610;</p> </td><td style="vertical-align:bottom;width:31.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accelerated filer &#x2610;</p> </td></tr>
<tr><td style="vertical-align:bottom;width:69.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><ix:nonNumeric name="dei:EntityFilerCategory" format="ixt-sec:entityfilercategoryen" contextRef="d_2021-01-01_2021-12-31">Non-accelerated filer</ix:nonNumeric> &#x2612;</p> </td><td style="vertical-align:bottom;width:31.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Smaller reporting company <ix:nonNumeric name="dei:EntitySmallBusiness" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2612;</ix:nonNumeric></p> </td></tr>
<tr><td style="vertical-align:top;width:69.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Emerging growth company <ix:nonNumeric name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p> </td><td style="vertical-align:bottom;width:31.1%;">&#xa0;</td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 45pt; text-align: justify;">If an emerging growth company, indicate by check mark if the registrant has elected to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#x2610;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicated by check mark whether the registrant has filed a report on and attestation to its management's assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes-Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. <ix:nonNumeric name="dei:IcfrAuditorAttestationFlag" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Indicate by check mark whether registrant is a shell company (as defined in Rule 12b-2 of the Act). Yes&#xa0;<ix:nonNumeric name="dei:EntityShellCompany" format="ixt-sec:boolballotbox" contextRef="d_2021-01-01_2021-12-31">&#x2610;</ix:nonNumeric> No &#x2612;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The aggregate market value of the registrant&#x2019;s common stock beneficially owned by non-affiliates of the registrant, calculated based upon the closing sale price of the common stock as quoted by the Nasdaq Capital Market on June 30, 2021 (the last business day of the registrant&#x2019;s second fiscal quarter), was approximately $<ix:nonFraction name="dei:EntityPublicFloat" scale="6" unitRef="USD" decimals="1" format="ixt:numdotdecimal" contextRef="i_2021-06-30">74.3</ix:nonFraction> million.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">As of March 14, 2022, <ix:nonFraction name="dei:EntityCommonStockSharesOutstanding" scale="0" unitRef="Share" decimals="INF" format="ixt:numdotdecimal" contextRef="i_2022-03-14">101,924,581</ix:nonFraction> shares of common stock of the registrant were outstanding.</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 45pt;">&#xa0;</p>
<p style="text-align: center; margin: 0pt;"><b>DOCUMENTS INCORPORATED BY REFERENCE</b></p></div>
  <p style="text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="text-align: center; margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <hr style="height: 1px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 3pt 0" />
  <hr style="height: 3px; color: #000000; background-color: #000000; width: 100%; border: none; margin: 0 0 3pt 0" />
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>TABLE OF CONTENTS</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&#xa0;</p>
   <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
    <tbody>
     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART I</p> </td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 1.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">BUSINESS</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">1</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">&#xa0;&#xa0;ITEM 1A.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">RISK FACTORS</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">25</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 1B.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">UNRESOLVED STAFF COMMENTS</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">43</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 2.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PROPERTIES</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">43</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 3.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">LEGAL PROCEEDINGS</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">43</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 4.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MINE SAFETY DISCLOSURES</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">43</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART II</p> </td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">44</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:top;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">&#xa0;&#xa0;ITEM 5.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MARKET FOR REGISTRANT&#x2019;S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">44</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align: top; width: 13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 5pt;">&#xa0;&#xa0;ITEM 6.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SELECTED FINANCIAL DATA</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">44</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 7.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">MANAGEMENT&#x2019;S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">45</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 7A.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">52</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 8.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">52</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 9.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">69</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 9A.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CONTROLS AND PROCEDURES</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">69</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 9B.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">OTHER INFORMATION</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">70</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART III</p> </td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">71</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 10.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">71</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 11.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXECUTIVE COMPENSATION</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">83</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 12.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">87</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 13.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">89</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 14.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PRINCIPAL ACCOUNTING FEES AND SERVICES</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">89</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">PART IV</p> </td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">90</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 15.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">EXHIBITS, FINANCIAL STATEMENT SCHEDULES</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">90</p> </td>
     </tr>

     <tr style="background-color: rgb(255, 255, 255);">
      <td style="vertical-align:bottom;width:13.6%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:80.5%;">&#xa0;</td>
      <td style="vertical-align:bottom;width:6.4%;">&#xa0;</td>
     </tr>

     <tr style="background-color: rgb(204, 238, 255);">
      <td style="vertical-align:bottom;width:13.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 9pt;">ITEM 16.</p> </td>
      <td style="vertical-align:bottom;width:80.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FORM 10-K SUMMARY</p> </td>
      <td style="vertical-align:bottom;width:6.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">92</p> </td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>INTRODUCTORY NOTES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Company References and Other Defined Terms</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Unless the context otherwise requires, in this Annual Report, (i) references to the &#x201c;Company,&#x201d; &#x201c;we,&#x201d; &#x201c;our,&#x201d; or &#x201c;us&#x201d; refer to Diffusion Pharmaceuticals Inc. and its subsidiaries and (ii) references to &#x201c;common stock&#x201d; refer to the common stock, par value $0.001 per share, of the Company. We have also used several other defined terms in this Annual Report, which are explained or defined below:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Term</b></p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Definition</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2015 Equity Plan</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan, as amended</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2017 Tax Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tax Cuts and Jobs Act of 2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">401(k) Plan</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals Inc. 401(k) Defined Contribution Plan</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Affordable Care Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Altitude Trial</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ongoing Phase 1b clinical trial evaluating TSC in normal healthy volunteers subjected to incremental levels of physical exertion while exposed to hypoxic and hypobaric conditions, or &#x201c;simulated altitude&#x201d;</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ANDA</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">abbreviated new drug application</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Annual Report</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">this Annual Report on Form 10-K</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">API</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">active pharmaceutical ingredient</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounting Standard Codification of the FASB</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC 815-40</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASC 815-40, <i>Derivatives and Hedging, Contracts in an Entity's Own Equity</i></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ASUs</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Accounting Standards Updates of the FASB</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bid Price Rule</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the minimum bid price requirement contained in Nasdaq Listing Rule 5550(a)(2)</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Black-Scholes Model</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Black-Scholes-Merton derivative investment instrument pricing model</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our board of directors</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Bylaws</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Company's bylaws, as amended</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Carlton Lease</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the Lease Agreement, dated March 31, 2017, related to our prior corporate headquarters located at 1317 Carlton Avenue in Charlottesville, Virginia</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">COVID-19</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Corona Virus Disease 2019, the novel coronavirus disease known as COVID-19, caused by severe acute respiratory syndrome coronavirus 2 viral infection</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">COVID Trial</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Phase 1b clinical trial evaluating TSC in hospitalized COVID-19 patients, completed in February 2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">cGMP</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">current good manufacturing practices</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CMO</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">contract manufacturing organization</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CMS</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Centers for Medicare &amp; Medicaid Services</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CRO</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">contract research organization</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">CTA</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">clinical trial application</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">December 2019 Offering</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our registered direct public offering and sale of 6,266,787 shares of common stock and concurrent private placement of warrants to purchase up to 6,266,787 shares of common stock completed in December 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion LLC</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diffusion Pharmaceuticals LLC, a Virginia limited liability company and our wholly owned subsidiary</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">DLCO</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">diffusion capacity of lung for carbon monoxide</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dodd-Frank Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">E.U.</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">European Union</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Exchange Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Exchange Act of 1934, as amended</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FASB</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Financial Accounting Standards Board</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDA</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Food and Drug Administration</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">FDC Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Federal Food, Drug, and Cosmetic Act</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">February 2021 Offering</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our public offering and sale of 33,658,538 shares of common stock completed in February 2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">G&amp;A</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">general and administrative</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GAAP</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. generally accepted accounting principles</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GBM</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">glioblastoma multiforme brain cancer</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GBM Trial</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Phase 3 clinical trial evaluating TSC in a newly diagnosed inoperable GBM patient population, initiated in December 2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GCP</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">good clinical practice</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">GLP</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">good laboratory practice</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HIPAA</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Health Insurance Portability and Accountability Act of 1996</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">HITECH</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Health Information Technology for Economic and Clinical Health Act of 2009</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Hypoxic Solid Tumor Program</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ongoing clinical development program to evaluate TSC as an adjunct to standard of care therapy for hypoxic solid tumors, first announced in November 2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ILD</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">interstitial lung disease</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">ILD-DLCO Trial</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our ongoing Phase 2a clinical trial evaluating TSC in patients with previously diagnosed ILD who have a baseline DLCO test result that is abnormal using DLCO as a surrogate measure of oxygen transfer efficiency</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IMM</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">irreversible morbidity and mortality</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IND</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">investigational new drug application</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IPR&amp;D</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">in-process research and development</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">IRB</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">institutional review board</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2019 Offering</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our registered direct public offering and sale of 1,317,060 shares of common stock and concurrent private placement of warrants to purchase up to 1,317,060 shares of common stock completed in May 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2020 Investor Warrant Exercise</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the exercise of the Prior Warrant in May 2020 pursuant to a warrant exercise agreement</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">May 2020 Offering</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our registered direct public offering and sale of 11,428,572 shares of common stock completed in May 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq&#xa0;or NASDAQ</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq Stock Market, LLC</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Nasdaq Staff</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the staff of the listing qualifications department of Nasdaq</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NDA</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">new drug application</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NOL</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">net operating loss</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">November 2019 Offering</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our public offering and sale of 5,104,429 shares of common stock, pre-funded warrants to purchase up to 6,324,143 shares of common stock, and warrants to purchase up to 22,857,144 shares of common stock completed in November 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Oxygenation Trials</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">collectively, the TCOM Trial, the Altitude Trial, and the ILD-DLCO Trial</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Planned Phase 2 Hypoxic Tumor Trial</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the first clinical trial in our Hypoxic Solid Tumor Program, which we currently expect to be a Phase 2 clinical trial commencing in the second half of 2022, subject to FDA feedback and the availability of clinical drug supply</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Prior Warrant</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a previously outstanding warrant to purchase up to 5,000,000 shares of common stock at an exercise price of $0.35 per share</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">R&amp;D</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">research and development</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulation S-K</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Regulation S-K promulgated under the Securities Act</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">REMS</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">risk evaluation and mitigation strategy</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Reverse Stock Split</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the proposed reclassification and combination of all shares of our common stock outstanding at a ratio of not less than one-for-two and not greater than one-for-50, the approval of which will be voted on by our stockholders at the Special Meeting</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SEC</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Securities and Exchange Commission</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Securities Act of 1933, as amended</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">SOX</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sarbanes-Oxley Act of 2002, as amended</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Special Meeting</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">the special meeting of our stockholders to be held on April 14, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Sunshine Act</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Physician Payments Sunshine Act</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Tax Code</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Internal Revenue Code of 1986, as amended</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TCOM</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">transcutaneous oxygen measurement</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TCOM Trial</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">our Phase 1b clinical trial evaluating the effects of TSC on peripheral tissue oxygenation in healthy normal volunteers using a TCOM device, completed in March 2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">TSC</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">trans sodium crocetinate, our lead product candidate</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S.</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">United States</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:19%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">USPTO</p> </td>
     <td style="vertical-align:bottom;width:74.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">U.S. Patent and Trademark Office</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Forward-Looking Statements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">This Annual Report (including, for purposes of this Note Regarding Forward-Looking Statements, any information or documents incorporated herein by reference) includes express and implied forward-looking statements. By their nature, forward-looking statements involve risks and uncertainties because they relate to events, competitive dynamics and industry change, and depend on the economic circumstances that may or may not occur in the future or may occur on longer or shorter timelines than anticipated. Although we believe that we have a reasonable basis for each forward-looking statement contained in this Annual Report, we caution you that forward-looking statements are not guarantees of future performance and that our actual results of operations, financial condition, liquidity and prospects may differ materially from the forward-looking statements contained in this Annual Report. In addition, even if our results of operations, financial condition, liquidity, and prospects are consistent with the forward-looking statements contained in this Annual Report, they may not be predictive of actual results or reflect unanticipated developments in future periods.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Forward-looking statements appear in a number of places throughout this Annual Report. We may, in some cases, use terms such as &#x201c;believes,&#x201d; &#x201c;estimates,&#x201d; &#x201c;anticipates,&#x201d; &#x201c;expects,&#x201d; &#x201c;plans,&#x201d; &#x201c;intends,&#x201d; &#x201c;may,&#x201d; &#x201c;could,&#x201d; &#x201c;might,&#x201d; &#x201c;will,&#x201d; &#x201c;should,&#x201d; &#x201c;approximately,&#x201d; or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Forward-looking statements also include statements regarding our intentions, beliefs, projections, outlook, analyses, or expectations, including our intentions, beliefs, projections, outlook, analyses, or expectations concerning, among other things:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to satisfy the continued listing requirements of the NASDAQ Capital Market or any other exchange on which our securities may trade in the future;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success and timing of our clinical and preclinical studies, including our ability to enroll subjects in our ongoing and planned clinical studies at anticipated rates and our ability to manufacture an adequate amount of drug supply for our studies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">obtaining and maintaining intellectual property protection for our product candidates and our proprietary technology;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the performance of third parties, including contract research organizations, manufacturers, suppliers, and outside consultants, to whom we outsource certain operational, staff and other functions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain additional financing in the future and continue as a going concern;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to obtain and maintain regulatory approval of our product candidates and, if approved, our products, including the labeling under any approval we may obtain;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our plans and ability to develop and commercialize our product candidates and the outcomes of our research and development activities;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our estimates regarding expenses, future revenues, capital requirements, and needs for additional financing;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our failure to recruit or retain key scientific or management personnel or to retain our executive officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the accuracy of our estimates of the size and characteristics of the potential markets for our product candidates, the rate and degree of market acceptance of any of our product candidates that may be approved in the future, and our ability to serve those markets;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the success of products that are or may become available which also target the potential markets for our product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to operate our business without infringing the intellectual property rights of others and the potential for others to infringe upon our intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any significant breakdown, infiltration, or interruption of our information technology systems and infrastructure;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">recently enacted and future legislation related to the healthcare system, including trends towards managed care and healthcare cost containment, the impact of any significant spending reductions or cost controls affecting publicly funded or subsidized healthcare programs, or any replacement, repeal, modification, or invalidation of some or all of the provisions of the Affordable Care Act;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other regulatory developments in the U.S., E.U., and other foreign jurisdictions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">uncertainties related to general economic, political, business, industry, and market conditions, including the ongoing COVID-19 pandemic; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other risks and uncertainties, including those discussed under the heading "Risk Factors" in this Annual Report and elsewhere in our other public filings.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a result of these and other factors, known and unknown, actual results could differ materially from our intentions, beliefs, projections, outlook, analyses, or expectations expressed in any forward-looking statements in this Annual Report. Accordingly, we cannot assure you that the forward-looking statements contained in this Annual Report will prove to be accurate or that any such inaccuracy will not be material. You should also understand that it is not possible to predict or identify all such factors, and you should not consider any such list to be a complete set of all potential risk or uncertainties. In light of the foregoing and the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. For all forward-looking statements, we claim the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any forward-looking statement that we make in this Annual Report speaks only as of the date of such statement, and, except as required by applicable law or by the rules and regulations of the SEC, we undertake no obligation to update such statements to reflect events or circumstances after the date of this Annual Report or to reflect the occurrence of unanticipated events. Comparisons of current and any prior period results are not intended to express any ongoing or future trends or indications of future performance, unless explicitly expressed as such, and should only be viewed as historical data.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Note Regarding Trademarks, Trade Names, and Service Marks</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This Annual Report contains certain trademarks, trade names, and service marks of ours, including &#x201c;DIFFUSIO2N.&#x201d; All other trade names, trademarks, and service marks appearing in this Annual Report are, to the knowledge of Diffusion, the property of their respective owners. To the extent any such terms appear without the trade name, trademark, or service mark notice, such presentation is for convenience only and should not be construed as being used in a descriptive or generic sense.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM">
       &#xa0;
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART I</b></p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>BUSINESS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Diffusion Pharmaceuticals: Enhancing Oxygen, Fueling Life</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are a biopharmaceutical company developing novel therapies that enhance the body&#x2019;s ability to deliver oxygen to the areas where it is needed most. Our lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Our Strategy</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our goal is to become a leading biopharmaceutical company focused on the development and commercialization of novel therapies that enhance the body&#x2019;s ability to deliver oxygen to areas where it is needed most and improve treatment outcomes for patients suffering from conditions complicated by hypoxia. To achieve this strategy, we are focused on the following key objectives:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Demonstrate the effects of TSC on the oxygenation pathway</i></b>. The results of our Oxygenation Trials &#x2013;&#xa0;a series of three short-term, pharmacodynamic studies to evaluate the effects of TSC on different components of the oxygenation pathway that we expect to complete by the middle of 2022 &#x2013;&#xa0;will be used to further inform the identification of potential indications appropriate for TSC and will guide the design of clinical trials aimed at supporting the commercialization of TSC as a treatment for conditions complicated by hypoxia. For additional information, see "<i>Business </i>&#x2014;<i>&#xa0;Our Lead Product Candidate: Trans Sodium Crocetinate -- The TSC Oxygenation Trials: Demonstrating Proof of Concept, Dose Response Relationships, and Potential Indications for Future Development.</i>&#x201d;&#xa0;&#xa0;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i><b>Develop TSC as an adjunct treatment for hypoxic solid tumors</b></i>. The prevalence of hypoxic regions across numerous primary solid tumor types is believed to directly contribute to treatment resistance, whether it be radiotherapy, chemotherapy, or immunotherapy, increasing the metastatic potential of these tumors and the probability of unsuccessful treatment. We believe TSC&#x2019;s novel mechanism of action supports the objective of developing TSC as a treatment for hypoxic solid tumors because TSC&#x2019;s ability to enhance the oxygenation of hypoxic tissues may increase the effectiveness of standard-of-care radiation therapy and chemotherapy. Accordingly, in November 2021, we announced our Hypoxic Solid Tumor Program and our intent to commence our Planned Phase 2 Hypoxic Solid Tumor Trial in the second half of 2022. The data obtained during 2021 and early 2022 from our Oxygenation Trials and COVID Trial regarding TSC&#x2019;s effects on oxygenation, dose response characteristics, pharmacokinetics, and pharmacodynamics are being used to guide the design of this trial. Through the combination of this new data, our past experiences, and further analyses and discussions of all available data with our Scientific Advisory Board and other external advisors, we believe we now have the necessary information to design the Hypoxic Solid Tumor Program to be more efficient and increase our likelihood of success compared to the Company&#x2019;s past efforts to develop TSC as a cancer treatment, which were terminated in 2019 due to financial constraints. For additional information, see "<i>Business </i>&#x2014;<i>&#xa0;Our Lead Product Candidate: Trans Sodium Crocetinate </i>&#x2013;<i>&#xa0;Our Hypoxic Solid Tumor Program</i>.&#x201d;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Accelerate development of TSC as a treatment for non-cancer indications</i></b>. Beyond cancer, hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases. We have previously undertaken clinical studies of TSC in a variety of non-cancer indications, including interstitial lung disease, COVID-19, stroke, and peripheral artery disease, and have evaluated TSC in preclinical models in an even wider range of indications. Data that we expect to obtain from our ongoing Altitude and ILD-DLCO Trials may identify additional, non-oncology development opportunities. Although our primary near-term focus will be our Hypoxic Solid Tumor Program, we will continue to explore pathways to progress TSC&#x2019;s development in non-oncology indications through our preclinical studies. For additional information, see "<i>Business </i>&#x2014;<i>&#xa0;Our Lead Product Candidate: Trans Sodium Crocetinate </i>&#x2013;<i>&#xa0;TSC</i>&#x2019;<i>s Potential to Treat Other Conditions Complicated by Hypoxia</i>.&#x201d;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       1
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>Maximize the commercial value of our pipeline</i></b>. We have invested, and plan to continue to invest, significant time, effort, and resources into the development and maintenance of our intellectual property portfolio as we seek to retain worldwide development and commercial rights to our product candidates. In parallel with advancing our development programs, we will evaluate the commercial landscape for TSC with the intent of improving patient access to maximize our chances of commercial success, should the product be approved.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; margin: 0pt; text-align: justify; font-size: 10pt;"><b><i>Opportunistically acquire or in-license additional product candidates that complement TSC and our overall strategy</i></b>. We believe we can leverage what we have learned from the development of TSC and the significant skills and experience of our team to opportunistically identify and acquire or in-license novel product candidates that complement TSC and further our efforts to improve patient outcomes by enhancing standard-of-care therapy for conditions complicated by hypoxia. We also believe diversifying our asset portfolio through an acquisition or in-licensing would reduce our Company&#x2019;s overall risk profile as an investment.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Lead Product Candidate: Trans Sodium Crocetinate</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       2
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Hypoxia is a condition in which there is an insufficient supply of oxygen to meet the energy demands of the cells in a tissue (e.g., skeletal muscle). Hypoxia is associated with the pathophysiology of many of medicine&#x2019;s most intractable and difficult-to-treat conditions, including cancers, cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases.&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">All currently approved treatments for hypoxia work by augmenting or supplementing the systemic availability of oxygen. For example, respirators use pressure to push oxygen across the lungs into the blood to increase oxygen concentration, certain medications and devices such as external mechanical pumps are designed to improve cardiac output, and blood transfusions are used to increase the concentration of red blood cells and oxygen-carrying hemoglobin molecules.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While these treatments are effective in certain circumstances, there are significant associated risks such as lung damage resulting from the use of respirators, toxic side effects and drug-to-drug interactions of medications that increase cardiac output, infections related to blood transfusions, and the risk of creating excessive oxygen-related tissue toxicity, or hyperoxia, by providing a patient with excessive amounts of oxygen, among others. In addition, in certain other indications, these currently approved therapies are ineffective in treating the associated hypoxia. For example, in the treatment of cancer, re-oxygenating hypoxic, cancerous tissue cells cannot typically be accomplished simply by increasing the systemic availability of oxygen.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe TSC is the first therapy specifically designed to enhance the efficiency of the oxygen diffusion process. Furthermore, in animal models, TSC&#x2019;s diffusion-enhancing mechanism of action has been observed to affect hypoxic tissue preferentially while avoiding excessive oxygen-related tissue toxicity.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       3
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">By supporting normal, physiologic levels of oxygen diffusion at the uptake and delivery points of the circulatory system, we believe TSC presents a significant opportunity to improve the current standard-of-care treatment for conditions complicated by hypoxia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="tsc01.jpg" src="tsc01.jpg" /></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>TSC's Mechanism of Action</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Blood plasma is approximately 90% water. The water molecules in the plasma are constantly moving, bound together in a loosely organized matrix by hydrogen bonds. TSC was designed to enhance the level of organization among the water molecules by increasing the amount of hydrogen bonding. This creates a less dense matrix of water molecules, reducing the resistance to oxygen diffusion across the concentration gradient.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="tsc02.jpg" src="tsc02.jpg" /></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Selected Preclinical Experiences</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">TSC has been evaluated in a variety of preclinical models intended to mimic relevant human conditions known to be complicated by hypoxia. In these studies, a variety of positive effects have been observed in connection with TSC administration, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Reducing hypoxia in rat brain tumors without hyper-oxygenation of normal tissue;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Improving survival in a rat brain tumor model when added to radiotherapy, whether alone or in combination with chemotherapy;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Improving tissue oxygenation without hyper-oxygenation of normal tissue and reducing infarct size in a rat ischemic stroke model;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Demonstrating a functional benefit in a rabbit ischemic stroke model, with or without tissue plasminogen activator at one-hour post-clot infection and with tissue plasminogen activator at three hours post-clot infection; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Improving levels of arterial partial pressure of blood oxygen in a rat model of acute respiratory distress syndrome.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="tsc03.jpg" src="tsc03.jpg" /></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:18pt;"><b>Positron emission tomography scans showing reduction in hypoxia in a rat C6 glioma brain tumor model 45 min after TSC administration.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>The TSC Oxygenation Trials: Demonstrating Proof of Concept, Dose Response Relationships, and Potential Indications for Future Development</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While our clinical trials evaluating TSC conducted prior to 2021 provided certain preliminary signals regarding TSC&#x2019;s mechanism of action and dose response characteristics, none of those studies were designed to demonstrate proof of concept by directly measuring TSC&#x2019;s effects on tissue oxygenation and a variety of questions remained regarding TSC&#x2019;s dose response characteristics, pharmacokinetics, and pharmacodynamics.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       4
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Given these identified gaps in our knowledge, in November 2020, we communicated our plan to design and execute our Oxygenation Trials, a series of short-term clinical studies using experimental models to evaluate the clinical effects of TSC on oxygenation, each designed to look at the effects of TSC on a different component of the oxygenation pathway. By quantifying the magnitude of effects of TSC on tissue oxygen levels and other direct clinical parameters assessing oxygen levels, and thereby demonstrating proof of concept of TSC&#x2019;s effects on tissue oxygenation, as well as supplementing our knowledge of TSC&#x2019;s dose response characteristics, pharmacokinetics and pharmacodynamics, we believe the data obtained from the Oxygenation Trials will allow us to significantly increase our clinical development strategy&#x2019;s likelihood of success.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>TCOM Trial: TSC's Effects on Peripheral Tissue Oxygenation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In March 2021, we initiated and completed enrollment in the first of the Oxygenation Trials, our TCOM Trial. In June 2021, we reported a positive trend in peripheral tissue oxygenation as compared to placebo among participants receiving TSC that persisted through the duration of the one-hour, post-dosing measurement period. Although the magnitude of this effect was not statistically significant due to limitations in the study design, the trends in the primary endpoint data indicated an improvement in peripheral oxygenation with TSC with no evidence of hyperoxygenation.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The figure below was created during a supplemental analysis of the TCOM Trial results by subtracting the median response observed in the TCOM Trial&#x2019;s placebo group from the median response observed in each TSC dosage group at each of the measurement times during the one-hour period following dosing. These data highlight the persistent increase in peripheral tissue oxygenation relative to the placebo group through the duration of the one-hour measurement period following TSC administration, particularly at the two highest doses tested.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="tsc04.jpg" src="tsc04.jpg" /></div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Effects of TSC on transcutaneous oxygen pressure.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe the TCOM Trial provides clinical evidence to support the hypothesis that TSC enhances the passive diffusion of oxygen from areas of high concentration to areas of low concentration without causing hyperoxygenation and that the data obtained from the study represent a positive and meaningful step towards the accomplishing of the Oxygenation Trials&#x2019; strategic objectives originally set forth in November 2020. These data have and will continue to guide the next steps of our development strategy, including the design of our Hypoxic Solid Tumor Program.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Altitude Trial: TSC's Effects Under Induced Hypoxic Conditions</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On November 22, 2021, we announced dosing of the first participants in our second Oxygenation Trial, the Altitude Trial.&#xa0;This study is a double-blind, randomized, placebo-controlled crossover study designed to evaluate the effects of TSC on maximal oxygen consumption and partial pressure of blood oxygen in normal healthy volunteers subjected to incremental levels of physical exertion while exposed to &#x201c;simulated altitude.&#x201d; The study will enroll 30 healthy volunteers and give each volunteer a single dose of TSC at one of three different doses. Due to enrollment delays experienced during early 2022 related to the omicron variant wave of the COVID-19 pandemic, we now anticipate completing dosing in the Altitude Trial in the second quarter of 2022, with topline results reported within two months of study completion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       5
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>ILD-DLCO Trial: TSC's Effects on Oxygen Transfer Efficiency</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On December 16, 2021, we announced dosing of the first patients in our third and final Oxygenation Trial, the ILD-DLCO Trial. This study is a double-blind, randomized, placebo-controlled, crossover study designed to evaluate the effects of TSC on the diffusion of carbon monoxide through the lungs, or DLCO, in patients with previously diagnosed ILD who have a baseline DLCO test result that is abnormal. DLCO is used in the study as a surrogate measure of oxygen transfer efficiency, or uptake, from the alveoli of the lungs through the plasma, and onto hemoglobin within red blood cells. The study will enroll 27 patients with confirmed ILD who will be randomized in a 2:1 ratio to a single dose of TSC or placebo via IV bolus. The study is statistically powered to evaluate the difference in effect of TSC versus placebo on improvement in DLCO measurements. In addition, patients will undergo a standard six-minute walk test intended to assess functional improvement in exercise capacity. Due to enrollment delays experienced during early 2022 related to the omicron variant wave of the COVID-19 pandemic, the effect of the omicron variant on patients with pulmonary diseases such as ILD, and staffing issues at the facilities where the ILD-DLCO Trial is being conducted,&#xa0;we now anticipate completing dosing in the ILD-DLCO Trial by the middle of 2022, with topline results reported within two months of study completion.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>TSC's Demonstrated Clinical Safety Profile</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">TSC has been observed to be safe and well-tolerated at most doses tested in over 220 subjects included to-date in clinical studies at a variety of doses administered via intravenous infusion. Our clinical studies have included patients with a variety of medical conditions often complicated by hypoxia, including patients afflicted with GBM, peripheral artery disease with intermittent claudication, stroke, COVID-19, and interstitial lung disease. In each of these conditions and many others, hypoxia is a significant contributor to morbidity and mortality, and a considerable treatment obstacle for medical providers.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During 2021, we obtained additional data further demonstrating TSC's safety at higher doses and increased dosing frequencies from our COVID Trial and Oxygenation Trials. In the COVID Trial, completed in February 2021, TSC was administered on a different dosing regimen than any of our prior trials, with patients receiving an infusion multiple times per day for up to 15 days. In the TCOM Trial, based in part on a recommendation from the COVID Trial&#x2019;s safety monitoring committee, arms evaluating even higher doses of TSC were included. No dose-limiting toxicities or serious adverse events were observed among any patients or participants in the either trial, including those who received the highest tested doses of TSC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Our Hypoxic Solid Tumor Program</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">We believe TSC&#x2019;s novel mechanism of action supports the objective of developing TSC as a treatment for hypoxic solid tumors because TSC&#x2019;s ability to enhance the oxygenation of hypoxic tissues may increase the effectiveness of standard-of-care radiation therapy and chemotherapy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Solid tumors comprise approximately 90% of all adult cancers and, according to the American Cancer Society, it was expected that roughly 1.9 million new cancer cases would be diagnosed in the U.S. during 2021. It is also well-documented in the scientific literature that the prevalence of hypoxic regions across numerous primary solid tumor types directly contributes to treatment resistance, whether it be radiotherapy, chemotherapy, or immunotherapy, increasing the metastatic potential of these tumors and the probability of unsuccessful treatment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Many of the challenges faced by practitioners in treating some of the most fatal and difficult-to-treat tumor types, including GBM, pancreatic cancer, and other solid tumors, are a product of those tumors&#x2019; highly hypoxic nature. Cancerous tumors are specifically susceptible to developing hypoxia due to a combination of rapid growth, structural abnormalities of the tumor microvessels, and disturbed circulation within the tumor. Hypoxic conditions within the tumor microenvironment have numerous negative consequences for patient outcomes and treatment, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;increased resistance to ionizing radiation, chemotherapy, immunotherapy and other treatment methods;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;a more clinically aggressive phenotype;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;increased potential for invasive growth and tumor progression; and</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;increased regional and distal tumor metastasis.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       6
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We have previously obtained and published evidence supporting TSC&#x2019;s ability to enhance oxygenation of C6 glioma tumors in animals, as well as clinical evidence of TSC&#x2019;s effects in unresectable GBM tumors from our previously completed Phase 2 clinical trial evaluating 59 patients with newly diagnosed GBM. This open-label, historically controlled trial demonstrated a favorable safety and tolerability profile for TSC when combined with standard of care treatment for GBM. Although not prospectively defined, a post hoc subgroup analysis of inoperable patients suggested a higher proportion of TSC-treated patients survived at two years compared to those in the historical control group.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In November 2021, based on the available preclinical and clinical data and the significant unmet medical need, we announced our intention to focus near-term efforts on developing TSC as an adjunct to standard of care therapy for hypoxic solid tumors. Through the combination of our past experiences, new knowledge gained from our Oxygenation Trials and COVID Trial regarding TSC&#x2019;s effects on oxygenation, dose response characteristics, pharmacokinetics, and pharmacodynamics, and further analyses and discussions of all available data with our Scientific Advisory Board and other external advisors, we believe we now have the necessary information to design the Hypoxic Solid Tumor Program to be more efficient and increase our likelihood of success compared to the Company&#x2019;s past efforts to develop TSC as a cancer treatment, which were terminated in 2019 due to financial constraints.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the ongoing design of our Planned Phase 2 Hypoxic Tumor Trial &#x2013; the first trial in our Hypoxic Solid Tumor Program which we currently expect to commence in the second half of 2022, subject to FDA feedback and the availability of clinical drug supply &#x2013; we are currently drafting a trial protocol which we intend to file with the FDA. In parallel, we will continue our work to optimize the TSC manufacturing process and support the continued availability of high-quality drug product and undertake preclinical studies and other opportunities to continue developing data designed to demonstrate TSC&#x2019;s potential uses in a broad spectrum of non-cancer indications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>TSC's Potential to Treat Other Conditions Complicated by Hypoxia</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Beyond cancer, hypoxia is a complicating factor in many other intractable and difficult-to-treat conditions as well, including cardiovascular diseases, cerebrovascular diseases, respiratory diseases, skin and soft tissue diseases, and neurodegenerative diseases. In addition to our oncology programs past and present, we have previously conducted a variety of preclinical and clinical studies evaluating the effects of TSC in several of these other indications complicated by hypoxia, including COVID-19, stroke, and peripheral artery disease with intermittent claudication,&#xa0;and we intend to continue to pursue potential partnering opportunities in non-oncology indications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div style="text-align: center;">
   <img alt="tsc05.jpg" src="tsc05.jpg" /></div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Certain medical conditions complicated by hypoxia.</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       7
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Our Phase 2 COVID-19 Trial</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We believe TSC&#x2019;s oxygen-enhancing mechanism of action could potentially provide benefit patients suffering from respiratory indications, such as COVID-19.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In September 2020, we announced the dosing of the first patients in our COVID Trial evaluating TSC in hospitalized COVID-19 patients at the National Institute of Infectious Diseases in Bucharest, Romania. The trial enrolled 24 patients divided into four sequential cohorts of six patients, with each patient in a cohort receiving the same intravenous doses of 0.25 mg/kg, 0.5 mg/kg, 1.0 mg/kg, or 1.5 mg/kg. All patients were administered intravenous doses of TSC every six hours for a minimum of five days and up to 15 days. On February 9, 2021, we completed dosing of the twenty-fourth and final patient in the trial.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The primary endpoint of the COVID Trial was to evaluate the safety and tolerability of TSC administered every six hours for at least five and up to 15 days, a more frequent dosing regimen than had been used in our previous clinical studies. Secondary endpoints included pharmacokinetic measurement of TSC levels after dosing, relative improvements in blood oxygen levels, and certain other clinical parameters related to COVID-19, such as improvement in WHO ordinal scale by day 7 and through day 29, time on oxygen supplementation, and hospital length of stay.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Data from the trial, evaluated by the study&#x2019;s independent safety monitoring committee, indicated TSC was safe and well-tolerated and that no dose-limiting toxicities or serious adverse events were observed among any patients in the study, including those who received the highest dose administered in the trial. Additionally, while the COVID Trial was not designed or powered to evaluate efficacy, the safety monitoring committee also observed that patients receiving the highest dose administered had improved outcomes in the trial&#x2019;s secondary and exploratory endpoints compared to those receiving lower doses. Further, no patients that received TSC required dialysis or developed acute kidney injury, nor were there any reports of pulmonary embolism or deep vein thrombosis. Based on their observations, the safety monitoring committee also recommended the Company consider testing of higher TSC doses and a continuous intravenous infusion in future studies.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       8
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Product Development</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Research and Development</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In recent years, the majority of our research and development expenditures have been directed to the development of TSC. For example, during the year ended December 31, 2021, we incurred approximately $8.5 million in costs related to research and development of our products, a decrease of approximately $0.9 million compared to the year ended December 31, 2020. The majority of these costs were related to the development of TSC and related personnel, including costs associated with the Oxygenation Trials and the COVID Trial, which was completed in February 2021. We expect this trend to continue for the foreseeable future, including planned expenditures related to completion of the remaining Oxygenation Trials, the initiation of the Hypoxic Solid Tumor Program, and other costs associated with the conduct of additional, supportive preclinical studies and general research and development activities related to TSC and any other product candidates we may acquire or in-license in the future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       9
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a development-stage company, we continuously evaluate opportunities to improve the value of our development pipeline, including potential acquisition and in-licensing opportunities. Our efforts include ongoing evaluation and modification of our development plans intended to maximize the probability of technical, developmental, and regulatory success while enhancing patient and stockholder value. These activities have, and we expect they will continue to be for the foreseeable future, focused on opportunities that are synergistic with our overall corporate strategy to develop novel treatments for the treatment of hypoxia and conditions complicated by hypoxia.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Intellectual Property</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe that a strong intellectual property portfolio is critical to our success. We are committed to obtaining and maintaining appropriate patent and other protections for our products candidates and other technologies, preserving and protecting our trade secrets and other confidential and proprietary information, and fiercely defending our intellectual property portfolio against any potential infringement by third parties. We attempt to protect our intellectual property through among other things, the filing of applications for patent, trademark, and other appropriate intellectual property protections, the use of confidentiality agreements with consultants, contractors and other third parties, our employee policies regarding confidentiality, invention disclosure, and the assignment of inventions, as well as regular meetings of members of our internal development and legal teams, which contains key members of our management team. We are also committed to operating our business without infringing on the intellectual property of others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In general, patents extend for varying periods according to the date of patent filing or grant and the legal term of patents in various countries where patent protection is obtained, with term adjustments or extensions possible in certain cases based on patent office delays or pursuant to certain administrative and legislative exceptions. The actual protection afforded by a patent, which can vary from country to country, depends on the type of patent, the scope of its coverage and the availability of legal remedies in the country.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We continue to invest significant time, effort, and resources into the development and maintenance of our patent portfolio. As of December 31, 2021, we owned 17&#xa0;issued U.S. patents and&#xa0;more than 35&#xa0;issued non-U.S. patents, and had numerous patent applications pending worldwide including issued patents and applications in major markets such as the U.S., E.U., China, Japan, and India. The normal life (i.e. with no adjustments or extensions) of our key issued patents related to the composition of matter of TSC extends to 2026, with potential patent term extensions to 2031, and the normal life of our patents related to an oral formulation of TSC extends to 2031, with potential patent term extensions to 2036. The normal life of our key issued patents related to methods of use of TSC extends to 2037, not including potential patent term extensions. For additional information regarding patent term extensions, see "<i>Business </i>&#x2014;<i> Government Regulation</i>&#x2014;<i> The Hatch-Waxman Amendments </i>&#x2014;<i> Patent Term Restoration and Marketing Exclusivity</i>. In addition, TSC has been granted Orphan Drug designation by the FDA for the treatment of both GBM and metastatic brain cancer, which may provide us with a right of exclusivity under certain FDA regulations. For additional information regarding orphan and ultra-orphan designations, see "<i>Business </i>&#x2014;<i> Government Regulation </i>&#x2014;<i> Certain Other FDA Regulations </i>&#x2014;<i> The Orphan Drug Act of 1983</i>.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Chemistry, Manufacturing, and Controls</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">TSC is currently formulated as a freeze-dried, injectable product, requiring a sophisticated manufacturing process.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       10
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We do not currently own or operate any facilities suitable for manufacturing TSC or any of our other product candidates on a scale required to support either clinical development or commercialization. We currently use third-party CMOs to manufacture API, other starting materials, and finished drug product for our preclinical studies and clinical trials and we intend to continue doing so for the foreseeable future. We anticipate this strategy will be scalable in a manner sufficient to support the production capacity required to support continued clinical development and ultimate commercialization. However, we do not have any formal agreements at this time with any CMO to cover commercial production of TSC or any other product candidate. Although the use of third party CMOs to manufacture pharmaceutical products is common within the industry, this dependence on third-party CMOs exposes our business to certain risks, including those described under the heading, &#x201c;Risk Factors &#x2013; Risks Related to Our Dependence on Third Parties.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Supply Chain Matters</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Recently, many companies across a variety of sectors have reported disruptions, shortages, and other supply chain-related issues. In the biopharmaceutical sector, delays and interruptions in the supply chain were particularly pronounced as CMOs redirected resources under the Defense Production Act and to otherwise support the COVID-19 vaccine roll-out across the globe.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During 2021, we were able to effectively manage our supply of TSC and its component materials in a manner that avoided any significant interruptions to our clinical programs. We also took actions designed to increase the robustness of our drug supply and overall supply chain to mitigate risks related to the availability of our drug supply in the future. However, as constraints on the supply chain continue to impact the cost and general availability of manufacturing materials, related delays and shortages could affect the cost and timing of our available clinical study drug supply of TSC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Competition</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Currently, medical options to improve oxygenation without risk of hyper-oxygenation are limited and we believe that TSC's diffusion enhancing mechanism of action make it a first-in-class, novel, small molecule. However, there are several companies currently developing or marketing oxygen enhancing products, therapeutics, or devices that may nevertheless be competitive with TSC, if approved, including Hemoglobin Oxygen Therapeutics LLC, Hemotek Medical Inc., NuvOx Pharma LLC, Omniox, Inc., and VirTech Bio Inc. In addition, in the first quarter of 2021, we became aware of a third party affiliated with a former outside consultant of the Company which claims to be in early-stage development of a product candidate that purportedly may operate through a similar mechanism of action to TSC. It is unclear if this Company&#x2019;s product candidate would, if developed and approved, actually be competitive with TSC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our industry is highly competitive and subject to rapid and significant change. Potential competitors in the United States are numerous and include major pharmaceutical and specialty pharmaceutical companies, smaller biopharmaceutical companies, research universities, and others. The biopharmaceutical and pharmaceutical industries are characterized by rapidly advancing technologies, intense competition, and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing, and marketing of health care products competitive with those that we are developing. Many of our competitors have longer operating histories, greater name recognition, substantially greater financial resources, and larger research and development staffs than we do, as well as substantially greater experience than us in developing products, obtaining regulatory approvals, and manufacturing and marketing pharmaceutical products. In addition, a significant amount of research is carried out at academic and government institutions. These institutions are aware of the commercial value of their findings and are aggressive in pursuing patent protection and negotiating licensing arrangements to collect royalties for use of technology that they have developed. One or more of these companies or other entities may have one or more products under development that would be competitive with TSC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Sales and Marketing</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We currently have no marketed products and, accordingly, currently have no sales or marketing personnel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       11
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Government Regulation</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Pharmaceuticals like TSC and other product candidates we may develop are highly regulated by governmental authorities in the U.S. and other countries at the federal, state, and local levels. These regulations are numerous and extensive in their scope, relating to, among other things, the research and development, manufacture, storage, quality control and testing, approval, labeling and packaging, promotion, marketing, and advertising, distribution, post-approval monitoring and reporting, export and import, and record keeping of pharmaceutical products.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>The FDA Drug Approval Process</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Generally, before a new pharmaceutical product can be marketed, considerable data demonstrating its quality, safety and efficacy must be obtained, organized into a format specific for each applicable regulatory authority, submitted for review, and approved by the competent regulatory authority. In the United States, the competent regulatory authority is the FDA, which, pursuant to the FDC Act, is responsible for the review and approval of all data required to support a license to commercially market pharmaceuticals such as TSC.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The process of obtaining regulatory approvals and the subsequent compliance with FDA regulations requires the expenditure of substantial time and financial resources and failure to comply with the applicable requirements at any time during the product development process, approval process, or, if approved, following approval may subject an applicant to administrative or judicial sanctions. These sanctions could include, among other actions, the FDA&#x2019;s refusal to approve pending applications, withdrawal of an approval, license revocation, a clinical hold, untitled or warning letters, voluntary or mandatory product recalls, market withdrawals, product seizures, total or partial suspension of production or distribution, injunctions, fines, refusals of government contracts, restitution, disgorgement and civil or criminal penalties, any of which could have a material adverse effect on our business, financial position, or results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Process Overview</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The FDA drug approval process generally involves the following steps:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">completion of extensive preclinical laboratory studies , including studies conducted in accordance with GLP requirements;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">submission to the FDA of an IND application, which must become effective before clinical trials involving human subjects or patients may begin;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">performance of adequate and well-controlled human clinical trials in accordance with applicable IND regulations, GCP requirements, and other clinical trial-related regulations to establish the safety and efficacy of the investigational product for each proposed indication, including approval by an IRB or independent ethics committee before each trial may be initiated;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">submission to the FDA of an NDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination by the FDA within 60 days of its receipt of an NDA as to whether it will accept the filing for review;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">satisfactory completion of one or more FDA pre-approval inspections of the manufacturing facility or facilities where the drug will be produced to assess compliance with cGMP requirements and to assure that the facilities, methods and controls are adequate to preserve the drug&#x2019;s identity, strength, quality and purity;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a potential FDA audit of the clinical trial sites that generated the data in support of the NDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">payment of user fees for FDA review of the NDA; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">FDA review and approval of the NDA, including consideration of the views of any FDA advisory committee, prior to any commercial marketing or sale of the biologic or drug in the United States.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       12
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The preclinical and clinical testing and approval process requires substantial time, effort, and financial resources and satisfaction of FDA pre-market approval requirements typically takes many years, though the actual time required may vary substantially based upon the type, complexity, and novelty of the applicable product or indication to be treated. We cannot be certain that any approvals for TSC or any product candidates we attempt to develop in the future will be granted on a timely basis or at all.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Preclinical Studies</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Preclinical studies include laboratory evaluation of product chemistry, formulation, and toxicity, as well as animal trials to assess the characteristics and potential safety and efficacy of the drug. The results of preclinical testing are submitted to the FDA as part of an IND along with other information related to the drug, including information regarding its chemical make-up, manufacturing process, and quality controls, as well as a proposed clinical trial protocol. Long-term preclinical tests, such as animal tests of reproductive toxicity and carcinogenicity, may continue after the IND is submitted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Clinical Trials</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Following completion of preclinical studies and the submission on an IND to the FDA, a 30-day waiting period is required. If the FDA has neither commented on nor questioned the IND within this 30-day period, the clinical trial proposed in the IND may begin.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Clinical trials involve the administration of an investigational new drug to healthy volunteers or patients under the supervision of a qualified investigator. These trials must be conducted in compliance with federal regulations as well as GCP, an international standard meant to protect the rights and health of patients and to define the roles of clinical trial sponsors, administrators, and monitors. Each trial is conducted under a protocol detailing the objectives of the trial, the parameters to be used in monitoring safety, and the effectiveness criteria to be evaluated. Each protocol involving testing on U.S. patients and subsequent protocol amendments must be submitted to the FDA as part of the IND.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Clinical trials to support NDAs for marketing approval are typically conducted in three sequential phases, but the phases may overlap, especially in certain indications such as cancer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Phase 1</span>&#xa0;- In Phase 1 trials, an investigational new drug is introduced into healthy human subjects and is evaluated to assess pharmacological actions, side effects associated with increasing doses and, in certain cases, early evidence on efficacy.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Phase 2</span>&#xa0;- In Phase 2 trials, the drug is introduced to a limited patient population in a particular indication to determine metabolism, pharmacokinetics, the effectiveness of the drug for the indication, dosage tolerance and optimum dosage, and to identify potential adverse effects and safety risks.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Phase 3</span>&#xa0;- In Phase 3 trials, if a drug has demonstrated evidence of effectiveness and an acceptable safety profile in prior Phase 2 trials, the drug is introduced to a larger patient population in the relevant indication to obtain the additional information about clinical efficacy and safety in a larger number of patients, typically at geographically dispersed clinical trial sites, to permit the FDA to evaluate the overall benefit-risk relationship of the drug, and to provide adequate information for the labeling of the drug, if approved.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Not all drug development programs are required to follow the order and content of all three phases. For example, in August 2018, the FDA released a draft guidance entitled &#x201c;Expansion Cohorts: Use in First-In-Human Clinical Trials to Expedite Development of Oncology Drugs and Biologics,&#x201d; which outlines how drug developers can utilize an adaptive trial design commonly referred to as a seamless trial design in early stages of oncology drug development, i.e., the first-in-human clinical trial, to compress the traditional three phases of trials into one continuous trial called an expansion cohort trial. Information to support the design of individual expansion cohorts is included in IND applications and assessed by FDA. Expansion cohort trials can potentially bring efficiency to drug development and reduce developmental costs and time.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       13
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Post-approval trials, sometimes referred to as Phase 4 clinical trials, may be conducted after initial marketing approval. These trials are used to gain additional experience from the treatment of patients in the intended therapeutic indication and are commonly intended to generate additional safety data regarding use of the product in a clinical setting. In certain instances, the FDA may mandate the performance of Phase 4 clinical trials as a condition of approval of an NDA.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Progress reports detailing the results of the clinical trials, among other information, must be submitted at least annually to the FDA and written IND safety reports must be submitted to the FDA and the investigators 15 calendar days after the trial sponsor determines the information qualifies for reporting for serious and unexpected suspected adverse events, findings from other studies or animal or in vitro testing that suggest a significant risk for human subjects and any clinically important increase in the rate of a serious suspected adverse reaction over that listed in the protocol or investigator brochure. The sponsor also must notify the FDA of any unexpected fatal or life-threatening suspected adverse reaction as soon as possible but in no case later than seven calendar days after the sponsor&#x2019;s initial receipt of the information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Phase 1, Phase 2, Phase 3, and other types of clinical trials may not be completed successfully within any specified period, if at all. The FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the patients are being exposed to an unacceptable health risk.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>New Drug Application and FDA Review Process</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">After completion of the required clinical testing, an NDA is prepared and submitted to the FDA containing data intended to provide substantial evidence that the drug is safe and effective in the relevant indication, and FDA approval of the NDA is required before commercial marketing of the product may begin in the United States. The NDA must include the results of all preclinical, clinical, and other testing and a compilation of data relating to the product&#x2019;s pharmacology, chemistry, manufacturing, and controls. The cost of preparing and submitting an NDA is substantial, and the submission of most NDAs is also subject to substantial initial and ongoing fees.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The FDA has 60 days from its receipt of an NDA to determine whether the NDA will be accepted for filing based on the agency&#x2019;s threshold determination that it is sufficiently complete to permit substantive review. Once the submission is accepted for filing, the FDA begins an in-depth review subject to certain performance goals agreed upon by the FDA. Priority review can be applied in certain instances, including with respect to drugs that the FDA determines offer major advances in treatment or provide a treatment where no adequate therapy exists. The review process, whether standard or priority, may be extended by the FDA for three additional months to consider certain late-submitted information or information intended to clarify information already provided in the submission.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Before approving an NDA, the FDA will typically inspect one or more clinical sites to assure compliance with GCP. Additionally, the FDA will inspect the facility or facilities at which the drug is manufactured to confirm compliance with cGMP. The FDA may also refer applications for novel drug products, or drug products that present difficult questions of safety or efficacy, to an advisory committee. This advisory committee is typically a panel that includes clinicians and other experts in the relevant indication or subject matter who review and evaluate the NDA and provide a recommendation to the FDA as to whether the application should be approved. The FDA is not bound by the recommendation of an advisory committee, but it generally follows such recommendations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">After the FDA evaluates the NDA, the clinical sites, the manufacturing facilities, and, as needed, receives a recommendation from the advisory committee, it issues either an approval letter or a complete response letter. A complete response letter generally outlines the deficiencies in the submission and may require substantial additional testing, or information, in order for the FDA to reconsider the application. The FDA has committed to reviewing such resubmissions in two to six months depending on the type of new information included.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       14
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>FDA Approval Letter</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">An FDA approval letter authorizes commercial marketing of the drug with specific prescribing information for specific indications. Moreover, product approval may require substantial post-approval testing and surveillance to monitor the drug&#x2019;s safety or efficacy including, in certain cases, REMS as described in more detail under the heading &#x201c;&#x2014;<i>Certain Other FDA Regulations </i>&#x2013;<i> Risk Evaluation and Mitigation Strategies</i>.&#x201d; Once granted, product approvals may be withdrawn if compliance with regulatory standards is not maintained or problems are identified following initial marketing.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Further, changes to some of the conditions established in an approved application, including changes in indications, labeling, or manufacturing processes or facilities, require submission and FDA approval of a new NDA or NDA supplement before the change can be implemented. An NDA supplement for a new indication typically requires clinical data similar to that in the original application, and the FDA uses similar procedures and actions in reviewing NDA supplements as it does in reviewing NDAs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>The Hatch-Waxman Amendments</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Drug Price Competition and Patent Term Restoration Act, commonly referred to as the Hatch-Waxman Amendments, is a 1984 U.S. federal law which established the modern system of generic drug regulation in the U.S. The Hatch-Waxman Amendments were enacted to encourage the manufacture of generic drugs by outlining the process for generic pharmaceutical manufacturers to file an abbreviated new drug application and to provide certain related protections to drug development innovators, namely a new kind of market exclusivity period and the ability to potentially extend patent life by a portion of the time a drug is under regulatory review by the FDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Orange Book Listing and Abbreviated New Drug Applications</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In seeking approval for a drug through an NDA, applicants are required to list with the FDA each patent whose claims cover the applicant&#x2019;s product. Upon approval of a drug, each of the patents listed in the application for the drug is then published in the FDA&#x2019;s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly known as the Orange Book. Drugs listed in the Orange Book can, in turn, be cited by potential generic competitors in support of approval of an ANDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An ANDA provides for marketing of a drug product that has the same active ingredients in the same strengths and dosage form as the listed drug and has been shown through bioequivalence testing to be therapeutically equivalent to the listed drug. Other than the requirement for bioequivalence testing, ANDA applicants are not required to conduct, or submit results of, preclinical or clinical tests to prove the safety or effectiveness of their drug product. Drugs approved in this way are commonly referred to as &#x201c;generic equivalents&#x201d; to the listed drug and can often be substituted by pharmacists under prescriptions written for the original listed drug.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An ANDA applicant is required to make certain certifications to the FDA concerning any such patents listed in the Orange Book for the approved reference drug intended to confirm that the proposed generic equivalent will not infringe on any intellectual property related to the reference drug, commonly referred to as a Paragraph IV certification. The ANDA process gives the owner of the reference drug an opportunity to assert a patent infringement claim if it believes its intellectual property rights are being infringed upon following the submission of a Paragraph IV certification.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">An ANDA will not be approved until all patents and non-patent exclusivity periods listed in the Orange Book for the reference drug have expired.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Patent Term Restoration and Marketing Exclusivity</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Certain of our current and future product candidates, including TSC, may be eligible for patent term restoration and marketing exclusivity under the Hatch-Waxman Amendment.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       15
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Hatch-Waxman Amendments permit restoration of the patent term of up to five years as compensation for patent term lost during product development and the FDA regulatory review process. Patent term restoration, however, cannot extend the remaining term of a patent beyond a total of 14 years from the product&#x2019;s approval date. The patent term restoration period is generally 50% of the amount of time between the effective date of an IND and the submission date of an NDA, plus the time between the submission date of an NDA and the approval of that application, except that the review period is reduced by any time during which the applicant failed to exercise due diligence. Only one patent applicable to an approved drug is eligible for such an extension and the application for the extension must be submitted prior to the expiration of the patent. The USPTO, in consultation with the FDA, reviews and approves the application for any patent term extension or restoration.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Marketing exclusivity provisions under the FDC Act can also delay the submission or the approval of certain marketing applications. The FDC Act provides three years of marketing exclusivity for an NDA, or supplement to an existing NDA, if new clinical investigations, other than bioavailability studies, that were conducted or sponsored by the applicant are deemed by the FDA to be essential to the approval of the application, for example investigations related to new indications, dosages, or strengths of an existing drug. This three-year exclusivity covers only the modification for which the drug received approval on the basis of the new clinical investigations and does not prohibit the FDA from approving ANDAs for drugs containing the active agent for the original indication or condition of use. The FDC Act also provides a five-year period of non-patent marketing exclusivity within the United States to the first applicant to obtain approval of an NDA for a new chemical entity, meaning the FDA has not previously approved any other new drug containing the same active moiety, which is the molecule or ion responsible for the action of the drug substance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the exclusivity period, the FDA may not accept for review an ANDA or a 505(b)(2) NDA submitted by another company for another drug based on the same active moiety, regardless of whether the drug is intended for the same indication as the original innovator drug or for another indication, where the applicant does not own or have a legal right of reference to all the data required for approval. However, an application may be submitted after four years if it contains a certification of patent invalidity or non-infringement to one of the patents listed with the FDA by the innovator NDA holder. Three-year and five-year exclusivity will not delay the submission or approval of a full NDA. However, an applicant submitting a full NDA would be required to conduct or obtain a right of reference to all of the nonclinical studies and adequate and well-controlled clinical trials necessary to demonstrate safety and efficacy.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Certain Other FDA Regulations</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>The Orphan Drug Act of 1983</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Under the Orphan Drug Act, the FDA may grant orphan designation to a drug product intended to treat a rare disease or condition, which is generally a disease or condition that affects fewer than 200,000 individuals in the United States, or more than 200,000 individuals in the United States and for which there is no reasonable expectation that the cost of developing and making the product available in the United States for this type of disease or condition will be recovered from sales of the product. Our lead product candidate, TSC, has been granted Orphan Drug designations by the FDA for the treatment of both GBM and metastatic brain cancer.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Orphan drug designation must be requested before submitting an NDA. After the FDA grants orphan drug designation, the identity of the therapeutic agent and its potential orphan use are disclosed publicly by the FDA. For example, we previously announced that TSC was granted orphan drug designation by the FDA for the treatment of GBM and metastatic brain cancer in July 2011 and in December 2012, respectively. However, orphan drug designation on its own does not convey any advantage in or shorten the duration of the regulatory review and approval process but may result in certain financial and marketing incentives if approved.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       16
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If a product that has orphan designation subsequently receives the first FDA approval for the disease or condition for which it has such designation, the product is entitled to orphan drug exclusivity, which means that the FDA may not approve any other applications to market the same drug for the same indication for seven years from the date of such approval, except in limited circumstances, such as a showing of clinical superiority to the product with orphan exclusivity by means of greater effectiveness, greater safety, or providing a major contribution to patient care, or in instances of drug supply issues. Competitors, however, may receive approval of either a different product for the same indication or the same product for a different indication. In the latter case, because health care professionals are free to prescribe products for off-label uses, the competitor&#x2019;s product could be used for the orphan indication despite our orphan exclusivity. Orphan drug exclusivity could also block the approval of one of our products for seven years if a competitor obtains approval before we do for the same drug and same indication, as defined by the FDA, for which we are seeking approval, or if our product is determined to be contained within the scope of the competitor&#x2019;s product for the same indication or disease. If we pursue marketing approval for an indication broader than the orphan drug designation we have received, we may not be entitled to orphan drug exclusivity. Orphan drug status in the E.U. has similar, but not identical, requirements and benefits.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Expedited Development and Review Programs</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The FDA has a fast track program that is intended to expedite or facilitate the process for reviewing new drugs that meet certain criteria. Specifically, new drugs are eligible for fast track designation if they are intended to treat a serious or life-threatening condition and preclinical or clinical data demonstrate the potential to address unmet medical needs for the condition. Fast track designation applies to both the product and the specific indication for which it is being studied. The sponsor can request the FDA to designate the product for fast track status any time before receiving NDA approval, but ideally no later than the pre-NDA meeting. Any product submitted to the FDA for marketing, including under a fast track program, may be eligible for other types of FDA programs intended to expedite development and review, such as priority review and accelerated approval. Any product is eligible for priority review if it treats a serious or life-threatening condition and, if approved, would provide a significant improvement in safety and effectiveness compared to available therapies. The FDA will attempt to direct additional resources to the evaluation of an application for a new drug designated for priority review in an effort to facilitate the review.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A product may also be eligible for accelerated approval, if it treats a serious or life-threatening condition and generally provides a meaningful advantage over available therapies. In addition, it must demonstrate an effect on a surrogate endpoint that is reasonably likely to predict clinical benefit or on a clinical endpoint that can be measured earlier than IMM that is reasonably likely to predict an effect on IMM or other clinical benefit. As a condition of approval, the FDA may require that a sponsor of a drug receiving accelerated approval perform adequate and well-controlled post-marketing clinical trials. If the FDA concludes that a drug shown to be effective can be safely used only if distribution or use is restricted, it will require such post-marketing restrictions, as it deems necessary to assure safe use of the product. If the FDA determines that the conditions of approval are not being met, the FDA can withdraw its accelerated approval for such drug.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Additionally, a drug may be eligible for designation as a breakthrough therapy if the product is intended, alone or in combination with one or more other drugs, to treat a serious or life-threatening condition and preliminary clinical evidence indicates that the product may demonstrate substantial improvement over currently approved therapies on one or more clinically significant endpoints. The benefits of breakthrough therapy designation include the same benefits as fast track designation, plus intensive guidance from the FDA to ensure an efficient drug development program.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Even if a product qualifies for one or more of these programs, the FDA may later decide that the product no longer meets the conditions for qualification or the time period for FDA review or approval may not be shortened. Furthermore, fast track designation, priority review, accelerated approval, and breakthrough therapy designation do not change the standards for approval, but may expedite the development or approval process.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       17
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Rare Pediatric Disease Priority Review Voucher Program</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In 2012, Congress authorized the FDA to award priority review vouchers to sponsors of certain rare pediatric disease product applications. This program is designed to encourage development of new drug and biological products for prevention and treatment of certain rare pediatric diseases. Specifically, under this program, a sponsor who receives an approval for a drug or biologic for a &#x201c;rare pediatric disease&#x201d; may qualify for a voucher that can be redeemed to receive a priority review of a subsequent marketing application for a different product. The sponsor of a rare pediatric disease drug product receiving a priority review voucher may transfer (including by sale) the voucher to another sponsor. The voucher may be further transferred any number of times before the voucher is used, as long as the sponsor making the transfer has not yet submitted the application. The FDA may also revoke any priority review voucher if the rare pediatric disease drug for which the voucher was awarded is not marketed in the U.S. within one year following the date of approval.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For purposes of this program, a &#x201c;rare pediatric disease&#x201d; is a (a) serious or life-threatening disease in which the serious or life-threatening manifestations primarily affect individuals aged from birth to 18 years, including age groups often called neonates, infants, children, and adolescents; and (b) a rare disease&#xa0;or condition&#xa0;within the meaning of the Orphan Drug Act. On December 27, 2020, the Rare Pediatric Disease Priority Review Voucher Program was extended. Under the current statutory sunset provisions, after September 30, 2024, FDA may only award a voucher for an approved rare pediatric disease product application if the sponsor has rare pediatric disease designation for the drug, and that designation was granted by September 30, 2024. After September 30, 2026, FDA may not award any Rare Pediatric Disease Priority Review Voucher.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Disclosure of Clinical Trial Information</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Sponsors of clinical trials of FDA-regulated products are required to register and disclose to the public certain clinical trial information, including information related to the product, patient population, phase of investigation, study sites, investigators, and other aspects of the trial design. Sponsors are also obligated to discuss the results of their clinical trials after completion. However, disclosure of the results of these trials can be delayed until the new product or new indication being studied has been approved as competitors may otherwise use this or other publicly-available information to gain knowledge regarding the progress of development programs and gain a competitive advantage.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Risk Evaluation and Mitigation Strategies and Other Post-Approval Requirements</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a condition of NDA approval, the FDA may require a REMS to help ensure that the benefits of the drug&#x2019;s continued approval outweigh the potential risks. In determining whether a REMS is necessary, the FDA must consider the size of the population likely to use the drug, the seriousness of the disease or condition to be treated, the expected benefit of the drug, the duration of treatment, the seriousness of known or potential adverse events, and whether the drug is a new molecular entity. If the FDA determines a REMS is necessary, the drug sponsor must agree to the REMS plan at the time of approval. REMS can include medication guides, communication plans for healthcare professionals, and elements to assure safe use. Elements to assure safe use can include, but are not limited to, special training or certification for prescribing or dispensing, dispensing only under certain circumstances, special monitoring requirements, and the use of patient registries. The requirement for a REMS can materially affect the potential market and profitability of a drug product.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Even if the FDA does not require a REMS, once an NDA is approved, a product will be subject to certain post-approval regulations. For instance, the FDA closely regulates the post-approval marketing and promotion of drugs, including standards and regulations for direct-to-consumer advertising, off-label promotion, industry-sponsored scientific and educational activities, and promotional activities involving the internet. Adverse event reporting and the submission of periodic reports are also required following FDA approval of an NDA.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       18
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Drug Approval Process and Other Regulations Outside of the U.S.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition to regulations in the U.S., we are and will be subject to the regulations of other countries in which we conduct any of our clinical trials or engage in commercial sales or other distribution of our products, if approved. Whether or not we obtain FDA approval for conduct of a clinical trial or distribution of a product, we must obtain approval from the competent regulatory authority of any country or economic area in which we would seek to commence a clinical trial or market products. For example, conduct of the COVID Trial in Bucharest, Romania, required certain approvals from regulatory authorities in Romania and the E.U. Certain countries outside of the United States have a process similar to the FDA&#x2019;s IND process which requires the submission of a CTA prior to the commencement of human clinical trials. In the E.U., for example, a CTA must be submitted to each country&#x2019;s national health authority and an independent ethics committee, which operates similar to an IRB under U.S. regulations. Once the CTA is approved in accordance with a country&#x2019;s requirements, the clinical trial may proceed in the applicable country. The approval process and requirements governing the conduct of clinical trials, product licensing, pricing, and reimbursement vary greatly from place to place, and the time may be longer or shorter than that required for FDA approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In particular, in the E.U. a company may submit marketing authorization applications (comparable to an NDA submission in the US to the FDA) under either a centralized or decentralized procedure. The centralized procedure, which is compulsory for medicines produced by biotechnology or those medicines intended to treat AIDS, cancer, neurodegenerative disorders, or diabetes and is optional for medicines which are highly innovative, provides for the grant of a single marketing authorization that is valid for all E.U. member states. The decentralized procedure provides for mutual recognition of national approval decisions. Under this decentralized procedure, the holder of a national marketing authorization in any E.U. member state may submit an application to the remaining member states. Within ninety days of receiving the applications and assessments report, each member state must decide whether to recognize approval. If a member state does not recognize the marketing authorization, the disputed points are eventually referred to the European Commission, whose decision is binding on all member states. The E.U. also has procedures similar to those of the FDA pursuant to which a company may obtain marketing exclusivity for a product for up to 11 years and/or orphan drug designation and related exclusivity for up to ten years, as well as other expedited approval pathways available to certain drugs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">In addition, in some non-U.S. jurisdictions, the proposed pricing for a product candidate must be approved before it may be lawfully marketed. The requirements governing drug pricing vary widely from country to country. For example, the E.U. provides options for its member states to restrict the range of medicinal products for which their national health insurance systems provide reimbursement and to control the prices of medicinal products for human use. A member state may approve a specific price for the medicinal product or it may instead adopt a system of direct or indirect controls on the profitability of the company placing the medicinal product on the market. There can be no assurance that any country that has price controls or reimbursement limitations for pharmaceutical products will allow favorable reimbursement and pricing arrangements for any of our product candidates. Historically, product candidates launched in the E.U. do not follow price structures of the U.S. and generally tend to be significantly lower.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Certain Other Legislation and Regulations</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Current Healthcare Laws and Regulations</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Healthcare providers, physicians, and third party payors, including governmental payors such as Medicare and Medicaid, will play a significant role in the recommendation and prescription of any products for which we obtain marketing approval. Our future arrangements with third party payors, healthcare providers, and physicians may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations that may constrain the business or financial arrangements and relationships through which we market, sell, and distribute any drugs for which we obtain marketing approval.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">These laws include, without limitation, state and federal anti-kickback, false claims, physician transparency, and patient data privacy and security laws and regulations, and other federal, state, and local regulations and legislation impacting the pharmaceutical and biopharmaceutical industries, including but not limited to those described below.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Health Insurance Portability and Accountability Act</span>&#xa0;- HIPAA imposes criminal and civil liability for, among other things, knowingly and willfully executing a scheme, or attempting to execute a scheme, to defraud any healthcare benefit program, including private payors, or falsifying, concealing, or covering up a material fact or making any materially false statements in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it in order to have committed a violation. HIPAA, as amended by HITECH and their respective implementing regulations, imposes, among other things, specified requirements on covered entities and their business associates relating to the privacy and security of individually identifiable health information, including mandatory contractual terms and required implementation of technical safeguards of such information. HITECH also created new tiers of civil monetary penalties, amended HIPAA to make civil and criminal penalties directly applicable to business associates, and gave state Attorneys General new authority to file civil actions for damages or injunctions in federal courts to enforce the federal HIPAA laws and seek attorneys&#x2019;&#xa0;fees and costs associated with pursuing federal civil actions.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       19
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Affordable Care Act</span>&#xa0;- The ACA was enacted in March 2010 and included measures intended to significantly change the way healthcare is financed in the U.S. by both governmental and private insurers which have and may continue to impact the pharmaceutical and biopharmaceutical industries, including expanded Medicare and Medicaid benefits, expansion of healthcare fraud and abuse laws, establishment of the CMS, annual reporting requirements for manufacturers and distributors. Since its enactment, there have been numerous judicial, administrative, executive, and legislative challenges to certain aspects of the Affordable Care Act, and we expect there will be additional challenges and amendments to the ACA in the future. In addition, subsequent legislation, including the Budget Control Act of 2011, American Taxpayer Relief Act of 2012, and Coronavirus Aid, Relief, and Economic Security Act of 2020, has limited and supplemented various provisions of the Affordable Care Act. While we cannot predict what effect further changes to the Affordable Care Act would have on our business, the Affordable Care Act is likely to continue to impact the regulatory regime to which we are subject for the foreseeable future, and we cannot predict the ultimate content, timing, or effect of any healthcare reform legislation or the impact of potential legislation on us.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">21st Century Cures Act</span>&#xa0;- The 21st Century Cures Act, which the U.S. House of Representatives passed in July 2015 and President Obama signed into law in December 2016, provides for a wide range of reforms that may impact our business, such as broadening the types of data required to support drug approval, extending protections from genetic competition, accelerating approval of breakthrough therapies, expanding the orphan drug product and compassionate use programs, and clarifying how manufacturers communicate about their products.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Anti-Kickback Laws</span>&#xa0;- The federal Anti-Kickback Statute makes it illegal for any person, including a prescription drug manufacturer (or a party acting on its behalf), to knowingly and willfully solicit, receive, offer, or pay any remuneration, directly or indirectly, in cash or in kind, that is intended to induce or reward referrals, including the purchase, recommendation, order or prescription of a particular drug or any other good or service, for which payment may be made under a federal healthcare program, such as Medicare or Medicaid. Violations of this law are punishable by up to five years in prison, criminal fines, administrative civil money penalties, and exclusion from participation in federal healthcare programs. In addition, a person or entity does not need to have actual knowledge of the statute or specific intent to violate it.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">False Claims Laws</span>&#xa0;- The federal False Claims Act imposes civil penalties, including through civil whistleblower or qui tam actions, against individuals or entities (including manufacturers) for, among other things, knowingly presenting, or causing to be presented, false or fraudulent claims for payment by a federal healthcare program or making a false statement or record material to payment of a false claim or avoiding, decreasing, or concealing an obligation to pay money to the federal government. The government may deem manufacturers to have &#x201c;caused&#x201d;&#xa0;the submission of false or fraudulent claims by, for example, providing inaccurate billing or coding information to customers or promoting a product off-label.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">Medicare Prescription Drug, Improvement, and Modernization Act</span>&#xa0;- The Medicare Prescription Drug, Improvement, and Modernization Act of 2003 imposes requirements on the distribution and pricing of prescription drugs for Medicare beneficiaries. Under Part D, Medicare beneficiaries may enroll in prescription drug plans offered by private entities which will provide coverage of outpatient prescription drugs. Part D plans include both stand-alone prescription drug benefit plans and prescription drug coverage as a supplement to Medicare Advantage plans, but plan sponsors are not required to pay for all covered Part D drugs, and each drug plan can develop its own drug formulary that identifies which drugs it will cover and at what tier or level. However, Part D prescription drug formularies must include drugs within each therapeutic category and class of covered Part D drugs, though not necessarily all the drugs in each category or class. Any reduction in payment that results from the these or similar regulations may result in a similar reduction in payments from non-governmental payors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       20
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">The Physician Payments Sunshine Act</span>&#xa0;- The Sunshine Act, enacted as part of the Affordable Care Act,, imposed new annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under Medicare, Medicaid, or the Children&#x2019;s Health Insurance Program, for certain payments and &#x201c;transfers of value&#x201d;&#xa0;provided to physicians (defined to include doctors, dentists, optometrists, podiatrists and chiropractors) and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Effective January 1, 2022, these reporting obligations will extend to include transfers of value made to certain non-physician providers such as physician assistants and nurse practitioners.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><span style="text-decoration: underline; ">State, Local, and Non-U.S. Legislation and Regulations</span>&#xa0;- In addition, to the legislation summarized above, we may also be subject now or in the future to analogous state, local, and non-U.S. laws and regulations, such as state anti-kickback and false claims laws, which may be broader in scope and apply regardless of payor. Such laws are enforced by various state agencies and through private actions. For example, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#x2019;s voluntary compliance guidelines and the relevant federal government compliance guidance, require drug manufacturers to report information related to payments and other transfers of value to physicians and other healthcare providers, and restrict marketing practices or require disclosure of marketing expenditures. Certain state and foreign laws also govern the privacy and security of health information in some circumstances and these data privacy and security laws may differ from both HIPAA and each other in significant ways, which would potentially increase our compliance burden.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions, and settlements in the healthcare industry. If our operations are found to be in violation of any of these laws or any other related governmental regulations that may apply to us, we may be subject to significant civil, criminal, and administrative penalties, damages, fines, imprisonment, disgorgement, exclusion of drugs from government funded healthcare programs, such as Medicare and Medicaid, reputational harm, additional oversight, and reporting obligations if we become subject to a corporate integrity agreement or similar settlement to resolve allegations of non-compliance with these laws and the curtailment or restructuring of our operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Future Healthcare Laws and Regulations</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the United States and foreign jurisdictions, there have been a number of proposed changes regarding the healthcare system and its regulation that could prevent or delay marketing approval of our product candidates, restrict or regulate post-approval activities, and affect our ability to profitably sell any product candidates for which we obtain marketing approval. We expect that further implementation of current laws, as well as other healthcare reform measures that may be adopted in the future, may result in more rigorous coverage criteria and in additional downward pressure on the price that we, or any strategic collaborators, may receive for any approved products. Further, there has recently been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which have resulted in several recent Congressional inquiries and proposed bills designed to, among other things, bring more transparency to product pricing, review the relationship between pricing and manufacturer patient programs, and reform government program reimbursement methodologies for products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>U.S. Environmental, Health, and Safety Laws</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are subject to numerous environmental, health, and safety laws and regulations. From time to time and in the future, our operations may involve the use of hazardous and flammable materials, including chemicals and biological materials, and may also produce hazardous waste products. Even if we contract with third parties for the disposal of these materials and waste products, we cannot completely eliminate the risk of contamination or injury resulting from these materials. In the event of contamination or injury resulting from the use or disposal of our hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties for failure to comply with such laws and regulations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       21
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">In addition, we may incur substantial costs in order to comply with current or future environmental, health, and safety laws and regulations. Current or future environmental laws and regulations may impair our research, development or production efforts. In addition, failure to comply with these laws and regulations may result in substantial fines, penalties or other sanctions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Public Company Status</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a public company, we incur significant legal, accounting and other expenses to comply with the reporting requirements of the Exchange Act and applicable requirements of SOX and the Dodd-Frank Act, as well as rules and regulations subsequently implemented by the SEC and Nasdaq, including the establishment and maintenance of effective disclosure and financial controls, changes in corporate governance practices and required filing of annual, quarterly and current reports with respect to our business and operating results. These requirements increase our legal and financial compliance costs and make some activities more time-consuming and costly. In addition, our management and other personnel devote significant time and attention to these public company requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our People and Human Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of December 31, 2021, we had 16 full-time employees, up from 12 employees as of December 31, 2020. We also regularly work with several independent consultants and other contract organizations to support our business and we regularly evaluate additional talent to help support our product manufacturing, development, financial, and other capabilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Diversity and Inclusion</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe that an inclusive culture is required to understand and develop products that benefit all patients. By embracing differences, we aim to foster an environment of respect and trust in an effort to facilitate creativity, spark passion, and help us achieve better outcomes for all those who work at and with Diffusion. We are committed to creating and maintaining a workplace free from discrimination or harassment, including on the basis of any class protected by applicable law, and our recruitment, hiring, development, training, compensation, and advancement practices are based on qualifications, performance, skills, and experience without regard to gender, race, or ethnicity. Our management team and employees are expected to exhibit and promote honest, ethical, and respectful conduct in the workplace, including adhering to the standards for appropriate behavior set forth in our code of conduct.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Compensation and Benefits</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We operate in a highly competitive environment for human capital, particularly as we seek to attract and retain talent with relevant experience in the biotechnology and pharmaceutical sectors. Therefore, we strive to provide a total rewards package to our employees that is competitive with our peer companies, including competitive pay, a comprehensive healthcare benefits package (including an 80% employer contribution to family medical coverage), 25 days of paid leave, a company-sponsored 401(k) savings plan, short-term and long-term disability, and other benefits, as well as remote working and flexible work schedules. We also offer every full-time employee the benefit of equity ownership in Diffusion through stock option grants. We believe these grants both help promote alignment between our employees and our stockholders and provide retention benefits, as the awards generally vest over a three-year period.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">We do not have any employees that are represented by a labor union or that have entered into a collective bargaining agreement with the Company.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       22
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Safety and Wellness</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">At Diffusion, we believe that health matters to everyone, and the safety health, and wellness of our employees is one of our top priorities. We are committed to developing and fostering a work environment that is safe, professional, and promotes teamwork, diversity, and trust in order to afford all of our employees the opportunity to contribute to the best of their abilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Over the past two years, in response to the COVID-19 pandemic, we have taken certain measures and responded to changes in our operational needs, including actions designed to provide a safe work environment for our employees. These actions included investing in technology solutions to support increased work-from-home capabilities, shifting work schedules to reduce the number of people present in our offices, requiring mask wearing and social distancing, making hand sanitizer readily available, and other measures intended to comply with health and safety protocols as required by federal, state, and local governmental agencies, as well as guidance from the U.S. Centers for Disease Control and Prevention and similar public health authorities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Employee Development and Training</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We believe our people are among our most important assets. We focus on attracting, retaining, and cultivating talented individuals and believe in investing in our people to help them grow. Employees are encouraged to attend scientific, clinical, technological, and other relevant meetings and conferences and we strive to provide employees access to a broad set of internal resources intended to help them be successful, including a variety of training and educational materials. During 2021, we intend to implement a new, comprehensive employee evaluation program tied to the achievement of individual, team, and company goals to help further support, retain, and develop our people and further promote alignment of interests between our employees, future target customers, and our stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><i>Directors and Executive Officers</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;">The information set forth in "<i>Part III </i>&#x2014;<i> Item 10 </i>&#x2014;<i> Directors, Officers, and Corporate Governance</i>," of this Annual Report is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Other Information About Our Company</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Corporate Information and History</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We were originally incorporated under the laws of the State of Nevada on January 10, 1995 and reincorporated under the laws of the State of Delaware on June 18, 2015 under the name, &#x201c;RestorGenex Corporation.&#x201d; On January 8, 2016, we completed the merger of our wholly owned subsidiary with and into Diffusion LLC, which was treated as a "reverse acquisition" under GAAP pursuant to which Diffusion LLC's historical results of operations replaced the Company's for all periods prior to the merger. Immediately following the closing of the merger, we changed our name from "RestorGenex Corporation" to "Diffusion Pharmaceuticals Inc."</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">On May 6, 2021, we received a written notice from the Nasdaq Staff indicating that we were not in compliance with the Bid Price Rule because the bid price for our common stock had closed below $1.00 per share for the previous 30 consecutive business days. On November 3, 2021, after failing to regain compliance with the Bid Price Rule within 180 days of our receipt of the first notice, we received an additional notice from the Staff providing that, although the Company had not regained compliance with the Bid Price Rule by the previously stated deadline, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company would be granted an additional 180 calendar days, or until May 2, 2022, to regain compliance with the Bid Price Rule. As part of our efforts to regain compliance with the Bid Price Rule, on February 28, 2022, we filed a definitive proxy statement related to a special meeting of our stockholders scheduled for Thursday, April 14, 2022 at which our stockholders will vote upon proposal, approved and recommended for stockholder approval by the Board, to amend our Certificate of Incorporation to effect a reverse stock split of our outstanding shares of common stock by a ratio of any whole number between 1-for-2 and 1-for-50 at any time prior to December 31, 2022, the timing and implementation of which will be subject to the discretion of the Board. To regain compliance, the bid price for the Company&#x2019;s common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       23
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our principal corporate office is located at 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, and our telephone number is (434) 220-0718. Our website, www.diffusionpharma.com, including the Investor Relations section, investors.diffusionpharma.com, and our social media channels &#x2013; Facebook (www.facebook.com/diffusionpharmaceuticalsinc/), Twitter (www.twitter.com/diffusionpharma) and LinkedIn (https://www.linkedin.com/company/diffusion-pharmaceuticals/) -- contain a significant amount of information about the Company. We encourage investors to visit these websites and social media channels as information is frequently updated and new information is shared. However, the information included on our website and available through our social media channels is not incorporated by reference into, and should not be considered part of, this Annual Report or any other filings we make with the SEC.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Available Information</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We make available on or through our website certain reports that we file with or furnish to the SEC in accordance with Exchange Act. These include our Annual Reports on Form 10-K, our Quarterly Reports on Form 10-Q, and our Current Reports on Form 8-K, as well as any amendments to those reports, filed or furnished pursuant to Section 13(a) or 15(d) of the Exchange Act. We make this information available free of charge as soon as reasonably practicable after we electronically file the information with, or furnish it to, the SEC. The SEC also maintains a website, www.sec.gov, that contains reports, proxy and information statements, and other information regarding the Company and other issuers that file electronically with the SEC. We also make available, free of charge and through our website, the charters of the committees of the Board, our Corporate Governance Guidelines, and our Code of Business Conduct and Ethics.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       24
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1A.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>RISK FACTORS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Investing in our common stock involves a high degree of risk. Set forth below are certain material risks and uncertainties known to us that could adversely affect our business, financial condition, or results of operations or could cause our actual results to differ materially from our expectations expressed elsewhere in this Annual Report. The occurrence of the events contemplated by one or more of the factors we describe below could cause the market price of our common stock to decline, resulting in the loss of all or part of any investment in our common stock. Furthermore, other risks that are currently unknown to us or that we currently believe to be immaterial may also, nevertheless, adversely affect our business, financial condition, or results of operations in a way that is material.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Before investing in our common stock, you should carefully consider these risks and uncertainties, together with all other information in this Annual Report, including our consolidated financial statements and related notes, the information included in, <i>Part II </i>&#x2014;<i> Item 7 </i>&#x2014;<i> Management</i>&#x2019;<i>s Discussion and Analysis of Financial Condition and Results of Operations,</i> and the information incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to the Development, Regulatory Approval, and Commercialization of TSC and Our Other Product Candidates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>The success of Diffusion is dependent on the successful development, regulatory approval, and, ultimately, commercialization of TSC and our other product candidates. However, the drug development process is expensive, time-consuming and uncertain. Our efforts to develop, obtain regulatory approval for, and commercialize TSC or any other product candidate could fail at any stage of the development process for a variety of reasons, including the possibility that TSC fails to adequately demonstrate efficacy or proof of concept in the Oxygenation Trials. Furthermore, because the results of preclinical studies and early-stage clinical trials are not necessarily predictive of future results, even if we are able to advance TSC or another product candidate into additional clinical trials </i></b>&#x2013;<b><i> for example, beyond our Planned Phase 2 Hypoxic Solid Tumor Trial </i></b>&#x2013;<b><i> we may not continue to experience favorable results.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The success of Diffusion, including our ability to finance our operations and generate revenue in the future, will depend primarily on the successful development, regulatory approval, and, ultimately, commercialization of our product candidates. Currently, the majority of our product development resources are dedicated to our lead product candidate, TSC. In the future, we may also seek to develop or commercialize additional product candidates, including product candidates that we may in-license or acquire to supplement our internally developed portfolio.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The drug development process is very expensive, time-consuming, difficult to design and implement, and its outcome is inherently uncertain. Most product candidates that commence clinical trials are never approved by regulatory authorities for commercialization and success in early-stage clinical trials does not ensure that later clinical trials will demonstrate the efficacy and safety of an investigational drug in a manner adequate to support regulatory approval. Countless other companies, including many with greater resources and experience, have failed or suffered significant setbacks attempting to navigate the drug development process, including failed attempts to develop treatments for hypoxia and indications on the hypoxia-continuum that we may ultimately choose to target with TSC, and there can be no assurance that we will have success where others have failed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our product candidates, including TSC, remain in early stages of the development process and we expect that the additional clinical trials necessary to support an NDA will take several years to complete. We do not know whether the clinical trials we may conduct will demonstrate adequate efficacy and safety or otherwise provide adequate information to result in regulatory approval to market any of our product candidates in any particular jurisdiction. Furthermore, the timeline for our clinical trials may be delayed in the future for a variety of reasons, including delays related to regulatory and IRB review and approval, slower than anticipated rates of enrollment in or early withdrawals from the trial, third party performance issues beyond our control including any CRO engaged in the conduct of the trial, discovery of series or unexpected toxicities or side effects, or a lack of effectiveness.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       25
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Whether we are able to successfully develop TSC or any of our other product candidates will depend on a large number of factors, including the following:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to complete our planned and future clinical trials in a timely manner and, with respect to any future trials beyond the ongoing Oxygenation Trials and our Planned Phase 2 Hypoxic Solid Tumor Trial, our ability to fund such trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to demonstrate safety and efficacy to the satisfaction of the FDA and similar foreign regulatory authorities, and whether we are required by any such body to conduct additional clinical trials to support approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the receipt of necessary regulatory approvals, including acceptance of our proposed indications and primary endpoint assessments, marketing approvals, and labeling claims;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a continued acceptable safety profile during development and following approval, including the prevalence, duration and severity of potential side effects experienced; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ability to commercialize successfully, including scaling our manufacturing capabilities, the development of sales and marketing capabilities internally or through a third party, acceptance by physicians and patients of the benefits, safety and efficacy of our treatments.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any of these factors, many of which are beyond our control, could result in significant delays or an inability to develop, obtain regulatory approvals for, or commercialize our product candidates, and we may ultimately be able to receive regulatory approval or generate revenue from the sale of TSC or any other product candidate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">A number of companies in the pharmaceutical and biopharmaceutical industry have suffered significant setbacks in later-stage Phase 3 clinical development even after promising results in earlier preclinical studies or clinical trials. If later-stage clinical trials do not produce favorable results for TSC or any other product candidate, or we are unable to complete the necessary clinical trials for any reason (including a lack of funding), our ability to achieve regulatory approval or successfully commercialize may be compromised. At any time, we may decide or be forced by circumstance to delay or discontinue the development or commercialization of TSC or any of our other product candidates, including as a result of unfavorable results in later-stage clinical trials, changes in our internal product, technology or indication focus, the appearance of new technologies that make our product candidate obsolete, competition from a competing product, or changes in (or failure to comply with) applicable regulatory requirements. If we decide or are forced to terminate the TSC development program or any future program in which we have invested significant resources, we will not receive any return on our investment despite the allocation of significant resources, we may not be able to execute on our business plan effectively, and our business, financial condition, results of operations may be materially and adversely affected.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Even if we are able to successfully complete the clinical trials and over development activities necessary to submit an NDA to the FDA or an application for marketing approval to an equivalent non-U.S. regulatory authority, we may be unable to obtain regulatory approval for TSC or any other product candidates we may attempt to develop in future, for the indications for which we initially seek approval or at all. The FDA and similar non-U.S. regulatory authorities have significant discretion in the approval process, including the ability to delay, limit, or deny approval of product candidates. The delay, limitation, or denial of regulatory approval for any of our product candidates, and TSC in particular, would limit or restrict altogether our ability to commercialize the product and generate revenue, which could materially and adversely impact our business, financial condition, and results of operations.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We currently have no products approved for sale, and we may never obtain regulatory approval to commercialize TSC or any other product candidates we may attempt to develop in the future. The research, testing, manufacturing, safety surveillance, efficacy, quality control, recordkeeping, labeling, packaging, storage, approval, sale, marketing, distribution, import, export, and reporting of safety and other post-market information related to drug products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and abroad, which often differ from country to country. We will not be permitted to market TSC or any of our other current product candidates in the U.S. until we receive approval of an NDA or other applicable regulatory filing from the FDA, and we will not be permitted to market TSC or any of our other current product candidates in any non-U.S. countries until we receive the requisite approval from the applicable regulatory authorities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       26
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To gain approval to market a new drug, such as TSC, the FDA and similar non-U.S. regulatory authorities require the submission of an NDA (or similar application) that contains preclinical and clinical data adequately demonstrating the safety, purity, potency, efficacy, and compliant manufacturing of the product for the intended indication. The FDA and their non-U.S. counterparts have substantial discretion in the drug approval process, including the ability to delay, limit, or deny approval of applications for many reasons, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">deemed issues with the design or execution of one or more clinical trials;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">deemed deficiencies in the formulation, quality control, labeling, or specifications of the product candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">deemed issues in our manufacturing processes or in the controls or facilities of third-party manufacturers or testing labs with which we contract;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that the data from preclinical studies and clinical trials included in the application is not sufficient to support approval, or do not meet a required level of statistical or clinical significance, including as a result of a differing interpretation of the data than that presented by the Company in our application;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that the perceived risks of approving the product candidate outweigh the clinical and other benefits of approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that additional preclinical studies or clinical trials are required, either prior to or as a contingency to approval, and, for certain target indications such as pediatric populations, in the targeted sub-population;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that a product candidate may only be approved on a contingent basis or for a more limited indication or patient population than we request;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">a determination that labeling we believe is necessary or desirable for successful commercialization cannot be approved; or</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">unanticipated future changes to the approval process and related regulations.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Historically, of the large number of drugs in development at any given time, only a small percentage successfully complete the regulatory approval processes and are ultimately commercialized. Our product candidates may not be approved for sale and marketing by the FDA or any other governmental authority, even if they meet specified endpoints in our clinical trials. The FDA or applicable foreign regulatory agencies may ask us to conduct additional costly and time-consuming clinical trials in order to obtain marketing approval or approval to enter into a further phase of clinical development, or may change the requirements for approval even after such agency has reviewed and commented on the design for the clinical trials.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any delay in obtaining, or inability to obtain, the regulatory approvals necessary to market and sell our product candidates would delay or prevent commercialization and would materially and adversely affect our business, financial condition, and result of operations. Furthermore, if we determine in the future that the development, approval, or commercial prospects of any product candidate are insufficient to justify our continued expenditure of the associated development and other costs, we may choose to delay, suspend, or abandon our development or commercialization efforts with respect thereto, which would reduce or eliminate our potential return on investment for those product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our ability to develop our product candidates depends, and, if TSC or any of our other product candidates are approved, our ability to successfully commercialize our products will depend, in part on our ability to successfully obtain sufficient quantities of the necessary APIs, other component substances and materials, and finished drug product for our product candidates. We are currently entirely dependent on third parties for the manufacture and supply of our product candidates and their component parts, including, with respect to TSC, a sole supplier. We may be unable to continue to develop or commercialize our product candidates or face significant delays in that process if we are unable to successfully obtain these materials or manufacture drug product in sufficient quantities.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Maintaining an adequate supply of TSC and our other product candidates to meet our needs is critical to the success of our business. However, manufacturing and supply of APIs, other substances and materials and finished drug products is a complex and technically challenging process, and changes beyond our direct control can impact the quality, volume, price, and successful delivery of our product candidates or impede, delay, limit or prevent the successful development and commercialization of our product candidates. Mistakes and mishandling are not uncommon in the biopharmaceutical and pharmaceutical industry and can affect successful production and supply significantly.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       27
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of the date of this Annual Report, we have no internal manufacturing capabilities and therefore we do not have direct control over our ability to maintain drug supply sufficient to serve our needs for our ongoing and planned clinical trials or, if any of our product candidates are approved, commercialization. Although we are ultimately responsible for ensuring compliance with regulatory requirements such as cGMPs, we are dependent on our third party CMOs and other contract suppliers and manufacturers for the manufacture of our drug product, including both APIs and finished products, as well as day-to-day compliance with cGMPs and certain other manufacturing-related regulatory requirements. Facilities used by our contract suppliers and manufacturers to produce the APIs and other substances and materials or finished products for commercial sale must pass inspection, provide regulators with certain technical information, and be approved by the FDA and other relevant regulatory authorities to confirm compliance with cGMP requirements and other regulatory requirements. If the safety of TSC or any of our other product candidates (or any component thereof) is found in the future to be compromised, we may not be able to successfully commercialize or obtain regulatory approval for the product candidate, and we may be held liable for injuries sustained as a result.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any disruption in our relationship with these third parties or their ability to manufacture the APIs and finished drug product we need for our clinical trials and other development activities could result in significant delays in our anticipated development timelines and/or significant additional supply costs. Such a disruption could be the result of any number of reasons, including contractual disputes with our partners, regulatory issues with our partners or at their facilities (whether or not related to Diffusion or our drug product), financial issues faced by our partners (including bankruptcy or insolvency), damages to our partners&#x2019; facilities or equipment, communication breakdowns, or acts of God. For example, during 2021 we faced certain delays in the manufacturing process for planned, new batches of TSC drug product due to the fact that, in connection with the U.S. federal government&#x2019;s Operation Warp Speed initiative in response to the COVID-19 pandemic, the facility at which our former, primary CMO partner conducts significant portions of the TSC manufacturing process had been mandated to devote the majority of the facility&#x2019;s available resources to the manufacture of components of the COVID-19 vaccine.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Amplifying this risk is the fact that, notwithstanding the improvements made to our supply chain during 2021 described under, "<i>Business - Product Development - Chemistry, Manufacturing, and Controls,"</i> we currently depend upon a sole source to manufacture our API for TSC and other aspects of our manufacturing process, limiting our available options to troubleshoot these issues. Although we actively manage this third-party relationship to ensure continuity, quality, and compliance with regulations and we intend to identify and develop alternative manufacturing and supply alternatives in the future, this process remains ongoing, will take time, and will involve significant costs. Even with these efforts, some events beyond our control, including global instability due to political unrest or from an outbreak of pandemic or contagious disease, such as COVID-19, could result in supply chain disruptions or the complete or partial failure of these manufacturing services. Any such failure or disruptions could materially adversely affect our business, financial condition, cash flows, and results of operations. Furthermore, due to the significant regulatory oversight of the pharmaceutical manufacturing process, any changes in the identity of our third-party partners or in our manufacturing processes &#x2013; even if in the best interests of the Company and successful &#x2013; could result in regulatory and other delays, as well as significant additional costs. In addition, if our current supplier terminated our arrangement or failed to meet our supply needs for any reason prior to the time we are able to identify sufficient alternative manufacturing capacity, we may be forced to delay our development plans significantly.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our CMO and other manufacturing and supply partners are also engaged to supply and manufacture materials or products for other biopharmaceutical and pharmaceutical companies, exposing them to regulatory risks unrelated to the work they are doing for Diffusion but which may nevertheless impact their ability to meet their contractual requirements to us or otherwise impede their ability to supply us with sufficient quantities of drug product. Failure to meet the regulatory requirements for the production of those materials and products may also affect the regulatory clearance of a contract supplier&#x2019;s or manufacturer&#x2019;s facility. If the FDA or a comparable foreign regulatory agency does not approve these facilities for the supply or manufacture of our product candidates or if it withdraws its approval in the future, even if such lack of approval is unrelated to Diffusion or our product candidates, we may need to find alternative supply or manufacturing facilities.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       28
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, to date we have only manufactured TSC and our other product candidates in relatively small quantities for preclinical studies and clinical trials. As we prepare for additional, later-stage clinical trials and potential commercialization, we will need to take steps to substantially increase the scale at which we are able to produce TSC, its API, and its other component parts. In order to meet these needs, our CMOs and suppliers will need to produce our API, other components, and finished product in larger quantities, more cost effectively and, in certain cases, at higher yields than they currently achieve. These third-party contractors may not be able to successfully increase the manufacturing capacity for any of such drug substance and product candidates in a timely or cost-effective manner or at all. Even if such a scale up is possible, it may require additional processes, technologies, and validation studies, which are costly, may not be successful, and which the FDA and foreign regulatory authorities would need to review and approve prior to any commercial sale of TSC or any other product candidate. In addition, quality issues may arise during those scale-up activities because of the inherent properties of a product candidate itself or in combination with other components added during the process of manufacturing, packaging, shipping, or storage.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our reliance on contract manufacturers and suppliers further exposes us to the possibility that they, or third parties with access to their facilities, will have access to and may misappropriate our trade secrets or other proprietary information. In addition, the manufacturing facilities of certain of our suppliers are located outside of the United States. This may give rise to difficulties in importing our product candidates or their components into the United States or other countries as a result of, among other things, regulatory agency approval requirements or import inspections, incomplete or inaccurate import documentation or defective packaging.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any of these factors could cause a delay or termination of preclinical studies, clinical trials, other development activities, regulatory submissions or approvals of our product candidates, or, if any of our product candidates is approved, commercial supply, and could result in significant, unanticipated costs or an inability to effectively develop our products candidates or commercialize our approved products on a timely basis, or at all, which could materially and adversely affect our business, financial condition, and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We expect to rely on third-party CROs and other third parties to conduct and oversee our clinical trials and other aspects of our development process for TSC and our other product candidates. If these third parties do not meet our requirements or otherwise conduct the trials or perform the other services for which they are engaged, we may not be able to successfully develop, obtain regulatory approval for, or commercialize our product candidates when expected or at all. Furthermore, if we are not able to establish and maintain the necessary collaborative relationships with our CROs and other third party partners, we may have to alter our development and commercialization plans.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Conducting our clinical trials in a safe, compliant, and timely manner is critical to our success. We currently rely on third-party CROs to conduct and oversee our clinical trials and other aspects of our product development, as well as various medical institutions, clinical investigators, contract laboratories, consultants, and other third parties to design and conduct our trials, to analyze the results therefrom, and to ensure that the trials are conducted in accordance with our clinical protocols and all applicable regulatory requirements, including the FDA&#x2019;s regulations and GCPs. These CROs and other third parties play a significant role in the conduct of these trials and the subsequent collection and analysis of data therefrom, as we control only certain aspects of their activities and rely heavily on them to execute our trials in a safe, compliant, and timely manner. Although we intend to internalize portions of some of these functions during 2021 and beyond as our organization grows, we expect to continue to rely on these third parties to a significant degree in the future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If any of our CROs, clinical trial sites, or other third party partners terminates their involvement in one of our clinical trials (or with Diffusion entirely) for any reason, we may not be able to enter into alternative arrangements sufficient to meet our needs, on a timely basis, on commercially reasonable terms, or at all. In addition, if our relationship with clinical trial sites is terminated, we may incur significant additional costs or experience the loss of follow-up information on patients enrolled in our ongoing clinical trials, unless we are able to transfer the care of those patients to another qualified clinical trial site.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We, as well as the CROs and other third-party contractors acting on our behalf, are required to comply with GCP and GLP requirements in all of our clinical trials, which are enforced through periodic inspections of trial sponsors, principal investigators, and trial sites. If we or any of these third parties fail to comply with applicable GCP, GLP, or other regulatory requirements, the clinical data generated in our clinical trials may be deemed unreliable and we may be required to perform additional clinical trials to supplement or replace such data before receiving approval of a product candidate from the FDA foreign regulatory authority. Our clinical trials must also generally be conducted with product produced under cGMP regulations. Our and our partners&#x2019; compliance with these various regulations may be reviewed by regulatory inspections at any time, processes over which we will have very little control or immediate visibility, and a failure to comply with these regulations and policies by us, our CROs, or any of our other third party partners may result in significant delays in our development programs. In addition, principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and could receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, the integrity of the data generated at the applicable clinical trial site may be questioned by the FDA.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       29
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, in order to fund or otherwise further development of our current or future product candidates, we may collaborate with other pharmaceutical and biotechnology companies on their development and potential commercialization of those product candidates. We would face significant competition in seeking appropriate partners and whether we reach a definitive agreement for a collaboration will depend on many factors, including, our assessment of a partner&#x2019;s resources and experience, the terms and conditions of the proposed collaboration, the likelihood of approval by the FDA or other regulatory authorities; the potential market for the subject product candidate; uncertainty with respect to our ownership of our intellectual property; and industry and market conditions generally. These types of collaborations are complex and time-consuming to negotiate and document and could ultimately result in lower returns on investment for our stockholders than would have been achieved developing the product candidate without a partner. Further, if we were to breach our obligations under the agreements governing any such future collaboration, we may face substantial consequences, including potential termination of the collaboration, and our rights to our partners&#x2019; product candidates, in which we have invested substantial time and money, would be lost.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Any failure to successfully enter into and maintain the necessary relationships with CROs and our other current and future third party partners and collaborators could materially and adversely affect our business, financial condition, and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General Risks Related to the Development, Regulatory Approval, and Commercialization of TSC and Our Other Product Candidates</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our business, financial condition, or results of operations may also be materially adversely affected by a number of general risks related to the development and regulatory approval of our product candidates that are not specific to our Company, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Our COVID Trial, which we completed in February 2021, was conducted in Bucharest, Romania and we may in the future conduct additional clinical trials for TSC or our other product candidates outside the U.S. In connection with an application for marketing approval, the FDA may determine not to accept data from clinical trials conducted outside of the U.S. if they determine the data presented therefrom cannot be considered valid without further inspection of the clinical trial site, are not applicable to the U.S. population and U.S. medical practice, or as a result of certain other factors. There can be no assurance that the FDA will accept any data we obtain from the COVID Trial or other trials we may conduct outside the U.S. in the future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;We face a number of risks related to the potential for one or more of our future product candidates to cause undesirable side effects, have other unexpected properties, contain manufacturing defects, or be subject to misuse or abuse. The occurrence of one or more of these events with respect to a product candidate or product could delay or prevent its regulatory approval, limit its commercial potential, result in additional pre- or post-approval regulatory requirements, or subject us to product liability exposure to consumers, health care providers, or others. Product liability claims could be brought in the future even if a product candidate is ultimately approved for commercial sale and manufactured in facilities licensed and regulated by the appropriate governmental authorities, and if product liability claims brought against us in the future were to be successful, we could incur substantial liability if our insurance coverage for those claims proved to be inadequate.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       30
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Our employees, independent contractors, principal investigators, consultants, vendors, CROs, and other third parties we work with in the course of our development activities may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements, during the course of their employment or other engagement with us. Any such misconduct or improper activities, whether intentional or negligent, could result in regulatory sanctions or other penalties against the Company, exclusion from federal healthcare programs such as Medicare and Medicaid, the incurrence of substantial defense costs, and serious harm to our reputation.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, although we currently have no marketed products, in the event TSC or any of our other product candidates are approved for marketing and commercial sale by the FDA or any other regulatory authority, our business, financial condition, or results of operations may be materially adversely affected by a number of general risks related to the commercialization of such products that are not specific to our Company, including:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Even if our product candidates obtain regulatory approval, they may fail to achieve the broad degree of physician and patient adoption and use necessary for commercial success. The degree and rate of physician and patient adoption will depend on a number of factors, including the clinical indications for which a product candidate is approved and its effectiveness compared to other therapies, cost and the availability of reimbursement and other coverage from third party payors, our ability to educate patients and healthcare providers regarding a new therapy, and the effectiveness of our sales and marketing efforts. Furthermore, we will face significant competition, often from products sold and marketed by companies with far greater resources than Diffusion, and our failure to effectively compete may prevent us from achieving significant market penetration.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;With respect to any such future products available only by prescription, if we are unable to achieve and maintain coverage and adequate levels of reimbursement from third party payors &#x2013; including governmental health programs such as Medicare and Medicaid and private insurance companies &#x2013; and access to such third party payors&#x2019; drug formularies, the commercial success of those products may be severely hindered. If any such products do not demonstrate attractive efficacy profiles, they may not qualify for coverage and reimbursement and, even if we obtain coverage for a given product, the resulting reimbursement payment rates might not be adequate, may require co-payments that patients find unacceptably high, and may vary from payor to payor, and there is no assurance that coverage and reimbursement levels necessary to achieve commercial success will be obtained.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Any such future products candidates that we commercialize will be subject to ongoing and continued regulatory review, including rules and regulations of the FDA and similar non-U.S. governmental authorities relating to advertising, marketing and labeling (including restrictions on the promotion of off-label use), potential REMS requirements, routine manufacturing and other review, and required compliance with GLP. If we or a regulatory agency discovers previously unknown problems with any such product, or any facility at or process by which it is manufactured, we may face restrictions on the sale or distribution of such product or on our Company as a whole, including regulatory actions requiring us to modify marketing or sales materials, suspend manufacturing or ongoing trials, initiate a recall or withdraw the product from the market entirely, enter into a consent decree, or submit to other civil or criminal investigations and penalties. If we are not able to achieve and maintain regulatory compliance, we may not be permitted to market our product candidates, which would adversely affect our ability to generate revenue and achieve or maintain profitability.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;The biopharmaceutical and pharmaceutical industries are highly regulated and the potential for future legislative reform provides uncertainty and potential threats to our business and our potential future revenue and profitability of any such future products. In the U.S., there have been, and we expect there will continue to be, a number of legislative and regulatory changes to the healthcare system intended to contain or reduce the costs of medical products and medical services including those described under the heading <i>Part I </i>&#x2013;<i> Item 1. Business </i>&#x2013;<i> Certain Other Legislation and Regulations </i>&#x2013;<i> Current Healthcare Laws and Regulations</i>. Additional state and federal healthcare reform measures may be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for our products once approved or additional pricing pressures. We cannot predict the likelihood, nature, or extent of government regulation that may arise from future legislation or administrative or executive action, whether in the U.S. or other market territories we may pursue.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       31
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Intellectual Property</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We may not be able to obtain or enforce patent rights or other intellectual property rights that cover our product candidates and technologies that are of sufficient breadth to prevent third parties from competing against us.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The pharmaceutical industry is characterized by rapidly advancing technologies, intense competition, and a strong emphasis on developing proprietary therapeutics. Numerous companies are engaged in the development, patenting, manufacturing, and marketing of health care products competitive with those that we are developing, and we face competition from a number of sources, such as pharmaceutical companies, generic drug companies, biotechnology companies and academic and research institutions. Accordingly, our ability to obtain and maintain patent protection in both the U.S. and non-U.S. jurisdictions will be critical to our ability to successfully develop, obtain regulatory approval for, and, in particular, commercialize TSC and our other product candidates. These protections are and will be essential to preserving and protecting our novel inventions, proprietary developments, and trade secrets and to preventing third parties from infringing upon them. In particular, our ability to protect any of our product candidates from unauthorized or infringing use by third parties depends in substantial part on our ability to obtain and maintain valid and enforceable patents in the U.S. and worldwide.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our patent portfolio includes patents and patent applications in the U.S. and other major markets covering our technology with varying scope, including issued U.S. patents related to composition of matter, formulation, methods of delivery, and methods of use and the scope of coverage vary from country to country. Although we believe that our intellectual property position is strong and are currently assessing our operations and existing portfolio for additional intellectual property opportunities, we do not have &#x2013; and may be unable to obtain &#x2013; patent protection for every aspect of our technology. For aspects of our technology for which we do not have patent coverage, or in countries where we do not have granted patents, we may not have any ability to prevent the unauthorized use of our technologies or technologies substantially similar to ours, and any patents that we may obtain in the future may be narrow in scope and thus easily circumvented by competitors. Further, in countries where we do not have granted patents, third parties may be able to make, use or sell products identical to or substantially similar to, our product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Due to legal standards relating to patentability, validity, enforceability and claim scope of patents covering pharmaceutical inventions, our ability to obtain, maintain and enforce patents is uncertain and involves complex legal and factual questions. The patent application process, also known as patent prosecution, is expensive and time-consuming, and we may not be able to prepare, file, and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of inventions made in the course of development and commercialization activities before it is too late to obtain patent protection on them. While we are currently engaged in efforts to obtain additional intellectual property and patent protections for TSC, there is no assurance we will obtain such protections through our applications. Therefore, these and any of our patents and applications may not be prosecuted and enforced in an optimal manner. It is also possible that defects of form in the preparation or filing of our patents or patent applications may exist, or may arise in the future, such as with respect to inadvertent prior public disclosures, proper priority claims, inventorship, claim scope, or patent term adjustments. If our current or future third party development partners are not fully cooperative or disagree with us as to the prosecution, maintenance, or enforcement of any patent rights, those patent rights could be compromised and we might not be able to prevent third parties from making, using and selling competing products. Moreover, our competitors may independently develop equivalent knowledge, methods and know-how. Accordingly, we cannot guarantee that any patents will issue from any of our currently pending patent applications, which could impair our ability to prevent competition from third parties.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Even for aspects of our technology for which we have obtained, or obtain in the future, patent protection, the complexity of legal and factual questions underlying such claims means they may not provide us with sufficient protection for our product candidates to afford a commercial advantage against competitive products or processes, including those from branded and generic pharmaceutical companies. We cannot guarantee that the claims of these patents are or will be held valid or enforceable by the courts or will provide us with any significant protection against competitive products or otherwise be commercially valuable to us. Third parties may design around or challenge the validity, enforceability or scope of such issued patents or any other issued patents we own or license, which may result in such patents being narrowed, invalidated or held unenforceable. If the breadth or strength of protection provided by the patents we hold or pursue with respect to our product candidates is challenged, it could dissuade companies from collaborating with us to develop, or threaten our ability to commercialize, our product candidates. Changes in either the patent laws or in the interpretations of patent laws in the U.S. and other countries may diminish the value of our intellectual property.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       32
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, patents have a limited lifespan, presenting further challenges in effectively protecting our technologies and associated commercial position. In the U.S., the natural expiration of a patent is generally 20 years after it is filed. Various extensions may be available under a variety of legislative and regulatory avenues but often the life afforded by these extensions and the protections they afford are limited relative to full patent protection. The extensive period of time between patent filing and regulatory approval for a product candidate limits the time during which we can market a product candidate under patent protection, which may particularly affect the profitability of our early-stage product candidates. Even if patents covering our products are obtained, once the patent life has expired, we may be open to competition from competitive products. If one of our products requires extended development, testing and/or regulatory review, patents protecting such products might expire before or shortly after such products are commercialized. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours, which could have a material adverse effect on our business, financial condition and results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To this point, we have been developing TSC since the founding of Diffusion LLC in the early 2000s and, as a result, portions of our patent portfolio, including certain patents related to TSC&#x2019;s composition of matter, will expire beginning in 2023, which may be prior to the time that we are able to obtain regulatory approval for and, if approved, commercialize TSC. Moreover, the normal life (i.e., with no adjustments or extensions) of our key issued patents related to the composition of matter of TSC extends to 2026, with potential patent term extensions to 2031, and the normal life of our patents related to an oral formulation of TSC extends to 2031, with potential patent term extensions to 2036. While the Company is actively engaged in efforts to obtain additional patent protection covering our product candidates, there is no assurance that we will successfully obtain such patent protection.. As a result, our owned and licensed patent portfolio may not provide us with sufficient rights to exclude others from commercializing products similar or identical to ours. For example, we are aware of other companies that currently use different formulations of TSC, which could adversely affect the Company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Furthermore, the laws of some foreign jurisdictions do not provide intellectual property rights to the same extent as in the United States and many companies have encountered significant difficulties in protecting and defending such rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents and other intellectual property protection, particularly those relating to pharmaceuticals, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally in those countries. If we encounter such difficulties in protecting or are otherwise precluded from effectively protecting our intellectual property in foreign jurisdictions, our business prospects could be substantially harmed.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Proprietary trade secrets and unpatented know-how are also very important to our business. Although we have taken steps to protect our trade secrets and unpatented know-how by entering into confidentiality agreements with third parties, and intellectual property protection agreements with certain employees, consultants and advisors, third parties may still obtain this information or we may be unable to protect our rights. We also have limited control over the protection of trade secrets used by our suppliers, manufacturers and other third parties. There can be no assurance that binding agreements will not be breached, that we would have adequate remedies for any breach or that our trade secrets and unpatented know-how will not otherwise become known or be independently discovered by our competitors. If trade secrets are independently discovered, we would not be able to prevent their use. Enforcing a claim that a third party illegally obtained and is using our trade secrets or unpatented know-how is expensive and time-consuming, and the outcome is unpredictable. In addition, courts outside the U.S. may be less willing to protect trade secret information.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we are unable to adequately obtain or enforce our patent and other intellectual property rights for any reason, it could materially and adversely affect our business, financial condition, and results of operations. For more information about our intellectual property and our competition, see the information included under the heading, &#x201c;Part I &#x2013; Item 1. Business &#x2013; Products, Product Development, and Our Competition &#x2013; Our Intellectual Property&#x201d; and &#x201c;&#x2014; Our Competition.&#x201d;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>If we become involved in lawsuits to protect or enforce our patents or other intellectual property, or if we are sued for infringing intellectual property rights of third parties, it will be costly and time-consuming, and an unfavorable outcome in that litigation could have a material adverse effect on our business, financial condition, or results of operations.</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       33
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our ultimate commercial success depends upon our ability to develop, manufacture, market, and sell our product candidates and use our proprietary technologies in the U.S. and non-U.S. markets. In order to do so, it is critical that we prevent third parties from infringing on our intellectual property rights and that we operate our business without infringing on the intellectual property rights of others.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">However, numerous U.S. and non-U.S. issued patents and pending patent applications owned by third parties exist in fields relating to TSC and our other product candidates, their potential methods of delivery, potential indications they may be used to treat, and their other features, and, as more patents are issued over time, the risk increases that others may assert that our product candidates, technologies, or methods of delivery or use infringe their patent or other intellectual property rights, or that we discover a third party infringing on our rights. Moreover, it is not always clear to industry participants, including us, which patents cover various drugs, biologics, drug delivery systems, or their methods of use, which of these patents may be valid and enforceable, and what inventions or technologies may be claimed by non-public patent applications. Patent applications in the U.S. and many foreign jurisdictions are typically not published until 18 months after their first non-provisional filing and publications in the scientific literature often lag behind actual discoveries, meaning we cannot be certain whether others, including our competitors, have filed patent applications for technology covered by patents or our pending applications and whether any such filing has priority over our own applications or patents.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In the biopharmaceutical and pharmaceutical industries in particular, there is a substantial amount of litigation involving patent and other intellectual property rights. This type of litigation may occur unexpectedly but may also be prompted by specific events, such as a patent application being made public by the USPTO or a non-U.S. governmental authority or under Paragraph IV of the Hatch-Waxman Amendments. For more information regarding the Hatch-Waxman Amendments and Paragraph IV thereunder, see the information included under the heading, &#x201c;<i>Part I </i>&#x2013;<i> Item 1. Business </i>&#x2013;<i> Government Regulation </i>&#x2013;<i> The Hatch-Waxman Amendments</i>.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As of the date of this Annual Report, no litigation asserting infringement claims has been brought against us, nor have we filed such a claim against any third party. However, we cannot assure you that the development or future commercialization of any of our product candidates or other technologies will not result in claims that our activities infringe on the existing or future intellectual property rights of third parties. Furthermore, potential competitors may infringe our intellectual property, including our patents. For example, in the first quarter of 2021, we became aware of a third party affiliated with a former outside consultant of the Company which claims to be in early-stage development of a product candidate that purportedly may operate through a similar mechanism of action to TSC.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">We may be required to file infringement claims to stop third-party infringement or unauthorized use or, if a third party claims we are infringing on their rights, respond to such claims. This process can be expensive and time consuming, and could result in a court deciding that a patent of ours is not valid or is unenforceable, that a third party is not required to stop using a technology we believe infringes on our rights, significant costs, or the diversion of management&#x2019;s time. An adverse determination in any litigation or other proceedings could put one or more of our patents at risk of being invalidated, interpreted narrowly, or amended such that they do not cover our product candidates in a manner sufficient to support our development and commercialization needs or that such product candidate needs to be significantly redesigned, or put our pending patent applications at risk of not issuing, or issuing with limited and potentially inadequate scope. Further, some of our competitors may be able to sustain the costs of complex patent litigation more effectively than we can because they have substantially greater resources.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In addition, interference, derivation, or other proceedings brought at the USPTO may be necessary to determine the priority or patentability of inventions with respect to our patents or patent applications. Litigation or USPTO proceedings brought by us may fail or may be invoked against us by third parties. Even if we are successful in these proceedings, domestic or foreign litigation or USPTO or foreign patent office proceedings may result in substantial costs and the diversion of management&#x2019;s time. We may not be able to prevent all misappropriation of our proprietary rights, particularly in countries with a legal framework that offers limited intellectual property protections or where the costs of enforcement outweigh the commercial and other benefits of maintaining intellectual property protections.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       34
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation or other proceedings, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation or other proceedings, including as a result of public announcements of the results of hearings, motions or other interim proceedings or developments, or public access to related documents. This type of disclosure could put us at a significant competitive disadvantage by disclosing important trade secrets or other proprietary information to our competitors and other third parties.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Any litigation or other challenge related to our intellectual property could materially and adversely affect our business, financial condition, and results of operations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General Risks Related to Our Intellectual Property</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our business, financial condition, or results of operations may also be materially adversely affected by a number of general risks related to our intellectual property that are not specific to our Company, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;As is common in the biopharmaceutical and pharmaceutical industries, some of our employees were formerly employed by companies in the industry, including our competitors or potential competitors, and some of our consultants actively work for other companies in the industry. As a result, although we have in place policies which prohibit the use of third-party confidential information in violation of any obligation to a former employer or otherwise, we may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed to us alleged trade secrets of their former employers or their former or current customers. In addition, if any of our current employees or consultants are engaged by a competitor in the future, it is possible that they may appropriate or otherwise improperly use our proprietary and confidential information. Any of the foregoing events could result in significant costs and the diversion of time and resources.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated as a result of any non-compliance with these requirements. We may also abandon certain intellectual property protections that we would otherwise maintain if we determine such protections are not expected to provide sufficient value relative to the cost of ongoing maintenance.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Patent laws and other intellectual property protections available in the U.S., E.U., or other jurisdictions are subject to change. These changes may be unpredictable, weaken our overall intellectual property position, increase our costs related to maintenance and enforcement, or otherwise diminish the value of patents in general, thereby impairing our ability to protect our product candidates and maximize our return on investment thereon.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Risks Related to Our Business, Financial Position, Results of Operation, and Organizational Structure</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We will require additional capital to fund our operations which may not be available on acceptable terms or at all. If we fail to obtain necessary financing, we may be forced to delay or curtail our clinical trials and other development activities or be unable to complete the development and commercialization of our product candidates due to a lack of sufficient resources.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Although we expect that our existing cash resources will enable us to fund our operating expenses and capital expenditure requirements through 2023, we expect to continue to spend substantial amounts as we continue to develop TSC and our other product candidates. As a result, we will need to obtain additional financing in the future in order to complete the development of TSC and fund our other development and operational activities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       35
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We cannot be certain that the additional funding we will require will be available on acceptable terms or at all. Investors may demand significant discounts to market prices or that we agree to restrictive covenants or other limitations on our ability to operate our business, and conditions in the capital markets may make equity and debt financing more difficult to obtain or negatively impact our ability to complete a financing transaction at all. If we are unable to raise additional capital in sufficient amounts or on terms acceptable to us, we may have to significantly delay, scale back, discontinue the development or commercialization of one or more of our product candidates, or seek alternative financing opportunities such as collaborations or licensing opportunities. For example, prior to completing the May 2020 Offering and February 2021 Offering, we determined that we did not have adequate resources to fully support the randomized portion of the GBM Trial and commencement of enrollment in the trial was suspended following the run-in portion.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Furthermore, our forecast of the period of time through which our financial resources will be adequate to support our operations is a forward-looking statement and involves the associated risks and uncertainties. Although we have based this estimate on assumptions that we believe to be reasonable, they may prove to be wrong, we could utilize our available capital resources sooner than we currently expect, and actual results could vary greatly from our expectations expressed in this Annual Report as a result. The magnitude and timing of our future funding requirements, both near and long-term, will depend on many factors, including, but not limited to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the number, development stage, and other characteristics of product candidates that we choose to develop, including any product candidates that we may in-license or otherwise acquire in the future;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the clinical development plans we establish for these product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the magnitude of costs associated with filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the initiation, progress, timing, costs, and results of clinical trials for such product candidates;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the outcome, timing and cost of regulatory approvals by the FDA and comparable foreign regulatory authorities, including the potential for the FDA or comparable foreign regulatory authorities to require that we perform more studies than those that we currently expect;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the cost and timing of completion of becoming a commercial organization; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the effect of competing technological and market developments.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We currently generate no revenue from the sale of products, have incurred significant losses since our inception, have a history of net losses and negative cash flow from operations, expect to incur losses for the foreseeable future, and may never become profitable. In addition, our operating results may fluctuate significantly, which makes our future operating results difficult to predict and could cause our operating results to fall below expectations. As a result, any investment in our common stock is speculative and risky.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are a clinical stage biotechnology company and, as a result, we have a limited operating history from which to assess how we will respond to competitive, economic, or other challenges to our business, and our business and prospects must be considered in light of the risks and uncertainties frequently encountered by similarly situated companies.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have limited cash resources, have generated substantial net losses and negative cash flow from operations since our inception, and we continue to incur significant research, development, and other expenses related to our ongoing operations, including the development of TSC and our other product candidates. To date, we have not yet obtained regulatory approvals for any of our product candidates and, accordingly, have not generated any revenues from the sale of products. We expect to continue to incur losses and negative cash flow for the foreseeable future. Furthermore, our future operating results may fluctuate due to a variety of other factors, many of which are outside of our control and may be difficult to predict, including the delays in our product development programs including as a result of regulatory review, increased expenditures related to manufacturing or the enforcement of intellectual property rights, other litigation costs, changes in accounting policies, or other unanticipated events.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       36
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to generate sufficient revenues from TSC or any of our other product candidates, if approved, will depend on numerous factors described throughout this Annual Report. Even if we are able to successfully develop and receive regulatory approval for TSC or any of our other product candidates, we do not know if or when any such product will achieve commercial success or generate revenue for us, and we will incur significant costs associated with the commercialization that will need to be offset by revenue before achieving a profit. We may also in the future enter into collaboration agreements and license agreements with other companies that include milestone expenditures and payments, in which case our ability to generate revenue or achieve profitability may be dependent on the achievement of those milestones. Even if we achieve profitability in the future, we may not be able to sustain profitability in subsequent periods, and our prior losses and expected future losses have had and will continue to have an adverse effect on our stockholders&#x2019; equity. Furthermore, due to the uncertainty of the drug development process, we are often unable to predict the timing or amount of increased expenses, or when we will be able to achieve or maintain profitability, if at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 18pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We will need to further increase the size and complexity of our organization in the future including, if TSC or any of our other product candidates are approved for commercial sale, establishing sales and marketing capabilities. We may experience difficulties in executing our growth strategy or managing any growth that we do experience if we are unable to recruit and retain talented individuals in key positions.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to succeed in the highly competitive pharmaceuticals industry depends upon our ability to attract and retain highly qualified personnel. As of the date of this Annual Report, we have 14 full-time employees and no part-time employees. Particularly given our near-term plans for the TSC development program and our compliance requirements with the FDA, SEC, and other regulatory bodies, we believe that our current staffing levels are inadequate to support our future needs. We anticipate adding additional personnel to our team throughout the organization during 2022 in an effort to support the development of TSC, grow our business more generally, and optimize the size of our organization. In addition, assuming success in our ongoing and planned clinical trials, we expect to further supplement and grow our scientific, clinical, regulatory, financial, and other human resources to support our planned research, development, and commercialization plans for TSC and our other product candidates.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our ability to effectively manage our anticipated growth will depend on multiple factors, including, among others, our ability to:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;effectively retain current talent and effectively recruit sufficient numbers of new talented employees;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;manage our third-party supply and manufacturing operations effectively and in a cost-effective manner,</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;while increasing production capabilities for our current product candidates to commercial levels;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;establish and maintain relationships with development and commercialization partners;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;manage our development and commercialization efforts effectively and in a cost-effective manner; and</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;continue to improve our operational, clinical, financial, management and regulatory compliance controls and reporting systems and procedures.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are highly dependent on our management and scientific personnel, including our executive officers, certain other key employees and consultants, and the members of our Board. The loss of the services of any of these individuals could impede, delay, or prevent completion of our ongoing and planned clinical trials, regulatory approval, or commercialization of TSC or any of our other product candidates. If we lose the services of any of these individuals, we might not be able to find suitable replacements on a timely basis or at all, and our business could be harmed as a result. All of our employees, including our executive officers with whom we have employment agreements, are employed on an at-will basis and their employment can be terminated by us or them at any time. As part of our efforts to retain our valuable employees, we, among other things, provide a generous salary and benefits package, as described in more detail under the heading, "<i>Part I </i>&#x2014;<i> Item 1. Business </i>&#x2013;<i> Our People and Human Capital Resources </i>&#x2013;<i> Employees</i>."</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Nevertheless, we may be unable to attract or retain qualified management and other key personnel in the future due to the intense competition among biotechnology, pharmaceutical, and other businesses. There may be a limited number of persons with the requisite skills to serve in these positions, and we cannot assure you that we will be able to identify or employ qualified personnel for any such position on acceptable terms, if at all, and the high levels of competition within the industry may mean that we will be required to expend significant financial resources in our employee recruitment and retention efforts. Many of the other pharmaceutical companies with whom we compete for qualified personnel have greater financial and other resources, different risk profiles and longer histories in the industry than we do. They also may provide more diverse opportunities and better chances for career advancement. If we are not able to attract and retain the necessary personnel to accomplish our business objectives, we may experience constraints that will harm our ability to implement our business strategy and achieve our business objectives. Furthermore, as we currently have no marketed products, we currently have no sales or marketing personnel or capabilities. To commercialize TSC or any of our other product candidates, if approved, we will need to build our marketing, sales, distribution, and other related capabilities or arrange with third parties to perform these services, and we may not be successful in doing so.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       37
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, we have historically utilized the services of certain outside independent contractors to perform a number of critical functions for our company, including with respect to clinical development, regulatory matters, accounting, and human resources, a practice we expect to continue and may choose to expand in the future. We rely on these independent contractors and effectively managing our relationships with them is and will remain a priority. However, there can be no assurance that we will be able to manage these relationships effectively, that such contractors will be able or choose to continue working with us in the future, or that we will be able to find additional or replacement services if and as needed, on economically reasonable terms or at all.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">If we are not able to effectively manage our growth and expand our organization through a combination of effectively retaining our existing employees and third-party contractors and successfully recruiting new employees and contractors, we may be unable to effectively execute on our product development and other strategic plans, which may adversely affect our business, financial condition, or results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>If we decide to in-license or acquire one or more additional product candidates or otherwise enter into a strategic transaction, it could impact our liquidity, increase our expenses, and present significant distractions to our management team.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We currently only have one product candidate under active development, TSC. We may in the future implement a strategy to in-license or acquire one or more additional product candidates to supplement our pipeline. We may also consider a variety of other strategic transactions, including spin-offs, partnerships, joint ventures, restructurings, divestitures, business combinations, and minority investments. Any such transaction would expose us to a number of risks and uncertainties, including the potential incurrence of recurring, non-recurring (including unknown liabilities), or other charges (including amortization expenses, write-downs, or other impairment charges), increase of short- and long-term expenditures, or dilution to our stockholders, as well as posing significant integration, implementation, or retention challenges and diverting our management team&#x2019;s focus on other priorities, including the TSC development program. Any of the foregoing could have a material adverse effect on our business, financial condition, or results of operation. which could adversely affect our operations and financial results. There can be no assurance that we will undertake such a transaction or, if we do, that we will successfully complete the transaction or that the transaction will be additive to our business, financial condition, or results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our ability to utilize our NOL carryforwards and other deferred tax assets may be limited as a result of past and future issuances of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2021, we had $23.4 million in federal and state NOL carryforwards available to reduce future taxable income, if any, for income tax purposes. If not utilized, the NOL carryforwards will begin expiring during the year ending December 31, 2034. Under Section 382 of the Tax Code, if a corporation undergoes an &#x201c;ownership change,&#x201d; generally defined as a greater than 50% change, measured by value, in its equity ownership over a three-year period, the corporation&#x2019;s ability to use its pre-ownership change NOL carryforwards and other pre-ownership change tax attributes &#x2013; such as research tax credits &#x2013; to offset its post-ownership change income may be limited. In the event we issue additional shares of common stock to fund our future development efforts and those issuances result in additional ownership changes for purposes of Section 382 of the Tax Code, as we did in the May 2020 Offering and the February 2021 Offering, our NOL carryforwards could be further reduced.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       38
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General Risks Related to Our Business, Financial Condition, Results of Operations, and Organizational Structure</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our business, financial condition, or results of operations may also be materially adversely affected by a number of general risks related thereto and to our organizational structure that are not specific to our Company, including:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;If we fail to maintain an effective system of internal control over financial reporting, we may not be able to accurately report our financial results or prevent fraud. Furthermore, our disclosure controls and procedures are subject to inherent limitations, human error, and other systematic breakdowns, and therefore may not prevent or detect all errors or acts of fraud. As a result, stockholders could lose confidence in our financial and other public reporting, which could harm our business, financial condition, or results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;As our Company, the industry in which we operate, and the world-at-large become increasingly virtual, our acquisition and implementation of additional information technology solutions and our compliance with global privacy and data security requirements could result in additional costs and liabilities or inhibit our ability to collect and process data globally. Furthermore, any failure to comply with applicable requirements or best practices &#x2013; as well as other events outside of our control &#x2013; could result in a security breach or other disruption to our information technology systems, limit our capacity to effectively monitor and control our operations, compromise our or third parties&#x2019; confidential information, or otherwise adversely affect our business, financial condition, or results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;We incur significant costs as a result of our public company status and devote substantial management time to operating as a public company, including complying with the applicable requirements of the Securities Act, the Exchange Act, the Dodd-Frank Act, SOX, and the rules and regulations of Nasdaq. If, in the future, we are required to include in our annual report an attestation of our independent registered public accounting firm regarding internal control over financial reporting, the amount of these compliance costs would increase significantly.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;Although we have in place business continuity and disaster recovery plans, our business, financial condition, or results of operations could be negatively affected by volatility, disruptions, or other uncertainty caused by market fluctuations, economic downturns or unfavorable global economic conditions, pandemics, natural disasters or other catastrophic events, events of war, terrorism, or other man-made problems, or other geopolitical events outside of our control, including the COVID-19 pandemic and Brexit.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;If we fail to comply with applicable laws and regulations, including the healthcare laws and regulations described under the heading, <i>Part I </i>&#x2013;<i> Item 1. Business </i>&#x2013;<i> Certain Other Legislation and Regulations </i>&#x2013;<i> Current Healthcare Laws and Regulations </i>and applicable environmental, health, and safety laws and regulations, we could become subject to fines, penalties, or other consequences.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Risks Related to Ownership of Our Common Stock</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b><i>If we cannot continue to satisfy the NASDAQ Capital Market continued listing standards and other NASDAQ rules, our Common Stock could be delisted, which would harm our business, the trading price of our Common Stock, our ability to raise additional capital and the liquidity of the market for our Common Stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock is currently listed on the NASDAQ Capital Market. To maintain the listing of our common stock on the NASDAQ Capital Market, we are required to meet certain listing requirements, including, among others, either: (i) a minimum bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and stockholders&#x2019; equity of at least $2.5 million; or (ii) a minimum bid price of $1.00 per share, a market value of publicly held shares (excluding shares held by our executive officers, directors and 10% or more stockholders) of at least $1 million and a total market value of listed securities of at least $35 million. There is no assurance that we will regain and continue to meet the Bid Price Rule and Nasdaq&#x2019;s other listing requirements.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       39
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As previously disclosed, on May 6, 2021, we received a written notice from the Staff indicating that the Company was not in compliance with the Bid Price Rule because the bid price for the Company&#x2019;s common stock had closed below $1.00 per share for the previous 30 consecutive business days. On November 3, 2021, after failing to regain compliance with the Bid Price Rule within 180 days of receipt of the first notice, we received an additional notice from the Staff providing that, although the Company had not regained compliance with the Bid Price Rule by the previously stated deadline, in accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company would be granted an additional 180 calendar days, or until May 2, 2022, to regain compliance with the Bid Price Rule.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To regain compliance with the Bid Price Rule, the bid price for our common stock must close at $1.00 per share or more for a minimum of 10 consecutive business days. NASDAQ&#x2019;s written notice has no effect on the listing or trading of our common stock at this time, and we are currently evaluating our alternatives to resolve this listing deficiency. We have filed with the SEC a proxy statement relating to the Special Meeting, to be held on April 14, 2022, at which our stockholders will vote on a proposal to approve an amendment to our Certificate of Incorporation to effect the Reverse Stock Split, with the final decision of whether to proceed with the Reverse Stock Split, the effective time of the Reverse Stock Split, and the exact ratio of the Reverse Stock Split to be determined by the Board, in its discretion, at any time prior to December 31, 2022. However, there can be no assurance that the Reverse Stock Split will be approved at the Special Meeting or, if approved, will result in a sustained higher stock price, if effected, that will allow us to regain compliance with the Bid Price Rule and meet the NASDAQ stock price listing requirements, and there is no guarantee we will continue to satisfy the other NASDAQ Capital Market continued listing standards.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the event that our common stock is delisted from NASDAQ and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult for us to raise capital and for our stockholders to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our stock price is volatile and any investment in our securities may suffer a decline in value. In addition, this volatility may subject our business to additional risks, such as an increased risk of securities litigation.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended December 31, 2021, the closing market price for our common stock as reported by Nasdaq varied between a high of $1.70 on February 16, 2021 and December 31, 2021 and a low of $0.31 on December 29-31, 2021. As a result of fluctuations in the price of our common stock, you may be unable to sell shares or our common stock at or above the price you paid for them, even if your holding period is relatively short. The market price of our common stock is likely to continue to be volatile and subject to significant price and volume fluctuations in response to market, industry and other factors, including the degree of analyst coverage of our stock, their valuations and recommendations, and whether any such analysts publish inaccurate or unfavorable research about our business. If the results of our business do not meet these analysts&#x2019; forecasts, the expectations of investors or the financial guidance we provide to investors in any period, the market price of our common stock could decline. Furthermore, despite this volatility, due to the fact that we have never declared or paid cash dividends on our common stock and do not currently anticipate declaring or paying any cash dividends in the foreseeable future, we expect that only appreciation of the price of our common stock, if any, will provide a return to our stockholders for the foreseeable future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Historically, the stock markets in general, and the markets for biotechnology stocks in particular, have experienced significant volatility that has at times been unrelated to the financial condition or results of operations of particular companies. These broad market fluctuations may adversely affect the trading price of our common stock and, consequently, adversely affect the price at which you are able to sell any shares of our common stock that you own. In the past, following periods of volatility in the market or significant price declines in individual securities or the market as a whole, securities class-action litigation has often been instituted against companies. Such litigation, if instituted against us, could result in substantial costs and diversion of management&#x2019;s attention and resources, which could materially and adversely affect our business, financial condition, results of operations and growth prospects.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       40
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>We have funded our operations to date through the issuance of securities, including common stock, warrants to purchase common stock, convertible preferred stock, and convertible debt securities, and we expect that in the future we will need to raise additional capital through similar means to fund our continued development efforts for TSC and our other liquidity needs. Assuming funding is available on acceptable terms, any future issuance of common stock or securities convertible for or exchangeable into common stock will result in dilution to our existing stockholders and could depress the market price of our common stock. Furthermore, the terms of future financing transactions may contain provisions that restrict our operations or require us to relinquish certain rights to our product candidates or other technologies. </i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Although we believe we have sufficient cash resources to fund our other operating expenses and capital expenditure requirements through 2023, we will in the future need to raise additional funds to continue our operations, fund additional clinical trials evaluating TSC and our other product candidates, and, if approved, commercializing TSC. We plan to continue to finance our operations with a combination of equity issuances, debt arrangements, and, potentially, licensing, or other partnering relationships. In addition, our Board may determine at any time to raise additional capital if it believes the terms are in the best interests of our stockholders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accordingly, new issuances of a substantial number of shares of our common stock could occur at any time. For example, in February 2021, we issued approximately 33.7 million shares of our common stock in connection with the completion of the February 2021 Offering. Any issuance or sale of shares, or the perception in the market of an intent to issue or sell shares in the near-term, by the Company or holders of a large number of shares could reduce the market price of our common stock. We also cannot assure you that any such sale of common stock or other securities will be at a price per share that is equal to or greater than the price per share paid by you for our common stock. Furthermore, a depressed stock price could limit our ability to raise necessary capital through the sale of additional equity securities on terms that are acceptable.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We may also seek additional capital through other methods, either alone or in combination with the issuance of additional securities, including debt financings, receivables or royalty financings, strategic partnerships and alliances, and licensing arrangements, any of which could be coupled with an equity component, such as warrants to purchase stock. The incurrence of indebtedness could result in increased fixed payment obligations, liens and other security interests being placed on certain of our assets, and certain restrictive covenants being imposed on the operation of our business, such as limitations on our ability to incur additional debt or acquire intellectual property rights. We may also in the future raise additional funds through strategic partnerships, alliances, and licensing arrangements with third parties, any of which could require us to relinquish valuable rights to TSC or our other product candidates. The restrictions imposed by any of these arrangements could materially decrease any potential returns on our investment in TSC or our other product candidates, or otherwise materially and adversely affect our business, financial condition, or results of operations.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Our organizational documents impose certain anti-takeover provisions and make the Delaware Chancery Court the exclusive forum for certain stockholder actions, which could depress the trading price of our common stock.</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our certificate of incorporation, as amended, and our Bylaws contain provisions that may make the acquisition of our company, a proxy contest, or the nomination of a director candidate by a stockholder more difficult than such actions would be in the absence of such provisions, including that:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">only our Board has the right to fill a vacancy on the Board created by an expansion or by the resignation, death, or removal of a director, which prevents stockholders from being able to fill vacancies on our Board;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">only our Chairman of the Board, our Chief Executive Officer, or a majority of our directors are authorized to call a special meeting of stockholders;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">we may issue undesignated preferred stock, the terms of which may be established and shares of which may be issued without stockholder approval (notwithstanding any requirements imposed by the SEC or any exchange on which our common stock may now or in the future trade), and which may include rights superior to the rights of the holders of common stock;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       41
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our Board is expressly authorized to amend, restate, or repeal our Bylaws; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">advance notice is required with respect to any nominations for election to our Board or for proposing matters that can be acted upon by stockholders at any meeting of stockholders.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition our Bylaws provide that, unless we consent in writing to the selection of an alternative forum, the Court of Chancery of the State of Delaware is the sole and exclusive forum for certain actions, including derivative actions brought on the Company's behalf, stockholder actions claiming breaches of a fiduciary duty owed by any of our directors or officers, and claims arising under our organizational documents, in each case, subject to said Court of Chancery having personal jurisdiction over the indispensable parties named as defendants therein. Although this provision would not apply to any stockholder claims under the Exchange Act, there is uncertainty regarding whether a court would enforce such a forum selection provision as written to stockholder claims under the Securities Act. Nevertheless, this forum selection provision may limit our stockholders&#x2019; ability to obtain a favorable judicial forum for disputes with us or our directors, officers, employees, or agents, which may discourage lawsuits against us and such persons.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The limitations on certain stockholder rights imposed by these provisions could also depress the trading price of our common stock.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       42
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 1B.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>UNRESOLVED STAFF COMMENTS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 2.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>PROPERTIES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On November 8, 2021, the Company entered into a Deed of Lease Termination Agreement with the Carlton Landlord providing for the early termination of the Carlton Lease related to the Company's prior corporate headquarters. The Carlton Lease was previously scheduled to expire on April 30, 2022. In connection with the termination, the Company made a one-time payment to the Carlton Landlord of approximately $14,000, net of a security deposit subsequently returned in accordance with the Carlton Lease. In lieu of the fixed office and laboratory space previously available to us under the Carlton Lease, the Company has entered into short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania.&#xa0;</p>
  <p style="margin: 0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 3.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>LEGAL PROCEEDINGS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The information in <i>Note 6, Commitments and Contingencies </i>&#x2014;<i> Legal Proceedings</i> to our consolidated financial statements set forth in, <i>Part II </i>&#x2014;<i> Item 8 </i>&#x2014;<i> Financial Statements</i> of this Annual Report is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, from time to time, we are subject to various pending or threatened legal actions and proceedings, including those that arise in the ordinary course of its business, which may include employment matters, breach of contract disputes and stockholder litigation. Such actions and proceedings are subject to many uncertainties and to outcomes that are not predictable with assurance and that may not be known for extended periods of time. We record a liability in our consolidated financial statements for costs related to claims, including future legal costs, settlements and judgments, when we have assessed that a loss is probable and an amount can be reasonably estimated. If the reasonable estimate of a probable loss is a range, we record the most probable estimate of the loss or the minimum amount when no amount within the range is a better estimate than any other amount. We disclose a contingent liability even if the liability is not probable or the amount is not estimable, or both, if there is a reasonable possibility that a material loss may have been incurred. In the opinion of management, as of the date hereof, the amount of liability, if any, with respect to these matters, individually or in the aggregate, will not materially affect our consolidated results of operations, financial position or cash flows.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 4.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MINE SAFETY DISCLOSURES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       43
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART II</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 5.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MARKET FOR REGISTRANT</b>&#x2019;<b>S COMMON EQUITY, RELATED STOCKHOLDER MATTERS AND ISSUER PURCHASES OF EQUITY SECURITIES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Market Information</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">Our common stock trades publicly on the Nasdaq Capital Market under the symbol &#x201c;DFFN.&#x201d;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Holders</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">As of March&#xa0;15, 2022, there were 343 record holders of our common stock. This does not include beneficial owners of our common stock whose stock is held in nominee or &#x201c;street name&#x201d;.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Dividends</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">To date, we have not declared or paid any cash dividends on our common stock and do not intend to do so in the near future.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Securities Authorized for Issuance Under Equity Compensation Plans</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The information set forth in, <i>Part III </i>&#x2014;<i> Item 12 (Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters)</i> of this Annual Report is incorporated herein by reference to the extent required by Item 201(d) of Regulation S-K.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Recent Unregistered Sales of Equity Securities and Use of Proceeds</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">None</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Purchases of Equity Securities by the Issuer and Affiliated Purchasers</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 6.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>SELECTED FINANCIAL DATA</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The information required by Item 6 of Form 10-K has been omitted from this Annual Report pursuant to the amendments to Regulation S-K adopted by the SEC on November 19, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       44
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 7.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>MANAGEMENT</b>&#x2019;<b>S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Introduction</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">This discussion and analysis contains information related to historical and prospective events intended to enable you to assess our financial condition and results of operations. The information contained in this discussion and analysis should be read in conjunction with our consolidated financial statements and the related notes contained elsewhere in this Annual Report, as well as the risks and uncertainties discussed under the heading, "<i>Part 1A </i>&#x2014;<i> Risk Factors.</i>"</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Diffusion Pharmaceuticals: Enhancing Oxygen, Fueling Life</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We are a biopharmaceutical company developing novel therapies that enhance the body&#x2019;s ability to deliver oxygen to the areas where it is needed most. Our lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Highlights from Fourth Quarter of 2021 </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Announced Lead Development Program</i>&#xa0;&#x2013;&#xa0;In November 2021, we announced our intent to develop TSC as an adjunct to standard of care therapy for hypoxic solid tumors.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Initiated Final Two Oxygenation Trials</i>&#xa0;&#x2013;&#xa0;On November 22, 2021, we announced dosing of the first participants in the Altitude Trial and, on December 16, 2021, we announced dosing of the first patients in the ILD-DLCO Trial. We currently expect to complete dosing in the Altitude Trial in the first quarter of 2022 and to complete dosing in the ILD-DLCO Trial in the second quarter of 2022.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Enhanced Intellectual Property Portfolio</i>&#xa0;&#x2013;&#xa0;On November 30, 2021, the USPTO granted to the Company United States Patent No. 11,185,523, &#x201c;Use of Bipolar Trans Carotenoids With Chemotherapy and Radiotherapy for Treatment of Cancer.&#x201d;&#xa0;This patent includes new claims related to methods of treating cancerous tumors by administering TSC in combination with radiation therapy and chemotherapy. This new patent extends the normal life of our cancer-related intellectual property claims into 2037.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><i>Implemented Cost-Saving Facility Changes</i>&#xa0;&#x2013;&#xa0;In November 2021, we terminated the Carlton Lease for our prior corporate headquarters, furthering our shift to a remote-work culture. During 2021, we also entered into short-term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania, resulting in cost savings.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Our Strategic Priorities for 2022</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In 2022, we plan to continue and further our focus on the development of TSC for the treatment of hypoxia and as a platform to enhance standard-of-care treatment for conditions complicated by hypoxia with a particular near-term focus on hypoxic solid tumors.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of March 15, 2022, TSC has been administered to more than 220 subjects across 11 clinical trials. Data from these clinical trials support our understanding of the safety, tolerability, pharmacokinetics and pharmacodynamic effects of TSC. In addition, post hoc analyses of two prior studies involving patients with PAD with claudication and unresected GBM tumors have provided preliminary evidence of TSC&#x2019;s potential. However, the data available from these studies and the post hoc analyses of their outcomes are limited in several meaningful ways. For example, neither study was powered to formally demonstrate efficacy at a statistically significant level, there was no evaluation of whether TSC increased oxygenation in the target tissues in either study, and, in the GBM Trial, no dose exploration was conducted.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       45
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During 2021, to address these identified gaps in our TSC knowledge base, further inform our identification of potential indications appropriate for TSC, and guide the future of our TSC development program, we designed and executed on our Oxygenation Trials. The Oxygenation Trials are a series of three short-term, clinical studies designed to provide clinical evidence of the relationship between TSC dose and the effects on oxygenation, each specifically tailored to evaluate the effects of TSC on a different component of the oxygen delivery pathway. We completed the first of these studies, the TCOM Trial, in March 2021. The first participants and patients in the remaining two Oxygenation Trials, the Altitude Trial and the ILD-DLCO Trial, were dosed in November 2021 and December 2021, respectively. We currently expect to complete dosing in the Altitude Trial in the second quarter of 2022 and to complete dosing in the ILD-DLCO Trials in the middle of 2022 and, in each case, to report top-line results within two months of study completion.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In November 2021, based on the available preclinical and clinical data and the significant unmet medical need, we announced our intention to focus near-term efforts on developing TSC as an adjunct to standard of care therapy for hypoxic solid tumors. Through the combination of our past experiences, new knowledge gained from our Oxygenation Trials and COVID Trial regarding TSC&#x2019;s effects on oxygenation, dose response characteristics, pharmacokinetics, and pharmacodynamics, and further analyses and discussions of all available data with our Scientific Advisory Board and other external advisors, we believe we now have the necessary information to design the Hypoxic Solid Tumor Program to be more efficient and increase our likelihood of success compared to the Company&#x2019;s past efforts to develop TSC as a cancer treatment, which were terminated in 2019 due to financial constraints.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As part of the ongoing design of our Planned Phase 2 Hypoxic Tumor Trial &#x2013; the first trial in our Hypoxic Solid Tumor Program which we currently expect to commence in the second half of 2022, subject to FDA feedback and the availability of clinical drug supply &#x2013; we are currently drafting a trial protocol which we intend to file with the FDA.&#xa0;In parallel, we will continue our work to optimize the TSC manufacturing process and support the continued availability of high-quality drug product and undertake preclinical studies and other opportunities to continue developing data designed to demonstrate TSC&#x2019;s potential uses in a broad spectrum of non-cancer indications.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Financial Summary</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December 31, 2021, we had a cash and cash equivalents balance of $37.3 million. We have incurred operating losses since inception, have not generated any product sales revenue, and have not achieved profitable operations. We incurred net losses of $24.1 million and $14.2 million for the years ended December 31, 2021 and 2020, respectively. To date, we have funded our operations and short-term liquidity needs primarily through the issuance and sale of common stock, warrants to purchase common stock, convertible debt, and convertible preferred stock. We expect to continue funding our operations through similar means for the foreseeable future, assuming the availability of additional capital, though we may enter into strategic partnerships or other alternative transactions in order to fund our ongoing capital requirements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our accumulated deficit as of December 31, 2021, was $130.0 million and we expect to continue to incur substantial losses in future periods for the foreseeable future. We also anticipate that our operating expenses will increase substantially as we continue to advance the development of TSC, including any costs related to:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">our ongoing and planned clinical trials, including the ongoing Oxygenation Trials and our Planned Phase 2 Hypoxic Solid Tumor Trial;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">any additional studies we may undertake to evaluate TSC, including other preclinical and clinical studies to support the filing of any NDA with the FDA;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">near-term investments intended to improve the quality and robustness of our supplier relationships and overall supply chain;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       46
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">other research, development, and manufacturing activities designed to develop and optimize formulation, manufacturing processes, dosage, dose forms, and other characteristics prior to regulatory approval;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the maintenance, expansion, and protection our global intellectual property portfolio;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the hiring of additional clinical, manufacturing, scientific, sales, or other personnel;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">research and development related to any other product candidates we may acquire or in-license in the future; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">investments in operational, financial, and management information systems.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of TSC. We expect that our cash and cash equivalents as of December 31, 2021 will enable us to fund our operating expenses and capital expenditure requirements through 2023.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Financial Operations Overview</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Revenues</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We have not yet generated any revenue from product sales. We do not expect to generate revenue from product sales for the foreseeable future.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Research and Development Expense</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">R&amp;D expenses include, but are not limited to, third-party CRO arrangements and employee-related expenses, including salaries, benefits, stock-based compensation, and travel expense reimbursement. R&amp;D activities are central to our business model. Product candidates in later stages of clinical development generally have higher development costs than those in earlier stages of clinical development, primarily due to the increased size and duration of later-stage clinical studies. As we advance our product candidates, we expect the amount of R&amp;D costs will continue to increase for the foreseeable future. R&amp;D costs are charged to expense as incurred.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;"><b><i>Intangible Asset Impairment Charge</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the third quarter of 2021, the Company made a determination to no longer dedicate resources to the Company&#x2019;s DFN-529 intangible asset and any future development efforts were abandoned. In connection with this decision, the Company concluded that DFN-529 was impaired in its entirety.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>General and Administrative Expense</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">G&amp;A expenses consist principally of salaries and related costs for executive and other personnel, including stock-based compensation, other employee benefit costs, expenses associated with investment bank and other financial advisory services, and travel expenses. Other G&amp;A expenses include, facility-related costs, communication expenses and professional fees for legal, patent prosecution and maintenance, consulting, accounting, and other professional services.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Interest Income</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Interest income consists of interest earned from our cash and cash equivalents.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Income Tax Benefit&#xa0;</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recorded an income tax benefit of $0.4 million during the year ended December 31, 2021. The income tax benefit was due to the tax effect of the reduction in the deferred tax liability associated with the basis difference from the IPR&amp;D indefinite lived intangible asset. The Company maintains a full valuation allowance against its deferred tax assets due to the Company&#x2019;s history of losses as of December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       47
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our NOLs and tax credit carryforwards are subject to review and possible adjustment by the Internal Revenue Service and state tax authorities. NOL and tax credit carryforwards may become subject to an annual limitation in the event of a greater than 50.0% cumulative change in the ownership interest of significant stockholders over a three year period, as defined under Sections 382 and 383 of the Internal Revenue Code as well as similar state provisions. The amount of the annual limitation is determined based on the Company&#x2019;s value immediately prior to the ownership change, and subsequent ownership changes may further affect the limitation in future years. We have not yet performed an analysis to determine whether or not ownership changes that have occurred in the year ended December 31, 2020 or during the year ended December 31, 2021 give rise to any further limitations.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Critical Accounting Policies&#xa0;and Estimates</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Certain of our critical accounting policies require estimates that involve the application of significant judgment by management in selecting the appropriate assumptions in determining the estimate. By their nature, these judgments are subject to an inherent degree of uncertainty. We develop these judgments based on our historical experience, terms of existing contracts, our observance of trends in the industry, and information available from other outside sources, as appropriate. Actual results may differ from these judgments under different assumptions or conditions. Different, reasonable estimates could have been used for the current period. Additionally, changes in accounting estimates are reasonably likely to occur from period to period. Both of these factors could have a material impact on the presentation of our financial condition, changes in financial condition, or results of operations. We believe the accounting policies described below are among the most critical to aid in fully understanding and evaluating our financial statements, as they require estimates which involve our most subjective or complex judgments.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"><b><i>Intangible Assets</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our sole intangible asset as of December 31, 2020 consisted of DFN-529, which was acquired in 2016 pursuant to our merger with RestorGenex Corporation and was&#xa0;accounted for as an IPR&amp;D intangible asset. The fair value of the IPR&amp;D asset was determined as of the acquisition date using the cost approach, often referred to as current replacement cost, which establishes a value based on the cost of reproducing or replacing the asset. The cost approach was chosen as we were not able to estimate an income stream attributable to the IPR&amp;D asset, given the fact that the related products had only completed limited preclinical and clinical trials and the timeline to commercial viability, if the FDA approval process were to be successful, was uncertain, would take a number of years, and the costs would have been significant. In the third quarter of 2021, we made a determination to no longer dedicate resources to our DFN-529 intangible asset and any future development efforts were abandoned. In connection with this decision, we concluded that DFN-529 was impaired in its entirety.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       48
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Results of Operations for Year Ended December 31, 2021 Compared to Year Ended December 31, 2020 </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table summarizes our results of operations for the years ended December 31, 2021 and 2020:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended December 31,</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"><b>&#xa0;</b></td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Change</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 55%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,499,414</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,427,667</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(928,253</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Intangible asset impairment charge</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,639,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,639,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,445,277</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,444,109</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,001,168</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">93,416</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">103,168</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(9,752</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Loss from operations</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24,677,107</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,974,944</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8,702,163</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest income</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">137,487</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">114,257</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">23,230</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Loss from operations before income taxes</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(24,539,620</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(15,860,687</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(8,678,933</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Income tax benefit (expense)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">443,893</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,675,381</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(1,231,488</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(24,095,727</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(14,185,306</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(7,447,445</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Research and development expenses were $8.5 million during the year ended December 31, 2021 compared to $9.4 million during the year ended December 31, 2020, a decrease of 10%. This decrease was due to lower project spending due to the completion and/or wind-down of our clinical studies evaluating TSC in Covid-19, GBM, and stroke.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In the third quarter of 2021, the Company made a determination to no longer dedicate resources to the Company&#x2019;s DFN-529 intangible asset and any future development efforts were abandoned.&#xa0; As a result, we recognized a nonrecurring $8.6 million non-cash impairment charge related to the write down of our DFN-529 IPR&amp;D asset.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">General and administrative expenses were $7.4 million during the year ended December 31, 2021 compared to $6.4 million during the year ended December 31, 2020, an increase of 16%. The increase was primarily due to increased headcount resulting in higher compensation expense and other costs associated with the hiring of new employees as well as an increase in expense related to consulting services.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the year ended December 31, 2021, we recognized an income tax benefit of $0.4 million due to the tax effect of the reduction in the deferred tax liability associated with the basis differences from the DFN-529 IPR&amp;D intangible asset that was written down in the third quarter of 2021. For the year ended December 31, 2020, we recognized an income tax benefit of $1.7 million to reflect the utilization of indefinite deferred tax liabilities as a source of income against indefinite lived portions of our deferred tax assets. Prior to 2021, we recognized the full income tax benefit allowed by the 2017 Tax Act to utilize indefinite deferred tax liabilities as a source of income against indefinite lived portions of our deferred tax assets.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       49
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Liquidity and Capital Resources</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Working Capital</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The following table summarizes our working capital as of December 31, 2021 and 2020:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">37,313,558</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">18,515,595</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Prepaid expenses, deposits and other assets</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">510,015</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">260,825</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total current liabilities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,927,684</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">2,435,783</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Working capital</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">34,895,889</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">16,340,637</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We expect to continue to incur net losses for the foreseeable future. We intend to use our existing cash and cash equivalents for working capital and to fund the research and development of TSC and our other product candidates through 2023.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash Flows</i></b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt;">The following table sets forth our cash flows for the years ended December 31, 2021 and 2020:</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash (used in) provided by:</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(14,501,789</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(13,552,629</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Investing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">4,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Financing activities</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">33,295,752</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,890,875</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">18,797,963</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">4,338,246</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Operating Activities</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the year ended December 31, 2021, net cash used in operating activities increased $0.9 million, or 7% compared to the year ended December 31, 2020.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in operating activities of $14.5 million during the year ended December 31, 2021 was primarily attributable to our net loss of $24.1 million and a $0.4 million change in deferred income taxes. These amounts were partially offset by a $8.6 million non cash impairment charge in connection with the write down of our DFN-529 IPR&amp;D asset, our net change in operating assets and liabilities of $0.4 million, and non-cash charges comprised of $0.9 million of stock-based compensation expense, the loss on the disposal of property and equipment of $0.1 million and depreciation expense of $0.1 million.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash used in operating activities of $13.6 million during the year ended December 31, 2020 was primarily attributable to our net loss of $14.2 million and a $1.7 million change in deferred income taxes. This amount was offset by our net change in operating assets and liabilities of $1.5 million, and non-cash charges comprised of $0.7 million of stock-based compensation expense and depreciation expense of $0.1 million.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Investing Activities</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended December 31, 2021, we received $4,000 from the sale of property and equipment. For the year ended December 31, 2020, we had no cash flows from investing activities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Financing Activities</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">For the year ended December 31, 2021, net cash provided by financing activities increased $15.4 million, or 86% compared to the year ended December 31, 2020.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash provided by financing activities of $33.3 million during the year ended December 31, 2021 was attributable to net proceeds of $31.1 million received from the sale of our common stock in connection with the February 2021 Offering and $2.2 million in proceeds received from the exercise of previously issued common stock warrants.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       50
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Net cash provided by financing activities of $17.9 million during the year ended December 31, 2020 was primarily attributable to the $10.8 million in proceeds (net of underwriting discounts and commissions payable by us) received in connection with the May 2020 Offering and $8.0 million in proceeds received in connection with the exercise of common stock warrants stock during the year. These cash inflows were offset in part by the payment of $1.0 million in additional financing costs.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Capital Requirements</i></b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We expect to continue to incur substantial expenses and generate significant operating losses as we continue to pursue our business strategy of developing TSC. Our operations have consumed substantial amounts of cash since inception and we expect to continue to spend substantial amounts of cash to advance the clinical development of TSC and any other product candidates we may in-license or acquire in the future. As of the date of this Annual Report, most of our cash resources for clinical development are dedicated to our ongoing and planned clinical trials. While we believe we have adequate cash resources to continue operations through 2023, we anticipate that we will need additional funding in order to complete development of TSC which, if available, could be obtained through additional capital raising transactions, entry into strategic partnerships or collaborations, or alternative financing arrangements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As of December&#xa0;31, 2021, we did not have any credit facilities in place under which we could borrow funds or any other sources of committed capital. In the future, we may seek to raise additional funds through various sources. However, we can give no assurances that we will be able to secure additional sources of funds to support our operations, or if such funds are available to us, that such additional financing will be sufficient to meet our needs or be on terms acceptable to us. This risk may increase if economic and market conditions deteriorate. If we are unable to obtain additional financing when needed, we may need to terminate, significantly modify, or delay the development of TSC or our product candidates, or we may need to obtain funds through collaborations or otherwise on terms that may require us to relinquish rights to our technologies or product candidates that we might otherwise seek to develop or commercialize independently. If we are unable to raise adequate additional capital as and when required in the future, we could be forced to cease development activities and terminate our operations, and you could experience a complete loss of your investment.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To the extent that we raise additional capital in the future through the sale of our common stock or securities convertible or exchangeable for common stock such as common stock warrants, convertible preferred stock, or convertible debt instruments, the interests of our current stockholders may be diluted or otherwise impacted. In particular, specific rights granted to future holders of preferred stock or convertible debt securities may include voting rights, preferences as to dividends and liquidation, conversion and redemption rights, sinking fund provisions, and restrictions on our ability to merge with or sell our assets to a third party. Debt financing, if available, may involve agreements that include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Off-Balance Sheet Arrangements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We do not have any off-balance sheet arrangements, as defined by the rules and regulations of the SEC that have or are reasonably likely to have a material effect on our financial condition, changes in financial condition, revenue or expenses, results of operations, liquidity, capital expenditures or capital resources. As a result, we are not materially exposed to any financing, liquidity, market or credit risk that could arise if we had engaged in these arrangements.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Recently Issued Accounting Pronouncements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The information in <i>Note 3, Basis of Presentation and Summary of Significant Accounting Policies</i> to our consolidated financial statements set forth in, <i>"Part II </i>&#x2014;<i> Item 8 </i>&#x2014;<i> Financial Statements</i>" of this Annual Report is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       51
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 7A.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As a "smaller reporting company" (as such term is defined in Rule 12b-2 of the Exchange Act), we are not required to provide the information described in Item 305 of Regulation S-K and, accordingly, the information required by Item 6 of Form 10-K has been omitted from this Annual Report.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <div><table style="width: 100%; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: top;"><td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 8.</b></p> </td><td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA</b></p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<table style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;" cellspacing="0" cellpadding="0" border="0"><tbody><tr><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Page</b></p> </td></tr>
<tr><td style="vertical-align:bottom;width:88.3%;">&#xa0;</td><td style="vertical-align:bottom;width:12.2%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Report of Independent Registered Public Accounting Firm&#xa0;(<ix:nonNumeric name="dei:AuditorName" contextRef="d_2021-01-01_2021-12-31">KPMG LLP</ix:nonNumeric>, <ix:nonNumeric name="dei:AuditorLocation" contextRef="d_2021-01-01_2021-12-31">McLean, Virginia</ix:nonNumeric> Auditor Firm ID: <ix:nonNumeric name="dei:AuditorFirmId" contextRef="d_2021-01-01_2021-12-31">185</ix:nonNumeric>)</p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">53</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:88.3%;">&#xa0;</td><td style="vertical-align:bottom;width:12.2%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Balance Sheets as of December 31, 2021 and 2020</p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">54</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:88.3%;">&#xa0;</td><td style="vertical-align:bottom;width:12.2%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Operations for the years ended December 31, 2021 and 2020</p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">55</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:88.3%;">&#xa0;</td><td style="vertical-align:bottom;width:12.2%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Changes in Stockholders&#x2019;&#xa0;Equity for the years ended December 31, 2021 and 2020</p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">56</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:88.3%;">&#xa0;</td><td style="vertical-align:bottom;width:12.2%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Consolidated Statements of Cash Flows for the years ended December 31, 2021 and 2020</p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">57</p> </td></tr>
<tr style="background-color: rgb(255, 255, 255);"><td style="vertical-align:bottom;width:88.3%;">&#xa0;</td><td style="vertical-align:bottom;width:12.2%;">&#xa0;</td></tr>
<tr style="background-color: rgb(204, 238, 255);"><td style="vertical-align:bottom;width:88.3%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Notes to the Consolidated Financial Statements for the years ended December 31, 2021 and 2020</p> </td><td style="vertical-align:bottom;width:12.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">58</p> </td></tr>
</tbody></table>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    52
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Report of Independent Registered Public Accounting Firm</b></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">To the Stockholders and Board of Directors</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Diffusion Pharmaceuticals Inc.:</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Opinion on the Consolidated Financial Statements</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have audited the accompanying consolidated balance sheets of Diffusion Pharmaceuticals Inc. and subsidiaries (the Company) as of December 31, 2021 and 2020, the related consolidated statements of operations, changes in stockholders&#x2019; equity, and cash flows for the years then ended, and the related notes (collectively, the consolidated financial statements). In our opinion, the consolidated financial statements present fairly, in all material respects, the financial position of the Company as of December 31, 2021 and 2020, and the results of its operations and its cash flows for each of the years then ended, in conformity with U.S. generally accepted accounting principles.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt;"><i>Basis for Opinion</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">These consolidated financial statements are the responsibility of the Company&#x2019;s management. Our responsibility is to express an opinion on these consolidated financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules and regulations of the Securities and Exchange Commission and the PCAOB.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the consolidated financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits, we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#x2019;s internal control over financial reporting. Accordingly, we express no such opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the consolidated financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the consolidated financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the consolidated financial statements. We believe that our audits provide a reasonable basis for our opinion.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;"><i>Critical Audit Matters</i></p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt;">Critical audit matters are matters arising from the current period audit of the consolidated financial statements that were communicated or required to be communicated to the audit committee and that: (1) relate to accounts or disclosures that are material to the&#xa0;consolidated financial statements and (2) involved our especially challenging, subjective, or complex judgments. We determined that there are no critical audit matters.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ KPMG LLP</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">We have served as the Company&#x2019;s auditor since 2015.</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">McLean, Virginia</p>
<p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">March 18, 2022</p>
<p style="margin: 0pt;">&#xa0;</p>
<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
 <div class="PGFTR" style="text-align: center; width: 100%">
  <div class="hf-row">
   <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
    53
   </div>
  </div>
 </div>
 <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
 <div class="PGHDR" style="text-align: left; width: 100%">
  <div class="hf-row">
   <div class="hf-cell TOCLink">
    &#xa0;
   </div>
  </div>
 </div>
</div>
<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></div>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED BALANCE SHEETS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current assets:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash and cash equivalents</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208347" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">37,313,558</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208348" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="0" format="ixt:numdotdecimal" decimals="INF">18,515,595</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Prepaid expenses, deposits and other current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208349" contextRef="i_2021-12-31" unitRef="USD" name="dffn:PrepaidExpensesDepositsAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">510,015</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208350" contextRef="i_2020-12-31" unitRef="USD" name="dffn:PrepaidExpensesDepositsAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">260,825</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208351" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">37,823,573</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208352" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AssetsCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">18,776,420</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Property and equipment, net</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208353" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208354" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:PropertyPlantAndEquipmentNet" scale="0" format="ixt:numdotdecimal" decimals="INF">149,198</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208355" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208356" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill" scale="0" format="ixt:numdotdecimal" decimals="INF">8,639,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208357" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208358" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">149,162</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208359" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">15,578</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208360" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAssetsNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">15,771</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total assets</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208361" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">37,839,151</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208362" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Assets" scale="0" format="ixt:numdotdecimal" decimals="INF">27,729,551</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Liabilities and Stockholders</b>&#x2019;<b> Equity</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Current liabilities:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accounts payable</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208365" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">947,495</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208366" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccountsPayableCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">545,844</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accrued expenses and other current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208367" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,980,189</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208368" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,776,470</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Current operating lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208369" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208370" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">113,469</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total current liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208371" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,927,684</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208372" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">2,435,783</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred income taxes</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208373" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208374" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilitiesNet" scale="0" format="ixt:numdotdecimal" decimals="INF">443,893</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Noncurrent operating lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208375" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208376" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">35,693</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Total liabilities</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208377" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,927,684</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208378" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:Liabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,915,369</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);" class="GFJY4-DFU-com-rdg-thunderdome-client-resources-CssResource-html-lineItem-v2v-addition"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Commitments and Contingencies (Note 5)</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c82208380">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;<span style="-sec-ix-hidden:c82208381">&#xa0;</span></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stockholders&#x2019; Equity:</p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Common stock, $<span style="-sec-ix-hidden:c82208385"><span style="-sec-ix-hidden:c82208386">0.001</span></span> par value: <span style="-sec-ix-hidden:c82208387"><span style="-sec-ix-hidden:c82208388">1,000,000,000</span></span> shares authorized; <span style="-sec-ix-hidden:c82208389"><span style="-sec-ix-hidden:c82208391">101,914,280</span></span> and <span style="-sec-ix-hidden:c82208390"><span style="-sec-ix-hidden:c82208392">64,015,441</span></span> shares issued and outstanding at December 31, 2021 and 2020, respectively</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208383" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">101,914</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208384" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CommonStockValue" scale="0" format="ixt:numdotdecimal" decimals="INF">64,016</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Additional paid-in capital</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208393" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">164,814,664</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208394" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AdditionalPaidInCapitalCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">130,659,550</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Accumulated deficit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208395" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">130,005,111</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208396" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:RetainedEarningsAccumulatedDeficit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">105,909,384</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Total stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208397" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">34,911,467</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208398" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">24,814,182</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total liabilities and stockholders' equity</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208399" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">37,839,151</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208400" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="0" format="ixt:numdotdecimal" decimals="INF">27,729,551</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       54
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED STATEMENTS OF OPERATIONS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating expenses:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Research and development</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208402" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">8,499,414</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208403" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">9,427,667</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Intangible asset impairment charge</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208404" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" format="ixt:numdotdecimal" decimals="INF">8,639,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208405" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">General and administrative</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208406" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">7,445,277</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208407" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GeneralAndAdministrativeExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">6,444,109</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208408" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationNonproduction" scale="0" format="ixt:numdotdecimal" decimals="INF">93,416</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208409" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationNonproduction" scale="0" format="ixt:numdotdecimal" decimals="INF">103,168</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Loss from operations</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208410" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,677,107</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208411" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:OperatingIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">15,974,944</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other income:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Interest income</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208413" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" format="ixt:numdotdecimal" decimals="INF">137,487</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208414" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:InterestIncomeExpenseNonoperatingNet" scale="0" format="ixt:numdotdecimal" decimals="INF">114,257</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Loss before income taxes</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208415" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,539,620</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208416" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">15,860,687</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Income tax benefit</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208417" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">443,893</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208418" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,675,381</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208419" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,095,727</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208420" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">14,185,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deemed dividend arising from warrant exchange</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208421" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="dffn:DeemedDividendFromWarrantExchange" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208422" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="dffn:DeemedDividendFromWarrantExchange" scale="0" format="ixt:numdotdecimal" decimals="INF">1,950,378</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss applicable to common stockholders</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208423" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,095,727</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208424" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">16,135,684</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Share information:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss per share of common stock, basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208426" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.25</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208427" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareBasic" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">0.30</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Weighted average shares outstanding, basic and diluted</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208428" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">97,626,748</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208429" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:EarningsPerShareDiluted" scale="0" format="ixt:numdotdecimal" decimals="INF">53,831,973</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       55
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED STATEMENTS OF CHANGES IN STOCKHOLDERS</b>&#x2019;<b> EQUITY </b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="18" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stockholders' Equity</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Common Stock</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
      <td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     </tr>

     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Shares</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Amount</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Additional</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Paid-in</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Capital</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Accumulated</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Deficit</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stockholders'</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Equity</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 40%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2019</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208430" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">33,480,365</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208431" contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">33,481</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208432" contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">111,824,859</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208433" contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">91,724,078</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208434" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">20,134,262</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 9pt; text-indent: -9pt;">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208435" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">11,428,572</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208436" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">11,429</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208437" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">10,330,202</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208438" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208439" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">10,341,631</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock upon exercise of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208440" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">19,106,504</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208441" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">19,106</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208442" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">7,768,370</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208443" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208444" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">7,787,476</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208446" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208447" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">736,119</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208448" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208449" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">736,119</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208451" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208452" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208453" contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">14,185,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208454" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">14,185,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208455" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">64,015,441</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208456" contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">64,016</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208457" contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">130,659,550</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208458" contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">105,909,384</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208459" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">24,814,182</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock and warrants, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208460" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">33,658,538</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208461" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">33,658</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208462" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">31,060,644</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208463" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208464" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">31,094,302</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Issuance of common stock upon exercise of warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208465" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">4,230,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208466" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">4,230</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208467" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,197,220</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208468" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208469" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,201,450</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vesting of restricted stock units</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208470" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="INF">10,301</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208471" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="INF">10</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208472" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">10</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208473" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208474" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208476" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208477" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">897,260</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208478" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208479" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="0" format="ixt:numdotdecimal" decimals="INF">897,260</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208481" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208482" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208483" contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,095,727</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208484" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,095,727</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2021</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208485" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="Share" name="us-gaap:SharesOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">101,914,280</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208486" contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">101,914</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208487" contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">164,814,664</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208488" contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">130,005,111</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208489" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" scale="0" format="ixt:numdotdecimal" decimals="INF">34,911,467</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       56
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>CONSOLIDATED STATEMENTS OF CASH FLOWS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div>
   <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
    <tbody>
     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year Ended December 31,</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom;">
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Operating activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net loss</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208491" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">24,095,727</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208492" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetIncomeLoss" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">14,185,306</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Depreciation and amortization</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208494" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">93,416</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208495" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DepreciationDepletionAndAmortization" scale="0" format="ixt:numdotdecimal" decimals="INF">103,168</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Loss on disposal of property and equipment</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208496" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">51,782</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208497" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Stock-based compensation expense</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208498" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">897,260</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208499" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">736,119</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Abandonment of in-process research and development intangible asset</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208500" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentInProcess" scale="0" format="ixt:numdotdecimal" decimals="INF">8,639,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208501" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ResearchAndDevelopmentInProcess" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Change in deferred income taxes</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208502" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">443,893</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208503" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxExpenseBenefit" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">1,675,381</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Changes in operating assets and liabilities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Prepaid expenses, deposits and other assets</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208505" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">248,997</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208506" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">518,169</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 27pt;">Accounts payable, accrued expenses and other liabilities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208507" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">605,370</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208508" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">950,602</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash used in operating activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208509" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">14,501,789</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208510" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF" sign="-">13,552,629</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows provided by investing activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Cash received from sale of property and equipment</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208512" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" format="ixt:numdotdecimal" decimals="INF">4,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208513" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by investing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208514" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">4,000</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208515" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash flows provided by financing activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from the sale of common stock, net of issuance costs</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208517" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">31,094,302</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208518" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="0" format="ixt:numdotdecimal" decimals="INF">10,827,100</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Proceeds from the sale of common stock warrants</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208519" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="dffn:ProceedsFromSaleOfCommonStockWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">2,201,450</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208520" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="dffn:ProceedsFromSaleOfCommonStockWarrants" scale="0" format="ixt:numdotdecimal" decimals="INF">8,046,103</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Payment of offering costs</p> </td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208521" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:PaymentsOfFinancingCosts" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td>
      <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208522" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:PaymentsOfFinancingCosts" scale="0" format="ixt:numdotdecimal" decimals="INF">982,328</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net cash provided by financing activities</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208523" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">33,295,752</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208524" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="0" format="ixt:numdotdecimal" decimals="INF">17,890,875</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net increase in cash and cash equivalents</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208525" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">18,797,963</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208526" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="0" format="ixt:numdotdecimal" decimals="INF">4,338,246</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at beginning of year</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208527" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="INF">18,515,595</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208528" contextRef="i_2019-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="INF">14,177,349</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Cash and cash equivalents at end of year</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208529" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="INF">37,313,558</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208530" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="0" format="ixt:numdotdecimal" decimals="INF">18,515,595</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
      <td>&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Supplemental disclosure of non-cash investing and financing activities:</p> </td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     </tr>

     <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
      <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt; margin-left: 18pt;">Vesting of restricted stock units</p> </td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208532" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="dffn:RestrictedStockUnitsVestedAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">10</ix:nonFraction></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
      <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><em style="font: inherit;">&#x2014;</em></td>
      <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
     </tr>

    </tbody>
   </table>
  </div>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><i>See accompanying notes to consolidated financial statements.</i></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       57
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:NatureOfOperations" id="c2066658" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">1.</em> Organization and Description of Business</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Diffusion Pharmaceuticals Inc. ("the Company"), a Delaware corporation, is a biopharmaceutical company developing novel therapies that enhance the body&#x2019;s ability to deliver oxygen to areas where it is needed most. The Company&#x2019;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions. In <em style="font: inherit;"> November 2021, </em>based on the preclinical and clinical data accumulated to date and the significant unmet medical need, the Company announced that its near-term focus will be the design and execution of a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="dffn:LiquidityDisclosureTextBlock" id="c2066659" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">2.</em> Liquidity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has <em style="font: inherit;">not</em> generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. <em style="font: inherit;">No</em> assurance can be given that any such financing will be available when needed, or at all, or that the Company&#x2019;s research and development efforts will be successful.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with <em style="font: inherit;">third</em> parties and other strategic alliances and business transactions. The Company does <em style="font: inherit;">not</em> have any commitments to obtain additional funds and <em style="font: inherit;"> may </em>be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with <em style="font: inherit;">third</em> parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it <em style="font: inherit;"> may </em>receive lower consideration upon commercialization of such products than if it had <em style="font: inherit;">not</em> entered such arrangements or if it entered into such arrangements at later stages in the product development process.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company&#x2019;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#x2019;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#x2019;s financial condition and future operations. The Company expects that its existing cash and cash equivalents as of <em style="font: inherit;"> December 31, 2021 </em>will enable it to fund its operating expenses and capital expenditure requirements through <em style="font: inherit;">2023.</em></p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="c2066660" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">3.</em></b>&#xa0;<b>Basis of Presentation and Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="c82209484" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Basis of Presentation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying consolidated&#xa0;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:UseOfEstimates" id="c82209486" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">58</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="c82209487" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ConcentrationRiskCreditRisk" id="c82209488" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="c82209489" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash and Cash Equivalents</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company considers any highly-liquid investments, such as money market funds, with an original maturity of <em style="font: inherit;">three</em> months or less to be cash and cash equivalents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="c82209490" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c82208549" format="ixt-sec:duryear">2</ix:nonNumeric> to <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember" name="us-gaap:PropertyPlantAndEquipmentUsefulLife" id="c82208551" format="ixt-sec:duryear">15</ix:nonNumeric> years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations. In <em style="font: inherit;"> November 2021, </em>the Company terminated the lease of its prior corporate headquarters and in connection with the termination the Company disposed of all of its related property and equipment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock" id="c82209491" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Intangible Asset</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021,</em> the Board of Directors made a determination to <em style="font: inherit;">no</em> longer dedicate financial resources to the Company's DFN-<em style="font: inherit;">529</em> intangible asset and any future internal development efforts were abandoned. In connection with this decision, the Company concluded that DFN-<em style="font: inherit;">529</em> was impaired in its entirety and as such, the Company recognized a non-cash impairment charge of $<ix:nonFraction id="c82208563" contextRef="d_2021-10-01_2021-12-31" unitRef="USD" name="us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" scale="6" format="ixt:numdotdecimal" decimals="-5">8.6</ix:nonFraction> million during the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021.</em> The abandonment also resulted in an income tax benefit of $<ix:nonFraction id="c82208570" contextRef="d_2021-10-01_2021-12-31" unitRef="USD" name="us-gaap:IncomeTaxExpenseBenefit" scale="6" format="ixt:numdotdecimal" decimals="-5" sign="-">0.4</ix:nonFraction> million due to the tax effect of the reduction in the deferred tax liability associated with the asset.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="c82209492" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">At the end of the reporting period, the Company compares payments made to <em style="font: inherit;">third</em>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <em style="font: inherit;"> may </em>record net prepaid or accrued expenses relating to these costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">59</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Upfront payments made to <em style="font: inherit;">third</em> parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:LegalCostsPolicyTextBlock" id="c82209493" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Patent Costs</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxPolicyTextBlock" id="c82209494" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&#xa0;<em style="font: inherit;">not</em>&#xa0;that some portion or all of a deferred tax asset will&#xa0;<em style="font: inherit;">not</em>&#xa0;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&#xa0;<em style="font: inherit;">not</em>&#xa0;to be sustained.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">FASB ASC Subtopic <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> <i>Accounting for Uncertainty of Income Taxes</i>, (&#x201c;ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10&#x201d;</em>) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company <em style="font: inherit;"> may </em>recognize the tax benefit from an uncertain tax position only if it is more likely than <em style="font: inherit;">not</em> such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than <em style="font: inherit;">50%</em> likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> the Company&#x2019;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="c82209495" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Stock-based Compensation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended <em style="font: inherit;"> December 31, 2020, </em>it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. <ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c82208586" format="ixt-sec:duryear">10</ix:nonNumeric> years) of the stock option and therefore the Company began to use the contractual life as the expected term.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <em style="font: inherit;">no</em> dividend yield because dividends are <em style="font: inherit;">not</em> expected to be paid in the near future, which is consistent with the Company&#x2019;s history of <em style="font: inherit;">not</em> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">60</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:EarningsPerSharePolicyTextBlock" id="c82209496" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Net Loss Per Common Share</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are <em style="font: inherit;">not</em> included in the calculation as the impact is anti-dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="c2066661" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208616" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">6,499,469</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208617" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">9,100,112</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208618" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">3,626,223</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208619" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">2,240,204</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208620" contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">275,450</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208621" contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">153,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208622" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">10,401,142</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208623" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">11,493,316</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p></ix:nonNumeric><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i></i></b></p><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="c82209497" escape="true"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Recently Issued But <em style="font: inherit;">Not</em> Yet Adopted Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> Financial Instruments&#x2014;<i>Credit Losses, Measurement of Credit Losses on Financial Instruments</i> (Topic <em style="font: inherit;">326</em>). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will <em style="font: inherit;">no</em> longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective for the Company as of <em style="font: inherit;"> January 1, 2022. </em>The Company is currently evaluating the impact of this ASU but&#xa0;does <em style="font: inherit;">not</em> expect that adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> &#x201c;Income Taxes (Topic <em style="font: inherit;">740</em>): <i>Simplifying the Accounting for Income Taxes</i>.&#x201d; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have <em style="font: inherit;">not</em> been issued and interim periods therein. The Company adopted this standard in <em style="font: inherit;"> January 2021 </em>and the adoption did <em style="font: inherit;">not</em> have a material impact on its related disclosures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">61</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude></ix:exclude></ix:nonNumeric><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b></b></p>
  </ix:nonNumeric>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" id="c2066662" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">4.</em></b>&#xa0;<b>Accrued Expenses and Other Current Liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued expenses and other current liabilities consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:OtherCurrentLiabilitiesTableTextBlock" id="c2066663" escape="true">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom;">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208625" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">879,971</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208626" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedSalariesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">653,899</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208627" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">247,704</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208628" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:AccruedProfessionalFeesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">31,809</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208629" contextRef="i_2021-12-31" unitRef="USD" name="dffn:AccruedClinicalStudiesExpensesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">786,579</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208630" contextRef="i_2020-12-31" unitRef="USD" name="dffn:AccruedClinicalStudiesExpensesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,055,398</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208631" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">65,935</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208632" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherSundryLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">35,364</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208633" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,980,189</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208634" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:OtherAccruedLiabilitiesCurrent" scale="0" format="ixt:numdotdecimal" decimals="INF">1,776,470</ix:nonFraction></td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td>
      </tr>

     </tbody>
    </table>
   </ix:nonNumeric>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="c2066664" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">5.</em></b>&#xa0;<b>Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Office Space Lease Commitment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> November 8, 2021, </em>the Company entered into a Deed of Lease Termination Agreement with the Carlton Landlord providing for the early termination of the Carlton Lease related to the Company's prior corporate headquarters. The Carlton Lease was previously scheduled to expire on <em style="font: inherit;"> April 30, 2022. </em>In connection with the termination, the Company made a <em style="font: inherit;">one</em>-time payment to the Carlton Landlord of approximately $<ix:nonFraction id="c82208637" contextRef="d_2021-11-08_2021-11-08" unitRef="USD" name="us-gaap:OperatingLeasePayments" scale="0" format="ixt:numdotdecimal" decimals="INF">14,000</ix:nonFraction>, net of a security deposit subsequently returned in accordance with the Carlton Lease. In lieu of the fixed office and laboratory space previously available to us under the Carlton Lease, the Company has entered into short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Rent expense related to the Company's operating lease for both the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was approximately $<ix:nonFraction id="c82208641" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:OperatingLeaseExpense" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development Arrangements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which <em style="font: inherit;"> may </em>require upfront payments and long-term commitments of cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Defined Contribution Retirement Plan</i></b>&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has established a <em style="font: inherit;">401</em>(k)&#xa0;defined contribution plan that covers all employees who qualify under the terms of the plan. Eligible employees <em style="font: inherit;"> may </em>elect to contribute to the <em style="font: inherit;">401</em>(k) Plan up to <ix:nonFraction id="c82208645" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" scale="-2" format="ixt:numdotdecimal" decimals="1">90</ix:nonFraction>% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of <ix:nonFraction id="c82208646" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent" scale="-2" format="ixt:numdotdecimal" decimals="2">4</ix:nonFraction>% of the participant&#x2019;s compensation. The Company made matching contributions under the <em style="font: inherit;">401</em>(k) Plan of approximately $<ix:nonFraction id="c82208648" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">75,000</ix:nonFraction> and $<ix:nonFraction id="c82208649" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="0" format="ixt:numdotdecimal" decimals="INF">68,000</ix:nonFraction> for the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">62</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:9pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> August 7, 2014, </em>a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#x2019;s legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case <em style="font: inherit;">No.</em> <em style="font: inherit;">BC553996</em>). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#x2019; fees and costs. On <em style="font: inherit;"> December 30, 2014, </em>the Company filed a petition to compel arbitration and a motion to stay the action. On <em style="font: inherit;"> April 1, 2015, </em>the plaintiff filed a petition in opposition to the Company&#x2019;s petition to compel arbitration and a motion to stay the action. After a related hearing on <em style="font: inherit;"> April 14, 2015, </em>the court granted the Company&#x2019;s petition to compel arbitration and a motion to stay the action. On <em style="font: inherit;"> January 8, 2016, </em>the plaintiff filed an arbitration demand with the American Arbitration Association. On <em style="font: inherit;"> November 19, 2018 </em>at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds <em style="font: inherit;">not</em> to dismiss the case and an arbitration hearing was scheduled, originally for <em style="font: inherit;"> November 2020 </em>but later postponed due to the COVID-<em style="font: inherit;">19</em> pandemic and related restrictions on gatherings in the State of California. In addition, following the <em style="font: inherit;"> November 2018 </em>hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On <em style="font: inherit;"> October 22, 2021, </em>following a determination by the bankruptcy trustee <em style="font: inherit;">not</em> to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on <em style="font: inherit;"> February 23, 2022 </em>at which a trial date of <em style="font: inherit;"> May 24, 2023 </em>was set, and the parties have agreed to stipulate to mediation in advance of the trial.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company believes the claims in this matter are without merit and intends to defend itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter <em style="font: inherit;"> may </em>have on the Company&#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#x2019;s financial position, results of operations and cash flows.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:StockholdersEquityNoteDisclosureTextBlock" id="c2066665" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">6.</em></b>&#xa0;<b>Stockholders' Equity and Common Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i><em style="font: inherit;">2021</em> Common Stock Offering</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> February 2021, </em>the Company completed the <em style="font: inherit;"> February 2021 </em>Offering in which it offered and sold <ix:nonFraction id="c82208666" contextRef="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">33,658,538</ix:nonFraction> shares of its common stock in an underwritten, public offering for a purchase price to the public of $<ix:nonFraction id="c82208667" contextRef="i_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.025</ix:nonFraction> per share, inclusive of shares offered and sold pursuant to the exercise in full by the underwriter of its <ix:nonNumeric contextRef="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" name="dffn:UnderwriterOptionToPurchaseAdditionalSharesTerm" id="c82208668" format="ixt-sec:durday">30</ix:nonNumeric>-day option to purchase additional shares. The <em style="font: inherit;"> February 2021 </em>Offering resulted in aggregate net proceeds to the Company of $<ix:nonFraction id="c82208669" contextRef="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">31.1</ix:nonFraction> million, after deducting underwriting commissions, discounts, and expenses. In addition, at the closings of the <em style="font: inherit;"> February 2021 </em>Offering, the Company issued to designees of the underwriter of the transaction warrants to purchase up to an aggregate of <ix:nonFraction id="c82208670" contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">1,682,927</ix:nonFraction> shares of common stock to designees. The underwriter warrants have an exercise price of $<ix:nonFraction id="c82208671" contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.28125</ix:nonFraction> per share and a term of <span style="-sec-ix-hidden:c82208672">five</span> years from the date of issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i><em style="font: inherit;">2020</em> Common Stock Offering</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> May 2020, </em>the Company completed the <em style="font: inherit;"> May 2020 </em>Offering, a public offering of <ix:nonFraction id="c82208674" contextRef="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" format="ixt:numdotdecimal" decimals="INF">11,428,572</ix:nonFraction> shares of common stock for a purchase price of $<ix:nonFraction id="c82208675" contextRef="i_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember" unitRef="USDPerShare" name="us-gaap:SharesIssuedPricePerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">1.05</ix:nonFraction> per share for net proceeds of $<ix:nonFraction id="c82208676" contextRef="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember" unitRef="USD" name="us-gaap:ProceedsFromIssuanceOfCommonStock" scale="6" format="ixt:numdotdecimal" decimals="-5">10.3</ix:nonFraction> million after deducting commissions, discounts, and other offering costs. In addition, at the closing of the <em style="font: inherit;"> May 2020 </em>Offering, the Company issued warrants to purchase up to <ix:nonFraction id="c82208677" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">571,429</ix:nonFraction> shares of common stock to designees of the placement agent for the <em style="font: inherit;"> May 2020 </em>Offering. The placement agent's warrants have an exercise price of $<ix:nonFraction id="c82208678" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.3125</ix:nonFraction> per share and a term of <span style="-sec-ix-hidden:c82208679">five</span> years from the date of issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, also in <em style="font: inherit;"> May 2020, </em>the Company entered into a warrant exercise agreement with an investor who held the Prior Warrant, a previously outstanding warrant to purchase up to an aggregate of <ix:nonFraction id="c82208680" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction> shares of our common stock at an exercise price of $<ix:nonFraction id="c82208681" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.35</ix:nonFraction> per share. In consideration for the exercise of the Prior Warrant for cash and an additional $<ix:nonFraction id="c82208682" contextRef="d_2020-05-01_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember" unitRef="USDPerShare" name="dffn:ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" scale="0" format="ixt:numdotdecimal" decimals="INF">0.125</ix:nonFraction> per each share of common stock in the Prior Warrant being exercised, the exercising investor received new unregistered warrants to purchase up to an aggregate of <ix:nonFraction id="c82208683" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">5,000,000</ix:nonFraction> shares of common stock in a private placement. The warrants are exercisable immediately at an exercise price of $<ix:nonFraction id="c82208684" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.5263</ix:nonFraction> per share and exercisable until <em style="font: inherit;"> November 8, 2025. </em>During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recognized a deemed dividend of $<ix:nonFraction id="c82208685" contextRef="d_2020-05-01_2020-05-31" unitRef="USD" name="dffn:DeemedDividendFromWarrantExchange" scale="6" format="ixt:numdotdecimal" decimals="-6">2.0</ix:nonFraction> million to reflect the consideration given as an inducement for the investor to exercise the warrants. This deemed dividend was recorded in the Company's consolidated statement of operations during the year ended <em style="font: inherit;"> December 31, 2020 </em>as an increase to the net loss applicable to common stockholders for purposes of computing net loss per share, basic and diluted.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">63</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with the <em style="font: inherit;"> May 2020 </em>Investor Warrant Exercise, the Company issued warrants to purchase up to <ix:nonFraction id="c82208687" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction> shares of common stock to the placement agent with an exercise price of $<ix:nonFraction id="c82208688" contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.5938</ix:nonFraction> per share and otherwise have identical terms to the warrants issued to the investor.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Common Stock Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During its evaluation of equity classification for the Company's common stock warrants issued in <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the Company considered the conditions as prescribed within ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40,</em> <i>Derivatives and Hedging, Contracts in an Entity</i>&#x2019;<i>s own Equity</i>. The conditions within ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em> are <em style="font: inherit;">not</em> subject to a probability assessment. The warrants do <em style="font: inherit;">not</em> fall under the liability criteria within ASC <em style="font: inherit;">480</em> <i>Distinguishing Liabilities from Equity </i>as they are <em style="font: inherit;">not</em> puttable and do <em style="font: inherit;">not</em> represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC <em style="font: inherit;">815,</em> but are eligible for the scope exception as they are indexed to the Company&#x2019;s own stock and would be classified in permanent equity if freestanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had the following warrants outstanding to acquire shares of its common stock:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" id="c2066666" escape="true">
    <table class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;" cellspacing="0" cellpadding="0"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Outstanding</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Range of exercise </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price per share</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration dates</b></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208710" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">903,870</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c82208712" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">33.30</ix:nonFraction></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 2022</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the January 2018 common stock offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208715" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,181,421</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;">$<ix:nonFraction id="c82208716" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">12.00</ix:nonFraction></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$<ix:nonFraction id="c82208718" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">15.00</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">January 2023</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208720" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,382,913</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;">$<ix:nonFraction id="c82208721" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">5.00</ix:nonFraction></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$<ix:nonFraction id="c82208723" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">6.11875</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">May and December 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the November 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208725" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">213,570</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c82208727" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.35</ix:nonFraction></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">May 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the December 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208730" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">313,339</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c82208732" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.6981</ix:nonFraction></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208735" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">571,429</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c82208737" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.3125</ix:nonFraction></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Investor Warrant Exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><ix:nonFraction id="c82208740" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">250,000</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c82208742" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">0.5938</ix:nonFraction></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">November 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the February 2021 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208745" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">1,682,927</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$<ix:nonFraction id="c82208747" contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" unitRef="USDPerShare" name="us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" scale="0" format="ixt:numdotdecimal" decimals="INF">1.28</ix:nonFraction></td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#xa0;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">February 2026</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208750" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ClassOfWarrantOrRightOutstanding" scale="0" format="ixt:numdotdecimal" decimals="INF">6,499,469</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 4%;"><em style="font: inherit;">&#xa0;</em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#xa0;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 16%;"><em style="font: inherit;">&#xa0;</em></td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2021, </em><ix:nonFraction id="c82208703" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="dffn:ClassOfWarrantOrRightsExpired" scale="0" format="ixt:numdotdecimal" decimals="INF">53,570</ix:nonFraction> warrants expired and <ix:nonFraction id="c82208704" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="dffn:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">4,230,000</ix:nonFraction> warrants were exercised for proceeds of approximately $<ix:nonFraction id="c82208705" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:numdotdecimal" decimals="-5">2.2</ix:nonFraction> million. During the year ended <em style="font: inherit;"> December 31, 2020, </em><ix:nonFraction id="c82208706" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="dffn:ClassOfWarrantOrRightsExpired" scale="0" format="ixt-sec:numwordsen" decimals="-3">no</ix:nonFraction> warrants expired and <ix:nonFraction id="c82208707" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="dffn:ClassOfWarrantOrRightExercisedDuringPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">19,106,504</ix:nonFraction> warrants were exercised for gross proceeds of $<ix:nonFraction id="c82208708" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:ProceedsFromWarrantExercises" scale="6" format="ixt:numdotdecimal" decimals="-6">8.0</ix:nonFraction> million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">64</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p></ix:exclude><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b></b></p>
  </ix:nonNumeric>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="c2066667" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:12pt;"><b><em style="font: inherit;">7.</em></b>&#xa0;<b>Stock-Based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:9pt;"><b><i><em style="font: inherit;">2015</em> Equity Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The <em style="font: inherit;">2015</em> Equity Plan provides for increases to the number of shares reserved for issuance thereunder each <em style="font: inherit;"> January 1 </em>equal to <ix:nonFraction id="c82208758" contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Pure" name="dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" scale="-2" format="ixt:numdotdecimal" decimals="2">4.0</ix:nonFraction>% of the total shares of the Company&#x2019;s common stock outstanding as of the immediately preceding <em style="font: inherit;"> December 31, </em>unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, <ix:nonFraction id="c82208759" contextRef="d_2022-01-01_2022-01-01_PlanNameAxis-EquityIncentivePlan2015Member_SubsequentEventTypeAxis-SubsequentEventMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" scale="0" format="ixt:numdotdecimal" decimals="INF">4,076,571</ix:nonFraction> shares were added to the reserve as of &#xa0;<em style="font: inherit;"> January 1, 2022. </em>All such shares <em style="font: inherit;"> may </em>be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the <em style="font: inherit;">2015</em> Equity Plan. As of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were <ix:nonFraction id="c82208763" contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" scale="0" format="ixt:numdotdecimal" decimals="INF">580,925</ix:nonFraction> shares of common stock available for future issuance under the <em style="font: inherit;">2015</em> Equity Plan. Generally, the options have a <span style="-sec-ix-hidden:c82208765">ten</span> (<em style="font: inherit;">10</em>) year contractual term and vest in equal monthly installments over <span style="-sec-ix-hidden:c82208767">three</span> (<em style="font: inherit;">3</em>) years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="c2066668" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208812" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">154,041</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208813" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">164,791</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208814" contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">743,219</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208815" contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">571,328</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208816" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">897,260</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208817" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">736,119</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table summarizes the activity related to all stock options:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="c2066669" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise price</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>per share</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>contractual life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208818" contextRef="i_2019-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">309,276</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208819" contextRef="i_2019-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">55.78</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208822" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,931,100</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208823" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.68</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208826" contextRef="d_2020-01-01_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">172</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208827" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">142.50</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208830" contextRef="i_2020-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">2,240,204</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208831" contextRef="i_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">8.28</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208833" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="0" format="ixt:numdotdecimal" decimals="INF">289,067</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208834" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">1,815,767</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208835" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">0.89</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208838" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">429,748</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208839" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.37</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208842" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,626,223</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208843" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.40</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="c82208844" format="ixt-sec:duryear">8.52</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208846" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">2,140,524</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208847" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">8.58</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" id="c82208848" format="ixt-sec:duryear">8.09</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208850" contextRef="i_2021-12-31" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">3,626,223</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208851" contextRef="i_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">5.40</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" id="c82208852" format="ixt-sec:duryear">8.52</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The weighted average grant date fair value of stock option awards granted was $<ix:nonFraction id="c82208769" contextRef="d_2021-01-01_2021-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.89</ix:nonFraction> and $<ix:nonFraction id="c82208770" contextRef="d_2020-01-01_2020-12-31" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.64</ix:nonFraction> during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. The total fair value of options vested during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> were $<ix:nonFraction id="c82208777" contextRef="d_2021-01-01_2021-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">0.8</ix:nonFraction> million and $<ix:nonFraction id="c82208778" contextRef="d_2020-01-01_2020-12-31" unitRef="USD" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" format="ixt:numdotdecimal" decimals="-5">0.7</ix:nonFraction> million, respectively. <ix:nonFraction id="c82208779" contextRef="d_2021-01-01_2021-12-31" unitRef="Share" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" format="ixt-sec:numwordsen" decimals="-3">No</ix:nonFraction> options were exercised during any of the periods presented. At <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there was $<ix:nonFraction id="c82208783" contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">1.1</ix:nonFraction> million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&#xa0;<ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c82208784" format="ixt-sec:duryear">1.7</ix:nonNumeric> years. During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company granted <ix:nonFraction id="c82208785" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" format="ixt:numdotdecimal" decimals="INF">385,267</ix:nonFraction> performance-based stock options with an exercise price of $<ix:nonFraction id="c82208786" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" format="ixt:numdotdecimal" decimals="INF">1.11</ix:nonFraction> per share, subject to vesting based on the satisfaction of specified performance criteria. Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. The Company recorded stock-based compensation expense of approximately $<ix:nonFraction id="c82208787" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million year ended <em style="font: inherit;"> December 31, 2021, </em>for service-based awards with performance conditions deemed probable of achievement and/or achieved. For performance-based awards containing performance conditions which were <em style="font: inherit;">not</em> deemed probable of achievement at <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">no</em> stock compensation expense was recognized and any previously recognized expense related to those awards originally deemed probable was reversed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">65</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The grant date fair value of employee stock options is determined using the Black-Scholes Model. The following assumptions were used during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="c2066670" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#xa0;</td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c82208855" format="ixt-sec:duryear">10</ix:nonNumeric></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c82208857" format="ixt-sec:duryear">5.31</ix:nonNumeric></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonNumeric contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="c82208859" format="ixt-sec:duryear">10</ix:nonNumeric></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c82208860" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.3</ix:nonFraction>%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208862" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.7</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c82208863" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">0.4</ix:nonFraction>%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208865" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" format="ixt:numdotdecimal" decimals="3">1.7</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c82208866" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">122.6</ix:nonFraction>%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208868" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">125.8</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"><ix:nonFraction id="c82208869" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">113.4</ix:nonFraction>%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#x2014;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208871" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" scale="-2" format="ixt:numdotdecimal" decimals="3">124.8</ix:nonFraction>%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonFraction id="c82208873" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"><ix:nonFraction id="c82208876" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember" unitRef="Pure" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" scale="-2" format="ixt:numdotdecimal" decimals="-3">0</ix:nonFraction>%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#xa0;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Restricted Stock Unit Awards</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="c82208794" format="ixt-sec:durmonth">18</ix:nonNumeric> months after the respective grant date. The fair value of a RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The following table summarizes activity related to RSU stock-based payment awards:</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" id="c2066671" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Units</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>grant date fair value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208878" contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">153,000</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208879" contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.65</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208880" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">138,800</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208881" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.72</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208882" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" scale="0" format="ixt:numdotdecimal" decimals="INF">16,350</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208883" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.51</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208884" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" scale="0" format="ixt:numdotdecimal" decimals="INF">275,450</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208885" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="USDPerShare" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" scale="0" format="ixt:numdotdecimal" decimals="INF">0.70</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>) The Company withheld <ix:nonFraction id="c82208796" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember" unitRef="Share" name="us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation" scale="0" format="ixt:numdotdecimal" decimals="INF">6,049</ix:nonFraction> shares of common stock to cover the tax liability associated with the vesting of these units in <em style="font: inherit;">2021.</em> </sup></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognized approximately $<ix:nonFraction id="c82208798" contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">54,000</ix:nonFraction> and $<ix:nonFraction id="c82208799" contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="USD" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="0" format="ixt:numdotdecimal" decimals="INF">18,000</ix:nonFraction> in expense related to these units during the years ended <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;"> December 2020, </em>respectively. At <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there was approximately $<ix:nonFraction id="c82208804" contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" unitRef="USD" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" format="ixt:numdotdecimal" decimals="-5">0.1</ix:nonFraction> million of unrecognized compensation cost that will be recognized over a weighted average period of <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="c82208805" format="ixt-sec:duryear">2.12</ix:nonNumeric> years.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:IncomeTaxDisclosureTextBlock" id="c2066672" escape="true">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">8.</em></b>&#xa0;<b> Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">66</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p></ix:exclude><p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. &#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="c2066673" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208901" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">6,033,726</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208902" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">3,864,189</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208903" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">1,641,354</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208904" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="0" format="ixt:numdotdecimal" decimals="INF">1,571,227</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208905" contextRef="i_2021-12-31" unitRef="USD" name="dffn:DeferredTaxAssetsOrphanDrugCredits" scale="0" format="ixt:numdotdecimal" decimals="INF">647,937</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208906" contextRef="i_2020-12-31" unitRef="USD" name="dffn:DeferredTaxAssetsOrphanDrugCredits" scale="0" format="ixt:numdotdecimal" decimals="INF">541,384</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208907" contextRef="i_2021-12-31" unitRef="USD" name="dffn:DeferredTaxAssetsLeaseLiability" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208908" contextRef="i_2020-12-31" unitRef="USD" name="dffn:DeferredTaxAssetsLeaseLiability" scale="0" format="ixt:numdotdecimal" decimals="INF">38,394</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208909" contextRef="i_2021-12-31" unitRef="USD" name="dffn:DeferredTaxAssetsCapitalizedCostsAndOther" scale="0" format="ixt:numdotdecimal" decimals="INF">12,403,925</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208910" contextRef="i_2020-12-31" unitRef="USD" name="dffn:DeferredTaxAssetsCapitalizedCostsAndOther" scale="0" format="ixt:numdotdecimal" decimals="INF">10,709,631</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208911" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">20,726,942</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208912" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="0" format="ixt:numdotdecimal" decimals="INF">14,906,646</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208913" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:zerodash" decimals="INF">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208914" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxAssetsNet" scale="0" format="ixt:numdotdecimal" decimals="INF">1,818,179</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td><td>&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><ix:nonFraction id="c82208916" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208917" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" scale="0" format="ixt:numdotdecimal" decimals="INF">2,223,678</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208918" contextRef="i_2021-12-31" unitRef="USD" name="dffn:DeferredTaxLiabilitiesRightOfUseAsset" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208919" contextRef="i_2020-12-31" unitRef="USD" name="dffn:DeferredTaxLiabilitiesRightOfUseAsset" scale="0" format="ixt:numdotdecimal" decimals="INF">38,394</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"><ix:nonFraction id="c82208920" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(<ix:nonFraction id="c82208921" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredIncomeTaxLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">2,262,072</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#xa0;</td><td style="padding-bottom: 1px;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="padding-bottom: 1px;">&#xa0;</td><td style="padding-bottom: 1px;">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"><ix:nonFraction id="c82208922" contextRef="i_2021-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:zerodash" decimals="INF" sign="-">&#x2014;</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208923" contextRef="i_2020-12-31" unitRef="USD" name="us-gaap:DeferredTaxLiabilities" scale="0" format="ixt:numdotdecimal" decimals="INF">443,893</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The Company does <em style="font: inherit;">not</em> have unrecognized tax benefits as of <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> or <em style="font: inherit;"> December 31, 2020. </em>The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The Company had NOL carryforwards for federal and state income tax purposes at <em style="font: inherit;"> December&#xa0;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> of approximately:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock" id="c2066674" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Combined NOL Carryforwards:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208924" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">23,442,045</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208925" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">15,013,388</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208926" contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">23,436,624</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><ix:nonFraction id="c82208927" contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember" unitRef="USD" name="us-gaap:OperatingLossCarryforwards" scale="0" format="ixt:numdotdecimal" decimals="INF">15,007,966</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The pre-<em style="font: inherit;">2018</em> net operating loss carryforwards begin expiring in <em style="font: inherit;">2021</em> for both federal and state income tax purposes. In <em style="font: inherit;"> November 2019, </em>the Company increased the number of shares outstanding resulting in a change of ownership, under the provisions of Internal Revenue Code Section <em style="font: inherit;">382</em> and similar state provisions. These provisions limit the Company&#x2019;s ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation. The Company recorded a <ix:nonFraction id="c82208897" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="dffn:DeferredTaxAssetsValuationAllowancePercentage" scale="-2" format="ixt:numdotdecimal" decimals="0">100</ix:nonFraction>% valuation allowance of the deferred tax assets as of <em style="font: inherit;"> December 31, 2021 </em>because of the uncertainty of their realization.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:exclude>
    <div class="PGFTR" style="text-align: center; width: 100%">
     <div class="hf-row">
      <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       <em style="font: inherit;">67</em>
      </div>
     </div>
    </div>
    <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
    <div class="PGHDR" style="text-align: left; width: 100%">
     <div class="hf-row">
      <div class="hf-cell TOCLink">
        &#xa0;
      </div></div></div></ix:exclude><ix:exclude><div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt"><div class="PGHDR" style="text-align: left; width: 100%"><div class="hf-row"><div class="hf-cell TOCLink"></div>
     </div>
    </div>
   </div>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b>NOTES TO CONSOLIDATED FINANCIAL STATEMENTS</b></p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p></ix:exclude><p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"></p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
   <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="c2066675" escape="true">
    <table class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;" cellspacing="0" cellpadding="0" border="0"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Rate reconciliation:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208928" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208929" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" format="ixt:numdotdecimal" decimals="2">21.0</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208930" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:numdotdecimal" decimals="3">4.7</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208931" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" format="ixt:numdotdecimal" decimals="3">4.7</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208932" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" scale="-2" format="ixt:numdotdecimal" decimals="3">0.4</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(<ix:nonFraction id="c82208933" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" scale="-2" format="ixt:numdotdecimal" decimals="3">2.9</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208934" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="3">24.3</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"><ix:nonFraction id="c82208935" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" scale="-2" format="ixt:numdotdecimal" decimals="3">18.1</ix:nonFraction></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total provision</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208936" contextRef="d_2021-01-01_2021-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">1.8</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#xa0;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(<ix:nonFraction id="c82208937" contextRef="d_2020-01-01_2020-12-31" unitRef="Pure" name="us-gaap:EffectiveIncomeTaxRateContinuingOperations" scale="-2" format="ixt:numdotdecimal" decimals="3" sign="-">10.5</ix:nonFraction></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td></tr>
</tbody></table>
   </ix:nonNumeric>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#xa0;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company&#x2019;s <ix:nonNumeric contextRef="d_2021-01-01_2021-12-31" name="us-gaap:OpenTaxYear" id="c82208899">2018</ix:nonNumeric> to <em style="font: inherit;">2021</em> tax years remain open and subject to examination. All net operating losses and credits remain subject to review until utilized.</p>
  </ix:nonNumeric>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       68
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <div>
    &#xa0;
  </div>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CHANGES IN AND DISAGREEMENTS WITH ACCOUNTANTS ON ACCOUNTING AND FINANCIAL DISCLOSURE</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9A.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CONTROLS AND PROCEDURES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Evaluation of Disclosure Controls and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The term &#x201c;disclosure controls and procedures&#x201d; means our controls and other procedures that are designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is recorded, processed, summarized and reported, within the time periods specified in the SEC&#x2019;s rules and forms. Disclosure controls and procedures include, without limitation, controls and procedures designed to ensure that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our principal executive officer and principal financial officer, or persons performing similar functions, as appropriate to allow timely decisions regarding required disclosure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">We carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of our disclosure controls and procedures (as defined in Exchange Act Rules 13a &#x2013; 15(e) and 15d &#x2013; 15(e)). Based upon that evaluation, our principal executive officer and principal financial officer concluded that, as of the end of the period covered in this report, our disclosure controls and procedures were effective to ensure that information required to be disclosed in reports filed under the Exchange Act is recorded, processed, summarized and reported within the required time periods and is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate to allow timely decisions regarding required disclosure.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our principal executive officer and principal financial officer do not expect that our disclosure controls or internal controls will prevent all error and all fraud. Although our disclosure controls and procedures were designed to provide reasonable assurance of achieving their objectives, a control system, no matter how well conceived and operated, can provide only reasonable, not absolute assurance that the objectives of the system are met. Further, the design of a control system must reflect the fact that there are resource constraints, and the benefits of controls must be considered relative to their costs. Because of the inherent limitations in all control systems, no evaluation of controls can provide absolute assurance that all control issues and instances of fraud, if any, within our company have been detected. These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of a simple error or mistake. Additionally, controls can be circumvented if there exists in an individual a desire to do so. There can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Management</b>&#x2019;<b>s Report on Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting, as such term is defined in Exchange Act Rules 13a-15(f) and 15d-15(f). Under the supervision and with the participation of our Chief Executive Officer and Chief Financial Officer, our management conducted an evaluation of the effectiveness of our internal control over financial reporting based on the framework in <i>Internal Control</i>&#x2014;<i>Integrated Framework (2013)</i> issued by the Committee of Sponsoring Organizations of the Treadway Commission. Based on that evaluation, our management concluded that our internal control over financial reporting was effective as of December&#xa0;31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       69
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Attestation Report of the Independent Registered Public Accounting Firm</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">This report does not include an attestation report of our independent registered public accounting firm regarding internal control over financial reporting. As a "smaller reporting company" (as such term is defined in Rule 12b-2 of the Exchange Act), pursuant to Section 989G of the Dodd-Frank Act, we are exempt from the requirement subjecting management&#x2019;s report to attestation by our independent registered public accounting firm.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Change in Internal Control Over Financial Reporting</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">There was no change in our internal control over financial reporting that occurred during our fourth quarter ended December 31, 2021 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 9B.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>OTHER INFORMATION</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">None.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       70
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART III</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 10.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>DIRECTORS, EXECUTIVE OFFICERS AND CORPORATE GOVERNANCE</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CORPORATE GOVERNANCE</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Introduction</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our common stock is currently listed for quotation on the Nasdaq Capital Market under the symbol &#x201c;DFFN.&#x201d; As required by the Listing Rules of the Nasdaq Capital Market, the Board has adopted certain governance standards, including its standard of independence.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Corporate Governance Guidelines</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Board has adopted Corporate Governance Guidelines, a copy of which can be found on the Investor Relations&#x2014;Corporate Governance section of our corporate website at www.diffusionpharma.com. Among the topics addressed in our Corporate Governance Guidelines are:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board size, composition and qualifications;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Retirement, term limits, and resignation policy;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Selection of directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board compensation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board leadership;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Loans to directors and executive officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board committees;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Executive Officer evaluation;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board and committee meetings;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board and committee evaluations;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Executive sessions of outside directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director continuing education;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Meeting attendance by directors and non-directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Succession planning;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Appropriate information and access;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Related person transactions;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Ability to retain advisors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Communication with directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Conflicts of interest and director independence;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director attendance at annual meetings of stockholders; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Board interaction with corporate constituencies;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Change of principal occupation and board memberships.</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width:18pt;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Stock ownership by directors and executive officers;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Directors &amp; Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board has determined that six of our seven current directors &#x2014; Robert Adams, Eric Francois, Mark T. Giles, Jane H. Hollingsworth, Diana Lanchoney, and Alan Levin &#x2014; are &#x201c;independent directors&#x201d; under the Listing Rules of the Nasdaq Capital Market.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       71
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Board Leadership Structure</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes that our stockholders are best served if the Board retains the flexibility to adapt its leadership structure to applicable facts and circumstances, which necessarily change over time. Accordingly, under our Corporate Governance Guidelines, the office of Chairman of the Board and Chief Executive Officer may or may not be held by one person. The Board believes it is best not to have a fixed policy on this issue and that it should be free to make this determination based on what it believes is best under the circumstances.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Currently, Jane H. Hollingsworth serves as the Chair of the Board and Robert J. Cobuzzi, Jr. serves as our Chief Executive Officer. The Board believes that it is currently in the best interests of the Company&#x2019;s stockholders to separate these offices. This separation allows for our Board Chair to act as a bridge between the Board and the operating organization, while our Chief Executive Officer focuses on running the Company&#x2019;s business. The Board believes that this separation allows for a more effective utilization of the proven leadership capabilities, breadth of industry experience and business success of the individuals holding both positions, and that the Company and its stockholders are best currently served by this leadership structure.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Executive Sessions</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Generally, at regular meetings of the Board, our independent directors meet in executive session with no company management present during a portion of the meeting. Ms. Hollingsworth typically presides over these executive sessions and serves as a liaison between the independent directors and our Chief Executive Officer.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Board Meetings and Attendance</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During 2021, the Board held nine meetings, including one joint meeting with the Compensation Committee. Each of our directors attended 75 percent or more of the meetings of the Board and all committees on which he or she served during 2021. In addition, the Company&#x2019;s directors are expected to participate in the annual meetings of stockholders, and all of the Company&#x2019;s directors participated in the 2021 annual meeting of stockholders.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Board Committees</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board has three standing committees: the Audit Committee, the Compensation Committee, and the Nominating and Corporate Governance Committee. Each of these committees has the composition and responsibilities described below. The Board, from time to time, may establish other committees to facilitate the management of the Company and may change the composition and the responsibilities of the existing committees. Each of the three standing committees has a charter which can be found on the Investor Relations&#x2014;Corporate Governance section of our corporate website at www.diffusionpharma.com.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Audit Committee</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Responsibilities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The primary responsibilities of the Audit Committee include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;overseeing our accounting and financial reporting processes, systems of internal control over financial reporting and disclosure controls and procedures on behalf of the Board and reporting the results or findings of its oversight activities to the Board;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;having sole authority to appoint, retain and oversee the work of our independent registered public accounting firm and establishing the compensation to be paid to the independent registered public accounting firm;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;establishing procedures for the receipt, retention and treatment of complaints regarding accounting, internal accounting controls and/or auditing matters and for the confidential, anonymous submission by our employees of concerns regarding questionable accounting or auditing matters;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       72
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;reviewing and pre-approving all audit services and permissible non-audit services to be performed for us by our independent registered public accounting firm as provided under the federal securities laws and rules and regulations of the SEC; and</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;overseeing our system to monitor and manage risk, and legal and ethical compliance programs, including the establishment and administration (including the grant of any waiver from) a written code of ethics applicable to each of our principal executive officer, principal financial officer, principal accounting officer or controller or persons performing similar functions.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Audit Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Composition and Audit Committee Financial Expert</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The current members of the Audit Committee are Messrs. Francois, Giles, and Levin and Ms. Hollingsworth. Mr. Levin is the chair of the Audit Committee.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Each current member of the Audit Committee qualifies as &#x201c;independent&#x201d; for purposes of membership on audit committees under the Listing Rules of the Nasdaq Capital Market and the rules and regulations of the SEC and is &#x201c;financially literate&#x201d; under the Listing Rules of the Nasdaq Capital Market. In addition, the Board has determined that Mr. Levin qualifies as an &#x201c;audit committee financial expert&#x201d; as defined by the rules and regulations of the SEC and meets the qualifications of &#x201c;financial sophistication&#x201d; under the Listing Rules of the Nasdaq Capital Market as a result of his experience in senior financial positions. Stockholders should understand that these designations related to the Audit Committee members&#x2019; experience and understanding with respect to certain accounting and auditing matters are disclosure requirements of the SEC and the Nasdaq Capital Market and do not impose upon any of them any duties, obligations or liabilities that are greater than those generally imposed on a member of the Audit Committee or of the Board.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Meetings</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-align: justify;">The Audit Committee met five times during 2021.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Processes and Procedures for Complaints</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Audit Committee has established procedures for the receipt, retention and treatment of complaints received by us regarding accounting, internal accounting controls, or auditing matters, and the submission by our employees, on a confidential and anonymous basis, of concerns regarding questionable accounting or auditing matters. Our personnel with such concerns are encouraged to discuss their concerns with their supervisor first, who in turn will be responsible for informing our Chief Executive Officer of any concerns raised. If an employee prefers not to discuss a particular matter with his or her own supervisor, the employee may instead discuss such matter with our Chief Executive Officer. If an individual prefers not to discuss a matter with the Chief Executive Officer or if the Chief Executive Officer is unavailable and the matter is urgent, the individual is encouraged to contact the Chair of the Audit Committee, Mr. Levin.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Compensation Committee</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Responsibilities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The primary responsibilities of the Compensation Committee include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;determining the annual salaries, incentive compensation, long-term incentive compensation, special or supplemental benefits or perquisites and any and all other compensation applicable to our Chief Executive Officer and other executive officers;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin: 0pt 0pt 0pt 36pt;text-indent:18pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       73
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;determining any revisions to corporate goals and objectives with respect to compensation for our Chief Executive Officer and other executive officers and establishing and leading a process for the full Board to evaluate the performance of our Chief Executive Officer and other executive officers in light of those goals and objectives;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;administering our equity-based compensation plans, including determining specific grants of options and other awards for executive officers and other employees under our equity-based compensation plans; and</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;establishing and leading a process for determination of the compensation applicable to the non-employee directors on the Board.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Compensation Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Composition</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The current members of the Compensation Committee are Messrs. Adams and Francois, Ms. Hollingsworth, and Dr. Lanchoney. Mr. Adams is the chair of the Compensation Committee. Each of the four current members of the Compensation Committee is an &#x201c;independent director&#x201d; under the Listing Rules of the Nasdaq Capital Market and a &#x201c;non-employee director&#x201d; within the meaning of Rule 16b-3 under the Exchange Act.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Meetings</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Compensation Committee met seven times during 2021, including one joint meeting with the Board.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Processes and Procedures for Consideration and Determination of Executive Compensation</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Compensation Committee has authority to determine all compensation applicable to our executive officers. In setting executive compensation for our executive officers, the Compensation Committee considers, among other things, the following primary factors: each executive&#x2019;s position within the Company and the level of responsibility; the ability of the executive to affect key business initiatives; the executive&#x2019;s individual experience and qualifications; compensation paid to executives of comparable positions by companies similar to our Company; Company and individual performance; and the executive&#x2019;s current and historical compensation levels. The Compensation Committee has also from time to time &#x2013; including during 2021 &#x2013; retained the services of its independent consulting firm, Radford, to provide advice with respect to executive compensation, such as developing a group of comparable peer companies and reviewing executive and director compensation levels. In making decisions regarding the form and amount of compensation to be paid to our executives, the Compensation Committee may consider information gathered by, and the recommendations of, Radford, when necessary and appropriate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In making decisions regarding the form and amount of compensation to be paid to our executive officers (other than our Chief Executive Officer), the Compensation Committee considers and gives weight to the recommendations of our Chief Executive Officer recognizing that due to his reporting and otherwise close relationship with each executive, the Chief Executive Officer often is in a better position than the Compensation Committee to evaluate the performance of each executive (other than himself). In making decisions regarding the form and amount of compensation to be paid to our Chief Executive Officer, the Compensation Committee considers the recommendation of the Chief Executive Officer with respect to his own compensation and the Compensation Committee&#x2019;s own assessment of the Chief Executive Officer&#x2019;s annual performance and input from other Board members. The Compensation Committee meets in executive session regularly and makes all executive compensation decisions about the Chief Executive Officer without the presence of the Chief Executive Officer or any executive or employee of our company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Processes and Procedures for Consideration and Determination of Director Compensation</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board has delegated to the Compensation Committee the responsibility, among other things, to establish and lead a process for determining compensation payable to our non-employee directors. The Compensation Committee makes recommendations regarding compensation payable to our non-employee directors to the entire Board, which then makes the final decision.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       74
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In making decisions regarding compensation to be paid to our non-employee directors, the Board considers factors such as its own views as to the form and amount of compensation to be paid, the current and anticipated time demands placed on non-employee directors and other factors that may be relevant, including the recommendations of Radford, when necessary and appropriate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Nominating and Corporate Governance Committee</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Responsibilities</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The primary responsibilities of the Nominating and Corporate Governance Committee are:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;identifying individuals qualified to become Board members;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;recommending director nominees for each annual meeting of our stockholders and director nominees to fill any vacancies that may occur between meetings of stockholders;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;general management and director succession planning;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;being aware of best practices in corporate governance and developing and recommending to the Board a set of corporate governance standards to govern the Board, its committees, our company and our employees in the conduct of our business and affairs;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;developing and overseeing a Board and Board committee evaluation process; and</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 18pt; text-align: justify;">&#x2022;&#xa0;&#xa0;&#xa0;&#xa0;reviewing and discussing with our Chief Executive Officer and reporting periodically to the Board plans for executive officer development and succession plans for the Chief Executive Officer and other key executive officers and employees; and</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Nominating and Corporate Governance Committee has the authority to engage the services of outside experts and advisors as it deems necessary or appropriate to carry out its duties and responsibilities.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Composition</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The current members of the Nominating and Corporate Governance Committee are Messrs. Adams, Giles, and Levin and Dr. Lanchoney. Mr. Giles is the chair of the Nominating and Corporate Governance Committee. Each of the four current members of the Nominating and Corporate Governance Committee is an &#x201c;independent director&#x201d; within the meaning of the Listing Rules of the Nasdaq Capital Market.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Meetings</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Nominating and Corporate Governance Committee met three times during 2021.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Processes and Procedures for Consideration Director Nominations</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In selecting nominees for the Board, the Nominating and Corporate Governance Committee first determines whether the incumbent directors are qualified to serve, and wish to continue to serve, on the Board. The Nominating and Corporate Governance Committee believes that our Company and stockholders benefit from the continued service of certain qualified incumbent directors because those directors have familiarity with and insight into our Company&#x2019;s affairs that they have accumulated during their tenure with Diffusion. Appropriate continuity of Board membership also contributes to the Board&#x2019;s ability to work as a collective body. Accordingly, it is the practice of the Nominating and Corporate Governance Committee, in general, to re-nominate an incumbent director at the upcoming annual meeting of stockholders if the director wishes to continue his or her service with the Board, the director continues to satisfy the Nominating and Corporate Governance Committee&#x2019;s criteria for membership on the Board, the Nominating and Corporate Governance Committee believes the director continues to make important contributions to the Board and there are no special, countervailing considerations against re-nomination of the director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       75
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In identifying and evaluating new candidates for election to the Board, the Nominating and Corporate Governance Committee intends to first solicit recommendations for nominees from persons whom the Nominating and Corporate Governance Committee believes are likely to be familiar qualified candidates having the qualifications, skills and characteristics required for Board nominees from time to time. Such persons may include members of the Board and senior management of Diffusion. In addition, the Nominating and Corporate Governance Committee may engage a search firm to assist it in identifying qualified candidates. The Nominating and Corporate Governance Committee then intends to review and evaluate each candidate whom it believes merits serious consideration, taking into account available information concerning the candidate, any qualifications or criteria for Board membership established by the Nominating and Corporate Governance Committee, the existing composition of the Board (including with respect to diversity), and other factors that it deems relevant. In conducting its review and evaluation, the Nominating and Corporate Governance Committee may solicit the views of our management, other Board members and any other individuals it believes may have insight into a candidate. The Nominating and Corporate Governance Committee may designate one or more of its members and/or other Board members to interview any proposed candidate.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Nominating and Corporate Governance Committee will consider recommendations for the nomination of directors submitted by our stockholders. The Nominating and Corporate Governance Committee will evaluate candidates recommended by stockholders in the same manner as those recommended described above.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">There are no formal requirements or minimum qualifications that a candidate must meet in order for the Nominating and Corporate Governance Committee to recommend the candidate to the Board. The Nominating and Corporate Governance Committee believes that each nominee should be evaluated based on his or her merits as an individual, taking into account the needs of the Company and the Board. However, in evaluating candidates, there are a number of criteria that the Nominating and Corporate Governance Committee generally views as relevant and is likely to consider. Some of these factors include:</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the candidate is an &#x201c;independent director&#x201d;&#xa0;under applicable independence tests under the federal securities laws and rules and regulations of the SEC;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the candidate is &#x201c;financially sophisticated&#x201d;&#xa0;and otherwise meets the requirements for serving as a member of an audit committee;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the candidate is an &#x201c;audit committee financial expert&#x201d;&#xa0;under the rules and regulations of the SEC for purposes of serving as a member of the Audit Committee;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the needs of the Company with respect to the particular talents and experience of our directors;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the personal and professional integrity and reputation of the candidate;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the candidate&#x2019;s level of education and business experience;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the candidate&#x2019;s business acumen;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the candidate&#x2019;s level of understanding of our business and industry and other industries relevant to our business;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the candidate&#x2019;s ability and willingness to devote adequate time to the work of the Board and its committees;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the fit of the candidate&#x2019;s skills and personality with those of other directors and potential directors in building a board of directors that is effective, collegial and responsive to the needs of our company;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">whether the candidate possesses strategic thinking and a willingness to share ideas;</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the candidate&#x2019;s diversity of experiences, expertise and background, in general and as compared to other directors on the Board; and</p> </td>
    </tr>

   </tbody>
  </table>
  <table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">
   <tbody>
    <tr>
     <td style="width: 18pt; text-align: justify;">&#xa0;</td>
     <td style="vertical-align:top;width:18pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#x2022;</p> </td>
     <td style="vertical-align:top;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">the candidate&#x2019;s ability to represent the interests of all stockholders and not a particular interest group.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">While we do not have a stand-alone diversity policy, in considering whether to recommend any director nominee, including candidates recommended by stockholders, the Nominating and Corporate Governance Committee will consider the factors described above. The Nominating and Corporate Governance Committee seeks nominees with a broad diversity of experience, expertise, and backgrounds. The Nominating and Corporate Governance Committee does not assign specific weights to particular criteria and no particular criterion is necessarily applicable to all prospective nominees. We believe that the backgrounds and qualifications of the directors, considered as a group, should provide a significant mix of experience, knowledge and abilities that will allow the Board to fulfill its responsibilities.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       76
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Board Oversight of Risk</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board as a whole has responsibility for risk oversight, with more in-depth reviews of certain areas of risk being conducted by the relevant Board committees that report on their deliberations to the full Board. The oversight responsibility of the Board and its committees is enabled by management reporting processes that are designed to provide information to the Board about the identification, assessment and management of critical risks and management&#x2019;s risk mitigation strategies. The areas of risk that we focus on include regulatory, operational, financial (accounting, credit, liquidity and tax), legal, compensation, competitive, health, safety and environment, economic, political and reputational risks.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The committees of the Board oversee risks associated with their respective principal areas of focus. The Audit Committee&#x2019;s role includes a particular focus on the qualitative aspects of financial reporting to stockholders, our processes for the management of business and financial risk, our financial reporting obligations, and our compliance with significant applicable legal, ethical and regulatory requirements. The Audit Committee, along with management, is also responsible for developing and participating in a process for review of important financial and operating topics that present potential significant risk to our company. The Compensation Committee is responsible for overseeing risks and exposures associated with our compensation programs and arrangements, including our executive and director compensation programs and arrangements. The Nominating and Corporate Governance Committee oversees risks relating to our corporate governance matters and policies and management and director succession planning.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We recognize that a fundamental part of risk management is understanding not only the risks a company faces and what steps management is taking to manage those risks, but also understanding what level of risk is appropriate for our Company. The involvement of the full Board in setting our business strategy is a key part of the Board&#x2019;s assessment of management&#x2019;s appetite for risk and also a determination of what constitutes an appropriate level of risk for our company.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We believe our current Board leadership structure is appropriate and helps ensure proper risk oversight for our company for a number of reasons, including: (1) general risk oversight by the full Board in connection with its role in reviewing our key long-term and short-term business strategies and monitoring on an on-going basis the implementation of our key business strategies; (2) more detailed oversight by our Board committees that are currently comprised of and chaired by our independent directors and (3) the focus of our Chairman of the Board on allocating appropriate Board agenda time for discussion regarding the implementation of our key business strategies and specifically risk management.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Code of Business Conduct and Ethics</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Code of Business Conduct and Ethics applies to all of our directors, executive officers and other employees, and meets the requirements of the SEC. A copy of our Code of Business Conduct and Ethics is available on the Investor Relations&#x2014;Corporate Governance&#x2014;Code of Business Conduct and Ethics section of our corporate website at www.diffusionpharma.com.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Policy Regarding Director Attendance at Annual Meetings of Stockholders</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">It is the policy of the Board that directors standing for re-election should attend our annual meeting of stockholders, if their schedules permit.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Process Regarding Stockholder Communications with Board</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Stockholders may communicate with the Board or any one particular director by sending correspondence, to our General Counsel &amp; Corporate Secretary via e-mail to info@diffusionpharma.com or via mail to 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, with an instruction to forward the communication to the Board or one or more particular directors. Our General Counsel &amp; Corporate Secretary will forward promptly all such stockholder communications to the Board or the one or more particular directors, with the exception of any advertisements, solicitations for periodical or other subscriptions and other similar communications.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       77
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>DIRECTORS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Number of Directors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Our Bylaws provide that the Board will consist of at least one member, or such other number as may be determined by the Board or our stockholders. The Board has currently fixed the number of directors at seven.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Information About Our Directors</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below sets forth, as of March 15, 2022, certain information that has been furnished to us by our current directors.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:77%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Age</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Since</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert Adams</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">71</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2016</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">57</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2020</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Eric Francois</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">47</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2021</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Mark T. Giles</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">67</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2016</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Jane H. Hollingsworth</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">63</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2020</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Diana Lanchoney, M.D.</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">55</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2021</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:70.8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Alan Levin</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">59</p> </td>
     <td style="vertical-align:top;width:15%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2016</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, the paragraphs below provide further information about each current director, including all positions he or she holds, his or her principal occupation and business experience for the past five years, and the names of other publicly held companies of which he or she currently serves as a director or served as a director during the past five years. We believe that all of our directors and director nominees display personal and professional integrity; satisfactory levels of education and/or business experience; broad-based business acumen; an appropriate level of understanding of our business and its industry and other industries relevant to our business; the ability and willingness to devote adequate time to the work of the Board and its committees; a fit of skills and personality with those of our other directors that helps build a board of directors that is effective, collegial and responsive to the needs of our company; strategic thinking and a willingness to share ideas; a diversity of experiences, expertise and background; and the ability to represent the interests of all of our stockholders. The information presented below regarding each director and nominee for director also sets forth specific experience, qualifications, attributes and skills that led the Board to the conclusion that he or she should serve as a director in light of our business and structure.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Robert Adams</i></b> &#x2014; Mr. Adams has served as a director since January 2016 and as a director of Diffusion LLC since 2002. Prior to his retirement in 2015, Mr. Adams was a partner in the intellectual property law firm of Nixon &amp; Vanderhye P.C, where he had practiced for over 25 years, focusing on patent litigation and international patent licensing and negotiations. During that time period, Mr. Adams was lead litigation counsel in more than 50 major intellectual property lawsuits, where he directly handled, for example, all intellectual property valuations and settlements on behalf of his U.S. and foreign clients. Moreover, Mr. Adams served as the head negotiator for a well-known Japanese consumer products company for 15 years in various complicated licensing situations. Those negotiations typically involved the cross-licensing of up to hundreds of U.S. and foreign patent rights. His lead licensing activities on behalf of that client included, among other things, multi-year negotiations with Texas Instruments, Advanced Micro Devices and Freescale. Mr. Adams received a B.A. from the University of Maryland and a J.D. from George Washington University (with honors), and is a member of the Virginia State Bar.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes Mr. Adams&#x2019; perspective and experience as a director of Diffusion, as well as the depth and breadth of his intellectual property experience, provide him with the qualifications to serve as a director.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       78
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Robert J. Cobuzzi, Jr., Ph.D.</i></b> &#x2013; Dr. Cobuzzi has served as a director since January 2020 and as our President and Chief Executive Officer since September 2020.&#xa0;Cobuzzi also currently serves as a Venture Partner and Chairman of the Business Development Board for Sunstone Life Science Ventures, an early-stage, European-focused investor in human therapeutics.&#xa0; He also serves on behalf of Sunstone as a Board Observer for Synendos Therapeutics, a venture-backed, Swiss-based biopharmaceutical company focused on developing therapeutics for neuropsychiatric disorders.&#xa0; Previously, Dr. Cobuzzi served as an Advisor to the Mitochondrial Disease Research Program at the Children&#x2019;s Hospital of Philadelphia, an internationally recognized hospital and research center devoted to children, from January 2019 to April 2020, and as President and Chief Executive Officer of MitoCUREia, Inc., an affiliated company, from July 2019 to July 2020. From 2005 to 2018, Dr. Cobuzzi served in various roles at Endo International PLC, a specialty branded and generic pharmaceuticals manufacturer, most recently serving as President of Endo Ventures Ltd. Dr. Cobuzzi received his Bachelor of Arts in Biochemistry and Art History from Colby College and his Ph.D. in Molecular and Cellular Biochemistry from Loyola University Chicago. He served as a Post-doctoral Fellow in Experimental Therapeutics at Roswell Park Cancer Institute.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes Dr. Cobuzzi&#x2019;s experience and insight with drug development and business development and funding, both in the U.S. and abroad, as well as his experience and background as our Chief Executive Officer, provide him with the qualifications to serve as a director.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Eric Francois</i></b> &#x2013; Mr. Francois has served as a director since June 2021. Since November 2021, Mr. Francois has served as a Managing Director at the investment banking firm of Credit Suisse. From November 2015 until November 2021, Mr. Francois&#xa0;served as Chief Financial Officer of Scynexis, Inc., a pharmaceutical company pioneering innovative medicines to potentially help millions of patients worldwide in need of new options to overcome and prevent difficult-to-treat and drug-resistant infections. He previously served as co-founder and Chief Operating Officer of Topi, Inc., a technology startup, from July 2013 to October 2015, where he was responsible for all marketing, commercial and financial activities and helped grow the company from inception to over 250 clients worldwide. Previously, Mr. Francois served from September 2007 to July 2013 as a Director in the Equity Capital Markets Group at Lazard Ltd where he led capital raisings and advisory assignments for healthcare and biotechnology companies. He started his career in September 2000 at Cowen and Company in the Equity Capital Markets and Convertible Debt Groups. Mr. Francois holds a B.A. in Economics and Business Administration and a M.A. in Marketing from Pantheon-Sorbonne University, France.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes that the combination of Mr. Francois&#x2019;s perspective and industry experience, his experience in financial reporting, corporate finance, and capital raising transactions, and his executive-level experience in the pharmaceutical industry all provide him with the qualifications and skills to serve as a director.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Mark T. Giles</i></b> &#x2014; Mr. Giles has served as a director since January 2016 and as a director of Diffusion LLC since 2008. Since July 2007, Mr. Giles has been the sole managing member of Panda Holdings, LLC, which engages in the investment and management of private capital. Since February 2015, Mr. Giles has been a general partner of Anchormark Holdings, LLC, which engages in the investment and management of private capital. Prior to joining Panda Holdings and Anchormark Holdings, Mr. Giles served as the Chief Executive Officer of Virginia National Bank from July 1998 until June 2007 and thereafter continued to serve as the non-executive Chairman until December 2011. Prior to joining Virginia National Bank, Mr. Giles also served as the president of two publicly traded bank holding companies and subsidiary banks in Texas and practiced law with the banking group of a Houston law firm. He chairs the board of Expedition Trust Company. Mr. Giles received a B.S. from the McIntire School of Commerce at the University of Virginia and a J.D. from the University of Virginia School of Law.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes Mr. Giles&#x2019; perspective and experience as a director of Diffusion, as well as the depth and breadth of his business and legal experience, provide him with the qualifications to serve as a director.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Jane H. Hollingsworth</i></b> &#x2013; Ms. Hollingsworth has served as a director since September 2020. She currently serves as the founding Managing Partner of Militia Hill Ventures, an organization that creates, builds, and invests in life sciences companies, a role she has held since 2013. While at Militia Hill, Jane co-founded and currently serves as Executive Chair of Eliksa Therapeutics, a regenerative medicine company, co-founded and served as Executive Chair of Spirovant Sciences, a gene therapy company sold to Sumitomo Dainippon Pharma, and served as Executive Chair and CEO of Immunome Inc., a cancer immunotherapy company. Prior to founding Militia Hill, Ms. Hollingsworth co-founded and served as Chief Executive Officer of NuPathe, Inc., a neuroscience focused biopharmaceutical company. . She also co-founded and served as EVP of Auxilium Pharmaceuticals, a urology and rare disease focused biopharmaceutical company.&#xa0; Ms. Hollingsworth also currently serves on the board of various industry and community organizations, including &#xa0;Afimmune Ltd., Ribonova, the University City Science Center, the Kimmel Center for the Performing Arts and Breatcancer.Org. Ms. Hollingsworth received her B.A. from Gettysburg College and her J.D. from Villanova University.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       79
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes Ms. Hollingsworth&#x2019;s industry perspective and experience, including as chief executive officer and director of a publicly-traded biopharmaceutical company, as well as her depth of her other operating and senior management experience in our industry and educational background, provide her with the qualifications to serve as a director.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Diana Lanchoney, M.D.</i></b> &#x2013;&#xa0;Dr. Lanchoney has served as a director since June 2021. Since 2014, Dr. Lanchoney has served as a Vice President of CSL Behring, Inc., a global biopharmaceutical company manufacturing plasma-derived and recombinant therapeutic products, since&#xa0;October 2021 as Vice President, R&amp;D Strategy Implementation, from January 2018 to October 2021 as Vice President, Clinical Pharmacology and Translational Development and prior to that as Vice President, R&amp;D Project Management, from October 2014 to December 2017. Prior to joining CSL, Dr. Lanchoney served in positions of increasing responsibility with Merck &amp; Co., a global pharmaceutical company, most recently as Associate Vice President, Corporate Strategy. Dr. Lanchoney received her B.A. in Economics and German Studies from Tufts University and her M.D. from the University of Pennsylvania.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes Dr. Lanchoney&#x2019;s professional and academic background and experience provide her with the qualifications to serve as a director, including the depth and breadth of her experience with clinical development, corporate strategy, and pharmaceutical industry partnering.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Alan Levin</i></b> &#x2014; Mr. Levin has served as a director since January 2016 and as a director of Diffusion LLC since June 2015. He previously served as Executive Vice President and Chief Financial Officer of Endo Health Solutions Inc., a global specialty healthcare company, from June 2009 until his retirement in September 2013. Prior to joining Endo, Mr. Levin worked with Texas Pacific Group, a leading private equity firm, and one of their start-up investments. Before that, he was Senior Vice President &amp; Chief Financial Officer of Pfizer, Inc. where he worked for 20 years in a variety of executive positions of increasing responsibility, including Treasurer and Senior Vice President of Finance &amp; Strategic Management for the company&#x2019;s research and development organization. Mr. Levin received a bachelor&#x2019;s degree from Princeton University and a master&#x2019;s degree from New York University&#x2019;s Stern School of Business. Mr. Levin is a certified public accountant. Mr. Levin currently serves as a member of the board of directors of Biocryst Pharmaceuticals, Inc., a Nasdaq-traded biopharmaceuticals company. He is also a member of the Advisory Board of Auven Therapeutics, a private equity fund; and the Critical Path Institute, a nonprofit collaboration between the Food and Drug Administration and pharmaceutical industry participants focused on streamlining and accelerating the development and regulatory pathways for innovative medicines. From December 2013 to July 2019, he was a member of the board of directors of Aceto Corporation, a Nasdaq-traded company specialized in generics and pharmaceutical intermediate products.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Board believes that the combination of Mr. Levin&#x2019;s perspective and experience as a director of Diffusion; his experience in financial reporting, treasury and corporate finance (including his prior positions as chief financial officer of Endo and Pfizer, Inc.); and his executive-level experience in the pharmaceutical industry all provide him with the qualifications and skills to serve as a director.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Overview of Non-Employee Director Compensation Program</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As described in more detail under the heading &#x201c;Corporate Governance&#x2014;Compensation Committee&#x2014;Responsibilities,&#x201d; the Board has delegated to the Compensation Committee the responsibility, among other things, to establish and lead a process for the determination of compensation payable to our non-employee directors. The Compensation Committee makes recommendations regarding compensation payable to our non-employee directors to the entire Board, which then makes final decisions regarding such compensation. Dr. Cobuzzi, our Chief Executive Officer, is not compensated separately for serving on the Board while also serving as an employee.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">As further described below, the principal elements of our non-employee director compensation program for 2021 included cash compensation in the form of annual cash retainers and long-term equity-based incentive compensation, in the form of stock options and restricted stock units.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Cash Compensation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The cash compensation paid to our non-employee members of the Board consists of the following cash retainers:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px; margin-left: 36pt;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 83%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Description</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>Annual Cash Retainer</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Board Member</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">40,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Chair&#xa0;of the Board</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">25,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Audit Committee Chair</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">15,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation Committee Chair</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">10,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nominating and Corporate Governance Committee Chair</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">8,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Audit Committee Member (other than Chair)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">7,500</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Compensation Committee Member (other than Chair)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">5,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Nominating and Corporate Governance Committee Member (other than Chair)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">4,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The annual cash retainers are paid in regular installments and otherwise&#xa0;in accordance with the Company&#x2019;s standard payroll practices. The Compensation Committee has also reserved the right to make a portion of such payments in the form of equity rather than cash under certain conditions. During the fiscal year 2021, all retainers were paid in cash.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       80
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Long-Term Equity-Based Incentive Compensation</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition to cash compensation, our non-employee directors receive long-term equity-based incentive compensation in the form of options to purchase shares of our common stock and restricted stock units. Upon a non-employee director&#x2019;s initial appointment to the Board, he or she shall receive a stock option award to purchase a number of shares of common stock equal to 0.114% of our shares of common stock outstanding on the grant date, vesting in 18 equal monthly installments following his or her appointment to the Board. In addition, upon appointment he or she also receives a restricted stock unit award for an equivalent number of shares, vesting in six tri-monthly installments commencing on the 18-month anniversary of his or her appointment to the Board. Directors appointed prior to January 1, 2020 received the entirety of this initial appointment award in the form of an option.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, each non-employee director annually receives a stock option award to purchase a number of shares of common stock equal to 0.114% of our shares of common stock outstanding on the grant date, vesting in equal monthly installments over one year, unless otherwise provided by the Compensation Committee.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">All option awards granted to our non-employee directors have a ten-year term and an exercise price equal to the fair market value of our common stock on the grant date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Compensation Table for 2021</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below provides summary information concerning the compensation of each individual who served as a non-employee director of the Company during the year ended December 31, 2021:</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="width: 34%;"><b>Name</b></td>
     <td style="width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; width: 1%;"> <p style="margin: 0pt;"><b><b>Fees</b> <b>Earned</b></b></p> <p style="margin: 0pt;"><b><b>or </b></b></p> <p style="margin: 0pt;"><b><b>Paid in</b> <b>Cash</b></b></p> </td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; width: 1%;"> <p style="margin: 0pt;"><b><b>Stock </b></b></p> <p style="margin: 0pt;"><b><b>Awards </b></b></p> <p style="margin: 0pt;"><b><b>(1)</b></b></p> </td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; width: 1%;"> <p style="margin: 0pt;"><b><b>Option</b> </b></p> <p style="margin: 0pt;"><b><b>Awards </b></b></p> <p style="margin: 0pt;"><b><b>(2)</b></b></p> </td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; width: 1%;"> <p style="margin: 0pt;"><b><b>All</b></b></p> <p style="margin: 0pt;"><b><b>Other </b></b></p> <p style="margin: 0pt;"><b><b>Compensation</b></b></p> </td>
     <td style="width: 1%;">&#xa0;</td>
     <td style="width: 1%;">&#xa0;</td>
     <td colspan="2" style="text-align: center; width: 1%;"><b><b>Total</b></b></td>
     <td style="width: 1%;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert Adams</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,616</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,084</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,700</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert J. Cobuzzi, Jr., Ph.D. (3)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">170,735</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">612,617</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(3)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">783,352</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Eric Francois (4)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">27,185</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,968</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,167</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">141,352</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">John L. Gainer, Ph.D. (4)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,288</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">19,288</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Mark T. Giles</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,911</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,084</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,995</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Jane H. Hollingsworth</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">67,374</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,084</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">124,458</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">David G. Kalergis (4)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,932</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">28,932</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diana Lanchoney (4)</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,373</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">49,968</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">114,167</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">139,540</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 34%;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Alan Levin</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">61,411</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">57,084</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 1%;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 10%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">118,495</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">1)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The amounts shown in this column reflect the grant date fair value of restricted stock unit awards granted during 2021 to the identified directors upon their respective initial appointments to the Board, calculated in accordance with the provisions of ASC Topic 718 and determined without regard to forfeitures. See the assumptions used in the Black-Scholes Model in Note 7 to the audited financial statements included in our Annual Report. As of December 31, 2021, the aggregate number of shares underlying restricted stock units granted to our directors were as follows: Dr. Cobuzzi &#x2013;&#xa0;98,100, 16,350 of which were vested; Mr. Francois &#x2013;&#xa0;69,400, none of which were vested; Ms. Hollingsworth &#x2013;&#xa0;54,900, none of which were vested; and Dr. Lanchoney &#x2013;&#xa0;69,400, none of which were vested.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">2)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The amounts shown in this column reflect the grant date fair value of option awards granted during 2021 to the identified directors and former directors, calculated in accordance with the provisions of ASC Topic 718 and determined without regard to forfeitures. See the assumptions used in the Black-Scholes Model in Note 7 to the audited financial statements included in our Annual Report. As of December 31, 2021, the aggregate number of shares subject to options awarded to our each of our directors and former directors were as follows: Mr. Adams &#x2013;&#xa0;177,745, of which 136,125 were vested; Dr. Cobuzzi &#x2013;&#xa0;761,726, of which 410,041 were vested; Dr. Gainer &#x2013;&#xa0;258,770, of which 258,770 were vested; Mr. Francois &#x2013;&#xa0;166,600, of which 69,417 were vested; Mr. Giles &#x2013;&#xa0;177,191, of which 135,541 were vested; Ms. Hollingsworth &#x2013;&#xa0;150,700, of which 101,562 were vested; &#xa0;Mr. Kalergis &#x2013;&#xa0;291,592, of which 291,592 were vested; Dr. Lanchoney &#x2013;&#xa0;166,600, of which 69,417 were vested; and Mr. Levin &#x2013;176,557, of which 134,907 were vested.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">3)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Reflects compensation for Dr. Cobuzzi&#x2019;s service as our President and Chief Executive Officer.&#xa0;&#xa0;See &#x201c;<i>Item 11. Executive Compensation -- Summary Compensation Table</i>&#x201d;&#xa0;for additional information.&#xa0;&#xa0;Dr. Cobuzzi does not receive any additional compensation for his service as a director.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">4)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Dr. Gainer and Mr. Kalergis did not stand for re-election to the Board at our 2021 annual meeting of stockholders and their service on the Board ended upon Mr. Francois&#x2019;&#xa0;and Dr. Lanchoney&#x2019;s election to the Board at such meeting on June 25, 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       81
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>EXECUTIVE OFFICERS</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Information About Our Executive Officers</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The table below sets forth, as of March 15, 2022, certain information concerning our executive officers. Biographical information for Dr. Cobuzzi is included above under the heading, &#x201c;Directors &#x2014; Information About Our Directors," and incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:82%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Name</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:14.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Age</b></p> </td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:46.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Position with Diffusion</b></p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p> </td>
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">57</p> </td>
     <td style="vertical-align:top;width:46.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William K. Hornung</p> </td>
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">53</p> </td>
     <td style="vertical-align:top;width:46.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(204, 238, 255);">
     <td style="vertical-align:top;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Christopher D. Galloway, M.D.</p> </td>
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">51</p> </td>
     <td style="vertical-align:top;width:46.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Medical Officer</p> </td>
    </tr>

    <tr style="background-color: rgb(255, 255, 255);">
     <td style="vertical-align:top;width:40.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William R. Elder</p> </td>
     <td style="vertical-align:top;width:14.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">39</p> </td>
     <td style="vertical-align:top;width:46.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">General Counsel &amp; Corporate Secretary</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In addition, the paragraphs below provide further information about each current director, including all positions he or she holds, his or her principal occupation and business experience for the past five years, and the names of other publicly held companies of which he or she currently serves as a director or served as a director during the past five years.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>William K. Hornung</i></b> &#x2013; Mr. Hornung serves as our Chief Financial Officer, a position he has held since September 2018. Prior to his appointment as Chief Financial Officer, Mr. Hornung served as the Chief Business Officer at Diffusion from July 2017 through September 2018. Previously, Mr. Hornung served as Chief Financial Officer of Contravir Pharmaceuticals from June 2014 to November 2015 and helped the company up-list to Nasdaq and raise nearly $30 million. Prior to Contravir, from 2002 through 2014 Mr. Hornung held positions of increasing responsibility with PTC Therapeutics, most recently serving as Vice President of Finance from April 2012 to March 2014. While at PTC Therapeutics he oversaw the IPO process and raised more than $1 billion. From 1998 through 2002, Mr. Hornung was with Elan Pharmaceuticals (formerly The Liposome Company) in various financial roles. At Liposome and Elan he was responsible for strategic planning and operations of the company's UK-based European headquarters. Earlier in his career Mr. Hornung worked for a clinical research organization where he was responsible for project management and nearly all financial aspects of the company. Mr. Hornung holds a Bachelor of Science in Accounting from the William Paterson State University of New Jersey.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>Christopher D. Galloway, M.D.</i></b> &#x2013; Dr. Galloway has served as our Chief Medical Officer since October 2020. Prior to joining Diffusion, Dr. Galloway served as senior medical director in critical care for La Jolla Pharmaceutical Company from August 2018 to September 2020, where he chaired and oversaw La Jolla&#x2019;s investigator-initiated and collaborative research programs and supported the commercial and medical teams in connection with the launch of GIAPREZA&#x2122;(angiotensin II), which has been approved by the U.S. Food and Drug Administration as a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock. Prior to his time at La Jolla, Dr. Galloway served as medical director for global clinical development at Rakuten Medical Inc. (f/k/a Aspyrian Therapeutics, Inc.), a biotechnology company developing cell-targeting investigative immuno-oncology therapies, from December 2016 to July 2018 and as medical affairs director within Merck &amp; Co., Inc.&#x2019;s immunotherapy division from August 2015 to November 2016. Dr. Galloway received his doctor of medicine from the University of Texas Medical Branch at Galveston, completed his residency in emergency medicine at Carolinas Medical Center in Charlotte, NC, and received a B.A. in biology from the University of Texas at Austin. He is licensed to practice medicine in the State of Colorado and is a diplomate of the American Board of Emergency Medicine.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><b><i>William R. Elder</i></b> &#x2013; Mr. Elder has served as our General Counsel &amp; Corporate Secretary since September 2020. Prior to joining Diffusion, Mr. Elder principally served as president and chief executive officer of BillyVonElds, LLC, a season-long and daily fantasy sports company, where he managed all corporate, legal, and operational aspects of the business from April 2019 to September 2020. From July 2020 to September 2020, Mr. Elder also served as a part-time consultant to Diffusion. From 2011 to February 2019, Mr. Elder served as a corporate and securities associate for Dechert LLP, an international law-firm, where Mr. Elder&#x2019;s practice focused primarily on counseling public companies on securities laws and regulatory requirements, corporate governance matters, and financial transactions in the equity and debt markets. He received his J.D. from the University of Pennsylvania Law School, an M.S. in finance from Villanova University, and a B.A. in economics from Tufts University.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       82
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 11.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXECUTIVE COMPENSATION</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Summary Compensation Table</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The table below provides summary compensation information concerning compensation awarded for service during the years ended December 31, 2021 and December 31, 2020 to the individuals that served as our named executive officers during the year ended December 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: &quot;Times New Roman&quot;; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 22.6%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name and Principal Position</b></p> </td>
     <td style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; width: 5.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Year</b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Salary (1)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Bonus </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Compensation </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(2)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Stock</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Awards </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(3)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Option</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Awards </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(4)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>All Other </b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Compensation</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(5)</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Total</b></b></p> </td>
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
     <td>&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert J. Cobuzzi, Jr., Ph.D. (6)</p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">410,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">164,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">170,735</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">38,617</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">783,352</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Chief Executive Officer</i></p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">129,046</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">67,650</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">50,031</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">512,233</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">58,535</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">817,495</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">William K. Hornung</p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">324,929</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">96,667</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">84,838</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">29,084</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">535,518</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Chief Financial Officer</i></p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">298,100</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">93,902</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">130,083</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">17,866</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">539,951</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Christopher D. Galloway, M.D. (6)</p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">375,000</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">127,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">86,393</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,092</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">625,985</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>Chief Medical Officer</i></p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,827</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">37,500</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">190,882</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">4,599</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">299,808</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">William R. Elder (6)</p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2021</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">256,250</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">76,234</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">66,246</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">5,877</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">404,607</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: &quot;Times New Roman&quot;; font-size: 10pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><i>General Counsel</i></p> </td>
     <td style="text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;">2020</p> </td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">68,270</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">24,750</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">-</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">147,429</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">25,266</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 9%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">265,715</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">1)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents cash portion of base salary as described below under &#x201c;&#x2014;<i>Employment Agreements</i>.&#x201d;</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">2)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Represents the annual cash incentive bonuses for service during the applicable year by our named executive officers as described further below under &#x201c;&#x2014;<i>2021 Bonus Compensation</i>&#x201d;.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">3)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The amount shown in this column reflects the grant date fair value of a restricted stock unit award made to Dr. Cobuzzi in connection with his initial appointment to the Board in January 2020, calculated in accordance with the provisions of ASC Topic 718 and determined without regard to forfeitures. The assumptions used in the Black-Scholes model are disclosed in Note 7 to the audited financial statements included in this Annual Report.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">4)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The amounts shown in this column reflect the grant date fair value of option awards granted for service during the applicable year, calculated in accordance with the provisions of ASC Topic 718 and determined without regard to forfeitures. Amounts shown for 2020 include time-based awards for service during 2020 granted in March 2021 and (i) with respect to Dr. Cobuzzi, $49,971 granted in January 2020 in connection with his initial appointment to the Board, $50,867 granted in June 2020 in connection with his service as a non-employee director during 2020, and $354,483 granted in September 2020 in connection with his initial appointment as Chief Executive Officer; (ii) with respective to Dr. Galloway, $162,083 granted in October 2020 in connection with his initial appointment as Chief Medical Officer, and (iii) with respect to Mr. Elder, $54,523 granted in September 2020 in connection with his initial appointment as General Counsel. Amounts shown for 2021 include the full grant date fair value of milestone-based, performance awards also granted in March 2021. Pursuant to the terms of the corresponding award agreements, two-thirds of the underlying shares originally granted were automatically forfeited due to the first patient in the ILD-DLCO Trial not being dosed on or before September 30, 2021. The Company announced dosing of the first patients in the ILD-DLCO Trial on&#xa0;December 16, 2021.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">5)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The amounts reported in this column for 2020 represent (w) with respect to Dr. Cobuzzi, (i) $50,076 in fees for his service as a non-employee director from January 2020 to September 2020 prior to his appointment as Chief Executive Officer in September 2020 (including fees for committee service), (ii) $5,162 in 401(k) Plan matching contributions by the Company, and (iii) $3,297 in Company-paid health insurance premiums, (x) with respect to Mr. Hornung, (i) $6,459 in 401(k) Plan matching contributions by the Company and (ii) $11,407 in Company-paid health insurance premiums, (y) with respect to Dr. Galloway, (i) $2,500 in 401(k) Plan matching contributions by the Company and (ii) $2,099 in Company-paid health insurance premiums, and (z) with respect to Mr. Elder, (i) $24,775 in fees for his service as a consultant to the Company from July 2020 to September 2020 prior to his appointment as General Counsel &amp; Corporate Secretary and (ii) $491 in Company-paid health insurance premiums. The amounts reported in this column for 2021 represent (w) with respect to Dr. Cobuzzi, (i) $11,600 in 401(k) Plan matching contributions by the Company and (iii) $27,017 in Company-paid health insurance premiums, (x) with respect to Mr. Hornung, (i) $11,600 in 401(k) Plan matching contributions by the Company and (ii) $17,484 in Company-paid health insurance premiums, (y) with respect to Dr. Galloway, (i) $11,600 in 401(k) Plan matching contributions by the Company and (ii) $25,492 in Company-paid health insurance premiums, and (z) with respect to Mr. Elder, $5,877 in Company-paid health insurance premiums.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 18pt;">&#xa0;</td>
     <td style="width: 18pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;">6)</p> </td>
     <td style="width: auto;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">Dr. Cobuzzi began his employment as President &amp; Chief Executive Officer on September 8, 2020 and began his service as a director on January 7, 2020, Dr. Galloway began his employment as Chief Medical Officer on October 19, 2020, and Mr. Elder began his employment as General Counsel &amp; Corporate Secretary on September 23, 2020.&#xa0;&#xa0;Accordingly, during 2020, each received pro-rated compensation in accordance with his respective term of service.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Employment Agreements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Robert J. Cobuzzi, Jr., Ph.D., President &amp; Chief Executive Officer</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Effective September 8, 2020, we entered into an employment agreement with Dr. Cobuzzi pursuant to which he serves as our President &amp; Chief Executive Officer. The employment agreement has an indefinite term. Dr. Cobuzzi is currently entitled to an initial annual base salary of $410,000, subject to increase at the discretion of the Board. Dr. Cobuzzi has the opportunity to earn a target annual bonus of 50 percent of his base salary. The Board may, in its discretion, pay a portion of Dr. Cobuzzi&#x2019; annual salary and annual bonus in the form of equity or equity-based compensation, provided that commencing with the year following the year in which a &#x201c;change of control&#x201d; (as defined in the employment agreement) occurs, Dr. Cobuzzi&#x2019; entire base salary and annual bonus will be paid in cash. For 2021, Dr. Cobuzzi&#x2019; entire pro-rated base salary was paid in cash. The employment agreement contains certain severance and change of control provisions as described in more detail under the heading &#x201c;&#x2014;Post-Termination Severance and Change in Control Arrangements.&#x201d; The employment agreement also contains certain non-competition and non-solicitation provisions (each applicable during employment and for 24 months thereafter), as well as confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       83
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>William K. Hornung, Chief Financial Officer</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Effective September 21, 2018, we entered into an amended and restated employment agreement with Mr. Hornung pursuant to which he serves as our Chief Financial Officer. The employment agreement has an indefinite term. Mr. Hornung was entitled to an annual base salary of $298,100 during 2020, subject to increase at the discretion of the Board. Mr. Hornung has the opportunity to earn a target annual bonus of 35 percent of his base salary. The Board may, in its discretion, pay a portion of Mr. Hornung&#x2019;s annual salary and annual bonus in the form of equity or equity-based compensation, provided that commencing with the year following the year in which a &#x201c;change of control&#x201d; (as defined in the employment agreement) occurs, Mr. Hornung&#x2019;s entire base salary and annual bonus will be paid in cash. For 2021, Mr. Hornung&#x2019;s entire base salary was paid in cash. The employment agreement contains certain severance and change of control provisions as described in more detail under the heading &#x201c;&#x2014;Post-Termination Severance and Change in Control Arrangements.&#x201d; The employment agreement also contains certain non-competition and non-solicitation provisions (each applicable during employment and for 18 months thereafter), as well as confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>Christopher D. Galloway, Chief Medical Officer</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Effective October 19, 2020, we entered into an employment agreement with Dr. Galloway pursuant to which he serves as our Chief Medical Officer. The employment agreement has an indefinite term. Dr. Galloway is entitled to an initial annual base salary of $375,000, subject to increase at the discretion of the Board. Dr. Galloway has the opportunity to earn a target annual bonus of 40 percent of his base salary. The employment agreement contains certain severance and change of control provisions as described in more detail under the heading &#x201c;&#x2014;Post-Termination Severance and Change in Control Arrangements.&#x201d; The employment agreement also contains certain non-competition (applicable during employment and for 12 months thereafter) and non-solicitation provisions (applicable during employment and for 24 months thereafter), as well as confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"><i>William R. Elder, General Counsel &amp; Corporate Secretary</i></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Effective September 23, 2020, we entered into an employment agreement with Mr. Elder pursuant to which he serves as our General Counsel &amp; Corporate Secretary. The employment agreement has an indefinite term. Mr. Elder is entitled to an initial annual base salary of $250,000, subject to increase at the discretion of the Board. Mr. Elder has the opportunity to earn a target annual bonus of 30 percent of his base salary. The Board may, in its discretion, pay a portion of Mr. Elder&#x2019;s annual salary and annual bonus in the form of equity or equity-based compensation, provided that commencing with the year following the year in which a &#x201c;change of control&#x201d; (as defined in the employment agreement) occurs, Mr. Elder&#x2019;s entire base salary and annual bonus will be paid in cash. For 2021, Mr. Elder&#x2019;s entire pro-rated base salary was paid in cash. The employment agreement contains certain severance and change of control provisions as described in more detail under the heading &#x201c;&#x2014;Post-Termination Severance and Change in Control Arrangements.&#x201d; The employment agreement also contains certain non-competition and non-solicitation provisions (each applicable during employment and for 24 months thereafter), as well as confidentiality and non-disparagement provisions (each applicable during employment and at all times thereafter).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>Long-Term Equity Incentive Compensation and Other Compensatory Arrangements</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Compensation Committee administers the 2015 Equity Plan in which our named executive officers participate, the bonus payments made to our named executive officers provided for in the employment agreements described under the heading &#x201c;&#x2014;Employment Agreements,&#x201d; and any other compensation-related matters as they otherwise determine in their discretion. The option grants made for service during 2020 to the named executive officers vest and become exercisable in equal (or as near equal as possible) installments over a 36-month period until fully vested, subject to their continued employment through the applicable vesting date.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During 2021, the Compensation Committee determined that 50% of any annual long-term equity incentive awards granted to our named executive officers for service during the year would be granted at the outset of the year in the form of performance-based options the vesting of which will be dependent on the achievement of specified performance metrics during the year of grant. The remaining 50 percent were granted in the form of option awards subject to time-based vesting early in the subsequent year (i.e. 2022) at the discretion of the Compensation Committee in accordance with past practice. In 2022, the Compensation Committee determined to return to the Company's historic practice of granting all such awards as options subject to time-based vesting.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"><b>2021 Bonus Compensation</b></p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Executive bonuses are determined by the Compensation Committee. The Compensation Committee determines whether bonuses are earned and the amounts of the bonus payout by considering a number of factors, the principal factor being based upon the performance goals developed by the Compensation Committee. Other important factors include clinical trial progress, business development activities, status of public filings, capital raising transactions, and stock price performance.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       84
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Outstanding Equity Awards at Fiscal Year End</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Option Awards</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below provides information regarding unexercised stock option awards held by each of our named executive officers that remained outstanding as of December 31, 2021. Unless otherwise indicated, each grant was awarded under our 2015 Equity Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 25.9%; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name</b></p> </td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 8.7%; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Award </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Type</b></p> </td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 10.6%; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Grant Date</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Shares Underlying Unexercisable Options Exercisable</b></b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Shares Underlying Unexercisable Options Unexercisable</b></b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Exercise </b></b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b><b>Price</b></b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 9.8%; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Expiration </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/7/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">118,600</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.51</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/7/2030</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">6/17/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">61,300</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.00</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">6/17/2030</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">9/8/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">197,917</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">277,083</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.79</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">9/8/2030</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">14,920</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,793</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO**</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,904</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,809</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">William K. Hornung</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/2/2018</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17.70</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/2/2028</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/2/2019</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">16,334</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2.10</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/2/2029</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/2/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">35,067</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">17,533</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.46</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">1/2/2030</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">34,103</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">88,668</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO**</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">8,897</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">17,793</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Christopher D. Galloway, M.D.</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO*</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">10/19/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77,778</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">122,222</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.85</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">10/19/2030</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">7,550</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">19,630</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO**</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">9,060</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18,119</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">William R. Elder</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO*</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">9/22/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">29,167</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">40,833</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.82</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">9/22/2030</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">24,357</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">63,327</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">NQO**</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2021</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,947</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">13,894</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.11</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt;">3/1/2031</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">* - Non-plan based equity award grant made as an inducement to the individual&#x2019;s acceptance of employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">** - Pursuant to the terms of the corresponding award agreements, two-thirds of the underlying shares originally granted were automatically forfeited due to the first patient in the ILD-DLCO Trial not being dosed on or before September 30, 2021. The Company announced dosing of the first patients in the ILD-DLCO Trial on December 16, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><i>Restricted Stock Unit Awards</i></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">The table below provides information regarding restricted stock unit awards held by each of our named executive officers that remained outstanding as of December 31, 2021, if any. Each grant was awarded under our 2015 Equity Plan.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 7.5%; margin-left: 7.5%; width: 85%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 33.8%; vertical-align: top;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name</b></p> </td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 15.1%; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Award Type</b></p> </td>
     <td style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; width: 15.1%; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Grant Date</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of Shares That Have Not Vested</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; vertical-align: top;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; vertical-align: top;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Market Value of Shares That Have Not Vested*</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">RSU</p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1/7/2020</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">81,750</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 15%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">25,343</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">* - Based on a price per share of $0.31, the closing price of our common stock on December 31, 2021 as reported by Nasdaq. The award was granted to Dr. Cobuzzi in connection with his appointment as a non-employee director in January 2020 and vests in six tri-monthly installments. The first such installment vested on October 31, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       85
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>401(k) Retirement Plan</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">We maintain our 401(k) Plan pursuant to which all eligible employees are entitled to make pre-tax and after-tax contributions of their compensation. In addition, the Company makes discretionary matching contributions at a rate of 100% for contributions up to 3% of the participant&#x2019;s eligible compensation and 50% for any additional contributions up to 5% of the participant&#x2019;s eligible compensation. The matching contributions received by our named executive officers in 2021 and 2020 are reported in the &#x201c;All Other Compensation&#x201d; column of the Summary Compensation Table above.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Post-Termination Severance and Change in Control Arrangements</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">As described under the heading &#x201c;&#x2014;Employment Agreements,&#x201d; we have entered into employment agreements with each of Drs. Cobuzzi and Galloway and Messrs. Hornung and Elder that provide for certain severance and change of control benefits, subject to the execution and non-revocation of a release of claims by the executive or his estate (as applicable).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under Dr. Cobuzzi&#x2019;s employment agreement, if his employment is terminated by us other than for &#x201c;cause,&#x201d; death or &#x201c;disability,&#x201d; or by Dr. Cobuzzi for &#x201c;good reason&#x201d; (as such terms are defined in the employment agreement), Dr. Cobuzzi will be entitled to any unpaid bonus earned in the year prior to the termination, a pro-rata portion of the bonus earned during the year of termination, continuation of base salary for 12 months, plus 12 months of COBRA premium reimbursement, provided that if such termination occurs within 60 days before or within 24 months following a &#x201c;change of control&#x201d; (as defined in the employment agreement), then Dr. Cobuzzi will be entitled to receive the same severance benefits as described above, except that he will receive (a) a payment equal to two times the sum of his base salary and the higher of his target annual bonus opportunity and the bonus payment he received for the year immediately preceding the year in which the termination occurred instead of 12 months of base salary continuation, and (b) a payment equal to 36 times the monthly COBRA premium for him and his eligible dependents instead of 12 months of COBRA reimbursements (the payments in clauses (a) and (b) are paid in a lump sum in some cases and partly in a lump sum and partly in installments over 12 months in other cases). In addition, if Dr. Cobuzzi&#x2019;s employment is terminated by us without cause or by Dr. Cobuzzi for good reason, in either case, upon or within 24 months following a change of control, then Dr. Cobuzzi will be entitled to full vesting of all equity awards received by him from us (with any equity awards that are subject to the satisfaction of performance goals deemed earned at not less than target performance, and with any equity award that is in the form of a stock option or stock appreciation right to remain outstanding and exercisable for 24 months following the termination date (but in no event beyond the expiration date of the applicable option or stock appreciation right)).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the employment agreements for each of Dr. Galloway and Messrs. Hornung and Elder, in the event that his employment is terminated by us other than for &#x201c;cause&#x201d;, death or &#x201c;disability&#x201d; or upon his resignation for &#x201c;good reason&#x201d; (as such terms are defined in the applicable employment agreement), the applicable executive will be entitled to any unpaid bonus earned in the year prior to the termination, a pro-rata portion of the bonus earned during the year of termination, continuation of base salary for 9 months, plus 12 months of COBRA premium reimbursement, provided that if such termination occurs within 60 days before or within 24 months following a &#x201c;change of control&#x201d; (as defined in the applicable employment agreement), then he will be entitled to receive the same severance benefits as described above, except that he will receive (a) a payment equal to 1.5 times the sum of his base salary and the higher of his target annual bonus opportunity and the bonus payment he received for the year immediately preceding the year in which the termination occurred instead of 9 months of base salary continuation and (b) a payment equal to 18 times the monthly COBRA premium for him and his eligible dependents instead of 12 months of COBRA reimbursements (the payments in clauses (a) and (b) are paid in a lump sum in some cases and in installments over 9 or 12 months in other cases). In addition, if the applicable executive&#x2019;s employment is terminated by the Company without cause or by the applicable executive for good reason, in either case, upon or within 24 months following a change of control, then the applicable executive will be entitled to full vesting of all equity awards received by him from us (with any equity awards that are subject to the satisfaction of performance goals deemed earned at not less than target performance, and with any equity award that is in the form of a stock option or stock appreciation right to remain outstanding and exercisable for 24 months following the termination date (but in no event beyond the expiration date of the applicable option or stock appreciation right)).</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       86
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Under the employment agreements for each of our current named executive officers, in the event that the executive&#x2019;s employment is terminated due to his death or disability, he (or his estate) will be entitled to any unpaid bonus earned in the year prior to the termination, a pro-rata portion of the bonus earned during the year of termination, 12 months of COBRA premium reimbursement and accelerated vesting of (a) all equity awards received in payment of base salary or an annual bonus and (b) with respect to any other equity award, the greater of the portion of the unvested equity award that would have become vested within 12 months after the termination date had no termination occurred and the portion of the unvested equity award that is subject to accelerated vesting (if any) upon such termination under the applicable equity plan or award agreement (with performance goals deemed earned at not less than target performance, and with any equity award that is in the form of a stock option or stock appreciation right to remain outstanding and exercisable for 12 months following the termination date or, if longer, such period as provided under the applicable equity plan or award agreement (but in no event beyond the expiration date of the applicable option or stock appreciation right)).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Further, under the terms of the stock option agreements with our named executives officers, upon a completion of a &#x201c;change of control&#x201d; (as defined in the 2015 Equity Plan), options held by our named executive officers will become immediately vested and remain exercisable through their expiration date regardless of whether the holder remains in the employment or service of the Company after the change of control. Alternatively, in connection with a change of control, the Compensation Committee may, in its sole discretion, cash out the options.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 12.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT AND RELATED STOCKHOLDER MATTERS</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Based on information available to us and filings with the SEC, the following table sets forth certain information regarding the beneficial ownership (as defined by Rule 13d-3 under the Exchange Act) of our outstanding common stock as of March 1, 2022 for (i) each person or group of affiliated persons known by us to be the beneficial owner of more than 5% of our common stock, if any, (ii) each of our current directors; (iii) each of our current executive officers (as defined in Item 402(a)(3) of Regulation S-K under the Exchange Act); and (iv) all of our current directors and named executive officers as a group. As of March 1, 2022, to our knowledge, no beneficial owner owned 5% or more of the shares of common stock then outstanding.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Beneficial ownership and percentage ownership are determined in accordance with the rules of the SEC and include voting or investment power with respect to shares of stock. This information does not necessarily indicate beneficial ownership for any other purpose. Under these rules, shares of common stock issuable under shares of preferred stock, stock options or warrants that are exercisable or convertible within 60 days of March 1, 2022 are deemed outstanding for the purpose of computing the beneficial ownership percentage of the holder thereof, but are not deemed outstanding for the purpose of computing the beneficial ownership percentage of any other person. Ownership is based upon information provided by each respective director and officer and public documents filed with the SEC, including Forms 3 and 4, Schedules 13D and 13G and certain other documents, which information may not be accurate as of the Record Date.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       87
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Unless otherwise indicated and subject to applicable community property laws, to our knowledge, each stockholder named in the following table possesses sole voting and investment power over their shares of common stock, except for those jointly owned with that person&#x2019;s spouse. Unless otherwise indicated below, the address of each person listed on the table is c/o Diffusion Pharmaceuticals Inc., 300 East Main Street, Suite 201, Charlottesville, Virginia 22902.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 5%; margin-left: 5%; width: 90%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0); width: 66%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Name and Address of Beneficial Owner</b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>Shares of Common Stock Beneficially Owned (1)</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
     <td colspan="2" style="font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b><b>Common Stock Beneficial Ownership Percentage (2)</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><i>Current Directors</i></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert Adams (3)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">166,515</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Robert J. Cobuzzi, Jr., Ph.D. (4)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">551,507</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.5</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Eric Francois (5)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">104,125</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.1</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Mark T. Giles (6)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">210,173</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Jane H. Hollingsworth (7)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">162,661</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Diana Lanchoney, M.D. (8)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">104,125</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.1</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Alan Levin (9)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">156,158</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b><i>Current Named Executive Officers</i></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
     <td style="font-family: Times New Roman; font-size: 10pt;"><i><b>&#xa0;</b></i></td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">William R. Elder (10)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">115,827</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.1</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Christopher D. Galloway, M.D. (11)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">171,063</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.2</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">William K. Hornung (12)</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">142,717</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">0.1</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">%</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>All Current Directors, Director Nominees, and Named Executive Officers as a Group (ten persons) (13)</b></p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><b>1,884,871</b></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"><b>&#xa0;</b></td>
     <td style="width: 14%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;"><b>1.8</b></td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><b>%</b></td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">* Indicates less than 0.1%</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">1.&#xa0;&#xa0;&#xa0;&#xa0;Includes shares of common stock held as of March 1, 2022 plus shares of common stock that may be acquired upon exercise of options, warrants and other rights exercisable within 60 days of the March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">2.&#xa0;&#xa0;&#xa0;&#xa0;Based on 101,924,581&#xa0;shares of common stock issued and outstanding as of March 1, 2022. The percentage ownership and voting power for each person (or all directors and executive officers as a group) is calculated by assuming (i) the exercise or conversion of all preferred stock, options, warrants and convertible securities exercisable or convertible within 60 days of March 1, 2022 held by such person and (ii) the non-exercise and non-conversion of all outstanding preferred stock, warrants, options and convertible securities held by all other persons (including our other directors and executive officers).</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">3.&#xa0;&#xa0;&#xa0;&#xa0;Consists of (a) 1,706 shares held directly by Mr. Adams, (b) 631 shares held jointly with Mr. Adams&#x2019; wife, (c) 1,260 shares held for the benefit of Mr. Adams in his 401(k) retirement account, and (d) 162,918 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">4.&#xa0;&#xa0;&#xa0;&#xa0;Consists of (a) 34,602 shares held directly by Dr. Cobuzzi and (b) 516,905 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">5.&#xa0;&#xa0;&#xa0;&#xa0;Consists of 104,125 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">6.&#xa0;&#xa0;&#xa0;&#xa0;Consists of (a) 294 shares held for the benefit of Mr. Giles in his individual retirement account, (b) 53,513 shares held by MTG Investment Holdings, LLC, and (c) 156,366 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022. Mr. Giles is the sole member of MTG Investment Holdings, LLC and may be deemed to be the beneficial owner of such securities. Mr. Giles disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">7.&#xa0;&#xa0;&#xa0;&#xa0;Consists of (a) 32,876 shares held directly by Ms. Hollingsworth and (b) 129,875 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">8.&#xa0;&#xa0;&#xa0;&#xa0;Consists of 104,125 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">9.&#xa0;&#xa0;&#xa0;&#xa0;Consists of (a) 1,654 shares held by Mr. Levin directly and (b) 154,504 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">10.&#xa0; Consists of (a) 15,000 shares held directly by Mr. Elder and (b) 100,827 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">11.&#xa0; Consists of (a) 20,000 shares held for the benefit of Dr. Galloway in his individual retirement account, (b) 10,000 shares held for the benefit of Dr. Galloway&#x2019;s wife in her individual retirement account, and (c) 141,063 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">12.&#xa0; Consists of 142,717 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">13.&#xa0; Includes 1,713,425 shares of common stock issuable upon the exercise of options exercisable within 60 days of March 1, 2022.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       88
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Delinquent Section 16(a) Reports</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Section 16(a) of the Exchange Act requires our directors and executive officers and all persons who beneficially own more than 10 percent of the outstanding shares of our common stock to file with the SEC initial reports of ownership and reports of changes in ownership of our common stock. Directors, executive officers and greater than 10 percent beneficial owners also are required to furnish us with copies of all Section 16(a) forms they file.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">To our knowledge, based on a review of the copies of such reports and amendments to such reports furnished to us with respect to the year ended December 31, 2021, and based on written representations by our directors and executive officers, all required Section 16 reports under the Exchange Act, for our directors, executive officers and beneficial owners of greater than 10 percent of our common stock were filed on a timely basis during the year ended December 31, 2021, except for the following, each of which were not timely filed: Forms 3 relating to Mr. Francois' and Dr. Lanchoney's respective elections to the Board on June 25, 2021, each filed on October 15, 2021; and a Form 4 relating to a July 1, 2021 grant of options and restricted stock units to Dr. Lanchoney in connection with her election to and service on the Board, filed on October 15, 2021.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 13.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>CERTAIN RELATIONSHIPS AND RELATED TRANSACTIONS, AND DIRECTOR INDEPENDENCE</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Certain Relationships and Related Party Transactions</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Our Audit Committee is charged with the responsibility of reviewing and approving or ratifying all related person transactions in accordance with the Listing Rules of the Nasdaq Capital Market and other applicable law, rules and regulations and any related policies and procedures adopted by or on behalf of the Company and then in effect.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">Since January 1, 2020 there has been no&#xa0;transaction to which we have been a party in which (i) the amount involved in the transaction exceeds $120,000 and (ii) any of our directors, executive officers or, to our knowledge, beneficial owners of more than 5% of our capital stock had or will have a direct or indirect material interest. Furthermore, no family relationships exist among any of our directors or executive officers.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Director Independence</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The information required by Item 13 of Form 10-K with respect to director independence included above under the heading, "Item 10. Directors, Executive Officers and Corporate Governance &#x2014; Corporate Governance," is incorporated herein by reference.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 14.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>PRINCIPAL ACCOUNTING FEES AND SERVICES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;"><b>Independent Registered Public Accounting Firm</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Audit Committee selected KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2021. The Audit Committee's selection of KPMG LLP was ratified by our stockholders at our 2021 annual meeting of stockholders.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Independent Registered Public Accounting Firm</b>&#x2019;<b>s Fees</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The table below presents fees billed to us for professional services rendered by KPMG LLP for the years ended December 31, 2021 and December 31, 2020.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="margin-right: 10%; margin-left: 10%; width: 80%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate Amount Billed</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom;">
     <td style="font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
     <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
     <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt; width: 62%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Audit Fees</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">365,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">508,060</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Audit-Related Fees</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Tax Fees</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">80,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">All Other Fees</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#x2014;</td>
     <td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

    <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
     <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">365,000</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#xa0;</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
     <td style="width: 16%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: right;">588,060</td>
     <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0; &#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Tax fees billed in 2020 represent fees paid to KPMG LLP in connection with an analysis under Section 382 of the Tax Code.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Pre-Approval Policies and Procedures</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Audit Committee has adopted procedures pursuant to which all audit, audit-related, and tax services and all permissible non-audit services provided by our independent registered public accounting firm must be pre-approved by the Audit Committee. All services rendered by KPMG during 2021 and 2020 were permissible under applicable laws and regulations and were approved in advance by the Audit Committee in accordance with the rules adopted by the SEC in order to implement requirements of SOX.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       89
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>PART IV</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 15.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>EXHIBITS, FINANCIAL STATEMENT SCHEDULES</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 36pt; text-indent: 27pt; text-align: justify;">1.&#xa0;&#xa0;&#xa0;&#xa0;Our financial statements are included in Part II, Item 8 of this Annual Report.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 63pt; text-align: justify;">2.&#xa0;&#xa0;&#xa0;&#xa0;All financial statement schedules have been omitted from this Item 15 as the required information is not applicable, is not present in amounts sufficient to require submission of such schedules, or because the information required is included in our financial statements or the related notes included in Part II, Item 8 of this Annual Report.</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">&#xa0;</p>
  <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 63pt; text-align: justify;">3.&#xa0;&#xa0;&#xa0;&#xa0;The exhibits set forth in the following "Index to Exhibits" are filed with, furnished with, and/or incorporated by reference into this Annual Report, as set forth therein. A copy of any of such exhibit will be furnished at a reasonable cost, upon receipt from any person of a written request for any such exhibit. Such request should be sent to Diffusion Pharmaceuticals Inc., 300 East Main Street, Suite 201, Charlottesville, Virginia 22902, Attention: General Counsel.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       90
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>INDEX TO EXHIBITS</b></p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: bottom; width: 9.1%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Exhibit</b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>No.</b></p> </td>
     <td style="vertical-align: top; width: 46%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>Description</b></p> </td>
     <td style="vertical-align: top; width: 45.4%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;"><b>Method of Filing</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919005256/ex_137220.htm" style="-sec-extract:exhibit;">Certificate of Incorporation of Diffusion Pharmaceuticals Inc., as amended</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 3.1 to the registrant&#x2019;s annual report on Form 10-K for the year ended December 31, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex3-4.htm" style="-sec-extract:exhibit;">Bylaws of Diffusion Pharmaceuticals Inc., as amended</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 3.4 to the registrant&#x2019;s annual report on Form 10-K for the year ended December 31, 2015</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774917004538/ex4-1.htm" style="-sec-extract:exhibit;">Form of 2017 Private Placement Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on March 15, 2017</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000800/ex_103239.htm" style="-sec-extract:exhibit;">Form of 2018 Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on January 19, 2018</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918000941/ex_103358.htm" style="-sec-extract:exhibit;">Form of 2018 Underwriter's Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.2 to the registrant&#x2019;s current report on Form 8-K filed on January 22, 2018</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/ex_145858.htm" style="-sec-extract:exhibit;">Form of May 2019 Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on May 28, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919010905/ex_145859.htm" style="-sec-extract:exhibit;">Form of May 2019 Placement Agent&#x2019;s Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.2 to the registrant&#x2019;s current report on Form 8-K filed on May 28, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164781.htm" style="-sec-extract:exhibit;">Form of November 2019 Series I Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on November 13, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.7</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164782.htm" style="-sec-extract:exhibit;">Form of November 2019 Series II Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.2 to the registrant&#x2019;s current report on Form 8-K filed on November 13, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.8</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164784.htm" style="-sec-extract:exhibit;">Form of November 2019 Pre-Funded Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.3 to the registrant&#x2019;s current report on Form 8-K filed on November 13, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.9</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919022699/ex_164785.htm" style="-sec-extract:exhibit;">Form of November 2019 Placement Agent&#x2019;s Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.4 to the registrant&#x2019;s current report on Form 8-K filed on November 13, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.10</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919024424/ex_167361.htm" style="-sec-extract:exhibit;">Form of December 2019 Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on December 13, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.11</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774919024424/ex_167362.htm" style="-sec-extract:exhibit;">Form of December 2019 Placement Agent&#x2019;s Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.2 to the registrant&#x2019;s current report on Form 8-K filed on December 13, 2019</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.12</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920010091/ex_185437.htm" style="-sec-extract:exhibit;">Form of May 2020 Common Stock Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on May 8, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.13</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920010091/ex_185438.htm" style="-sec-extract:exhibit;">Form of May 2020 Placement Agent's Warrant (In Respect of Exercise Transaction)</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.2 to the registrant&#x2019;s current report on Form 8-K filed on May 8, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.14</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920011442/ex_187389.htm" style="-sec-extract:exhibit;">Form of May 2020 Placement Agent's Warrant (In Respect of Offering Transaction)</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.3 to the registrant&#x2019;s current report on Form 8-K filed on May 20, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.15</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774921003299/ex_227273.htm" style="-sec-extract:exhibit;">Form of February 2021 Underwriter's Warrant</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.1 to the registrant&#x2019;s current report on Form 8-K filed on February 18, 2021</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.16</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920005469/ex_176595.htm" style="-sec-extract:exhibit;">Description of Securities</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 4.12 to the registrant's annual report on 10-K for the year ended December 31, 2019</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="margin: 0pt 0pt 0pt 9pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       91
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.1</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920019460/ex_203251.htm" style="-sec-extract:exhibit;">Employment Agreement dated as of September 8, 2020 by and between Robert J. Cobuzzi, Jr., Ph.D. and Diffusion Pharmaceuticals Inc.*</a></p> </td>
     <td style="vertical-align:bottom;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 10.2 to the registrant&#x2019;s current report on Form 8-K filed on September 9, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.2</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774918017551/ex_124640.htm" style="-sec-extract:exhibit;">Amended and Restated Employment Agreement, dated as of September 21, 2018, by and between William Karl Hornung and Diffusion Pharmaceuticals Inc. *</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 10.2 to the registrant's Current Report on Form 8-K filed September 27, 2018</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.3</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920021340/ex_207598.htm" style="-sec-extract:exhibit;">Employment Agreement, dated as of October 19, 2020, by and between Christopher D. Galloway, M.D. and Diffusion Pharmaceuticals Inc. *</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed October 20, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.4</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774920020264/ex_205132.htm" style="-sec-extract:exhibit;">Employment Agreement, dated as of September 23, 2020, by and between William Elder and Diffusion Pharmaceuticals Inc. *</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 10.1 to the registrant's Current Report on Form 8-K filed September 25, 2020</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.5</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan*</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Appendix C to the registrants definitive proxy statement on Schedule 14A filed on June 10, 2016</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.6</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916033633/dffn20160607_def14a.htm" style="-sec-extract:exhibit;">Amendment No. 1 to Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan*</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Appendix B to the registrants definitive proxy statement on Schedule 14A filed on June 10, 2016</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.7</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_348717.htm" style="-sec-extract:exhibit;">Form of Stock Option Award Agreement under 2015 Equity Incentive Plan*</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.8</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_348718.htm" style="-sec-extract:exhibit;">Form of Director RSU Agreement under 2015 Equity Incentive Plan*</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.9</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-24.htm" style="-sec-extract:exhibit;">Form of Diffusion Pharmaceuticals LLC Stock Option Award Agreement*</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 10.24 to the registrant&#x2019;s annual report on Form 10-K for the year ended December 31, 2015</p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.10</p> </td>
     <td style="vertical-align:top;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="http://www.sec.gov/Archives/edgar/data/1053691/000143774916028395/ex10-3.htm" style="-sec-extract:exhibit;">Form of Indemnification Agreement between Diffusion Pharmaceuticals Inc. and each of its Directors and Officers*</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Incorporated by reference to Exhibit 10.3 to the registrant&#x2019;s annual report on Form 10-K for the year ended December 31, 2015</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.1</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_348719.htm" style="-sec-extract:exhibit;">Subsidiaries of Diffusion Pharmaceuticals Inc.</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">23.1</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_348951.htm" style="-sec-extract:exhibit;">Consent of KPMG LLP, independent registered public accounting firm</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.1</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_346478.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">31.2</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_346479.htm" style="-sec-extract:exhibit;">Certification of Principal Financial Officer Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 and SEC Rule 13a-14(a)</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">32.1</p> </td>
     <td style="vertical-align:bottom;width:46%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><a href="ex_346480.htm" style="-sec-extract:exhibit;">Certification of Chief Executive Officer Pursuant to 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002</a></p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">101</p> </td>
     <td style="vertical-align:bottom;width:46%;">The following materials from the registrant&#x2019;s annual report on Form 10-K for the year ended December 31, 2021, formatted in iXBRL (Inline Extensible Business Reporting Language): (i) Consolidated Balance Sheets, (ii) Consolidated Statements of Operations, (iii) Consolidated Statements of Cash Flows, and (iv) Notes to Consolidated Financial Statements <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p> </td>
     <td style="vertical-align:top;width:45.4%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt 0pt 0pt 9pt;">Filed herewith</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:9.1%;">104</td>
     <td style="vertical-align:bottom;width:46%;">Cover Page Interactive Data File (embedded within the Inline XBRL and contained in Exhibit 101)</td>
     <td style="vertical-align:top;width:45.4%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:middle;width:9.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">*</p> </td>
     <td colspan="2" style="vertical-align:bottom;width:91.4%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Indicates a management contract or compensatory plan or arrangement.</p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="width: 100%; text-indent: 0px;">
   <tbody>
    <tr style="vertical-align: top;">
     <td style="width: 72pt;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>ITEM 16.</b></p> </td>
     <td style="width: auto;"> <p style="font-family: Times New Roman;font-size: 10pt;font-variant:normal;margin:0pt;"><b>FORM 10-K SUMMARY</b></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">None.</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#xa0;</p>
  <div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
   <div class="PGFTR" style="text-align: center; width: 100%">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       92
     </div>
    </div>
   </div>
   <hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000" />
   <div class="PGHDR" style="text-align: left; width: 100%">
    <div class="hf-row">
     <div class="hf-cell TOCLink">
       &#xa0;
     </div>
    </div>
   </div>
  </div>
  <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;text-indent:9pt;"><b>SIGNATURES</b></p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align:top;width:43.1%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Dated: March 18, 2022</p> </td>
     <td colspan="2" style="vertical-align:top;width:57.5%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><b>DIFFUSION PHARMACEUTICALS INC.</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:43.1%;">&#xa0;</td>
     <td style="vertical-align:top;width:5.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By:</p> </td>
     <td style="vertical-align:bottom;width:51.6%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>President, Chief Executive Officer, and Director</i></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><i>(Principal Executive Officer)</i></p> </td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">
   <tbody>
    <tr>
     <td style="vertical-align: top; width: 38.2%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Name and Signature</b></p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Title</b></p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Date</b></p> </td>
    </tr>

    <tr>
     <td style="vertical-align: top; width: 38.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D.</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President, Chief Executive Officer, and Director</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Executive Officer)</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ William K. Hornung</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">William K. Hornung</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(Principal Financial and Accounting Officer)</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Jane H. Hollingsworth</p> </td>
     <td style="vertical-align:bottom;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chair of the Board</p> </td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Jane H. Hollingsworth</p> </td>
     <td style="vertical-align:bottom;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Robert Adams</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Robert Adams</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Eric Francois</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Eric Francois</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Mark T. Giles</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Mark T. Giles</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:bottom;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Diana Lanchoney</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Diana Lanchoney</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:bottom;width:25.9%;">&#xa0;</td>
    </tr>

    <tr>
     <td style="border-bottom:solid 1px #000000;vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">/s/ Alan Levin</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director</p> </td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p> </td>
    </tr>

    <tr>
     <td style="vertical-align:top;width:38.2%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">Alan Levin</p> </td>
     <td style="vertical-align:top;width:3.5%;">&#xa0;</td>
     <td style="vertical-align:top;width:29.2%;">&#xa0;</td>
     <td style="vertical-align:top;width:3.7%;">&#xa0;</td>
     <td style="vertical-align:top;width:25.9%;">&#xa0;</td>
    </tr>

   </tbody>
  </table>
  <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#xa0;</p>
  <div class="LAST-PAGE-BREAK">
   <div class="PGFTR">
    <div class="hf-row">
     <div class="hf-cell PGNUM" style="text-align: center; font-size: 10pt; font-family: Times New Roman;">
       93
     </div>
    </div>
   </div>
  </div>
 </body>
</html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.7
<SEQUENCE>2
<FILENAME>ex_348717.htm
<DESCRIPTION>EXHIBIT 10.7
<TEXT>
<html><head>
	<title>ex_348717.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 2:01:59 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.7</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<div><img alt="a01.jpg" src="a01.jpg"></div>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>STOCK OPTION AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This STOCK OPTION AGREEMENT (this &#8220;<b><i>Agreement</i></b>&#8221;<b><i>)</i></b> is entered into and effective as of [_______], 202[__] (the &#8220;<b><i>Grant Date</i></b>&#8221;) by and between Diffusion Pharmaceuticals Inc., a Delaware corporation (the &#8220;<b><i>Company</i></b>&#8221;), and [_______] (&#8220;<b><i>Optionee</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A. The Company has adopted the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan (as such plan may be amended from time to time, the &#8220;<b><i>Plan</i></b>&#8221;) authorizing the Board of Directors (the &#8220;<b><i>Board</i></b>&#8221;) of the Company, or a committee as provided for in the Plan (the Board or such a committee to be referred to as the &#8220;<b><i>Committee</i></b>&#8221;), to grant stock options, among other incentive awards, to certain individuals.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B. The Company desires to grant [an incentive/a non-qualified] stock option to purchase shares of common stock, par value $0.001 per share, of the Company (the &#8220;<b><i>Common Stock</i></b>&#8221;) to Optionee pursuant to the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">C. All of the capitalized terms used in this Agreement not otherwise defined in this Agreement have the same respective meanings as defined in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Company and Optionee agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1. <u>Grant of Option; Exercise Price</u>. The Company hereby grants to Optionee, upon the terms and subject to the conditions set forth in this Agreement and the Plan, and effective as of the Grant Date, an option (the &#8220;<b><i>Option</i></b>&#8221;) to purchase all or any portion of [_______] shares (the &#8220;<b><i>Option Shares</i></b>&#8221;) of the Company&#8217;s Common Stock, at an exercise price of $[_______] per share, which represents 100% of the Fair Market Value of a share of Common Stock on the Grant Date, as determined in accordance with the Plan (such exercise price, as adjusted from time to time pursuant to Section 5 of this Agreement and Section 4.3 of the Plan, the &#8220;<b><i>Exercise Price</i></b>&#8221;). The Option [is/is not] intended to be an &#8220;incentive stock option,&#8221; as that term is used in Section 422 of the Internal Revenue Code of 1986, as amended (the &#8220;<b><i>Code</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2. <u>Vesting</u>. The option will vest and become exercisable in 36 equal (or as nearly equal as possible) installments on the last calendar day of each month over a 36-month period beginning on [_______].</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3. <u>Exercise of Option</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.1. Notice; Payment. Subject to the terms and conditions set forth in this Agreement, including vesting of the Option in Section 2 of this Agreement and termination of the Option in Section 4 of this Agreement, and the Plan, the Option may be exercised, in whole or in part, at any time and from time to time, by delivery to the Company of written notice of the exercise of the Option, in substantially the form as provided by the Company, stating the number of Option Shares being purchased (the &#8220;<b><i>Purchased Shares</i></b>&#8221;), and accompanied by payment in full of the total aggregate Exercise Price of the Purchased Shares. The Exercise Price shall be payable in full in any one of the following alternative forms:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Full payment in cash, personal check or certified bank or cashier&#8217;s check;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Any broker assisted cashless exercise procedure which is acceptable to the Company;</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Cashless net exercise.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">X = Y &#8211; [(A)(YB )]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">Where:&nbsp; &nbsp;X = the number of shares of Common Stock to be issued to Optionee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">Y = the number of Purchased Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:36pt;">A = the Exercise Price.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:18pt;">B = the Fair Market Value of one share of Common Stock on the date of exercise.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.2. <u>Issuance of Purchased Shares; No Fractional Shares</u>. Following receipt of the exercise notice and the payment referred to above (or upon a cashless net exercise), Optionee shall receive the number of shares of Common Stock equal to a number (as determined below) of shares of Common Stock computed using the following formula: and the payment referred to above, the Company shall, as soon as reasonably practicable thereafter, cause certificates (or book-entry notations) representing the Purchased Shares (or such fewer number of Purchased Shares if a cashless net exercise is used) to be delivered to Optionee either at Optionee&#8217;s address set forth in the records of the Company or at such other address as Optionee may designate in writing to the Company or issue and deposit the Purchased Shares for Optionee&#8217;s benefit with any broker with which Optionee has an account relationship or the Company has engaged to provide such services under the Plan; provided, however, that the Company shall not be obligated to issue a fraction or fractions of a share otherwise issuable upon exercise of the Option, and may pay to Optionee, in cash or cash equivalent, the Fair Market Value of any such fraction or fractions of a share as of the date of exercise. If requested by the Company in connection with any exercise of the Option, Optionee shall also deliver this Agreement to the Company, which shall endorse hereon a notation of the exercise and, and if the Option is exercised in part, shall return this Agreement to Optionee. The date of exercise of an Option that is validly exercised shall be deemed to be the date on which there shall have been delivered to the Company the notice referred to in Section 3.1 of this Agreement and full payment of the Exercise Price of the Purchased Shares. Optionee shall not be deemed to be a holder of any Purchased Shares pursuant to exercise of the Option until the date of issuance of a stock certificate or book-entry notation to Optionee for such shares following payment in full for the Purchased Shares.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.3. <u>Tax Withholding</u>. The Company is entitled to (a) withhold and deduct from future wages of Optionee (or from other amounts that may be due and owing to Optionee from the Company or a Subsidiary), or make other arrangements for the collection of, all amounts the Company reasonably determines are necessary to satisfy any and all federal, foreign, state and local withholding and employment related tax requirements attributable to the Option, including, without limitation, the grant, exercise or vesting of, the Option; (b) withhold cash paid or payable or shares of Common Stock from the shares issued or otherwise issuable to Optionee in connection with the Option; or (c) require Optionee promptly to remit the amount of such withholding to the Company before taking any action, including issuing any shares of Common Stock, with respect to the Option. Shares of Common Stock issued or otherwise issuable to Optionee in connection with the Option that gives rise to the tax withholding obligation that are withheld for purposes of satisfying Optionee&#8217;s withholding or employment-related tax obligation will be valued at their Fair Market Value on the Tax Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.4. <u>Remaining Option Shares</u>. Option Shares will no longer be outstanding under the Option (and will therefore not thereafter be exercisable) following the exercise of the Option to the extent of (a) shares used to pay the Exercise Price of an Option under the &#8220;cashless net exercise&#8221; method (b) shares actually delivered to Optionee as a result of such exercise and (c) any shares withheld for purposes of tax withholding.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4. <u>Termination of Option</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.1. <u>Time of Termination</u>. Except as provided in this Section 4 and Section 5 of this Agreement, the Option shall terminate, no longer be exercisable and expire at 5:00 p.m., Eastern Time, on [_______] (the &#8220;<b><i>Time of Termination</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.2. <u>Termination for Cause</u>. In the event Optionee&#8217;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated by the Company for Cause, the Option will immediately terminate without notice of any kind, and the Option will no longer be exercisable.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.3. <u>Termination Due to Death, Disability or Retirement</u> . In the event Optionee&#8217;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated by reason of Optionee&#8217;s death, Disability or Retirement, the Option will remain exercisable, to the extent exercisable as of the date of such termination, for a period of one (1) year after such termination (but in no event after the Time of Termination).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.4. <u>Termination for Other Reasons</u>. In the event Optionee&#8217;s employment (in the event that Optionee is an Employee) or other service (in the event that Optionee is a Consultant) with the Company and all Subsidiaries is terminated for any other reason, the Option will, to the extent exercisable as of such termination, remain exercisable for a period of three (3) months after such termination (but in no event after the Time of Termination).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.5. <u>Effect of Actions Constituting Cause or Adverse Action</u>. Notwithstanding anything in this Agreement to the contrary and in addition to the rights of the Committee under Sections 13.5 and 13.6 of the Plan, if Optionee is determined by the Committee, acting in its sole discretion, to have taken any action that would constitute Cause or an Adverse Action during or after the termination of employment or other service with the Company or a Subsidiary, irrespective of whether such action or the Committee&#8217;s determination occurs before or after termination of Optionee&#8217;s employment or other service with the Company or any Subsidiary and irrespective of whether or not Optionee was terminated as a result of such Cause or Adverse Action, (a) all rights of Optionee under the Option and this Agreement will terminate and be forfeited without notice of any kind, and (b) the Committee in its sole discretion will have the authority to rescind the exercise, vesting, settlement or issuance of, or payment in respect of, the Option that was exercised, vested, settled or issued, or as to which such payment was made, and to require Optionee to pay to the Company, within ten (10) days of receipt from the Company of notice of such rescission, any amount received or the amount of any gain realized as a result of such rescinded exercise, vesting, settlement, issuance or payment (including any dividends paid or other distributions made with respect to any shares of Common Stock subject to the Option). The Company may defer the exercise of the Option for a period of up to six (6) months after receipt of Optionee&#8217;s written notice of exercise or the issuance of Purchased Shares upon the vesting of the Option for a period of up to six (6) months after the date of such vesting in order for the Committee to make any determination as to the existence of Cause or an Adverse Action. The Company will be entitled to withhold and deduct from future wages of Optionee (or from other amounts that may be due and owing to Optionee from the Company or a Subsidiary) or make other arrangements for the collection of all amounts necessary to satisfy such payment obligations. This Section 4.5 will not apply to the Option following a Change in Control.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.6. <u>Clawback/Forfeiture</u>. The Option and Option Shares issued or issuable pursuant to the Option are subject to forfeiture or clawback by the Company to the extent required and allowed by law, including the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the Sarbanes Oxley Act of 2002 and any implementing rules and regulations promulgated thereunder, and pursuant to any forfeiture, clawback or similar policy of the Company, as such laws, rules, regulations and policy may be in effect from time to time.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5. <u>Adjustments</u>. In the event of any reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture, or extraordinary dividend (including a spin-off), or any other similar change in the corporate structure or shares of the Company, the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation), will make appropriate adjustment (which determination will be conclusive) as to the number and kind of securities or other property (including cash) subject to, and the Exercise Price of, the Option in order to prevent dilution or enlargement of the rights of Optionee.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6. <u>Change in Control</u>. The Option shall become immediately vested and exercisable upon completion of a Change in Control and remain exercisable through the Time of Termination regardless of whether Optionee remains in the employment or service of the Company. Notwithstanding any of the foregoing, in connection with a Change in Control, the Committee, in its sole discretion, at any time after the grant of the Option, may take whatever action it deems appropriate pursuant to Section 15.3 of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7. <u>Rights as a Stockholder</u>. Optionee will have no rights as a stockholder of the Company unless and until all conditions to the effective exercise of the Option (including, without limitation, the conditions set forth in Section 3 of this Agreement) have been satisfied and Optionee has become the holder of record of such shares. No adjustment will be made for dividends or distributions with respect to the Option as to which there is a record date preceding the date Optionee becomes the holder of record of such shares, except as may otherwise be provided in the Plan or determined by the Committee in its sole discretion.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8. <u>Restrictions on Transfer</u>. Except pursuant to testamentary will or the laws of descent and distribution or as otherwise expressly permitted by the Plan, no right or interest of Optionee in the Option prior to exercise may be assigned or transferred, or subjected to any lien, during the lifetime of Optionee, either voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise. Optionee, however, will be entitled to designate a beneficiary to receive the Option upon Optionee&#8217;s death, and, in the event of Optionee&#8217;s death, exercise of the Option (to the extent permitted pursuant to Sections 2 and 4 of this Agreement) may be made by Optionee&#8217;s legal representatives, heirs and legatees.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9. <u>Market Stand-off</u>. Optionee, if so requested by the Company or any representative of the underwriters in connection with a firmly underwritten public offering of securities by the Company pursuant to a registration statement under the Securities Act following the date of this Agreement, shall not sell or otherwise transfer any Option Shares during the 180-day period following the effective date of such registration statement. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restriction until the end of such 180-day period. This <u>Section 9</u> will not apply to the sale of any Option Shares to an underwriter pursuant to an underwriting agreement and shall only be applicable to Optionee if all then current executive officers and directors of the Company enter into similar agreements.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10. <u>Employment or Service</u>. Nothing in this Agreement or the Plan will interfere with or limit in any way the right of the Company or any Subsidiary to terminate the employment or service of Optionee at any time, nor confer upon Optionee any right to continue in the employment or other service with the Company or any Subsidiary.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11. <u>Option Subject to Plan</u>. The Option and the Option Shares granted and issued pursuant to this Agreement have been granted and issued under, and are subject to the terms of, the Plan. The terms of the Plan are incorporated by reference in this Agreement in their entirety, and Optionee, by execution of this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement will be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement will be interpreted by reference to the Plan. In the event that any provision of this Agreement is inconsistent with the terms of the Plan, the terms of the Plan will prevail. All of the capitalized terms used in this Agreement not otherwise defined in this Agreement have the same respective meanings as defined in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12. <u>General Provisions</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.1. <u>Governing Law; Venue</u>. This Agreement and all rights and obligations under this Agreement will be governed by and construed exclusively in accordance with the laws of the State of Delaware, notwithstanding the conflicts of laws principles of any jurisdictions. By acceptance of the Option, Optionee is deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of the State of Illinois to resolve any and all issues that may arise out of or relate to the Option or this Agreement.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.2. <u>Entire Agreement</u>. This Agreement and the Plan set forth the entire agreement and understanding of the parties to this Agreement with respect to the grant and exercise of the Option and the administration of the Plan and supersede all prior agreements, arrangements, plans, and understandings relating to the grant and exercise of the Option and the administration of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.3. <u>Failure to Enforce Not a Waiver</u>. The failure of the Company or Optionee to enforce at any time any provision of this Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.4. <u>Notices</u>. All notices, requests, demands and other communications (collectively, &#8220;<b><i>Notices</i></b>&#8221;) given pursuant to this Agreement shall be in writing, and shall be delivered by personal service, courier, facsimile transmission, email transmission of a pdf format data file or by United States first class, registered or certified mail, postage prepaid, addressed to the party at the address set forth on the signature page of this Agreement. Any Notice, other than a Notice sent by registered or certified mail, shall be effective when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the earlier of when received or the third day following deposit in the United States mails. Any party may from time to time change its address for further Notices hereunder by giving notice to the other party in the manner prescribed in this Section 12.4.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.5. <u>Successors and Assigns</u>. Except to the extent specifically limited by the terms and provision of this Agreement, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, assigns, heirs, and personal representatives.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.6. <u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email delivery of a &#8220;pdf&#8221; format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;pdf&#8221; signature page were an original thereof.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.7. <u>Titles, Captions and Sections</u>. Titles and captions contained in this Agreement are inserted for convenience of reference only and do not constitute a part of this Agreement for any other purpose. References to Sections in this Agreement refer to Sections of this Agreement unless otherwise stated.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.8. <u>Nature of the Grant</u>. In accepting the Option and by execution of this Agreement, Optionee acknowledges that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended, or terminated by the Company in its sole discretion at any time, unless otherwise provided in the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The grant of the Option is voluntary and occasional and does not create any contractual or other right to receive future Option grants, or benefits in lieu of Option grants, even if Option grants have been granted repeatedly in the past.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All decisions with respect to future Option grants, if any, will be at the sole discretion of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Optionee is voluntarily participating in the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Option grant is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments and in no event shall be considered as compensation for, or relating in any way to, past services for the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">f)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event that Optionee is not an employee of the Company, the Option will not be interpreted to form an employment contract or relationship with the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">g)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The future value of the Common Stock is unknown and cannot be predicted with certainty and if the Option vests and Optionee exercises the Option in accordance with the terms of this Agreement and is issued Purchased Shares, the value of those shares may increase or decrease.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">h)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In consideration of the grant of the Option, no claim or entitlement to compensation or damages shall arise from termination of the Option or diminution in value of the Option or Purchased Shares acquired upon exercise of the Option resulting from termination of Optionee&#8217;s employment or service by the Company (for any reason whatsoever and whether or not in breach of local labor laws) and Optionee irrevocably releases the Company and its Subsidiaries, and their respective directors, officers, employees and agents, from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by acceptance of the Option and execution of this Agreement, Optionee shall be deemed irrevocably to have waived his or her entitlement to pursue such claim.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Optionee&#8217;s participation in the Plan, or Optionee&#8217;s purchase or sale of the underlying Option Shares.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">j)</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Optionee is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan or the Option.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;[<u>Incentive Stock Option Limitations</u>.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.1&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation on Amount</u>. To the extent that the aggregate Fair Market Value (determined as of the Grant Date) of the shares of Common Stock with respect to which incentive stock options (within the meaning of Section 422 of the Code) are exercisable for the first time by the Optionee during any calendar year (under the Plan and any other incentive stock option plans of the Company or any subsidiary or parent corporation of the Company (within the meaning of the Code)) exceeds $100,000 (or such other amount as may be prescribed by the Code from time to time), such excess incentive stock options will be treated as non-statutory stock options in the manner set forth in the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.2&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>Limitation on Exercisability; Disposition of Option Shares</u>. Any incentive stock option that remains unexercised more than one year following termination of employment by reason of death or disability or more than three months following termination for any reason other than death or disability will thereafter be deemed to be a non-statutory stock option. In addition, in the event that a disposition (as defined in Section 424(c) of the Code) of shares of Common Stock acquired pursuant to the exercise of an incentive stock option occurs prior to the expiration of two years after its date of grant or the expiration of one year after its date of exercise (a &#8220;disqualifying disposition&#8221;), such incentive stock option will, to the extent of such disqualifying disposition, be treated in a manner similar to a non-statutory stock option.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.3. &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>No Representation or Warranty</u>. Section 422 of the Code and the rules and regulations thereunder are complex, and neither the Plan nor this Agreement purports to summarize or otherwise set forth all of the conditions that need to be satisfied in order for this Option to qualify as an incentive stock option. In addition, this Option may contain terms and conditions that allow for exercise of this Option beyond the periods permitted by Section 422 of the Code, including, without limitation, the periods described in Sections 2 and 4 of this Agreement. Accordingly, the Company makes no representation or warranty regarding whether the exercise of this Option will qualify as the exercise of an incentive stock option, and the Company recommends that the Optionee consult with the Optionee&#8217;s own advisors before making any determination regarding the exercise of this Option or the sale of the Option Shares.]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[<i>Remainder of page intentionally left blank; Signature page follows</i>]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement effective as of the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">OPTIONEE:&nbsp;</td>
			<td style="width: 50%;">DIFFUSION PHARMACEUTICALS INC.</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>________________________&nbsp;</td>
			<td>___________________________________</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Name: [_______]</td>
			<td>By: William Elder</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Title: General Counsel</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Address: 300 East Main Street, Suite 201</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td style="padding-left: 36pt;">Charlottesville, VA 22902</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By execution of this Agreement, Optionee acknowledges having received a copy of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.8
<SEQUENCE>3
<FILENAME>ex_348718.htm
<DESCRIPTION>EXHIBIT 10.8
<TEXT>
<html><head>
	<title>ex_348718.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 2:04:12 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 10.8</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><img alt="a01.jpg" src="a01.jpg"></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>NON-EMPLOYEE DIRECTOR </b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>RESTRICTED STOCK UNIT AGREEMENT</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">This RESTRICTED STOCK UNIT AGREEMENT (this &#8220;<b><i>Agreement</i></b>&#8221;<b><i>)</i></b> is made, entered into, and effective as of [____], 202[_] (the &#8220;<b><i>Grant Date</i></b>&#8221;) by and between Diffusion Pharmaceuticals Inc., a Delaware corporation (the &#8220;<b><i>Company</i></b>&#8221;), and [____] (&#8220;<b><i>Director</i></b>&#8221;).</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">A.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company has adopted the Diffusion Pharmaceuticals Inc. 2015 Equity Incentive Plan (as such plan may be amended and/or restated from time to time, the &#8220;<b><i>Plan</i></b>&#8221;) which authorizes the Board of Directors of the Company (the &#8220;<b><i>Board</i></b>&#8221;), or a committee thereof as provided for in the Plan (the Board or such committee in such capacity, the &#8220;<b><i>Committee</i></b>&#8221;), to grant restricted incentive awards to Participants, including Restricted Stock Units.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">B.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company desires to grant Restricted Stock Units denominated in shares of common stock, par value $0.001 per share, of the Company (the &#8220;<b><i>Common Stock</i></b>&#8221;) to the Director pursuant to the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">NOW, THEREFORE, in consideration of the mutual promises and covenants hereinafter set forth, the Company and Director agree as follows:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">1.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>RSUs Subject to Plan; Defined Terms</u>. The RSUs and the RSU Shares (each as defined in Section 2 below) granted and issued (if any) pursuant to this Agreement have been granted and issued under, and are subject to the terms of, the Plan. The terms of the Plan are incorporated by reference in this Agreement in their entirety, and Director, by execution of this Agreement, acknowledges having received a copy of the Plan. The provisions of this Agreement will be interpreted as to be consistent with the Plan, and any ambiguities in this Agreement will be interpreted by reference to the Plan. In the event any provision of this Agreement is inconsistent with the terms of the Plan, the terms of the Plan will prevail. All capitalized terms used and not otherwise defined in this Agreement have the meanings given to them in the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">2.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Grant of Restricted Stock Unit Award</u>. The Company hereby grants [____] Restricted Stock Units (the &#8220;<b><i>RSUs</i></b>&#8221;), denominated in shares of Common Stock (the &#8220;<b><i>RSU Shares</i></b>&#8221;), to the Director as of the Grant Date stated above.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">3.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Vesting</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Vesting</u>. Subject to the provisions of this Section 3, the RSUs subject to this Award shall become vested on the dates set forth below, provided that the Director has not incurred a &#8220;Separation from Service&#8221;&nbsp;within the meaning of Section 409A(a)(2)(A)(i) of the Code and Treas. Reg. Section 1.409A-1(h), other than due to the Director&#8217;s death or removal from the Board without cause, in which cases the RSUs shall become vested upon such event. There shall be no proportionate or partial vesting in the periods prior to the vesting date.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; width: 75.5065%; margin-left: 0pt; margin-right: auto; border: 1px solid rgb(0, 0, 0);">

		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50.6%; border-right: 1px solid rgb(0, 0, 0);">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u>Dates</u></b></p>
			</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:50.6%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><u># of Shares</u></b></p>
			</td>
		</tr>
		<tr>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: 50.6%; border-right: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:top;width:50.6%;">&nbsp;</td>
		</tr>
		<tr>
			<td style="vertical-align: top; width: 50.6%; border-right: 1px solid rgb(0, 0, 0);">&nbsp;</td>
			<td style="vertical-align: top; width: 50.6%;">&nbsp;</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Change in Control</u>. The RSUs shall become immediately vested upon completion of a Change in Control. Notwithstanding any of the foregoing, in connection with a Change in Control, the Committee, in its sole discretion, at any time after the grant of the RSUs, may take whatever action it deems appropriate pursuant to Section 15.3 of the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Forfeiture</u>. Except as set forth in Section 3(a), all unvested RSUs shall be immediately forfeited upon the Director&#8217;s termination of service with the Board.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Clawback</u>. The RSUs and RSU Shares issued or issuable pursuant to the RSUs are subject to forfeiture or clawback by the Company to the extent required and allowed by law, including the Dodd-Frank Wall Street Reform and Consumer Protection Act of 2010 and the Sarbanes Oxley Act of 2002 and any implementing rules and regulations promulgated thereunder, and pursuant to any forfeiture, clawback or similar policy of the Company, as such laws, rules, regulations and policy may be in effect from time to time.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">4.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Delivery of Shares</u>. Subject to the provisions of Section 17 hereof, within sixty (60) days following the applicable vesting date of the RSUs (or as soon as practicable thereafter), the Director shall receive the number of shares of Common Stock that correspond to the number of RSUs that have become vested on the applicable vesting date, less a number of shares of Common Stock equal to the product of (i) the Fair Market Value of the shares of Common Stock on the Tax Date and (ii) the highest marginal Federal tax rate applicable to individuals, with the result rounded down to the nearest whole share (the &#8220;<b><i>Tax Reduction</i></b>&#8221;). The Fair Market Value of the shares of Common Stock subject to the Tax Reduction shall be paid to the Director in cash at the same time as the delivery of the shares of Common Stock pursuant to this Section 4 (collectively, the &#8220;<b><i>RSU Settlement</i></b>&#8221;).</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">5.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Rights as a Stockholder; Adjustments</u>.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Rights as a Stockholder</u>. Director will have no rights as a stockholder of the Company unless and until all conditions to the effective settlement of the RSUs have been satisfied and Director has become the holder of record of such shares. No adjustment will be made for dividends or distributions with respect to the RSUs as to which there is a record date preceding the date Director becomes the holder of record of such shares, except as may otherwise be provided in the Plan or determined by the Committee in its sole discretion.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Adjustments</u>. In the event of any reorganization, merger, consolidation, recapitalization, liquidation, reclassification, stock dividend, stock split, combination of shares, rights offering, divestiture, or extraordinary dividend (including a spin-off), or any other similar change in the corporate structure or shares of the Company, the Committee (or, if the Company is not the surviving corporation in any such transaction, the board of directors of the surviving corporation), will make appropriate adjustment (which determination will be conclusive) as to the number and kind of securities or other property (including cash) subject to the RSUs in order to prevent dilution or enlargement of the rights of Director.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">6.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Restrictions on Transfer</u>. Except pursuant to testamentary will or the laws of descent and distribution or as otherwise expressly permitted by the Plan, no right or interest of Director in the RSUs prior to exercise may be assigned or transferred, or subjected to any lien, during the lifetime of Director, either voluntarily or involuntarily, directly or indirectly, by operation of law or otherwise. Director, however, will be entitled to designate a beneficiary to receive the RSUs upon Director&#8217;s death, and, in the event of Director&#8217;s death, settlement of the RSUs (to the extent otherwise permitted hereby) may be made to Director&#8217;s legal representatives, heirs and legatees.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">7.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Governing Law; Venue</u>. This Agreement and all rights and obligations under this Agreement will be governed by and construed exclusively in accordance with the laws of the State of Delaware, notwithstanding the conflicts of laws principles of any jurisdictions. By acceptance of the RSUs, Director is deemed to submit to the exclusive jurisdiction and venue of the federal or state courts of the State of Illinois to resolve any and all issues that may arise out of or relate to the RSUs or this Agreement. The obligation of the Company to sell and deliver Common Stock hereunder is subject to applicable laws and to the approval of any governmental authority required in connection with the authorization, issuance, sale, or delivery of such Common Stock.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">8.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Tax Withholding</u>. If the Director is subject to wage withholding at the source under the Code with respect to compensation paid to the Director by the Company, then the following provisions of this Section 8 shall apply: The Company may require the Director to pay to the Company, an amount the Company deems necessary to satisfy its current or future obligation to withhold federal, state or local income or other taxes, if any, that the Director incurs as a result of the Award. With respect to any required tax withholding, the Director may (a) direct the Company to withhold from the shares of Common Stock to be issued to the Director under this Agreement, an amount sufficient to satisfy any federal, state, local and foreign taxes of any kind which the Company, in its sole discretion, deems necessary to be withheld or remitted to comply with the Code and/or any other applicable law, rule or regulation with respect to the RSUs (such amount, in the aggregate, the &#8220;<b><i>Withholding Obligation</i></b>&#8221;), which determination will be based on the shares&#8217;&nbsp;Fair Market Value on the Tax Date; (b) deliver to the Company shares of Common Stock sufficient to satisfy the Withholding Obligation, based on the shares&#8217;&nbsp;Fair Market Value on the Tax Date; or (c) deliver cash to the Company sufficient to satisfy the Withholding Obligation. Without limiting the foregoing, the Company shall withhold shares of Common Stock otherwise deliverable to the Director hereunder in order to pay the Director&#8217;s income and employment taxes due upon vesting of the RSUs, but only to the extent permitted by applicable accounting rules so as not to affect accounting treatment.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">9.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Market Stand-off</u>. Director, if so requested by the Company or any representative of the underwriters in connection with a firmly underwritten public offering of securities by the Company pursuant to a registration statement under the Securities Act following the date of this Agreement, shall not sell or otherwise transfer any RSU Shares during the 180-day period following the effective date of such registration statement. The Company may impose stop-transfer instructions with respect to securities subject to the foregoing restriction until the end of such 180-day period. This <u>Section 9</u>&nbsp;will not apply to the sale of any RSU Shares to an underwriter pursuant to an underwriting agreement and shall only be applicable to Director if all then current executive officers and directors of the Company enter into similar agreements.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">10.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Nature of the Grant</u>. In accepting the RSUs and by execution of this Agreement, Director acknowledges that:</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">a.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Plan is established voluntarily by the Company, it is discretionary in nature and it may be modified, amended, suspended, or terminated by the Company in its sole discretion at any time, unless otherwise provided in the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">b.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The grant of the RSUs is voluntary and occasional and does not create any contractual or other right to receive future RSU grants, or benefits in lieu of RSU grants, even if RSU grants have been granted repeatedly in the past.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">c.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">All decisions with respect to future RSU grants, if any, will be at the sole discretion of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">d.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director is voluntarily participating in the Plan.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">e.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">This grant of RSUs is not part of normal or expected compensation or salary for any purposes, including, but not limited to, calculating any severance, resignation, termination, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments and in no event shall be considered as compensation for, or relating in any way to, past services for the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">f.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In the event that Director is not an employee of the Company, the RSUs will not be interpreted to form an employment contract or relationship with the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">g.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The future value of the Common Stock is unknown and cannot be predicted with certainty and if the RSUs vest in accordance with the terms of this Agreement and RSU Shares are issued in settlement thereof, the value of those shares may increase or decrease.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">h.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In consideration of the grant of the RSUs, no claim or entitlement to compensation or damages shall arise from termination of the RSUs or diminution in value of the RSUs or RSU Shares resulting from termination of Director&#8217;s employment or service by the Company (for any reason whatsoever and whether or not in breach of local labor laws) and Director irrevocably releases the Company and its Subsidiaries, and their respective directors, officers, employees and agents, from any such claim that may arise; if, notwithstanding the foregoing, any such claim is found by a court of competent jurisdiction to have arisen, then, by acceptance of the RSUs and execution of this Agreement, Director shall be deemed irrevocably to have waived his or her entitlement to pursue such claim.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">i.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Company is not providing any tax, legal or financial advice, nor is the Company making any recommendations regarding Director&#8217;s participation in the Plan, or Director&#8217;s purchase or sale of the underlying RSU Shares.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:54pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">j.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Director is hereby advised to consult with his or her own personal tax, legal and financial advisors regarding his or her participation in the Plan before taking any action related to the Plan or the RSUs.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">11.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Entire Agreement</u>. This Agreement and the Plan set forth the entire agreement and understanding of the parties to this Agreement with respect to the grant and settlement of the RSUs and the administration of the Plan and supersede all prior agreements, arrangements, plans, and understandings relating to the grant and settlement of the RSUs and the administration of the Plan. This Agreement may be amended by the Board or by the Committee at any time (a) if the Board or the Committee determines, in its sole discretion, that an amendment is necessary or advisable in light of any addition to or change in any federal or state, tax or securities law or other law or regulation, which change occurs after the Grant Date and by its terms applies to the Award; or (b) other than in the circumstances described in clause (a) or provided in the Plan, with the Director&#8217;s consent.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">12.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Notices</u>. All notices, requests, demands and other communications (collectively, &#8220;<b><i>Notices</i></b>&#8221;) given pursuant to this Agreement shall be in writing, and shall be delivered by personal service, courier, facsimile transmission, email transmission of a pdf format data file or by United States first class, registered or certified mail, postage prepaid, addressed to the party at the address set forth on the signature page of this Agreement. Any Notice, other than a Notice sent by registered or certified mail, shall be effective when received; a Notice sent by registered or certified mail, postage prepaid return receipt requested, shall be effective on the earlier of when received or the third day following deposit in the United States mails. Any party may from time to time change its address for further Notices hereunder by giving notice to the other party in the manner prescribed in this Section 12.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">13.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Employment or Service</u>. Nothing in this Agreement or the Plan will interfere with or limit in any way the right of the Company or any Subsidiary to terminate the employment or service of Director at any time, nor confer upon Director any right to continue in the employment or other service with the Company or any Subsidiary.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">14.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Transfer of Personal</u>&nbsp;Data. The Director authorizes, agrees and unambiguously consents to the transmission by the Company (or any Subsidiary) of any personal data information related to the RSUs awarded under this Agreement for legitimate business purposes (including, without limitation, the administration of the Plan). This authorization and consent is freely given by the Director.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">15.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Compliance with Securities Laws</u>. Notwithstanding any provision of this Agreement to the contrary, the issuance of the RSUs and any RSU Shares pursuant to this Agreement will be subject to compliance with all applicable requirements of federal, state, or foreign law with respect to such securities and with the requirements of any stock exchange or market system upon which the Common Stock may then be listed. No Common Stock will be issued hereunder if such issuance would constitute a violation of any applicable federal, state, or foreign securities laws or other law or regulations or the requirements of any stock exchange or market system upon which the Stock may then be listed. The inability of the Company to obtain from any regulatory body having jurisdiction the authority, if any, deemed by the Company&#8217;s legal counsel to be necessary to the lawful issuance and sale of any shares subject to the Award will relieve the Company of any liability in respect of the failure to issue such shares of Common Stock as to which such requisite authority has not been obtained. As a condition to any issuance hereunder, the Company may require the Director to satisfy any qualifications that may be necessary or appropriate to evidence compliance with any applicable law or regulation and to make any representation or warranty with respect to such compliance as may be requested by the Company. From time to time, the Board and appropriate officers of the Company are authorized to take the actions necessary and appropriate to file required documents with governmental authorities, stock exchanges, and other appropriate Persons to make shares of Common Stock available for issuance.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">16.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Section 409A</u>. This Agreement and the Plan are intended to comply with the applicable requirements of Section 409A of the Code and shall be limited, construed and interpreted in accordance with such intent. To the extent that this Award is subject to Section 409A of the Code, it shall be paid in a manner that will comply with Section 409A of the Code, including proposed, temporary or final regulations or any other guidance issued by the Secretary of the Treasury and the Internal Revenue Service with respect thereto. The Company shall have no liability to a Director, or any other party, if an Award that is intended to be exempt from, or compliant with, Section 409A of the Code is not so exempt or compliant or for any action taken by the Committee or the Company and, in the event that any amount or benefit under this Agreement or the Plan becomes subject to penalties under Section 409A of the Code, responsibility for payment of such penalties shall rest solely with the affected Directors and not with the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">17.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Successors and Assigns</u>. Except to the extent specifically limited by the terms and provision of this Agreement, this Agreement shall be binding upon and inure to the benefit of the parties hereto and their respective successors, assigns, heirs, and personal representatives.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGFTR" style="text-align: center; width: 100%">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">
<div class="hf-row">
<div class="hf-cell TOCLink">&nbsp;</div>
</div>
</div>
</div>

<p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">18.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Titles, Captions and Sections</u>. Titles and captions contained in this Agreement are inserted for convenience of reference only and do not constitute a part of this Agreement for any other purpose. References to Sections in this Agreement refer to Sections of this Agreement unless otherwise stated.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">19.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Execution</u>. This Agreement may be executed in two or more counterparts, all of which when taken together shall be considered one and the same agreement and shall become effective when counterparts have been signed by each party and delivered to the other party, it being understood that both parties need not sign the same counterpart. In the event that any signature is delivered by facsimile transmission or by email delivery of a &#8220;pdf&#8221;&nbsp;format data file, such signature shall create a valid and binding obligation of the party executing (or on whose behalf such signature is executed) with the same force and effect as if such facsimile or &#8220;pdf&#8221;&nbsp;signature page were an original thereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">20.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Further Assurances</u>. Each party hereto shall do and perform (or shall cause to be done and performed) all such further acts and shall execute and deliver all such other agreements, certificates, instruments and documents as either party hereto reasonably may request in order to carry out the intent and accomplish the purposes of this Agreement and the Plan and the consummation of the transactions contemplated thereunder.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">21.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Severability</u>. If any provision of this Agreement is held to be illegal or invalid for any reason, the illegality or invalidity shall not affect the remaining provisions hereof, but such provision shall be fully severable and this Agreement shall be construed and enforced as if the illegal or invalid provision had never been included herein.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="width:100%;font-family:Times New Roman;font-size:10pt;">

		<tr>
			<td style="width:18pt;">&nbsp;</td>
			<td style="vertical-align:top;width:18pt;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">22.</p>
			</td>
			<td style="vertical-align:top;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><u>Failure to Enforce Not a Waiver</u>. The failure of the Company or Director to enforce at any time any provision of this Agreement shall in no way be construed to be a waiver of such provision or of any other provision hereof.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;">[<i>Remainder of Page Intentionally Left Blank. Signature Page Follows.</i>]</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="PGBK" style="width: 100%; margin-left: 0pt; margin-right: 0pt">
<div class="PGNUM" style="text-align: center; width: 100%">&nbsp;</div>

<hr style="PAGE-BREAK-AFTER: always; border: none; width: 100%; height: 2px; color: #000000; background-color: #000000">
<div class="PGHDR" style="text-align: left; width: 100%">&nbsp;</div>
</div>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">IN WITNESS WHEREOF, the parties to this Agreement have executed this Agreement effective as of the Grant Date.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-size: 10pt; font-family: &quot;Times New Roman&quot;, Times, serif; width: 100%;">

		<tr>
			<td style="width: 50%;">PARTICIPANT:</td>
			<td style="width: 50%;">DIFFUSION PHARMACEUTICALS INC.</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>________________________</td>
			<td>___________________________________</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>Name: [________]&nbsp;</td>
			<td>By: William Elder</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>&nbsp;</td>
		</tr>
		<tr>
			<td>&nbsp;</td>
			<td>Title: General Counsel</td>
		</tr>

</table>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">By execution of this Agreement, Director acknowledges having received a copy of the Plan.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-21.1
<SEQUENCE>4
<FILENAME>ex_348719.htm
<DESCRIPTION>EXHIBIT 21.1
<TEXT>
<html><head>
	<title>ex_348719.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 2:04:36 AM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 21.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:40.5882352941176%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:auto;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>SIGNIFICANT SUBSIDIARIES OF THE REGISTRANT</b></p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 60%; margin-left: 20%; margin-right: 20%;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Name of Subsidiary</b></p>
			</td>
			<td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>State or Other</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Jurisdiction of</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Incorporation or</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Organization</b></p>
			</td>
			<td style="vertical-align: bottom; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Direct or Indirect</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Ownership Interest by</b></p>

			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Company</b></p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Canterbury Laboratories, LLC</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">DE</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">100%</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Hygeia Therapeutics, Inc.</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">DE</p>
			</td>
			<td style="vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">100%</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">Diffusion Pharmaceuticals LLC</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">VA</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: top; width: auto; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; text-align: center; margin: 0pt;">100%</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>5
<FILENAME>ex_348951.htm
<DESCRIPTION>EXHIBIT 23.1
<TEXT>
<html><head>
	<title>ex_348951.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 7:12:58 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="margin-bottom: 0px; text-align: right; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt"><b>Exhibit 23.1</b></font></p>

<p style="margin-bottom: 0px; text-align: left; margin-top: 0px"><font style="font-family: 'Times New Roman', Times, serif; font-size: 10pt">&nbsp;</font></p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>Consent of Independent Registered Public Accounting Firm</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">We consent to the incorporation by reference in the registration statements (No. 333-206408, No. 333-206409, No. 333-218060, No 333-226782, No. 333-233381, No. 333-238233, and No. 333-258760) on Form S-8, (No. 333-222203, No. 333-233686, No. 333-234234, No 333-235670, and No. 333-238818) on Form S-1, and (No. 333-218062, No. 333-222879, No. 333-231541, and No. 333-249057) on Form S-3 of our report dated March 18, 2022, with respect to the consolidated financial statements of Diffusion Pharmaceuticals Inc.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ KPMG LLP</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">McLean, Virginia<br>
March 18, 2022</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>6
<FILENAME>ex_346478.htm
<DESCRIPTION>EXHIBIT 31.1
<TEXT>
<html><head>
	<title>ex_346478.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 12:02:44 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO SECTION 302 OF THE</b><br>
<b>SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, Robert J. Cobuzzi, Jr., Ph.D., certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 10-K of Diffusion Pharmaceuticals Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 18, 2022</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Robert J. Cobuzzi, Jr., Ph.D.</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Principal Executive Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>7
<FILENAME>ex_346479.htm
<DESCRIPTION>EXHIBIT 31.2
<TEXT>
<html><head>
	<title>ex_346479.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 12:02:57 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size:10pt;font-family:'Times New Roman';padding:0in .1in;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 31.2</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL FINANCIAL OFFICER PURSUANT TO SECTION 302 OF THE</b><br>
<b>SARBANES OXLEY ACT OF 2002 AND SEC RULE 13a-14(a)</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">I, William K. Hornung, certify that:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">1.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I have reviewed this annual report on Form 10-K of Diffusion Pharmaceuticals Inc.;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">2.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">3.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">4.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(c)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(d)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;">5.&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;The registrant&#8217;s other certifying officer(s) and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(a)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 72pt;">(b)&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table cellpadding="0pt" cellspacing="0pt" style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; width: 100%; margin-left: 0pt; margin-right: 0pt;">

		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Date:</p>
			</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">March 18, 2022</p>
			</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">/s/ William K. Hornung&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">William K. Hornung</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">Chief Financial Officer</p>
			</td>
		</tr>
		<tr style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<td style="vertical-align: bottom; width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 45%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt;">
			<p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 10pt; font-variant: normal; margin: 0pt;">(Principal Financial and Accounting Officer)</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>8
<FILENAME>ex_346480.htm
<DESCRIPTION>EXHIBIT 32.1
<TEXT>
<html><head>
	<title>ex_346480.htm</title>

	<!-- Generated by ThunderDome Portal - 3/18/2022 12:04:18 PM --><meta charset="utf-8"><meta name="format-detection" content="telephone=no">
</head>
<body style="font-size: 10pt; font-family: &quot;Times New Roman&quot;; padding: 0in 0.1in; cursor: auto;">
<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:right;margin:0pt;"><b>Exhibit 32.1</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b>CERTIFICATION OF PRINCIPAL EXECUTIVE OFFICER PURSUANT TO 18 U.S.C. SECTION 1350, AS ADOPTED PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002</b></p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">In connection with the Annual Report on Form 10-K of Diffusion Pharmaceuticals Inc. (the &#8220;Company&#8221;) for the period ended December 31, 2021&nbsp;as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), we, Robert J. Cobuzzi, Jr., Ph.D. and William K. Hornung, President and Chief Executive Officer and Chief Financial Officer, respectively, of the Company, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to our knowledge:</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(1)</p>
			</td>
			<td style="vertical-align:top;width:86.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:top;width:8.7%;">&nbsp;</td>
			<td style="vertical-align:top;width:3.5%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">(2)</p>
			</td>
			<td style="vertical-align:top;width:86.4%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align:bottom;width:49.3%;">&nbsp;</td>
			<td style="border-bottom:solid 1px #000000;vertical-align:bottom;width:49.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ Robert J. Cobuzzi, Jr., Ph.D</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:49.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:49.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Robert J. Cobuzzi, Jr., Ph.D</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:49.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:49.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">President and Chief Executive Officer</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align:bottom;width:49.3%;">&nbsp;</td>
			<td style="vertical-align:bottom;width:49.3%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18, 2022</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<table border="0" cellpadding="0" cellspacing="0" style="font-family:Times New Roman;font-size:10pt;width:100%;margin-left:auto;margin-right:auto;">

		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="border-bottom: 1px solid rgb(0, 0, 0); vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">/s/ William K. Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">William K. Hornung</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">Chief Financial Officer (Principal Financial and Accounting Officer)</p>
			</td>
		</tr>
		<tr>
			<td style="vertical-align: bottom; width: 50%;">&nbsp;</td>
			<td style="vertical-align: bottom; width: 50%;">
			<p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;">March 18,&nbsp;2022</p>
			</td>
		</tr>

</table>

<p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&nbsp;</p>

<div class="LAST-PAGE-BREAK">
<div class="PGFTR">
<div class="hf-row">
<div class="hf-cell PGNUM">&nbsp;</div>
</div>
</div>
</div>


</body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>9
<FILENAME>dffn-20211231.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:59PM UTC 2022-03-18--><xsd:schema xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:country="http://xbrl.sec.gov/country/2021" xmlns:currency="http://xbrl.sec.gov/currency/2021" xmlns:dei="http://xbrl.sec.gov/dei/2021q4" xmlns:dffn="http://www.diffusionpharma.com/20211231" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:exch="http://xbrl.sec.gov/exch/2021" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:naics="http://xbrl.sec.gov/naics/2021" xmlns:sic="http://xbrl.sec.gov/sic/2021" xmlns:srt="http://fasb.org/srt/2021-01-31" xmlns:srt-types="http://fasb.org/srt-types/2021-01-31" xmlns:stpr="http://xbrl.sec.gov/stpr/2021" xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31" xmlns:us-types="http://fasb.org/us-types/2021-01-31" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.diffusionpharma.com/20211231">
  <xsd:import namespace="http://xbrl.sec.gov/country/2021" schemaLocation="https://xbrl.sec.gov/country/2021/country-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/naics/2021" schemaLocation="https://xbrl.sec.gov/naics/2021/naics-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xsd:import namespace="http://fasb.org/us-gaap/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd"/>
  <xsd:import namespace="http://fasb.org/srt/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/stpr/2021" schemaLocation="https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/sic/2021" schemaLocation="https://xbrl.sec.gov/sic/2021/sic-2021.xsd"/>
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/exch/2021" schemaLocation="https://xbrl.sec.gov/exch/2021/exch-2021.xsd"/>
  <xsd:import namespace="http://fasb.org/us-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2021q4" schemaLocation="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd"/>
  <xsd:import namespace="http://xbrl.sec.gov/currency/2021" schemaLocation="https://xbrl.sec.gov/currency/2021/currency-2021.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd"/>
  <xsd:import namespace="http://fasb.org/srt-types/2021-01-31" schemaLocation="https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd"/>
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd"/>
  <xsd:annotation>
    <xsd:appinfo>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20211231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20211231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20211231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="dffn-20211231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="statement-document-and-entity-information" roleURI="http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">000 - Document - Document And Entity Information</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-" roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">001 - Statement - Consolidated Balance Sheets</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-balance-sheets-parentheticals" roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">002 - Statement - Consolidated Balance Sheets (Parentheticals)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-operations-" roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">003 - Statement - Consolidated Statements of Operations</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-changes-in-stockholders-equity-" roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-consolidated-statements-of-cash-flows-" roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">005 - Statement - Consolidated Statements of Cash Flows</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-1-organization-and-description-of-business" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">006 - Disclosure - Note 1 - Organization and Description of Business</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-2-liquidity" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">007 - Disclosure - Note 2 - Liquidity</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-and-other-current-liabilities" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">009 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-commitments-and-contingencies-" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">010 - Disclosure - Note 5 - Commitments and Contingencies</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-and-common-stock-warrants" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">011 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">012 - Disclosure - Note 7 - Stock-based Compensation</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">013 - Disclosure - Note 8 - Income Taxes</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-significant-accounting-policies-policies" roleURI="http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">014 - Disclosure - Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">015 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-and-other-current-liabilities-tables" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">016 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-and-common-stock-warrants-tables" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">017 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-tables" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">018 - Disclosure - Note 7 - Stock-based Compensation (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-tables" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">019 - Disclosure - Note 8 - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">020 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">021 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">022 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-5-commitments-and-contingencies-details-textual" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">023 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">024 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">025 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-details-textual" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">026 - Disclosure - Note 7 - Stock-based Compensation (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">027 - Disclosure - Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-stock-option-activity-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">028 - Disclosure - Note 7 - Stock-based Compensation - Stock Option Activity (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-fair-value-assumptions-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">029 - Disclosure - Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">030 - Disclosure - Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-details-textual" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">031 - Disclosure - Note 8 - Income Taxes (Details Textual)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">032 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-operating-loss-carryforwards-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">033 - Disclosure - Note 8 - Income Taxes - Operating Loss Carryforwards (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
      <link:roleType id="statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details">
        <link:definition xmlns="http://www.xbrl.org/2003/linkbase">034 - Disclosure - Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:definition>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
        <link:usedOn>link:presentationLink</link:usedOn>
      </link:roleType>
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:element id="dffn_AccruedClinicalStudiesExpensesCurrent" name="AccruedClinicalStudiesExpensesCurrent" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" name="ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:perShareItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" name="ClassOfWarrantOrRightExercisedDuringPeriod" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ClassOfWarrantOrRightsExpired" name="ClassOfWarrantOrRightsExpired" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DeemedDividendFromWarrantExchange" name="DeemedDividendFromWarrantExchange" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" name="DeferredTaxAssetsCapitalizedCostsAndOther" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxAssetsLeaseLiability" name="DeferredTaxAssetsLeaseLiability" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxAssetsOrphanDrugCredits" name="DeferredTaxAssetsOrphanDrugCredits" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element id="dffn_DeferredTaxAssetsValuationAllowancePercentage" name="DeferredTaxAssetsValuationAllowancePercentage" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_DeferredTaxLiabilitiesRightOfUseAsset" name="DeferredTaxLiabilitiesRightOfUseAsset" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_DocumentAndEntityInformation" name="DocumentAndEntityInformation" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" name="EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_EquityIncentivePlan2015Member" name="EquityIncentivePlan2015Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_HCWainwrightAndCoLLCMember" name="HCWainwrightAndCoLLCMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_LiquidityDisclosureTextBlock" name="LiquidityDisclosureTextBlock" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:textBlockItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NewWarrantsIssuedMay82020Member" name="NewWarrantsIssuedMay82020Member" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NoteToFinancialStatementDetailsTextual" name="NoteToFinancialStatementDetailsTextual" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatements" name="NotesToFinancialStatements" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_NotesToFinancialStatementsAbstract" name="NotesToFinancialStatementsAbstract" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" name="PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:percentItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_PrepaidExpensesDepositsAndOtherAssets" name="PrepaidExpensesDepositsAndOtherAssets" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="instant"/>
  <xsd:element abstract="true" id="dffn_PriorWarrantMember" name="PriorWarrantMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_ProceedsFromSaleOfCommonStockWarrants" name="ProceedsFromSaleOfCommonStockWarrants" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="debit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" name="PublicOfferingInclusiveOfUnderwriterSharesMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_RestrictedStockUnitsVestedAmount" name="RestrictedStockUnitsVestedAmount" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" name="StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:sharesItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" name="StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" nillable="true" substitutionGroup="xbrli:item" type="xbrli:monetaryItemType" xbrli:balance="credit" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020InvestorWarrantExerciseMember" name="TheMay2020InvestorWarrantExerciseMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020OfferingMember" name="TheMay2020OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020OfferingWarrantsMember" name="TheMay2020OfferingWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_TheMay2020PAWarrantsMember" name="TheMay2020PAWarrantsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element id="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" name="UnderwriterOptionToPurchaseAdditionalSharesTerm" nillable="true" substitutionGroup="xbrli:item" type="xbrli:durationItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" name="UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_UnvestedRestrictedStockUnitsMember" name="UnvestedRestrictedStockUnitsMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" name="WarrantsAttachedToSeriesAConvertiblePreferredStockMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" name="WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" name="WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" name="WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" name="WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" nillable="true" substitutionGroup="xbrli:item" type="dtr-types:domainItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" name="statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" name="statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" name="statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" name="statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" name="statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" name="statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" name="statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" name="statement-statement-note-7-stockbased-compensation-stock-option-activity-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" name="statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-7-stockbased-compensation-tables" name="statement-statement-note-7-stockbased-compensation-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" name="statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" name="statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" name="statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-note-8-income-taxes-tables" name="statement-statement-note-8-income-taxes-tables" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
  <xsd:element abstract="true" id="dffn_statement-statement-significant-accounting-policies-policies" name="statement-statement-significant-accounting-policies-policies" nillable="true" substitutionGroup="xbrli:item" type="xbrli:stringItemType" xbrli:periodType="duration"/>
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>10
<FILENAME>dffn-20211231_cal.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION CALCULATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:59PM UTC 2022-03-18--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:calculationArc order="1" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:calculationArc order="0" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="dffn_DeemedDividendFromWarrantExchange" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:calculationArc order="3" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:calculationArc order="5" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:calculationArc order="6" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:calculationArc order="7" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:calculationArc order="2" weight="-1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
  </link:calculationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-" xlink:href="dffn-20211231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:calculationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:calculationArc order="3" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:calculationArc order="4" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:calculationArc order="0" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:calculationArc order="1" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:calculationArc order="2" weight="1.0" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
  </link:calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>11
<FILENAME>dffn-20211231_def.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION DEFINITION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:59PM UTC 2022-03-18--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" xlink:type="simple"/>
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity" xlink:href="dffn-20211231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dffn_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20211231.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information" xlink:href="dffn-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:definitionArc order="17" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:definitionArc order="18" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:definitionArc order="19" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:definitionArc order="20" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:definitionArc order="21" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:definitionArc order="22" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:definitionArc order="23" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:definitionArc order="24" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:definitionArc order="25" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:definitionArc order="26" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:definitionArc order="27" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:definitionArc order="28" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:definitionArc order="29" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:definitionArc order="30" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:definitionArc order="31" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:definitionArc order="32" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:definitionArc order="33" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="34" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:definitionArc order="35" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
    <link:definitionArc order="36" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dffn-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-" xlink:href="dffn-20211231.xsd#statement-note-5-commitments-and-contingencies-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:href="dffn-20211231.xsd#statement-note-5-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeemedDividendFromWarrantExchange" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain-default" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_PlanNameDomain" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain-default" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="arc"/>
    <link:definitionArc order="12" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="13" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
    <link:definitionArc order="14" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:definitionArc order="15" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:definitionArc order="16" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="arc"/>
    <link:definitionArc order="11" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationNonproduction" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="dffn_DeemedDividendFromWarrantExchange" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_RestrictedStockUnitsVestedAmount" xlink:label="dffn_RestrictedStockUnitsVestedAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_RestrictedStockUnitsVestedAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-" xlink:href="dffn-20211231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain-default" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="arc"/>
  </link:definitionLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity-" xlink:type="simple"/>
  <link:definitionLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain-default" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain-default" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:definitionArc order="0" xbrldt:closed="true" xbrldt:contextElement="segment" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:definitionArc order="1" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding" xlink:type="arc"/>
    <link:definitionArc order="2" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="arc"/>
    <link:definitionArc order="3" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="4" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="arc"/>
    <link:definitionArc order="5" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="6" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:definitionArc order="7" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:definitionArc order="8" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:definitionArc order="9" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc"/>
    <link:definitionArc order="10" xbrldt:closed="true" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc"/>
  </link:definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>12
<FILENAME>dffn-20211231_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:59PM UTC 2022-03-18--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel" xlink:type="simple"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel" xlink:type="simple"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DocumentAndEntityInformation" xlink:label="dffn_DocumentAndEntityInformation" xlink:type="locator"/>
    <link:label xlink:label="dffn_DocumentAndEntityInformation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document And Entity Information</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DocumentAndEntityInformation" xlink:to="dffn_DocumentAndEntityInformation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Dividend yield</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Fair Value of Financial Instruments, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:label xlink:label="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note To Financial Statement Details Textual</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="dffn_NoteToFinancialStatementDetailsTextual-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="dffn_statement-statement-significant-accounting-policies-policies-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Accrued Expenses and Other Current Liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:to="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Risk-free interest rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:label="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Stockholders' Equity and Common Stock Warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:to="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockbased-compensation-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stock-based Compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-tables" xlink:to="dffn_statement-statement-note-7-stockbased-compensation-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-tables" xlink:label="dffn_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-income-taxes-tables-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-income-taxes-tables" xlink:to="dffn_statement-statement-note-8-income-taxes-tables-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stock-based Compensation - Stock Option Activity (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:to="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:to="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="dffn_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Liquidity Disclosure [Text Block]</link:label>
    <link:label xlink:label="dffn_LiquidityDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The entire disclosure for the liquidity of the company.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_LiquidityDisclosureTextBlock" xlink:to="dffn_LiquidityDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Attached to Series A Convertible Preferred Stock [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents warrants that are attached to Series A Convertible Preferred Stock.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:to="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected volatility</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:to="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAssetsNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:label="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Operating Loss Carryforwards (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:to="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:label xlink:label="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatements" xlink:label="dffn_NotesToFinancialStatements" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatements-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatements" xlink:to="dffn_NotesToFinancialStatements-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expected term (Year)</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:label xlink:label="dffn_NotesToFinancialStatementsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Notes To Financial Statements [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="dffn_NotesToFinancialStatementsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Earnings Per Share, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingExpensesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating expenses:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested, Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, Weighted-average grant date fair value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Unvested, shares (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Unvested, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, shares (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Vested, shars (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationDepletionAndAmortization-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Depreciation and amortization</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Public Offering, Inclusive of Underwriter Shares [Member]</link:label>
    <link:label xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information regarding a public offering, inclusive of shares offered and sold pursuant to the exercise-in-full by the underwriter of its option to purchase additional shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</link:label>
    <link:label xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LegalCostsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Costs, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LegalCostsPolicyTextBlock" xlink:to="us-gaap_LegalCostsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesIssuedPricePerShare</link:label>
    <link:label xlink:label="us-gaap_SharesIssuedPricePerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Shares Issued, Price Per Share (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesIssuedPricePerShare" xlink:to="us-gaap_SharesIssuedPricePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vested and expected to vest, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AssetsCurrent</link:label>
    <link:label xlink:label="us-gaap_AssetsCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total current assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders' Equity Note Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Exercisable (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average remaining contractual life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, aggregate intrinsic value</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Interest income</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 101,914,280 and 64,015,441 shares issued and outstanding at December 31, 2021 and 2020, respectively</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Offering [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020OfferingMember" xlink:to="dffn_TheMay2020OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Adjustments to reconcile net loss to net cash used in operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020OfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Offering Warrants [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020OfferingWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 offering warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020OfferingWarrantsMember" xlink:to="dffn_TheMay2020OfferingWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_PriorWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prior Warrant [Member]</link:label>
    <link:label xlink:label="dffn_PriorWarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the prior warrant.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PriorWarrantMember" xlink:to="dffn_PriorWarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DeemedDividendFromWarrantExchange</link:label>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deemed Dividend From Warrant Exchange</link:label>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Deemed dividend arising from warrant exchange</link:label>
    <link:label xlink:label="dffn_DeemedDividendFromWarrantExchange-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The amount of deemed dividend from the exchange of warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeemedDividendFromWarrantExchange" xlink:to="dffn_DeemedDividendFromWarrantExchange-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Forfeited, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesIssued-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares issued (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Expired, weighted-average exercise price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, par value (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted, weighted-average exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exchange, Additional Consideration Per Share (in dollars per share)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">the amount of additional consideration per share given in the exchange of a class of warrant or right.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:to="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other current assets</link:label>
    <link:label xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 Investor Warrant Exercise [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Related to the May 2020 Investor Warrant Exercise.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeasePayments</link:label>
    <link:label xlink:label="us-gaap_OperatingLeasePayments-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Payments</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MaximumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Maximum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Supplemental disclosure of non-cash investing and financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:label xlink:label="srt_MinimumMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Minimum [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Options outstanding, number (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxAssetsNet</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsNet-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_RangeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statistical Measurement [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Expired (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash received from sale of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accrued expenses and other current liabilities</link:label>
    <link:label xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedSalariesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedSalariesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued payroll and payroll related expenses</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedSalariesCurrent" xlink:to="us-gaap_AccruedSalariesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PolicyTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_PolicyTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accounting Policies</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_PolicyTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Goodwill and Intangible Assets, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredIncomeTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Deferred tax liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AccruedProfessionalFeesCurrent</link:label>
    <link:label xlink:label="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued professional fees</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedProfessionalFeesCurrent" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</link:label>
    <link:label xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Incentive Plan 2015 [Member]</link:label>
    <link:label xlink:label="dffn_EquityIncentivePlan2015Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the 2015 equity incentive plan.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EquityIncentivePlan2015Member" xlink:to="dffn_EquityIncentivePlan2015Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Assets</link:label>
    <link:label xlink:label="us-gaap_Assets-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PropertyPlantAndEquipmentUsefulLife</link:label>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Useful Life (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Plan Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingLeaseExpense</link:label>
    <link:label xlink:label="us-gaap_OperatingLeaseExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Operating Lease, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</link:label>
    <link:label xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss applicable to common stockholders</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock option compensation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with May 2019 Public Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Information pertaining to warrants issued in connection with May 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_TheMay2020PAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">The May 2020 PA Warrants [Member]</link:label>
    <link:label xlink:label="dffn_TheMay2020PAWarrantsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the May 2020 PA Warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_TheMay2020PAWarrantsMember" xlink:to="dffn_TheMay2020PAWarrantsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:label xlink:label="dffn_NewWarrantsIssuedMay82020Member-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Warrants Issued May 8, 2020 [Member]</link:label>
    <link:label xlink:label="dffn_NewWarrantsIssuedMay82020Member-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents new unregistered warrants (the "New Warrants") issued May 8, 2020.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_NewWarrantsIssuedMay82020Member" xlink:to="dffn_NewWarrantsIssuedMay82020Member-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional paid-in capital</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property, Plant and Equipment, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AssetsCurrentAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current assets:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AwardTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Award Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_AwardTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:label xlink:label="us-gaap_NetIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Net loss</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at beginning of year</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents at end of year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Restricted Stock Units (RSUs) [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedStockUnitsRSUMember" xlink:to="us-gaap_RestrictedStockUnitsRSUMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</link:label>
    <link:label xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net increase in cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInFinancingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by financing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_Liabilities</link:label>
    <link:label xlink:label="us-gaap_Liabilities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingencies-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies (Note 5)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingencies" xlink:to="us-gaap_CommitmentsAndContingencies-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:label xlink:label="srt_DirectorMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Director [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_DirectorMember" xlink:to="srt_DirectorMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Sale of Stock [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PerformanceSharesMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Performance Shares [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PerformanceSharesMember" xlink:to="us-gaap_PerformanceSharesMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OperatingIncomeLoss</link:label>
    <link:label xlink:label="us-gaap_OperatingIncomeLoss-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss from operations</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EmployeeStockOptionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Option [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other income:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInOperatingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash used in operating activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilities</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilities-label" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="resource" xml:lang="en-US">Net deferred tax liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilities" xlink:to="us-gaap_DeferredTaxLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_NetCashProvidedByUsedInInvestingActivities</link:label>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Net cash provided by investing activities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrant [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantMember" xlink:to="us-gaap_WarrantMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="locator"/>
    <link:label xlink:label="dffn_ProceedsFromSaleOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of common stock warrants</link:label>
    <link:label xlink:label="dffn_ProceedsFromSaleOfCommonStockWarrants-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The cash inflow from the sale of common stock, warrants.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:to="dffn_ProceedsFromSaleOfCommonStockWarrants-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</link:label>
    <link:label xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Intangible assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Antidilutive Securities, Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnvestedRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Unvested Restricted Stock Units [Member]</link:label>
    <link:label xlink:label="dffn_UnvestedRestrictedStockUnitsMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents unvested restricted stock units.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnvestedRestrictedStockUnitsMember" xlink:to="dffn_UnvestedRestrictedStockUnitsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_CounterpartyNameAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Counterparty Name [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_RestrictedStockUnitsVestedAmount" xlink:label="dffn_RestrictedStockUnitsVestedAmount" xlink:type="locator"/>
    <link:label xlink:label="dffn_RestrictedStockUnitsVestedAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_RestrictedStockUnitsVestedAmount</link:label>
    <link:label xlink:label="dffn_RestrictedStockUnitsVestedAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:label xlink:label="dffn_RestrictedStockUnitsVestedAmount-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount related to restricted stock units vested.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_RestrictedStockUnitsVestedAmount" xlink:to="dffn_RestrictedStockUnitsVestedAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Intangible asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stockholders&#8217; Equity:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_EquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Commitments and Contingencies Disclosure [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Property and equipment, net</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsValuationAllowancePercentage-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DeferredTaxAssetsValuationAllowancePercentage</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsValuationAllowancePercentage-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Deferred Tax Assets, Valuation Allowance, Percentage</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsValuationAllowancePercentage-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Deferred tax Assets' percentage related to net of valuation allowance.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:to="dffn_DeferredTaxAssetsValuationAllowancePercentage-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ConcentrationRiskCreditRisk-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Concentration Risk, Credit Risk, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OtherSundryLiabilitiesCurrent</link:label>
    <link:label xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Other</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherSundryLiabilitiesCurrent" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:type="locator"/>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</link:label>
    <link:label xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows provided by investing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ProceedsFromWarrantExercises</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromWarrantExercises-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Warrant Exercises</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromWarrantExercises" xlink:to="us-gaap_ProceedsFromWarrantExercises-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Share information:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Retained Earnings [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Proceeds from the sale of common stock, net of issuance costs</link:label>
    <link:label xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Proceeds from Issuance of Common Stock</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:label xlink:label="srt_TitleOfIndividualAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of Individual [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounts payable, accrued expenses and other liabilities</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdditionalPaidInCapitalMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Additional Paid-in Capital [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common Stock [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeTaxExpenseBenefit</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Income Tax Expense (Benefit), Total</link:label>
    <link:label xlink:label="us-gaap_IncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Income tax benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxExpenseBenefit" xlink:to="us-gaap_IncomeTaxExpenseBenefit-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementEquityComponentsAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Components [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EquityComponentDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Equity Component [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Range of exercise price (in dollars per share)</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightDomain" xlink:to="us-gaap_ClassOfWarrantOrRightDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock warrants, outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</link:label>
    <link:label xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Loss before income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</link:label>
    <link:label xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_PaymentsOfFinancingCosts</link:label>
    <link:label xlink:label="us-gaap_PaymentsOfFinancingCosts-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Payment of offering costs</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfFinancingCosts" xlink:to="us-gaap_PaymentsOfFinancingCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Discretionary Contribution Amount</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_IcfrAuditorAttestationFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">ICFR Auditor Attestation Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and administrative</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</link:label>
    <link:label xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:type="locator"/>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_AccruedClinicalStudiesExpensesCurrent</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Accrued clinical studies expenses</link:label>
    <link:label xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_AccruedClinicalStudiesExpensesCurrent" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and cash equivalents</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StateAndLocalJurisdictionMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">State and Local Jurisdiction [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StateAndLocalJurisdictionMember" xlink:to="us-gaap_StateAndLocalJurisdictionMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeTaxAuthorityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Tax Authority [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxAuthorityDomain" xlink:to="us-gaap_IncomeTaxAuthorityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_AllocatedShareBasedCompensationExpense</link:label>
    <link:label xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Payment Arrangement, Expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DomesticCountryMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Domestic Tax Authority [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DomesticCountryMember" xlink:to="us-gaap_DomesticCountryMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentAnnualReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Annual Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_DeferredTaxLiabilitiesRightOfUseAsset</link:label>
    <link:label xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:label xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount of deferred tax liability attributable to taxable temporary differences from right-of-use asset.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash and Cash Equivalents, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Lease liability</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsLeaseLiability-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsLeaseLiability" xlink:to="dffn_DeferredTaxAssetsLeaseLiability-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:label xlink:label="dei_AmendmentFlag-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityIncorporationStateCountryCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">General and Administrative Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AccountingPoliciesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accounting Policies [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Significant Accounting Policies [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_OpenTaxYear</link:label>
    <link:label xlink:label="us-gaap_OpenTaxYear-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Open Tax Year</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OpenTaxYear" xlink:to="us-gaap_OpenTaxYear-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the December 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the December 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentTransitionReport-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Transition Report</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:label xlink:label="dei_CityAreaCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Basis of Accounting, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_UseOfEstimates-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Use of Estimates, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">New Accounting Pronouncements, Policy [Policy Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityInteractiveDataCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Interactive Data Current</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</link:label>
    <link:label xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Loss on disposal of property and equipment</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Right, Exercised During Period (in shares)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">The number of warrants or rights exercised during period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_SharesOutstanding</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:label xlink:label="us-gaap_SharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:type="resource" xml:lang="en-US">Balance (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharesOutstanding" xlink:to="us-gaap_SharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:label xlink:label="dei_SecurityExchangeName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_CommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Common stock, shares outstanding (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:label xlink:label="dei_Security12bTitle-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_CurrentFiscalYearEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current Fiscal Year End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired" xlink:type="locator"/>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_ClassOfWarrantOrRightsExpired</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Class of Warrant or Rights, Expired (in shares)</link:label>
    <link:label xlink:label="dffn_ClassOfWarrantOrRightsExpired-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Number of warrants or rights expired.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_ClassOfWarrantOrRightsExpired" xlink:to="dffn_ClassOfWarrantOrRightsExpired-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</link:label>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:role="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="resource" xml:lang="en-US">Prepaid expenses, deposits and other assets</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and Development Expense [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalPeriodFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Period Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentFiscalYearFocus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Fiscal Year Focus</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentPeriodEndDate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementLocationDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement Location [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFileNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityEmergingGrowthCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentType-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:label xlink:label="dei_EntitySmallBusiness-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Small Business</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityShellCompany-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Shell Company</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationLineItems-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Line Items]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:label xlink:label="dei_DocumentInformationTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Information [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityPublicFloat-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Public Float</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityFilerCategory-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Filer Category</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorFirmId-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Firm ID</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCurrentReportingStatus-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Current Reporting Status</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityVoluntaryFilers-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Voluntary Filers</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:label xlink:label="dei_AuditorLocation-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Auditor Location</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityWellKnownSeasonedIssuer-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Well-known Seasoned Issuer</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:type="resource" xml:lang="en-US">Intangible asset impairment charge</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</link:label>
    <link:label xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Anti-dilutive securities (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Stock-based compensation expense</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityTaxIdentificationNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCentralIndexKey-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLossCarryforwards-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Operating loss carryforwards</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLossCarryforwards" xlink:to="us-gaap_OperatingLossCarryforwards-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityRegistrantName-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityDomain" xlink:to="dei_EntityDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:label xlink:label="dei_LegalEntityAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Legal Entity [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LegalEntityAxis" xlink:to="dei_LegalEntityAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Summary of Operating Loss Carryforwards [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementTable-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement [Table]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressAddressLine1-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Financial Position [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareDiluted-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Weighted average shares outstanding, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressCityOrTown-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateContinuingOperations</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total provision</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressPostalZipCode-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EarningsPerShareBasic-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Net loss per share of common stock, basic and diluted (in dollars per share)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityAddressStateOrProvince-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Change in valuation allowance</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfCashFlowsAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Cash Flows [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:label xlink:label="dei_EntityCommonStockSharesOutstanding-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Common Stock, Shares Outstanding</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DepreciationNonproduction-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DepreciationNonproduction</link:label>
    <link:label xlink:label="us-gaap_DepreciationNonproduction-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Depreciation</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationNonproduction" xlink:to="us-gaap_DepreciationNonproduction-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Statement of Stockholders' Equity [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncomeStatementAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Income Statement [Abstract]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Other Current Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:label xlink:label="dei_TradingSymbol-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NatureOfOperations-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Nature of Operations [Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NatureOfOperations" xlink:to="us-gaap_NatureOfOperations-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock upon exercise of warrants (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:label xlink:label="dei_LocalPhoneNumber-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_TableTextBlock</link:label>
    <link:label xlink:label="us-gaap_TableTextBlock-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes Tables</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_TableTextBlock-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the January 2018 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the January 2018 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Vesting of restricted stock units</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</link:label>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the value of common stock and warrants issued during the period, net of issuance costs.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">State tax, net of Federal benefit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Warrants Issued in Connection with the November 2019 Offering [Member]</link:label>
    <link:label xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to the warrants issued in connection to the November 2019 public offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="locator"/>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)</link:label>
    <link:label xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the amount of shares and warrants issued during the period.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Granted (in shares)</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cash flows provided by financing activities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</link:label>
    <link:label xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Forfeited (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_WarrantsAndRightsOutstandingTerm</link:label>
    <link:label xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Warrants and Rights Outstanding, Term (Year)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WarrantsAndRightsOutstandingTerm" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</link:label>
    <link:label xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Federal tax benefit at statutory rate</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockIssuedDuringPeriodSharesNewIssues</link:label>
    <link:label xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Stock Issued During Period, Shares, New Issues (in shares)</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_LiabilitiesAndStockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total liabilities and stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm</link:label>
    <link:label xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Underwriter Option to Purchase Additional Shares, Term (Day)</link:label>
    <link:label xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the term of the underwiter's option to purchase additional shares.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:to="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Capitalized start-up costs and other</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentInProcess-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Abandonment of in-process research and development intangible asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentInProcess" xlink:to="us-gaap_ResearchAndDevelopmentInProcess-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_ResearchAndDevelopmentExpense-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Research and development</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Accumulated deficit</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:label xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Orphan Drug credits</link:label>
    <link:label xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</link:label>
    <link:label xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents information pertaining to warrants issued to designees of the underwriter in connection with the February 2021 common stock offering.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:type="locator"/>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="resource" xml:lang="en-US">Orphan drug credit</link:label>
    <link:label xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-label" xlink:type="arc"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:label xlink:label="dffn_HCWainwrightAndCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">H.C Wainwright &amp; Co., LLC [Member]</link:label>
    <link:label xlink:label="dffn_HCWainwrightAndCoLLCMember-label" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:type="resource" xml:lang="en-US">Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dffn_HCWainwrightAndCoLLCMember" xlink:to="dffn_HCWainwrightAndCoLLCMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Changes in operating assets and liabilities:</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_StockholdersEquity</link:label>
    <link:label xlink:label="us-gaap_StockholdersEquity-label" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:type="resource" xml:lang="en-US">Total stockholders' equity</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">us-gaap_DisclosureTextBlockAbstract</link:label>
    <link:label xlink:label="us-gaap_DisclosureTextBlockAbstract-label" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Notes to Financial Statements</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureTextBlockAbstract-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventMember-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event [Member]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventMember" xlink:to="us-gaap_SubsequentEventMember-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Noncurrent operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_StatementClassOfStockAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Class of Stock [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementClassOfStockAxis" xlink:to="us-gaap_StatementClassOfStockAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeAxis-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Axis]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeAxis-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Current operating lease liability</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_SubsequentEventTypeDomain-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Subsequent Event Type [Domain]</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTypeDomain" xlink:to="us-gaap_SubsequentEventTypeDomain-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Right of use asset</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset-label" xlink:type="arc"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:label xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Change in deferred income taxes</link:label>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit-label" xlink:type="arc"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>13
<FILENAME>dffn-20211231_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="US-ASCII" standalone="no"?>
<!--Generated by ThunderDome XBRL - 07:59PM UTC 2022-03-18--><link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:label="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity" xlink:href="dffn-20211231.xsd#statement-note-2-liquidity" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_LiquidityDisclosureTextBlock" xlink:label="dffn_LiquidityDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="dffn_LiquidityDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business" xlink:href="dffn-20211231.xsd#statement-note-1-organization-and-description-of-business" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NatureOfOperations" xlink:label="us-gaap_NatureOfOperations" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_NatureOfOperations" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information" xlink:href="dffn-20211231.xsd#statement-document-and-entity-information" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCentralIndexKey" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityRegistrantName" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AmendmentFlag" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CurrentFiscalYearEndDate" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalPeriodFocus" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentFiscalYearFocus" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentType" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentAnnualReport" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentPeriodEndDate" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentTransitionReport" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFileNumber" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityIncorporationStateCountryCode" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityTaxIdentificationNumber" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressAddressLine1" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressCityOrTown" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressStateOrProvince" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityAddressPostalZipCode" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_CityAreaCode" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_LocalPhoneNumber" xlink:type="arc"/>
    <link:presentationArc order="19" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_Security12bTitle" xlink:type="arc"/>
    <link:presentationArc order="20" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_TradingSymbol" xlink:type="arc"/>
    <link:presentationArc order="21" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_SecurityExchangeName" xlink:type="arc"/>
    <link:presentationArc order="22" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityWellKnownSeasonedIssuer" xlink:type="arc"/>
    <link:presentationArc order="23" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityVoluntaryFilers" xlink:type="arc"/>
    <link:presentationArc order="24" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCurrentReportingStatus" xlink:type="arc"/>
    <link:presentationArc order="25" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityInteractiveDataCurrent" xlink:type="arc"/>
    <link:presentationArc order="26" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityFilerCategory" xlink:type="arc"/>
    <link:presentationArc order="27" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntitySmallBusiness" xlink:type="arc"/>
    <link:presentationArc order="28" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityEmergingGrowthCompany" xlink:type="arc"/>
    <link:presentationArc order="29" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_IcfrAuditorAttestationFlag" xlink:type="arc"/>
    <link:presentationArc order="30" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityShellCompany" xlink:type="arc"/>
    <link:presentationArc order="31" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityPublicFloat" xlink:type="arc"/>
    <link:presentationArc order="32" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_EntityCommonStockSharesOutstanding" xlink:type="arc"/>
    <link:presentationArc order="33" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorName" xlink:type="arc"/>
    <link:presentationArc order="34" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorLocation" xlink:type="arc"/>
    <link:presentationArc order="35" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_AuditorFirmId" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:href="dffn-20211231.xsd#statement-consolidated-balance-sheets-parentheticals" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesIssued" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-" xlink:href="dffn-20211231.xsd#statement-note-5-commitments-and-contingencies-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:label="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_StockholdersEquityNoteDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NotesToFinancialStatementsAbstract" xlink:label="dffn_NotesToFinancialStatementsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DisclosureTextBlockAbstract" xlink:label="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NotesToFinancialStatementsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DisclosureTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureTextBlockAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:href="dffn-20211231.xsd#statement-significant-accounting-policies-policies" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-significant-accounting-policies-policies" xlink:label="dffn_statement-statement-significant-accounting-policies-policies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:label="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LegalCostsPolicyTextBlock" xlink:label="us-gaap_LegalCostsPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PolicyTextBlockAbstract" xlink:label="us-gaap_PolicyTextBlockAbstract-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-significant-accounting-policies-policies" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PolicyTextBlockAbstract-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PolicyTextBlockAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_LegalCostsPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:label="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:label="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_OtherCurrentLiabilitiesTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:label="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:label="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-tables" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-tables" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-tables" xlink:label="dffn_statement-statement-note-8-income-taxes-tables" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:label="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_TableTextBlock" xlink:label="us-gaap_TableTextBlock-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-income-taxes-tables" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_TableTextBlock-2" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentUsefulLife" xlink:label="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentUsefulLife-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:href="dffn-20211231.xsd#statement-note-5-commitments-and-contingencies-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent" xlink:label="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent" xlink:label="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeasePayments-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLeaseExpense-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare" xlink:label="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightExercisedDuringPeriod" xlink:label="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ClassOfWarrantOrRightsExpired" xlink:label="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_HCWainwrightAndCoLLCMember" xlink:label="dffn_HCWainwrightAndCoLLCMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NewWarrantsIssuedMay82020Member" xlink:label="dffn_NewWarrantsIssuedMay82020Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PriorWarrantMember" xlink:label="dffn_PriorWarrantMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:label="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingMember" xlink:label="dffn_TheMay2020OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020PAWarrantsMember" xlink:label="dffn_TheMay2020PAWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm" xlink:label="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights" xlink:label="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromWarrantExercises" xlink:label="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesIssuedPricePerShare" xlink:label="us-gaap_SharesIssuedPricePerShare-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantsAndRightsOutstandingTerm" xlink:label="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_PublicOfferingInclusiveOfUnderwriterSharesMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="dffn_TheMay2020OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_PriorWarrantMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_NewWarrantsIssuedMay82020Member" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020PAWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_CounterpartyNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis" xlink:to="dffn_HCWainwrightAndCoLLCMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesIssuedPricePerShare-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_WarrantsAndRightsOutstandingTerm-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeemedDividendFromWarrantExchange-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightsExpired-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_ClassOfWarrantOrRightExercisedDuringPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ProceedsFromWarrantExercises-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EquityIncentivePlan2015Member" xlink:label="dffn_EquityIncentivePlan2015Member" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis" xlink:label="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_DirectorMember" xlink:label="srt_DirectorMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualAxis" xlink:label="srt_TitleOfIndividualAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:label="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PerformanceSharesMember" xlink:label="us-gaap_PerformanceSharesMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation" xlink:label="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventMember" xlink:label="us-gaap_SubsequentEventMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventTypeDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_TitleOfIndividualWithRelationshipToEntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_PlanNameAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis" xlink:to="dffn_EquityIncentivePlan2015Member" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_SubsequentEventTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTypeAxis" xlink:to="us-gaap_SubsequentEventMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_PerformanceSharesMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_TitleOfIndividualAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_TitleOfIndividualAxis" xlink:to="srt_DirectorMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1-2" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue-2" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1-2" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised-2" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized-2" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1-2" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross-2" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-details-textual" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsValuationAllowancePercentage" xlink:label="dffn_DeferredTaxAssetsValuationAllowancePercentage-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_NoteToFinancialStatementDetailsTextual" xlink:label="dffn_NoteToFinancialStatementDetailsTextual" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OpenTaxYear" xlink:label="us-gaap_OpenTaxYear-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_NoteToFinancialStatementDetailsTextual" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsValuationAllowancePercentage-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OpenTaxYear-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:href="dffn-20211231.xsd#statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020InvestorWarrantExerciseMember" xlink:label="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_TheMay2020OfferingWarrantsMember" xlink:label="dffn_TheMay2020OfferingWarrantsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:label="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:label="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:label="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:label="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightAxis" xlink:label="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightDomain" xlink:label="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:label="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ClassOfWarrantOrRightOutstanding" xlink:label="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="us-gaap_ClassOfWarrantOrRightDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_ClassOfWarrantOrRightAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020OfferingWarrantsMember" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_TheMay2020InvestorWarrantExerciseMember" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ClassOfWarrantOrRightAxis" xlink:to="dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightOutstanding" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice-5" xlink:type="arc"/>
    <link:presentationArc order="12" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2-2" xlink:type="arc"/>
    <link:presentationArc order="13" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber-2" xlink:type="arc"/>
    <link:presentationArc order="14" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice-2" xlink:type="arc"/>
    <link:presentationArc order="15" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1-2" xlink:type="arc"/>
    <link:presentationArc order="16" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber" xlink:type="arc"/>
    <link:presentationArc order="17" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice" xlink:type="arc"/>
    <link:presentationArc order="18" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MinimumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis" xlink:to="srt_MaximumMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RestrictedStockUnitsRSUMember" xlink:label="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AwardTypeAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AwardTypeAxis" xlink:to="us-gaap_RestrictedStockUnitsRSUMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber-5" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue-5" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:label="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsLeaseLiability" xlink:label="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:label="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeferredTaxLiabilitiesRightOfUseAsset" xlink:label="dffn_DeferredTaxLiabilitiesRightOfUseAsset-n8" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:label="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilities" xlink:label="us-gaap_DeferredTaxLiabilities-n10" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets" xlink:label="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsOrphanDrugCredits" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsLeaseLiability" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxAssetsCapitalizedCostsAndOther" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance-n8" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxAssetsNet-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets-n8" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_DeferredTaxLiabilitiesRightOfUseAsset-n8" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredIncomeTaxLiabilities-n10" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_DeferredTaxLiabilities-n10" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:label="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DomesticCountryMember" xlink:label="us-gaap_DomesticCountryMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityAxis" xlink:label="us-gaap_IncomeTaxAuthorityAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxAuthorityDomain" xlink:label="us-gaap_IncomeTaxAuthorityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLossCarryforwards" xlink:label="us-gaap_OperatingLossCarryforwards" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StateAndLocalJurisdictionMember" xlink:label="us-gaap_StateAndLocalJurisdictionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_IncomeTaxAuthorityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeTaxAuthorityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_DomesticCountryMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxAuthorityAxis" xlink:to="us-gaap_StateAndLocalJurisdictionMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingLossCarryforwards" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:href="dffn-20211231.xsd#statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent" xlink:label="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-n8" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:label="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate-n8" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-operations-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_DeemedDividendFromWarrantExchange" xlink:label="dffn_DeemedDividendFromWarrantExchange-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationNonproduction" xlink:label="us-gaap_DepreciationNonproduction-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill" xlink:label="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest" xlink:label="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeTaxExpenseBenefit" xlink:label="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:label="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic" xlink:label="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NonoperatingIncomeExpenseAbstract" xlink:label="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OperatingExpensesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpense" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill-1" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_GeneralAndAdministrativeExpense" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_DepreciationNonproduction-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_InterestIncomeExpenseNonoperatingNet" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_IncomeTaxExpenseBenefit-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLoss-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="dffn_DeemedDividendFromWarrantExchange-n8" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NonoperatingIncomeExpenseAbstract" xlink:to="us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic-3" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EarningsPerShareAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareBasic" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareDiluted" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-cash-flows-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:label="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_RestrictedStockUnitsVestedAmount" xlink:label="dffn_RestrictedStockUnitsVestedAmount-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:label="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:label="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PaymentsOfFinancingCosts" xlink:label="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:label="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:label="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentInProcess" xlink:label="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetIncomeLoss-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment-n8" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ShareBasedCompensation-1" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentInProcess" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_DeferredIncomeTaxExpenseBenefit" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2009/role/negatedTerseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets-n9" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_ProceedsFromIssuanceOfCommonStock" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="dffn_ProceedsFromSaleOfCommonStockWarrants" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_PaymentsOfFinancingCosts-n8" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect-3" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-4" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents-5" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract" xlink:to="dffn_RestrictedStockUnitsVestedAmount-2" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:href="dffn-20211231.xsd#statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_UnvestedRestrictedStockUnitsMember" xlink:label="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:label="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_WarrantMember" xlink:label="us-gaap_WarrantMember" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_WarrantMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_EmployeeStockOptionMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="dffn_UnvestedRestrictedStockUnitsMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:href="dffn-20211231.xsd#statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_AccruedClinicalStudiesExpensesCurrent" xlink:label="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:label="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedProfessionalFeesCurrent" xlink:label="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccruedSalariesCurrent" xlink:label="us-gaap_AccruedSalariesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherSundryLiabilitiesCurrent" xlink:label="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedSalariesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AccruedProfessionalFeesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_AccruedClinicalStudiesExpensesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherSundryLiabilitiesCurrent-2" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:href="dffn-20211231.xsd#statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:label="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_IncomeStatementLocationAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense-1" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-" xlink:href="dffn-20211231.xsd#statement-consolidated-balance-sheets-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-" xlink:type="extended">
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:label="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalCommonStock" xlink:label="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommitmentsAndContingencies" xlink:label="us-gaap_CommitmentsAndContingencies" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:label="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityAbstract" xlink:label="us-gaap_EquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:label="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent-3" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAccruedLiabilitiesCurrent" xlink:label="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity-3" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_LegalEntityAxis" xlink:to="dei_EntityDomain" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="dei_LegalEntityAxis" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AssetsCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="dffn_PrepaidExpensesDepositsAndOtherAssets" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_OtherAssetsNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_Assets-3" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_LiabilitiesCurrentAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableCurrent" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherAccruedLiabilitiesCurrent" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrent-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_DeferredIncomeTaxLiabilitiesNet" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_Liabilities-3" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_CommitmentsAndContingencies" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_EquityAbstract" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_CommonStockValue" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_AdditionalPaidInCapitalCommonStock" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_StockholdersEquity-3" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity-3" xlink:type="arc"/>
  </link:presentationLink>
  <link:roleRef roleURI="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-" xlink:href="dffn-20211231.xsd#statement-consolidated-statements-of-changes-in-stockholders-equity-" xlink:type="simple"/>
  <link:presentationLink xlink:role="http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-" xlink:type="extended">
    <link:loc xlink:href="dffn-20211231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="dffn-20211231.xsd#dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:label="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_SharesOutstanding" xlink:label="us-gaap_SharesOutstanding-5" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:label="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:label="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="locator"/>
    <link:loc xlink:href="https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd#us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest" xlink:label="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="locator"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_CommonStockMember" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_AdditionalPaidInCapitalMember" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_RetainedEarningsMember" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementLineItems" xlink:type="arc"/>
    <link:presentationArc order="0" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-4" xlink:type="arc"/>
    <link:presentationArc order="1" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-4" xlink:type="arc"/>
    <link:presentationArc order="2" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="3" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts" xlink:type="arc"/>
    <link:presentationArc order="4" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="5" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities" xlink:type="arc"/>
    <link:presentationArc order="6" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:type="arc"/>
    <link:presentationArc order="7" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_NetIncomeLoss" xlink:type="arc"/>
    <link:presentationArc order="8" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross" xlink:type="arc"/>
    <link:presentationArc order="9" preferredLabel="http://www.xbrl.org/2003/role/label" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross" xlink:type="arc"/>
    <link:presentationArc order="10" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_SharesOutstanding-5" xlink:type="arc"/>
    <link:presentationArc order="11" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" xbrldt:closed="true" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest-5" xlink:type="arc"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>a01.jpg
<TEXT>
begin 644 a01.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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40 4444 %%%% !1110 4444 ?_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>15
<FILENAME>logo.jpg
<TEXT>
begin 644 logo.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_X0 L17AI9@  34T *@    @  0$Q  (
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M_P $Q_"^LSZ#J_[<?[.8U*VF:WN%TSXB:3KUE!,AVO'+JN@OJ6E(8VRLFZ]
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M5--,^X:9_P )K_PD*:(UX+;]W_;)\"B+S?WAT3;\E?U/?LV?LY?"3]DKX)^
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M!XDM/C%X\GT]R,X6ZT>^URZTB^C&2?*O;&XCR<[,\T%^S\_P/]@^OAO_ (*
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M2!@)2?-;K??\3YP^#?\ P:0?L_>$?B3I?B7XP_M0^/OBU\/M(U6#4'^'>C>
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MB?/:M;#96L3%1G4P>"A0H8G&9EBZ=.<95*>%P\J.'YJ:Q>)PSJTN?^O^BO\
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M'OAX02>(=?%@)K;^T+]FN;+2-$L&N+>*\UW5=-@N+BVM7GN8O[B-=_X-8?\
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M_P $F?VUR#@_\*ST=<^S?$+P:I'X@D?C7^4W0:PV^?Z(_P!+S_@V:U33XO\
M@DU\)X9[ZRAFB^)WQO1XY+J".1?^+AZJZ;T:0,I,3QL 0"496Z,"?V0^,/[5
M'[-?[/VA7OB3XV?'?X4?##1["%IIY_&/CGP]H]PZC&([/3;B_&IZC<R$JD-I
MI]G=74\C)'##)(ZJ?\<6UUG5[*(066JZE:0@EA#:WUU;Q!F.6(CBE1 2>2<9
M)Y-5KF\N[V3S;RZN;N7 7S+F:6>3 Z#?*SM@=AG% .%W>_RL?UA?\%Q?^#@'
M0?VLO!>O?LB?L9S:[:_ _6;F.W^+'Q@U&UN] U/XJV-C<K/'X1\)Z+=)!JNE
M> I[J"&YUG4-8BLM6\3K%'IITK3]%%W_ &U_)Q%%+/+'!!')---(D4,,2-)+
M++(P2..-%!9Y'<A41069B  2:^K?V;/V%OVN_P!KS7;70?V=OV?_ (D?$IKF
M:*&;7M+\/W5CX,TOS651-K?CC6!I_A+1H0&$A?4M9MBT89HU< U_;=_P2+_X
M-P_"?[*/BCPQ^T?^V9J?AKXK?'3P]/;:SX%^&&AJVJ?#'X8:W"4FL]>U:_O8
M(3X\\9Z5,!+IDGV*U\,^'[Y!?646N:A!INKV .ZBK?\ #L^R_P#@WW_X)WZS
M^PA^Q?!K?Q-T5]&^/7[1M_IOQ+^(FF7<034_"/AV/3S!\/? -^I19+?4=%TF
M\O=9UVS<^98^(/$FIZ9-N.FH:[/_ (.&_P#E$7^U9_UP^%G_ *N'P'7[5U^*
MG_!PV?\ C47^U7_UP^%G_JX? =!FFW)/S1_EQ5_J)_\ !NQ_RB#_ &5/]_XR
M?^KS^)%?Y=E?ZB?_  ;KG/\ P2#_ &5,?W_C(/\ S.?Q(H+GM\_T9XO_ ,'0
M'_**GQ=_V6OX.?\ IXU&O\U2O]*O_@Z _P"45/B[_LM?P<_]/&HU_FJ4#A\'
M_;TORB?ZP7_!%+_E%5^Q#_V1>P_]/NN5^HU?ES_P12/_ !JJ_8A_[(O8?^GW
M7*_4:@R>[]7^9_C_ '_!1/\ Y/\ OVW_ /L[?]HO_P!6[XNK]U/^#2[_ )/W
M^-7_ &:]XB_]61\.*_"O_@HE_P G_?MO?]G;_M%_^K=\75^ZG_!I<?\ C/CX
MU?\ 9KWB+_U9'PXH-'\'R7Z'^A;7^=O_ ,'7_@>_T'_@H9\-_&DT4HT[Q[^S
M5X.^Q3D#R9+GPOXR\=Z3?PHP'^NA26RDFC)+I'<6[D!)8RW^B17\]7_!Q#_P
M30\7_MY?LP^&OB'\%=!;Q%^T!^S9>Z[XA\-^&;- =6\??#_Q#;V(\<^#M''!
MNO$$,FC:/XC\.6));4+G2K[1K-3?:Q;@A$'9Z]5;\O\ (_SP_P!EWXTW7[./
M[2/P(^/EG:R7\WP<^+?@#XD-I\6P2ZC;>$?$^FZU>Z?%YCI%YE_9V<]HGFL(
MMTP\W,>X'_76^#O[4/[/_P >OA+H?QQ^%OQ9\#>)OAEKNB6^NIXF@\2:1#:Z
M1;2VRW-Q:>)1->(WAS5=*R]OK&EZQ]DO-+NH9X+R*)XF%?XX&IZ9J6BZC?Z/
MK.GWVDZMI=W<:?J>EZG:3V&HZ=?VDKP7=E?65U'%<VEW;3H\-Q;7$4<T,J-'
M(BNI 2WO=1CBDLK6[O8X+HA9;2WGG6*X9L*%D@C<),6X4!D8G@4&DH\UNEC^
MB3_@Y-_;V^$?[9O[7/@3P7\"_$&F^-_AY^S?X-UKP=<?$#1;E+W0?%GCKQ/K
M,&I^*_\ A&K^(&WU3P_H<&E:)I%MK%K))9ZGJ4.KS6$MSIJV5Y<_@;\)Y4@^
M*7PVGD&Z.'Q[X/E<''*1^(-/=ASQR 1SQZ\5^B/C7_@E'\?/A'_P3IN_^"@'
MQGTS5OAQIFN_%#P#X*^&OPVUW29+'Q-KWA'Q59>(9;[XB:_:7AAO?#^D3W]A
MI&G^%+*YM4OM9ANKS5Y8;?2WTBYU+\V_ <RV_CGP9.Y"I#XK\/2NQX"I'J]F
M[$GL H))["@:VLNFG]>9_M.5YGX*^-'PC^)'B'QMX2\ _$OP/XP\5_#7Q!?>
M%/B#X8\/>)M(U3Q%X*\1Z<Z1WNC^)]$M+N34]%O8&= 8[^U@#[@8V<<UV>IZ
MY::7X>U#Q))'=7=AIVC7>N/%IUK-?WUS:6EE)?M'86=LCW%[=30QE;6V@1YK
MB9DBB1G=0?\ 'A^+WQW^,.I?M.?&#X[1>(/'?PQ^*GC;XJ>._'.IWFD:OX@\
M'^+O#^I^*/$FI:S/I_VRSFTS6M/EL/MHLUB9H)HXX51E7&*#*,>:_2Q_I_?M
M?_\ !'O_ ()^?MKVNM7?Q8^ ?AG0O'^L13?\7<^&%M;?#[XE6]]+EEU.ZUG1
M+:.P\37,4A\P1^,M)\16C$N'MSYCY_R_?VOO@7I_[,?[47Q\_9[TGQ=;>/=,
M^#OQ3\8?#_3_ !?;11P+KMGX=U>YL+>\N((9)H+?4!%$L.IV\$TL$&HQ744,
MCQ(C'W*;_@JO_P %);CPQ/X.F_;?_:5?P_<63:=-:'XK>*A<O9O#Y#0G5!?C
M5ANB^1I%OA*>6+[R6KXL\,^%O&_Q/\7:?X9\(>'_ !-X^\<^+-4%MIFAZ!IN
MI>)/$_B'6-0F+>7:V%C#>:EJ5_=SR,[[(Y9I9&9W))9J#2*:ZW[']5?_  :+
M>+/%%K^UQ^T_X&M9;D^#-=_9TL_%>M6X+FS'B;PK\2O".D>&;AQ_JUN1I?C'
MQ7%'TDEB>4C*0-M_0_\ X.[A_P 8K_LI-Z?'[Q$,?[WP]U(_^R_K7V;_ ,&^
M?_!*WQA_P3V^ _C'XC_'73K?2_VC/VA3X?N_$7AB.>*\F^&G@'0([NX\->"K
M^[MI9K.3Q+>7NJ7VM^+$LY);:TN&TG1O.FN-&N)I?C/_ (.[3_QBM^RG_P!E
M_P#$/_JO-4H)O>>G]:'\#2??7_>7^8K_ &0_V2?^35/V9?\ LWSX,?\ JN/#
M=?XWB??7_>7^8K_9#_9)/_&*G[,O_9OGP8_]5QX;H"IT^?Z'\=G_  4 ^$5_
M\%OVN/C5X5N;26WTW5?&&I^-?#4DBD1W7AOQK=3>(M.>V8D^9#9F^GTEW_Y^
MM-N8S\T;5Z+_ ,$P?VB- _9S_:K\,ZYXRU!-*\$>-]*U'X>>)]5N)/*LM&@U
MV:RN=*UF^8_)'9V&NZ;IGV^Y?"6>F37URQ B-?T3?\%&_P!@BP_;%\#V&N^$
MIK'1?C9X$M+F/PGJ=ZP@T[Q-I$KM<W'@[7;D*S6T,ER7N]$U,AUTO4)KE)D^
MQZC>/'_(7\2OA5\1?@[XJO\ P5\3/!^N^"_$^F2,EQI>MV,MI*Z*VU;JRF(-
MOJ%A-PUMJ-A-<V-RA62WN)$96/\ //$&59APIQ"LSP]*3PGU[Z[@:_*W0=ZG
MM7A*LHZ0E&\J,H-QE4I>_#=\O^WO@IXC<%_22\$JG &=9C2I\2/A+_5/C#)O
M;TZ>;KV.!CE]/B7+:56[Q%#$.G0S*EB:=.K1P68WPF)5Z</;?Z#4$\-S##<V
MTL5Q;W$4<\$\$BRPSPRH)(IH98RR212(RO'(C,CHP9200:_E]_X+=_M&>'?'
MGQ#\ ? CPCJUIJT/PL36-:\<3V,T=S;6_C#7ELK6TT-YXG:/[=H.E64CZA$"
MQ@N-:-G+Y=S9W$2_E!X>_:D_:.\)^$SX&\-?&_XHZ'X1$!M8M!TSQMXAL]/M
M;4C:;:QA@U!!8V^WY?(L_)B SA,LQ/DNB:#XG\;:]:Z/X?TC6O%/B36KOR[3
M3=*LKS5]8U2]N),E8+6UCGN[NXFD<LVQ'D=F+-DDFO0XCX]>>Y9_9>#P%7#2
MQ4J2Q4IU(U7)0G&HJ-",(J4E.K&%YR49.,7#V;YVU\3X#_0RCX/^('_$0N)N
M,<!GU/A^AF/^KV'PN K9=3I3QF$KX*KFV<5<7B*E*C+#9?B,3&GA*,J]*%>K
M'%2QR6&C3JW/ G@W7_B'XT\*^!?"UE)J/B+Q=K^D^'=&LHHY)&GU'5[Z"QM$
M*QJ[B/SIT,KA2(X@\C8521_=?XL_9X\+^,/V9+O]F?4G5?#D_P *M/\ AM;W
MX@61[&71]"M--T;78H<QA[K3=2L++6(EW(9+FW7<ZEBU?E[_ ,$P/^":.K_
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M#3W=S(D:+C<R_P ;OQ2\7_%?_@IC^V&9?".@7(O_ !EJ%KX=\':$Q,]KX+\
M:*SK!?:Y=P@Q06NG6DEUKOB._!\DZC>WJ69?SK*W;R^.LMR' X#!99EN78:&
M;XG$48X2GA:2^M.DFX3E5E'][5563C2A[:4I5*C<HW=.;7Z+]#OCOQEXOXTX
MM\0..N.<^Q?AID>19I5XEQO$>8U?]7:>9.-'%8>EEN&JN.7Y=6R[#PK9ABIY
M;1P]+ X",</75.&/PU.K_4G_ ,$\/'_B+XF?L:? KQ3XJN+F^UT^%[G0;O4+
MMFDN=1B\*:WJGAFPOKB5OGFN)].TJT-S.Y9Y[@2S.Q:0U_EC_P#!07_D^_\
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M<!BL3@<9AYJIA\7@Z]7#8FA46TZ->C*%6E-=)0E&2[GQ/-_P31_8:GNC=O\
ML]^%TD+%S'!K'C"WM=Q))Q:0>(X[9%RW$:1+&  H0 8KZ+^&'P!^"?P6@>#X
M4_"SP/X#,J>7/=^'?#^GV6IW2<\7NKB%M5O<Y.3=WDQ.>37KU%<E#*\LPM3V
MN&R[ X>K_P _:&$P]*I_X'3IQE^)]/F_B'Q_Q!@_[.S[CCC#.\O=KX'-^)<Z
MS+!OEVOA<9C:U!VLK7AI9!7E/QK^-/P]_9^^'.O_ !2^)VM+HGA7P_"IE=(V
MN+_4K^?<MAHVD6:$/?:MJ<Z^19VRE$W;IKB6"UAGN(O5J^:/VL/V9?#7[6GP
MFE^$GBOQ%K?A?29?$6C>(CJF@0V,U^+C1A=K%;[-0BEM_)F%X_F';O!1"IQN
M!TQTL7#!XF6 ITZN-5&H\+3JOEISK\K]FIMRC:/-:_O1TZK<XN$*/#6(XIX?
MH<98S&X#A2KFV!CQ%C,NI2K8_#Y.Z\/KU3!TXT<1*6(6'YU2M0K-3:DJ4[<K
M_DD_;0_;D^(?[9_Q @?7+R7P9\*-'U(Q^#/ T4T]QI^BVLDA@;Q#X@^QQN^M
M^))[9B]Y=QV\JVD)?3]'MT@\PW?ZH_L6?M4_\$S?V-?!3Z=X>\;>,/$WQ%U^
MVMQXY^(M[\,?$D5_J\L1\T:5H\!MI&T7PS:3G=:Z;'*\UU(B7NJ3W5TL1@],
M_P"'#_P+_P"BT?%/_P %_A7_ .0*/^'#_P "_P#HM'Q3_P#!?X5_^0*_(\%D
M?'.#S*OF\L!EV.S&N_\ >L=B*5:=%---8>,,52IT4X?NURPO"FO9TW"#E&7^
MFG%OB_\ 1 XJX$RCPRH<9<=<(\#92HK_ %?X.R3,<KPV:.$J=2E+.J^*X>S+
M&9E*%>$L7/VV(2Q>.J2QV/6+Q=/#UJ7ZV_ 3X_?#;]I3P!%\3/A3J6H:KX3F
MU?4M$2ZU+2KS1KK^T-*, O(S97R).$7[1$4D*[7#<<@@>9>(/V!_V'O%>N:Q
MXF\3_L@?LT>(?$7B'5+[6]>UW6?@E\.=2U?6M9U2YDO-2U75-1N_#LMW?ZC?
MW<TMU>7EU++<7-Q+)--(\CLQW_V4/V9O#7[)GPE@^$?A3Q#K7B?28/$.L^(1
MJFOQ64.H&XUG[+YL!33XXK?RH1:)Y9V[V+,6., ?2U?K> EC)8+"RS"%.GCG
M1IO%0HN]*-?E7M%3:E/W5*_+[\M.K/\ ,[C*EPOA^*^(*/!&)Q^,X1I9KC(<
M.8O,XN.8XC*(U9+!U<9%X?"-8B='E=5/#4'S7_=0V/ _A3^RK^S+\"=<O_$_
MP4_9\^"_PD\1ZKI4FA:GKWPX^&G@_P %ZSJ&BRW=K?R:1>ZEX>TC3[RYTV2^
ML;*\>RFF>V:YM+:<QF2&-E]\HHKK/F3YE^('[%G[('Q7\5ZIX[^)_P"R[^S_
M /$+QMK9MCK/B[QI\(O GB7Q)JILK2&PM#J.M:OH5WJ-Z;6RMK>TMS<7$AAM
MH(H(]L<:J)/A[^QC^R)\)/%NE^/?A;^S!\ ?ASXXT-;Y-&\8>"/A'X$\,>)M
M)34["YTO4ET[7-&T*SU*S%_IMY=Z?>"WN8Q<V=S/;3;X971OI:B@ HHHH *_
M@*_9=L?^"C?_  5L_P""IG_!3O\ 9UN?^"L/[67[+WPM_9-^+?Q"N? NB_"/
M49XT.EW7Q9\2>"M \,P0:/XC\%QV>C:#H^B@(MT^JO-(8F5(9C/<R_WZU_ +
M_P $6?VN?V8/V3?^"U__  6_U7]IKX]_"OX#:7XT^+'CK3O">J?%3QCH_@O3
M?$&H:/\ M ^.+K4[#2[_ %RYM+2ZOK.VO;:XEM$F-P8)#,D;QQ3-& >Y_MM:
MU_P6R_X-];/X?_M4M^W?K/\ P4B_8B7Q_P"'_ OQ3\ _'[PY%#\0/#-EKURY
MTT7?B"[U'Q!XA@.N&"ZTO2/&VB>,-NE^))=(L]=\)ZCI-X4N/??^#J?XU^&O
MCS_P0I^ WQ[^&U]?IX.^,?QW_9J^)'A>9Y#:Z@- \;?"SXF^(M/M;];69D2\
MMX+V*"^@266*.\@D57<1JY^>_P#@X;_X*T?L_?\ !0'X&>&/^"5__!-W7/\
MALCX^?M&_%;P#;^(KOX0:9J7B7PCX8T+PCXF36K;3['Q/'9+I>M:SJOB33='
MEO-0T:>]\.^'/"5KK6M:YK-C$UIYG4?\''O[/,W[)?\ P;C?L??LSW>HIJ^H
M? WXF?LH_#75M3AD:6WO];\+_"+XF:=K=U:2,D3O8S:M%>O8EXT?[(8=Z*V1
M0!_5_P#L,.\G[$W['LDCO)(_[+GP 9W=F=W9OA1X3+,[L2S,Q)+,Q)))))-?
M4]?QL? 7_@DC_P %!?\ @IS^QK^S]\9/VG?^"D?QX_9"TO5/@)\+T_9J_9@_
M9GCO/#O@;X5> -+\ :#I?P^\0_%>]A\2:%K7Q"\<>+-'LM/\5^);:2?2[S1Y
M-5_LNSUFR\G^RM+ZG_@WV_;7_;+^'_[;7[9/_!&+]O'XJZC\=OB#^RY9ZGXK
M^$?Q;\27][JGBC4_"7A[5_#.E:CI%QK>LC_A(?$/AS6] \9>#_''A.?Q#<:E
MKFBVVH:II,^I76FKID-@ ?U_45^/W_!1+_@FM^T-^WQ\4_ _]C?\%&_VCOV2
MOV9] \ 3Z/XT^#?[-[V/A'Q5\0/'<GB*ZOE\3WWQ'CFBO+731H4ECIC:-J6G
M>([*.?38[FPL["2\U":Y_F/_ &OD_:"_X-Q?VD?V2_C7\!/^"C'QN_:^_9-^
M,'Q5@^&?[07[//[0WQ/TSXEZ[I-M!':ZA?WD#07)LM-GO_#E_K>J^'-?TO0/
M#&IZ'K^BVEIJMUKND:O+:L ?WXT5_-U_P=,_%_XB?"W_ ()"^*_B+\%OB9XW
M^&WB6;XS? I-,\:_#;Q;KW@SQ"=&UC7;EYH+;7?#E_IFJ)8:E;&+[3;+<I#=
MP[8[A'3*U\>_L"_L=?\ !13_ (*H:_\ LM?\%1/VD_VW_BM^SK\"_#?BOX5?
M$']FK]BOP#/KFIZ-XI^$/POU#2(K+6?C'JMOXO\ #&GWVN?&C_A';O6]8U#4
MM&\8:A>Z5XB%T\]KI<UAX=L@#^P>BOX2?V^/VF/^"BNG_P#!RKXX_9$_8I^+
MOB'0-?\ VB/V=/AO\)?"J^+?$7B77/A5\ (/$GP\T#QCX]_:"TGX9S7TW@RZ
M\7>"?"WAKQ)J>F27ND.U_JM^L8-S?S6D$O,?\%2/^"<'_!0O_@CK\)--_P""
MGW[,W_!5/]K'X^>,/A1XT\(7'[0/AKXW^)]9U/0_$VF^+?$>DZ FL67A--<U
MCP[JW@Z?Q+J%AI7B3P1XCM;TV?A_5&U'3O$,<FE.K@'][M%?QO\ P@_8W_;T
M_P"#@OX+Z7^W9^T5^W;\:OV%/A%\3[&\;]E/]E_]E?5]2M_#WAGPEHEU<Z$O
MQ'^*VIOK7AZ[\9^(/%NOZ;J>IQZ<7@NH]$&G?8M?TBUEM]+M-?\ X-Y/VQ/V
MQOAO^VO^VU_P1J_;F^+>L?'7QO\ LN07_BWX1?$[Q7JU]K/B>\\+>']=T/1=
M9T[^V]?DE\3:[X9\0:'XS\#>-?"R:U=ZC?>'8;S5---[+8W%E'; ']A-%?C[
M_P %$?\ @FI^T+^WS\5?!#:1_P %&_VC_P!DS]F?0?A_)HWC'X,_LW2V7A#Q
M3X_\>2>(KR^/BB_^(R31W=MIO]@RV&EG1]2T[Q'91SZ:ES86=A)=WTMS_,?^
MUT?V@O\ @W%_:8_9(^,WP'_X*+?&[]K_ /9(^,OQ3B^&G[07[/G[0GQ/TSXE
M:]H]O;K97VHW=NT%R;+3KB]\-ZGK.K>&M>TO0?"^I:+K^AVUGJ]SKFD:Q);$
M _ORHK\6O^"X7_!5RR_X)9_L4K\9/ NE:3XX^.GQAU^Q^&W[./A;4X;N]T34
MO%FL:;-JUUXPUJRL9(+W4/#OA#087U62PMI[>36=8N_#V@FXM8]7>Z@_*KX#
M_P#!!?\ ;E_;&^'F@_M!?\%//^"K/[<7AWX\?$O3-/\ &3_!W]G?X@V_PU\%
M_!U=8MQ?V/A:ZL?L%[X=DUK2K2ZBMM5TWPMX4\+Z9HNH)=Z?!>ZYY?\ :DP!
M_7U17XLZIJ\__!"C_@E7\;OB-\9?VA_B_P#MI7/P)@\7>,?"_C'XYZ_>W'CS
MQ9J/C'7-,\.?"?X42ZK=:IXBFM]-L]7O_#^A3ZA9NL 2?6O$B:3IR2S6D/Y'
M_LP_\$C_ -L__@J]\%/"'[=/_!1+_@I1^V+\(?B#^T/I5K\3?A=\ OV5/'D'
MPN^%_P &?A=XDA.I_#[2WT6XT_5;2[U:\T"[L]7GCM;.SU"VM[V"'7-?\0ZZ
M^H:B #^Q:BOY)O\ @E;^U1^UU^Q%_P %5?BY_P $0/VU_CSXC_:F\-77@%OB
M[^QY^T!X\D>Y^(=[X9@T4>)!X0\4ZG?7U]JM_;WWABT\18M]4U/6I] \3^"M
M2L=(OI-"UNSAL>(USXY_&N/_ (/"?!WP.C^+_P 3T^"L_P"SI=:G/\(4\>>*
M%^&,VI+^RIXIUL:A+X#&J#PO)?C688=5%XVEFY&HQ1WGF^?&K@ _L0HK\P_^
M"TOB[Q7X"_X)1_M\>,_ WB;Q!X,\7^&_V;O'^J^'O%7A76-1\/>(]!U.WLHS
M;ZEHVMZ3<6FI:7?VY):"\LKF"XA;YHY%/-?DG_P2A^!'Q2_X*<_\&\_[+7@?
MX@?M@?M.?"GXA>)_'7Q.\3ZQ^T+\.OB/K4GQMO(O!'[1_P 6K.QT*Y\;:W?W
M>KW6D76FPV6ESP7%Y($T_3[*SC7[- D( /NW_@C[_P %?=2_X*K^+OVU+'_A
M1UI\&/#7[+?Q1\,_#?P[GQK/XSUSQ<-5;QK!J&KZW+_PCWAVPTIUG\)I)::=
M8P7GE0WC)/>SO$':?_@L[\&O^"O'Q@\.?LW6_P#P2B^-WA+X.:GX=^)>I:E\
M<O[>U;2_#]_KFA21:(OA*Y.I:QHFNVVI^$M"N(O$4OBWPE:VT6H:^E]IGDIJ
M"6<EFW\:_P#P;Z_\$H]<_;GU;]OZRTS]O7]L;]E[_A2GQI\.^#[FX_9^\>R>
M%9OB:^HW7Q$B'B'Q^T=Q&VIZW:?V"TEM<!B8WU74&#YES7[9?\'6'C_XV?LE
M_L1_\$Z_"WP<^/WQH\)ZWHGQPT'X<>(?'_AGXA>)_"'C/XAZ=X6^$<^FF_\
M&^K>%]4TR?6[O6KO3QK6JPWDDUK/JL\MUY6_:P /[%- BUJ#0M%@\1W=E?\
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M\6V%S:?#OSM/\0:CXEL-6L/ALR:5+'92L-.UFYMK^]_LO3_[2>SB_$;XE_\
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M/!.N:._B>YMEO]>TJYTB;5Y+G5X;V_OOE+X[?M>?M]_\%M/^"DOQU_X)T?\
M!/?]H/6/V/\ ]BS]DJXN/#_[3_[3G@2UE/Q%\9^(+'5+[PQK6B^&]<L;S3M6
MM(M4\266O>&_!WAW0]=\-IJMEX7\1>+_ !)J]YIL=IH40!_9S17\YG[.O_!O
MOK/[,?QW^#WQS\"_\%5O^"C7BJ;P)XYT'Q5\2? 'Q0^+;^*_ WQET72Y_MFJ
M^#];TW3I/#D^FZ5XANAY>H27MQXF_P");+=6)MI99Q>1_P!&= !1110 4444
M %?Y^7_!'/\ 8O\ V5/VT?\ @L[_ ,%P?"G[5?P&^'7QV\/^#OC%XQUWPKIG
MQ!T--7B\/ZO>_'[X@6-[?Z5)OAN+.:\M$2WNO)F5+B*.-9E<1IM_T#:_&;_@
MG]_P1X\+_L$_MH?MP_MC:+\=?$'Q)U3]M?Q'J?B'5O FJ>!M-\-Z?X DU+Q_
MKWCUK;3]=M/$>K7/B!89]=DTU);C3=*+0VZW#1^9(8T /OG]GG]B?]D+]DRU
MDM?V:/V:/@E\#VGMA9WFH_#CX<^&/#6O:E:C;B#5O$ECIT?B#5XOD4[=3U.[
M!8;S\Q)/\\?_  >1_P#*(_P[_P!G??!K_P!0KXNU_5Y7Y<_\%=O^"9'A_P#X
M*R?LIZ?^RYXD^+NL_!73[#XL^$/BJOC'0_"-CXUO);GPEHWBS1X]&?1M0USP
M]"L%ZGBJ6=[Q=0\R![*-%@E69R@!]._L*_\ )DG['??_ (Q:_9^_]5/X2K^3
MK]BXD_\ !Y1_P42S_P!&XZL/_,>_LFU_9!\$OAI;_!?X,_"3X/6FK3Z_:_"C
MX9> _AM;:[<VD=A<:U;^!O"VE>&(=6GL8IKF*SFU&/2UO);2.XGCMWF:%)I5
M0.WY:_![_@CUX6^$7_!7?X_?\%9K7XY^(-;\3?'GX>W?@"^^"MQX'TZRT+PY
M#=:#\+-"_M.U\:1^([C4-1DCC^&%O<?99O#UJK/J\T?GA;-&N #\.?VB?'/Q
MV_X+-?\ !=_XT_\ !*_Q%^T=\4_V;?V'/V0/ 5SXI\?> ?@MXLN/A_XY^/NK
M:)9_#Y=9@UC7[=))=4@U#Q'\0;1+.TO[;4-%T/PAH$VHZ?HTFOWS:VGYD_\
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M99^)[W3XM*N_$%MX&\-:=X<AUBYTR"YO(;"?48]/6ZELXKNYCMWE,2SRA0[
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M'KL&BGQA=Z=<(]I?2>'=)_M34-*M;U9+";78]*2_@N[,SV=Q^3/[ 7_! O\
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FBBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>16
<FILENAME>tsc01.jpg
<TEXT>
begin 644 tsc01.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0K44&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @ !
M.$))300"       $     #A"24T$"       $     $   )    "0      X
M0DE-!!0       0    ".$))300,      DE     0   '     V   !4
M1N    D) !@  ?_8_^  $$I&248  0(! $@ 2   _^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ -@!P P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M )FJF3]0>B6AGH=/&.YKV.);98X%@,VT;7VM8WUZ_P!%ZO\ @TP\5Z 4S1&
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M9.-CZ&6BMFFN[=NW_P!=)22G HK<'L?87;B\DV/(<YW=[=VUW\EJEF_S3/\
MC:O_ #XQ%KIIJW>DQK-QW.V@"3^\80LW^:9_QU7_ )\8C'<(.S__TO2VG);;
M=Z+:WM+Y.YSFD'97[8]-ZENS_P#1U?\ ;CO_ $BOEU)/T\/Q0'ZBW9_^CJ_[
M<=_Z22W9W^CJ_P"W'?\ I)?+J2&GA^*OM?J+=G?Z.K_/=_Z22W9W^CJ_SW?^
MDE\NI):>'XJU\7ZBW9W^CJ_[<=_Z22W9_P#HZO\ MQW_ *27RZDEIX?BK[7Z
MBW9_^CJ_[<=_Z12W9_\ HZO^W'?^D5\NI):?U?\ G*?J+=G_ .CJ_P"W'?\
MI%+=G_Z.K_MQW_I%?+J26G]7_G*^U^HMV?\ Z*K_ +<=_P"D4._[2YK!<VNM
MGJUDN:YSCH]I:W;Z;?IN]J^84D15]/Q0?J__V0 X0DE-! 8       < !
M  $! /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A   &UN=')21T(@6%E:
M( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M  #VU@ !     -,M2% @(
M                        $6-P<G0   %0    ,V1E<V,   &$    ;'=T
M<'0   'P    %&)K<'0   ($    %')865H   (8    %&=865H   (L
M%&)865H   )     %&1M;F0   )4    <&1M9&0   +$    B'9U960   -,
M    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,    )'1E8V@
M  0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,   0\   (#'1E
M>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP
M86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M$G-21T(@245#-C$Y-C8M,BXQ
M                              !865H@        \U$  0    $6S%A9
M6B                      6%E:(        &^B   X]0   Y!865H@
M    8ID  +>%   8VEA96B         DH   #X0  +;/9&5S8P         6
M245#(&AT=' Z+R]W=W<N:65C+F-H               6245#(&AT=' Z+R]W
M=W<N:65C+F-H
M             &1E<V,         +DE%0R V,3DV-BTR+C$@1&5F875L="!2
M1T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M              !D97-C         "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD
M:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F97)E;F-E(%9I
M97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X
M   !6%E:(       3 E6 %    !7'^=M96%S          $
M           "CP    )S:6<@     $-25"!C=7)V        !      %  H
M#P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &, : !M '( =P!\
M ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L T #5 -L X #E .L
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MMGFV\+=HM^"X6;C1N4JYPKH[NK6[+KNGO"&\F[T5O8^^"KZ$OO^_>K_UP'#
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M3?Z4\\U(_P /VG??])&GM_QZX\&+^=+_ $G_ !]>/)_-'^F_XZU^E?/%"?\
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M3_I&I^/_ #3B<>+^>?\ 2?\ 'EX\G\T?Z;_CO\+OTKYYV_YU^T/C34CMOO\
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M %2I%""#U!Q5N....-8XU"1H J(HH !L  .V*MXJ[%5D4$$7/THUC]1C))Q
M7DYZL:=6/CBJ_%78J[%78J[%78J[%78J[%78J[%78J[%78JE-K_RE6I?\P-C
M_P G;O+9']V/ZTO]XUCZC\$VRIL?_]/T/YO%;ORWM7_<O'VK_P >T_LW^?\
M+F1I^4OZGZ8_C_B_[N>/FYP_K_[R;(LQW(=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=BKL5=
MBKL5=BKL52FU_P"4KU+_ )@;'_D[=[Y=(_NQ_6E_O&N/U'X?I3;*6Q__U/0_
MF\5N_+>U?]R\?:O_ ![3^S?Y_P N9&GY2_J?IC^/^+_NYX^;G#^O_O)LBS'<
MAV*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5+KK7;.VUF
MSTJ2IGO$=U84XKP^R&J?]V?%P_U<46L_Q/H?*11<U:*1X2JQR$M)&Y1U0!?W
MA1U*OZ?+A^UBE8_FWRXD22F^0I)S*%0S$B-N+; $['%?Q_OFG\SV2:!+K91_
MJL3.M-JD),80P[<6IR_U<>Y72>;M C<K)<T*JS,OIREUX<O4YH$JG#@>7+_9
M80+5>OF;2I;RWM;>0SO<.ZJR TI&CL7&WQI6-D#IR7E^UD5&[H/-&A313RK<
MA$M8O7NV=600I\0K(Q'%?L/W_9PG90Z3S3H<2QF6X,;R.D:1%',A>0*57@%+
M5;U$XT^URQ1:%_QOH?UD1*TABJP:Y]-_3'"%9F-:;A4?]Y_OIO[SC@!'X_'X
M_A2?Q_LO^)_$O2OF\Z>7TF$*7'JL?4!=%=HU]*-I"SNJFD?%&_>#DF&D@6C1
MKNEM;&Z68M!S$22!'(D<GB%BHO[TUV_=\L3:!NIS>9-'@N_JD\YBN*J!&Z."
M>2&3D/A^R$5V=OV./QXE%[*#><=!64(TSJOI&9I3&X14#(J\JBJ^IZL?I;?O
M.7PXT4KH_-_EV3>.\##Q"24+$!N /'>2A_N_M_Y.-(M1OO.FB6EK=3F4RFU7
MD\,:.9!38\TX\H^+;-S^S_K?#@!!Y+?X_P!E_N4^PI=BKL52FU_Y2K4O^8&Q
M[_\ %MWETO[L?UI?[QKC]1^";92V/__5]#^;Q6[\M[5_W+Q]J_\ 'M/[-_G_
M "YD:?E+^I^F/X_XO^[GCYN</Z_^\FCM4*_64!/[%6'*A"J2QIO[?Y/V5^+B
MCLE'X_']%R+_ !\)?])?CT N) "MR)5:?#4'X2 0 3NW+B$^'CR_8^TD23U_
M'JCXG_%S_P!++^#B3(?C_3?['Z(_YTO3]<,FZ5)HU/M$%J; = #TVJE/M?ZG
MVB1T_'\?_%3_ -+P1_BRQ3]_Z_\ ._WW]]ZHSG/][BM#3NH-5JQJ02OB*[\-
MQ]IN'^7R>?/\<^/_ *:_YOJR?ZE%!.WO]W\TR_I?[[^\^J?B?O:H.1"D;4H"
MS; ;\B:]/YFX_9^Q_E-$_C^O_LI2XX?ULG]!E+OZ>K]/E_G?Y_[SBX^'440!
M4U*@5I4L#L!N0:THP;^;XHT3_*=&_G^/]]Z?YO\ >0^GT>"#^.7]+_B<O^[E
MZ,F3BLJ0&V(*BH 8DCVW.Y7C3_D7R^/FC(K;\?S?Q_1C./TQ\.>$T??_ +Z7
M_'OWG^R^OBS-E0I([JQ H7(HK;[BM>*A6Z<N'^P:0 _H_'^F_P!WBX?HCC6K
M_L_'\/B?SO5_.XY^+5!V!V\&/^Q[D;A>0/V53A_>\E]1_'^E_P"+]/\ IH</
MA^'!'/\ 'X_U27]*4_\ ADO%L<:BGCM1FI0'J/BZ"E%_RU^+BOVT_C\?CZ\7
MIGPXY)(_'^=+_9?7_.X_Z7B_O:'12%(J!3XF.^W@?V:?'_.R\8\-_C\?YLH_
MS>/'ZI\&.,@1SO\ I?C_ #>*?^ZG+]_Z[ %113U( #$FH_9&Y^/:J_Y'#^\:
M1>8_'X_K_P"^AP^'X4.(UOO^-OZO]+)_7X9?ZK/BPIM2G4"H8E2/VR*G[/%6
MX[_L<^?Q)S)'X_K'\1_V'J\.$T<^?X_'K_V7]YXN1H?LTKN*@!JGJ I%2">_
MP_MLO#BK8WO?X_I?T?Z?_);ZLD?3D2+_ !_/_$_J_F_[=*,[%/AK2@)"@,3]
M@;CK\9JNW\W^J\>#I^/YH_Z1_BC^]A]?JC(G\?C_ #LG];P\OU<>1P[D[[=>
M1/>HZ%1]E?CVX_N_]UL_PGGRZ_[[TQ_G?[3_ $OWD>+T_P!X#MS_ !PQ]?\
MO_ZTO$_U1P^UX]_M^!)KU04HGQ[?L?[K9GX-_B7^^_S_ /<S^O\ RQ(_'SXO
M]-ZOZW%+^?/AL57<U !!-20* ATWHM-C'7^3^\X?;5!R_'\T1_'_ "M]2#^/
MZWU?\5+U?]5N(3I@I=@=PI#"NXKL:KT6G!/^%_R\)'X_W7^F^O\ SYR]7I4C
M\?Z;A_V./^+^G_03?(H=BJ57^CZ*]T+R\XBZEE@$$SL.:O$W*-(2?LU;E55^
MWR?$<_Q^/X5)^2V?RSI+21W!,D4\+RO!.DC*R/<R%W*]OB9V7XOV6XX0:4J?
M^#M"#F2.)HWY1/&P8GTS#&81P#<A\4;,K\N7/[7V_BP  (IN?0=+M].O89KB
M6+39%9W3U"BPDR-,SHPHRGU&Y?:_R?L_#B/U))ZG\?SOQ_"AW\GZ--J'K1S.
M)$]07T:2?%*9ZDB6G0,KOM3^3^1<:6OQ^/Q_O5'\E:&ZA>,JA5:.(K(P*1R<
M^<:GJ$;U&Y8JK:1H6BZ<U[!8M^]FI]:C+!BO-GD7X*<4KZC\1QX\<5\D-9^3
M--M[Q9EJ(88X8[6-210Q3?6"[=JM+^RG%/3^#CP^%6P>7X_'$@CO_'X_'U*\
M7E#18D=%60(\<D9',[>L@CD8'J&91@V _'X_']9D225&'ROY>F@:WMY&:*/E
M18I15%G0U7DOQ<723;F6;C]G)?#\?B3&@C?\.V L19*TJPQRB:V^.K0LIJOI
MD@[+_E<L"4.GD[0UU!KXQ,\[^H&YL2")0X<'QY>M)U_FX_855Q\EZ;_C_>K3
MY,T5A\8E=^(0NTAY%5*&,&E/[HQ1M'_*RXJ=U6?RSI,B<I^9XR+<&3D$I+'$
M(A(. 55H%5_A''G\6(V7\??_ ,5+\<*A_@_0I1,\1E62Y0QW$\<K!I%E/.2K
M#;]\2&?C_L>.&U.Z?X%4HKNWEGF@C</+;E5G45^%G7D%)Z<N)#<?Y67^9<5M
M5Q5*;:O^*]1';ZC8T_Y'7>6R_NQ_6E_O&L?4?</]\FV5-C__UO0_F\5N_+>U
M?]R\?:O_ ![3^S?Y_P N9&GY2_J?IC^/^+_NYX^;G#^O_O)HW5V/KHN^Z?"M
M*UWWION=EXK\/Q<?^*\H!_'X_P ^/^=_G1R1W]W_ $E_NX0C_G?TT%56KOLP
M"FF]5-5!!%.M?M4_:X_!SX81T_'X_P"L$_ZJ=OQY?])2^KU>+_.R>+#>J67E
M56Z$@G:C!^5:U^TS<7^Q^Q_.WIOX_'^;]/\ 2\/T_P ":H_C^'_2_CCAZ8^)
M&&#$E5#49J!7'VJ\6XM0=PQ;[/+_ ()?A%_C_2?]4_$]?U1]7TRG*+7X^<?^
M/_UO^2D<.Y<A0#J* 4H-Z$4#'?TU]/OP^S\6)'?^/[S_ (KA_G?7]$H2X!^/
MQ_G3]/\ F?\ )"N2]>G0@CEL%(*]@?L;\O@95_D5.*D^?X_'XX>']T;'X^'%
M_O?]CQ?[0&EU'3H9A;RW4<,_P@1,X#@B@ -2OQBM5^Q]GA\'V( #^/Q_F\7^
M;P^ID,<B+ L>K\<OQ_1EP<#X]2L'OI;.*Y@-Y;AGDM(Y4,L8!Y#DFS*JT/[/
MVN'J<?V )@[7O_N?IC_L8_5_1A_3GXC+#(1XB)<)]/'_  R_A]/^=#^C^[X>
M'A^O&NBR4XJ*E.((J0 $.W84^-O\CA_D_O/2F-S^/Z/^Y_SO[K_E9 G\?C_8
M_P!+Z>'AAX.5BU./?B0!R%>13CL#51NFW^K_ ,5^E$?C_8\?];Z_]W_/R<;^
M/Q_IH\/T_P /T\,_#JH*U&_)5WV%03MOT_E7^6/X?VT7C(7^/5ZJ_P!EPPX_
MZ67@_F9I>(CR_'X_=_TOWG%Z8P]%EA1B?LA27)Y*.*]2>O +7=_YO]F^ '\?
M+_3</^YA_MWK17X_'_"Y1A'Z>+_:\?@Y'J%D0AN1!1P10E6Y#BP+ BJ]N?Q\
M^?\ NO!'I^/YL/\ I[]7];_5<D5JMN7+\?P\/T_\J8>CT1@[X5^"FPH!4E1\
M- HY;UV^'JW_  /%Y3'>OA^/]/PR_P"/9/6UW?\ %?T?^FF'B^GZH_YD[4U)
MXDU)*DDUZJ3T.R_%_P +]K[7[\>_\?\ %>G@]/\ /_GK70?YO^QC'_2_NO\
M>>K@DY2"5X]!3CT)%56C =?!5_V'[2P\T\M_Q_._V/\ N?5*7C94@B[Z7^D2
MX?\ 2_B7 TK KL>(XJ1N30?"-B/#@J[?:;@WV^*,:_WWW_\ 'OJ_JSX>'Q6(
M%#S_ ..?[J4O][P^B7[UPK79:O1304 K6@%/];X=OL_NX^2?[K (/X_G</\
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MRGB.($<,N&,.?%S'_27%]/%Q295YO_-6X\RR>6[S3I[C1%@N&6[MTD9T!5D
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M,YOR_BNG'E^*Y2YN52X4_NXK=>14J&?ZVM>"IQ^S_NOCRR0@/$KI]7V_B/\
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MCR[OT?\ $_[9_2].)#32Z S\>+24?BQ"T))8TK4@U 7^;C^W_OQ<A0(OF/\
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MOA%>7X_X_P#CZ68KO_'JE_-_G?[_ /I*9N;J3CZ: * .) 9B@^*A 7BE=O\
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M[ 58L0#V^)CQXK^[7#S_ !_2_J_YV./^=]"]+_'_ ![U0_BE#C_RCB*DUZ;
MM0$GX^70"M0Q'PL>?%OA_>8U?X_G?UOYW\7\/\/#P)'.OQZ?^)^GB_K<?\+C
ML:D<6 =B">_%234!6I_G\/\ =X.[X?[HR_WO^^G"7UHCR[_P/YHXOZW_ $SG
M]2K"H$X!%&%233?8<0*\ ./7IQ^S^URQ/Z_Q_6_'])?Q_N?^.RE_I?\ )HO
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M:?E+^I^F/X_XO^[GCYN</Z_^\FF]Y3F*T(X[ANGV@*&O[+=&I_LN2Y0#^/\
M<_Q?5_,_W4?XLGI^/Q^)<'K4ROQ4(K5B#4']H5K6FQ93\7P_ OP_9^/"?/\
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MHJSL2I_UFW_R_P#*P$4GG^/Q_54^/E!K$R4L?J4D@5F'I",R4-%/:O%FJO\
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J:XEN)/35I#%_?/(RKR:;C_-\7\N1G.4AOR]W#_N?\U,8@$H_*V;_ /_9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>17
<FILENAME>tsc02.jpg
<TEXT>
begin 644 tsc02.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0^84&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @ !
M.$))300"       $     #A"24T$"       $     $   )    "0      X
M0DE-!!0       0    ".$))300,      WI     0   '     Y   !4
M2M    W- !@  ?_8_^  $$I&248  0(! $@ 2   _^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ .0!P P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M+0!39Z7.XZSV/MVEO@LIW6G5^MA,W/ZBRKU&U/(J.V?3Q_?<;ZFV93RUC?\
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M-7J9%3:QP"!8QQ<T[+"ZC)JILJ9N;^C_ )SV*XDDI__9 #A"24T$!@
M!P $     0$ _^(,6$E#0U]04D]&24Q%  $!   ,2$QI;F\"$   ;6YT<E)'
M0B!865H@!\X  @ )  8 ,0  86-S<$U31E0     245#('-21T(
M         /;6  $     TRU(4" @
M                               18W!R=    5     S9&5S8P   80
M  !L=W1P=    ?     48FMP=    @0    4<EA96@   A@    49UA96@
M BP    48EA96@   D     49&UN9    E0   !P9&UD9    L0   "(=G5E
M9    TP   "&=FEE=P   ]0    D;'5M:0   _@    4;65A<P  ! P    D
M=&5C:   !#     ,<E120P  !#P   @,9U120P  !#P   @,8E120P  !#P
M  @,=&5X=     !#;W!Y<FEG:'0@*&,I(#$Y.3@@2&5W;&5T="U086-K87)D
M($-O;7!A;GD  &1E<V,         $G-21T(@245#-C$Y-C8M,BXQ
M       2<U)'0B!)14,V,3DV-BTR+C$
M                                     %A96B        #S40 !
M 1;,6%E:(                     !865H@        ;Z(  #CU   #D%A9
M6B        !BF0  MX4  !C:6%E:(        "2@   /A   ML]D97-C
M     !9)14,@:'1T<#HO+W=W=RYI96,N8V@              !9)14,@:'1T
M<#HO+W=W=RYI96,N8V@
M                    9&5S8P         N245#(#8Q.38V+3(N,2!$969A
M=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="               N245#(#8Q
M.38V+3(N,2!$969A=6QT(%)'0B!C;VQO=7(@<W!A8V4@+2!S4D="
M                     &1E<V,         +%)E9F5R96YC92!6:65W:6YG
M($-O;F1I=&EO;B!I;B!)14,V,3DV-BTR+C$              "Q2969E<F5N
M8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M                      !V:65W       3I/X %%\N !#/%  #[<P !!,+
M  -<G@    %865H@      !,"58 4    %<?YVUE87,          0
M                  */     G-I9R      0U)4(&-U<G8        $
M  4 "@ / !0 &0 > ", *  M #( -P [ $  10!* $\ 5 !9 %X 8P!H &T
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MR-CH^#E)66EYB9FIN<G9Z?DJ.DI::GJ*FJJZRMKJ^O_:  P# 0 "$0,1 #\
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MWD7-&2VWM5AC<*&MYA^[7@%7C]CX_BQ5(K+SC^=MS!?7-]IU[8VWI+>6JP6
M>X2/4KF%+:W*/'*SR:;"ET]YPBEG_>1,T#XJEZZU^=I6VUUH=3.K/H-Q + V
M3+:_68M7]-I6A",([O\ 1J_68>:K]8952./B_P!6Q5D>E^:?S%MY=.U'S%=S
MV_EW3]-OM2U:XCTQ^=P+>[$4$,@>&*2*9K8M,PBAA:3AZL<2)S7%?Q^/ZJ9?
MF[YE_,+2;O3H_*-G>S$(;B9K>R%Y;S%9XE:WE94EEB;T#+(O^\__ !F=_P!U
MBI8H?^5E:7K.K:AIEGJ,T@;6Q%(\4DR+#/Y@M^,D43GA/+'8>M+9Q?MQQ\8^
M7V7=EVZ?C\?C^=(3?>8OSW%A$-*MYKHW<]Y:V5W=6"V\@BLWCN8;NZ@X_N#=
MP+>62HXCY2+:2)%')/QQ5N/5/S?N;ZVU#ZG<V-SK$6E$R?4P[65K>ZM<B6WD
M5@8_5LM/:"2?U%]1'_O>/V,527S/^9GYJZ)IW"_O6T^^M;>;ZNS6$3O?2QZQ
M+9K)/$=[:-[)()8FC3TYGF=X^:^G%BK/?S0U_P#,;3M5BB\MQ3BV^H2S6)M[
M$7RW>J*]([.Z-:VMNT?Q>N/2_P!V-ZW[K@ZJ0ZIYM_-2VU+S;,\TMEHFE03W
M>@7=Q8QBWN'MI8WN[6><@<%C^.UT^4I!];61I^<S08A1^/Q_Q[_8I+YM_-7\
MQ-/\N0:ZUY^B[?4=*U#7-,B^JV\\F\Z_4;.Y4EFB1+1TD>XI\=P[)S^#TI C
MN334/-7YY)-YJ,=J\3V:7 TRV6PDE3]W<0I;2V\OI"*<RPO))/&T\_[?!+?T
MOC*1^/Q^/^)/-5;\Q[O\M?/^GRS7<NN6,MY;:!?6]N+:ZN8!;12QM&L?PLS2
M22PK)"%;X?@_>KBA#Z-YB_,UO-=A:%+RXTYKNW@,=SIYB@?26L!*]_-=E0T=
M\;H%&M2Z\7_=?5_]V*_>G[T+YSNOS#O?/UK9K'?KI=AK=E-9V]K9.]E+IXL7
M:2>>^5=Y/K;/$]J>*IQB^!U?U\5_'X_K,.B\H_F)JK6<U[)K5NEQ'Y0M;BS2
M.6.*.VD4/J45"JNB6\@Y7/Q\D_W<W[&.Z[LG7SC^<<MI/;"VN[:^L]/OFNKF
M;2I'C:\CU:*.W^KB*-O6YZ<\C+Z,<Z?[M>.5D=,5_'X_'$O7S=^=,MWY<2*R
MGM+::,+<RWMB\AN;@7K12BX^KP!K6'ZH%FA:2/3V^+U'^Q]7Q7\?C_CWI_TR
M8_F_YQ\^^7=2EN-,EELM%M[6R>VGCLDN8)[J>^]&YCNIY/AM5BM_2,6\?/U7
M^*5^,2JI5YD\Q_FG=V6K:4NF7TTUK!KQ:FGR"&8PWT(T@0S*J>J[6IE?]TZ^
MI^W\:\E5_'^F:\W:A^9VJ:5YIL1!J;7HED&GZ;#8&*TCB@U. 6DD.HQTEG,]
MKREN$3UFX^M_O-Z:I(H_'X_'_%*%_K_YE:;Q\UZD+F"[T/1;N774FB$5E)):
MZK"]S:P#^Y/K622?HV?E]8FB:-O4Y>KBDAZQY$N]>O?*MCJ&O474K\27;0!5
M7T(;B1I;> A?VH(&BB=JMR=&;EBJ?XJ[%7__T?27G'6[G0O*>L:U:VPO+C3+
M*>[CM68()##&7XECT'PXJ\^\N?G-J\VN"RUW1S!:7$VE6L5S;%"MO<:G8_60
MLQ:4M(K2#X#%'^[1D]3D^*_C\?C^)5M_SZLI='M]4?R[J$<4FGG7;F,O:EH=
M(!""[/[T!^;<^%NA];A&SLJ_NU=5%ZA^>?ENPBGGN;2X%O!+J\1E7@:_H:-9
M'8+R#4N!(HBV^U]OBOQ8J@=3_./6X=;M--@\NS1W=O>S6>L:9++;&:JZ4VI(
M89EE^KA?3X%V=O\ BM<53C6_S*NUL/).I^7M/.HVOFV9>-J_!+CT9+":[C"L
MTJ012AHT]7F[\5]3@KOB5/)*-(_.]=2OR+33I+R+4H],_P /6$?"*YDEOH+F
MXG6XDED$$?HI:/W_ &?]V,ZXK^/Q_61EK^>>@74<%S!IM\=/067Z8O&$*K8/
MJ5PUI;I(IDYS'UT82FV$JQQ\9/CY8JO\F_FG>>:?.<%A;Z<UGH%WI-SJ5C<S
ME3-<"&]2V2151V]*-E9F].5%E^Q_E8K^/Q^/X4JUG\\YET&[NM.T:>VNY$NW
MT6>[,4D%S^CK^.PO1QBD]6)HVE#1^LL:O_PN*HO4_P X?+MQ=:QITV@7&J?H
M=1=VWI+!=QW BO19-)'P:3TS!*RR.S#]U%R=^#KPQJUJV[K\]]*B2VE@T>YO
MX);>UN;F>SGM)$A^N7SZ<D98RISD6Z15D5?[OG\?'@^*K[O\]-(L[.QN+C2;
MM7GNIK._MEDMGEM)(+\:<S,B2L98S<5XRQ?NF5?M^I\&*\N;)/.=SIN@PQ>8
M8[& ZI)>6-@;WZLDL_IW=U';4+\HG"TEZ\_@_D?[.*&,0?GSI+PO)+HM_#ZT
M<CZ0I,#?7'CU!-+,:\9/W):\EB5&FXHT3>K^SB$A%:I^<D&DS^EJ.@7UN+;3
M[C5-6D$EK(MG!:SR6[\BDK>J[R1KZ*0\V995]3TN,G!&ZC=!7_Y^:78^7OTQ
M<Z'?1M$\XN[-F@65(K>-)&FBJX^L1<9D'.'DJ/R25D_:5 5=?_.FULSYEM([
M&>SN]$MI;BV>Z6,-<K"R*[PVSR0R21?O.22<O3X_WGI_"K"T7LW??GOH>G7.
MI#4=)OK:PT]M5BCOJ1.L\VC,!<)'&K^HO,,/2>541O\ )7XL*4PF_,VZ_P ,
M><-1319K35_*,+M=:;=RPT:1;-;Q?WL3NGI^G(M6Y?ZN*I!Y=_.#S&]RVEZK
MI(U#7I_J2:;IVG!86>2XT[](W/JRW$WH1K#'LE77G\*_&W/TU0KR_P#.17DJ
M(6CRV]U%!>QPW4$TJHH^I3VQF2Z<!BRQ?6%:Q;;_ 'H_FY)R"+1_F'\UKS1Y
M_*MS-I#1:-K6GWFJ:O)*Z_6+*&SM%NF7TU:CLBM\?$M]GBBX4ICH7YC66M6F
MK+>:3<:?=:590:G+87)@D,EI=1R2P2(87E2K>BZNA^*.1?Y>#LJD<7YZ6\MM
M8A?+>H#4M5&FRZ7IY>VY3V^K),UM,)!*8XQRMI5E29HWCQ\UL<^BI:_GMHER
M;V6/2;X:=8R4FU A/16&.]6QN97968)]7D?U2A/-[=7E7[#8DT@FN:S_ )77
M9&^C>*SGFM+ZW0Z3:*D8DNIIM4.FVKI.TRQK%=,5E7U$^"'][ZO^Z\4KY_SU
MT:"WU%YM+NX[G2;&^O=1M6:'E')IMU':3P!E=D=N<H99%;TN'VF7EB4$I;YO
M_-32B^N&+085\P>6&Y:;+K,<7)REW%;O-#$&^LB&LG..XB^#CPD;[2*SLDTR
M_P M?F1IVOZ]+H=M:31W]FMX=41RA%JUI=FT1).)/Q77%YX*?:@7U,58=;?G
M)'<:+>)YJ\NM<P5U*X0Q+ ]M-8Z7J@LYY&CFD9U-JC1SR>JB<^$GI+]G%/X_
M'X_TJ)US\VO*TTWUJ;RO+K$&GP7^J17H2TD*6.DW2VMQ>1>LZMQYEGA5/WDB
M+S^RRXH3:/\ .*QN+YK>PT>\NH)Y;ZTTB\Y0QQWEWID+33P*KN)(21%,L4DZ
M1Q.T7VT1D=E4J7\^]&ETS3/,:6EQ#Y=O[?5;F#FD;SW$>FF% T827]T[W$KP
M+%(/V><GI)\>*IYYI_,/6-'_ "WUOS0-$:VU72 5;2[N> KS#(.1EAD=?3XR
M>I]I)&_E7X<52F[_ #I&EW%W%J6E3L(-0FLYY@88;:T$%K;SLD]R\IAY_P"D
M?"S-%ZG%N/P+RQ5$:E^=NDZ?=>8(+C3+F,Z%&\J+*\,4MVD<J1-);PNPD> F
M4.DZAHV3^1N"LJMUO\\]$TK4+G3SI5]>7=M?7=FT-JJ.[1V$,$L\R#D.7^]<
M<<<7VY'YXJ]'MYTGMXIT!"2HKJ&%&HPJ*@]#BJVYM;6Z@:"ZA2>!Z<XI5#H:
M&HJK @T(KBJKBKL54+VPL;Z#T+VVBNH.2R>E,BR)SC8,C<6!')& 93^RV*J^
M*NQ5V*O_TO4.HK:/8SQWD)N+65#'/ (VFYHXXLIC4,65@:-\/V<4$TQ6S\M_
MEY9QQ1VVA/&L,UM<14L+LD2V<?I6SU,9-88O@7^5<6/B#S^4G7'EG\N;FWTR
M"?R_ZL.CH(M-1].NB(HEH1&*Q;QU16]-N2<E5N/+CBOB#GZOE)1OO*7Y?7=W
M?7OZ&DMM3U%)TN=0BT^?U2;J(03GXX9(BTD=%DY1LLG[?+CB5\3W_+\?C^J@
M/*'D#R'Y:B8QVM[?W;3O<K=W-C<<XW>U6S81"."-(^5LO!OAYOR?DV*^(//Y
M23F_T/R'J&E:?I-YHTL^GZ4J)IMNUC>4@"Q^D@C/I\DXQ_!U^SBCQ!Y_Z62G
M<>6_RZN+22TET FVD2VC,0T^[4*EDABM@G&(&/T$9DC]/CQ1L:7Q!Y_Z62\>
M7OR\6\T^\3R^$N=*1(M/D33+A?22'>)0%A"D0DEH.7]T_)HN+MBGQ!Y_Z62[
M1M$\A:)J4^J:1H;6-_<*Z37$&GW2,R2R>LZ[1 <3)\?'^;'HCQ!Y_P"EDE.A
M^0?RWTBRNK4:1<7;7C3&[NKFQN7FD6>Z-X4Y)"M$68H55%7^ZBY<FCQ4Y!_2
M_'X]/_%<:,_PA^67*\8>7>+WX=;MET^[!</*+AA41?#^_43+PX\9?C3X\5XQ
MY_*2K'Y:_+N.+T8]!*1A(X>*Z?=+\$-T;V,5$7[-VS7/_&5F? GC'G\I++SR
MK^6][*)[KR\9IEDFF$C:?=<B\\_UF1B?3^+E<?O]_LR?$GQ84>(.='_2_C\?
MTD9;6'E6'3#IC6%U/9_76U'TY[.Z<"Y:Z-X''[O;A/1TI]G_ (+!Q?<GQ/(_
M)0/E_P#+\V_U<Z 3!]7EM/2.GW)407$XN)8@#%]E[A5FV_;7GA1XGE)=8:%^
M7]@ACL]",4;VKZ?)&-.N2KVLTC2R0NK1$.DDDCO+S^VSMSQ7Q =M_P#2R04W
MDK\KI[&&QG\N&6VA]41K)87C&EP LO)S'S;F$3ES;_=<7^^X\5\0'O\ E)7F
M\K_EQ<3WD\V@-)+J$307;-87?QQR,#(M#'1?595];CQ]7BOJ\N.*1D'G_I9?
MC\<3M2\M>1;^UN(#I<\#W/UTM<1:?<<P^IKQO'I)!)&S7 /[WU(W1OVEQ43'
MG\I?C\?T4)Y2\G>3O+NBZII"Q7U_;ZVS'5/K5E<<9E>%;?TS''!'&J>B@1OA
MY-_NQL4>(/Z7RDC;WRW^7=]%+%=Z"TRS- S\M/NZAK>+T865A$&0I#^YJA7]
MU^[;X&Q7C'G_ *63>H^7?R[U*OU[R_ZZFRCTWBVFW/$64$RS16X41 "*.9%D
M1!]AEP@I&4#^=_I9)AJL?E;5;BSN-2TV:ZGT]WDLI)+&[+1,Z\7XGTOVT^!A
M]EU^' OB#S^4D%INB^2=)TR^TW1M*ETJ#4%:.X-K87*,>2%%/+TCM&I_=+]B
M+[*JN*/$'XB4#Y:\F?EUY>TRQLK'1YF-A]5D2ZEL+IIWFLXS##/(PA%955Y.
MWP^H_%<5\0?TOE+]2.BT+R#"^J/'HCJ=9CE@U,#3[NDT<U3,A'I4"S%B9>/'
MU6^WR;%?$'+?_2R=<:%Y N;<6L^AM);BRBTM8CI]UQ%G$PDB@ ]*@2)U5X_]
M]M]GCC:?%'G_ *62%O/)WY87MG:V=UY;$MK9)*EM"VG75%2XD]29:"+XO4E_
M>OR^U)^\^U\6*!E'G_I9*T_EG\NY[F_N)=!:2XU-72^=K"[)E5Y%F=36.@$D
ML<<C\>/J.BLV-I\3IOUZ*GEW3=!T/4=:U2(:A=:EK]RMUJ%W-93*Q$:".")5
MB@B41P1#BOP>H_Q/(\DKX$>)[_E^/Q_20^I^6_)]UID]E:6=SILDD-[;Q7EO
MI\S211ZE)ZUX(Q+!+&%N)!5UX?ZG'"O&.5?9+\?C^HES?EY^7$ESI#W&FW=S
M::)IJ:38V,]E=/"(4=)$9ZP\W?\ =4?F_!^3>HF*?$'GT_AE^I-9_+/Y<W-]
M?W\V@%KS58I(-0G_ $?=*TT<P"2AB(A_>JJK*?M2*OQ_#C=*,H\_]+)M?+OY
M>*\K_H TG6=98CIUR8RMTD<5POI^D8^,R00K*H7X_37%'B#G1_TI5K72/(]I
MY?N/+L&C2)HMV)1=67U"[9)?5_O#)6,L[-_.QY?9XXI\0#O^7X_X\@[ORC^6
MEW#Z-UY?::,R-,RO87AYNT:1OZE8_P!X'CCC5U?DK\/BP ($P._Y25I/+?Y=
MRW6H74N@&6XU6.2&_DDTZZ;U([@AI5/*(A1*RJTO'CR=>3_%A3X@Y;_Z67\2
M'7R=^6*V"6*^72+:.<W:+]0O.7KLBQM)S]/F6=(XUD^+]XJ+SY85\4<_5_I9
M,H_3UE7^YN^M/]X[K_JGD25X_(_+\?C^B[]/6=1^YO-_^7.Z_P"J>-H\3R/R
M6CS!:4!^KWH)I4?4[FHKX_N_';;_ (CC:?$\C\OQ^/Z+?Z?M-O\ 1[S>O_'G
M<_1_NOOC:\8\_E^/Q_FN&OV9']Q>#<C>SNNW_//OC?X_'X_S5\3R/R7QZW9O
M(J"*Z!8@*6M+I5W--V,8"_[+"CQ!Y_Z4H_%L=BK_ /_3]4XJ[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%
M78J[%78J[%78J[%78J[%78J[%78J[%78J[%78J[%7__4]%^?;J[M/)NL7-I(
M\-S#;.\4L1*NK =5(W!PAQ-=(QPR,3PGA^K^:^>!YT\XT .NZC7IM<M6O2E*
M'XN_7C]G[7+XK*K\?C\1G]'K\+DCJ\W\Z?\ II_\5]7^Q_G<,(_O-_C;S@!4
MZ[J(''E_O4QV()V/'V/#^?C_ ,$@#\?[[?ZOQ_/\)_-YOYTO]-/\?['B_P!E
MQ7_C3SE6GZ<U 'XA_O4U 02*?9-:4Z_S<$Q 'X_M^K_B9_1ZO#3K,W\^7^FE
M_P 5_#_'_#'A_C_CK_&WG"E?TYJ/$;U-RW2E?#PWI\7P?ZZ<D1L?C^E_%^/X
M_P";/@/YS-?U2_TT_P"=_-XOZ7];^'T3=_C7SE7_ ([FH&E :7+$;EA78?%N
MOP_S?Y/Q<'S_ !_#]7^F_P!U_F@:S-_/E_II_P#%^KT^K_-_K\._QMYQI7].
MZA0+R)%RQ  ZFO'[-/BKQ_X5L-4?V?[W\>KCXN'U<*-9F->N73^*7_%?S_\
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MN</RU\ACC30[7X:4^#PXT[_Y"X_G,O\ ./X_'XX8J=-C_FAR_EIY"6E-#M:
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M_E6?D+_JR6W_  )_K_G_ +''\YE_G'\?C_92_GR1^5Q]SO\ E6?D+_JR6W_
MG^O^?^QQ_.9?YQ_'X_V4OY\E_*X^YO\ Y5IY"_ZL=J-Z[)3^/^?P_P JX_G,
MO\X_C\?[*?\ /DDZ;'W!5MOR^\EVMU#=6VCV\-Q ZRPR(O$JZ'DI%#V/_&O\
MN"6KRD49'?\ '_%?Z:2?R^.[H,@S';G8J__6]4XJE>K.([ZRD/*B+<,>)H=H
ML1S06&ZGKNE:C/:W4IU6QFC^$1V\3?:8<E9E%2%65V3^7X?M*OQ8 -MOQ_TC
M_P >95^/]D[3-4T[3+Q"^I:QJ)9& BDC9D$CBO.0+3BY^,_L\6Y?9XXD#N1[
M_P ?C\<7%ZI9IUU%=:I;7,)/I7%B9HPWPL%>4, 5)V*@T(I\.':U _'X'X_I
M(K7KFXM].,MN_IS>K"JDTWY2JO'?^:M,QM5.487$T>*/^Z:\AH,/TFVUVU\R
MV+P^8)=3FN"WZ;TR9U=(EXGFR1BGU?TI/3"<57E]C]OEF2>?3\?C_>MQB1N1
M0>@8L5.Y+"VE*DA@C4(ZUIVH#^K&D2-"TATS1-%DTRS+V,+/);IR)4$_$@J:
MGXOI^U\6:<Y)6=V^4>?X_H_C_.25+;S"KOZOEK39*UX(K1HQW'Q;E@5 9N2_
MS<<GQ#ODQ('X_']+_=?YRE_8ZZ(H/J7EW3C*R,9_4X,JN&8*!NA8<:$_Z^#C
M'>5X1?X_'\[^L[ZMJU!R\JVE%%7_ 'L7Q5%7H #QJ>7!/C_8^+^5$]_J*G?O
MW\_Q^/ZJQ%U*2-+D>7[ 6Y@$DX=T1XY1R]17K]BB4_U>7QM\&$FN9E_IOQQ?
MTO\ 5$U9V_W4OQ^/\U9-^D5O+>S_ ,-6<7K$%GDEC 90?B5"HVD'+]VHY?\
M IRP@WRE*_Z/X_J^I'X_'X^KA]2>:OHVDII=_)'90HZV\I5E0 @\&.VWO^S_
M ,:Y7"<K&Y_'X_WR:_']9--"FDGT6PFE;G(]O$SN34EB@J2?'QS<-2.Q5AFL
MWVHQSN;23U;GZV\4L,MP\*I$5 C^%7B Y;<6_:^U]K[3TV_'/_??]4Y?T7?\
M?YOX_P Y"0:KJDKP1R1""%^(EN&U&1@B[_$565232G[7_#2JV-?CZO\ CO\
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M[>RM++5+M'U3TP&#LBRR $JKE ?M,!\7$?;QM2A+[S]Y,L->30+S6+:'6).
M%FS_ ! R_85S]E&?]E7*LWP_S+E9RQ!HERL6BS9(&<(RE&'U<(3.ZU-8+GZN
M+>:9_3$I,2J0%+<.[ D_ZHRQQ5/],&M/J-U6M*<4ZTK3[?A_G]GDVM_BC^/Q
M_6=^EG_Y8+OO^PO:E?VO?!8181%E?+=K(1%)"T3A'24!6!**_8G]EQA2B,5=
MBK__U_5.*H>[L8+HQF3FKQ$E'C=D85%&%5(^T-O^;L2JB-(B%#]8NJC_ (OD
MW/4GK[?ZN/X_'X_V7J4?C\?CZOZO#%_,>HZG9ZU9Z'HEM+>WL\7UB66ZN[B*
M*.&IB'$I5I)"=VK_ '?'G^WC^/Q^/]BA5N/-&B:;I%WJ9NHAKL4,D":;<7@E
MD^M)NML%#;L\O$+1?4XNOPI]G&^C/@)W 2>WAUL:!]>US6!JGUC@QMWC2-8+
MI6)7B(U)1"?@DB<O\'P9@=H^'X),QM8X>*_+_CW^Z:,Q'#9_']'^+U>K_I'^
M'D/Y>^5OS@TC\SGU5;:Z%[<-(NM7MW%(UG/$Y)+57@KU90T7H_9_E^UE>GEE
M\3<;$_C\?[E[SM;%V>='$XL@,HQ_=P$N+Z?X.'_)_P"QC_IGN.EZIY]M=:TT
M:N;6[TS6"Z^G;Q,DEJP1Y$(;DPDCHH63G\7Q)_EKFR>(9'=:M%)]8@M4:X,(
MD6ZE6@CB*I4J7(*L_0<$Y\?V^.'9!Y*-I:Q3Z#!:2IRA>T2.2(U0D&,"G('X
M3\OLYI2?5?+=O.SSE$LWFI)Y%U@C]TG,RU'Q,B,E'D7]VHD9Y)/VEB;_ (JR
M\^<OQ_NO^/L?+\=/Q_1]7HX4QU"PL=4O[":Z\K:K)<WEM;"6[Y^C]5XRN@61
M5=(_4AY>I]AE:/[?^4^H7O7/]'_%*?QR2$^6=.MKAW?R9J^H2R3&,-+<L8EB
M4*.4?I-&6,C0JW^D+SYMZGJ?L9+C)Z_?_%_IOYTOZWT*-_+\</\ N?QZ4>^D
M:5?ZO)=WGE/5X%DN)9KKU)52'D%F]24>DY;X^?P_&GJ?NOV%; +&P(O^S_B?
MX?\ B$=-_P ?Q?C_ #D"^B:3>>@D?D?6469%22=YF1K="AY&)9&/*1 [?:"M
MS_:]7EC9KGT_TW^D_P"L:;L[_C\?P_Z?ZGJ>K0K'HE['&H6..TE2-1O\(CH!
M^&40)XMN]E^/Q]2(\NU_0&FUK_O+#UI_(/#-R&D<DPQ5V*NQ5CWF#4KE=3AT
M^/FD)@:>1D<QL[<PJIR6C@+U;TVY-_DX_C\?C_B5^_\ '_'O^DN%\H>;X-)M
M?/VKRVDT<^EW-_,HG5G98+H.)+BVD>4#][$[?%]KX63TWS3:O$8SL<CZOQ^/
MZSZ5[.]I1R:88R?5#T2C_0_S?Q_L&,6UZD.J:R(65HS<1<9#6AI;(M44<2M:
M]?Y<QLTJC"AT/^Z/^Y=UV=BXLVHE(\'[R'3^=AQR_$?^//0OR>LQ<>:/\47\
MGU+2]'AD$=PDAB+3R#TZ1GXZJD+2%_M)^S^WF;V?CWXB-GF?:S7Q$?!C+B,C
MZOZOU>J7JXN+_3/I[RWJLNH6TXE99)+:8PB50!S3BKHYXDIR96!;C\/^QS:O
M IOBKL58E!H%AJNDZ=++/<6[I:I&!!,T8HX'6A(8\A\!;-3.9$C[VT#R_'^^
M_K?Q_5],DNU;2M%\MZ=\-OJNHV]XWH21VCO</&J S%N-10%HOB_UL8R,N[\?
M])?P_P":@CK^/Q_22/5I[>UU:X@M-#\P:A-;<$$PD9$;U4+_  <JB18T0+_R
M3X_!DQN.8_'\^7XXO]-%?V?C^K_Q[^DB;.XT&XU)6AL_,8GF!F2Y:.58Z01M
M*@W^&O[@P1HR\G;]W\2X"3WQ/X^K_9?[I=OQ^/QPH#5O\.:A>W.LW>D>:5O)
M8GG:*.-D,<:IP81JK\5Y*B[*W)^7_ D$@5<?Q^/4OX_'X_FJ>N:?Y9L92KP^
M9DN+BGU:]C>698WG5'4#]YT3UF7TG^']W.B809=\?QQ?[K_=(/+\?P_])?UO
M4JV5MIFJZA!I<]MYCL+EXH[&"[F=XE,MM:,ID*DA1Q2LW/[+S<&X^IZ/)NA>
MWX^/U?[+ZO6D\_Q^/5^.%D5O^6&CK=2SS:IJ=PTKL\2_6Y%6-6(=11#\7%DJ
MLK_&W[65>*:_'X_'^E-'GO\ -.M-C9_,GF",$QM)%;4930CE&P##[C3;-AHY
M4 3W_3^/Q]+5EB2#7=^O\?Z5CUMJ7GK58].M=(O(K&*VTZWFNKRXC$[W$[IQ
M:OJ%>*(R_O&'Q^IFPU<.'-.(_G'\?B/_ !+B=G3E/3PD=Y<(XOYW''TS_P [
MB_WO$\A_.W0OS2\RZ_IS7EG<7&FI ATZ+3K>984N)!^\YGXW]5FXK^\95X)\
M&:362R7Z1<?]-^/QPO?^S>'1^$99,HAD]7%#B\/TPXOI_P!4XX1X_P"C_I7J
MGDGRY^8.G13C6H(+ZZUJ**2]U&20<XG:%4>.6,4Y-#QHOH\HW_F7,^!E0XN?
MX_']9Y+51QC+(8_[KBEP?U>+TS_WW\/_ !/*]6_YQ^O])\\6EH-;2[T_5WEN
M9)&1Q=C@R>JH5?4Y-(7_ '<G)5_GX_M8.71&4@;Y5]7X_P!U_5>KT'M4,&.<
M3'U2!X>$>CCE_I>&#Z#U&\:&ZGN;:"2\:*UB_P!&CKZK S.II4?;3XFHW+XE
M_P!U_:S8U^/Q_LGCO/\ 'X_J\,OZS%;R&UU&\ENIM!U:&YN$*SO;DKQ*\:+7
MB&'-5Y<OM_O&_GQ]_P"/]S_$B_Q^/I_J_P!64?5PHW2+E-*EFBM-%U:2%P@>
M:7E,M$Y +'RJ."^ILR?WB?:Q!_'^^_A9#;\?\3P_C_8RW2U(N-2!K7ZRNY_Y
MAH?\^K8AB.0_'X_V2/Q5V*O_T/5.*NQ5V*H2\L]/,JZA.H2:U5B+D$JRQ_:8
M$KN4V^SB%JWRYYD_*:?S'^9VIR^5)5GBNF6[4W3O%/;J2JN]+@)))")26C>#
MU?W;QIFMU.ER2(X?I+VG8?;FDQ8CX]^+ <./AC_-^CA_F?TOXGNE]IOF^:*&
MTLEMFCA3_1IK@&>-XXRH$CKS4//-U8O))Q3XE_>,V68L,IDG)],?[N/]'^=_
M7XH1G_0>(D>.9E(?5?I_'^9_1]/^:NA\Z>:;W0M,-AI<+:[?R7$,BS-(MK']
M4<H\@(#2,CMQX?ZWVO@S.9I[Y7O+[4;"5]6L(K34H99+:Z2/XD<"C!E+?%P=
M64\6_:P+MS_'^]_'I3A(((X1!'&J0J.(B4 *%\.(VIA&W)4F;R;HG1!<1*-E
M5+B8*NP&R\Z#ID>"/=^/^._PK9_'X_'^DX;_ ,(:12G.ZIX?6[CI6H'V^U?]
ME^WRP>''N'X]/X_JIL]_X_'^ZDT/)NC 4#7(&PH+J?<#Q^/?'PX]P_'X_P!E
M) /X^7X_SI-CR?I Z278[U^MW'7??[?6AI_S?\6/AQ[A^/Q'_214DGJX^3](
MI3G=TH13ZW<=.P^WVJ?];]OECX<>X?+\?CZ>%23WN/D_1B:EKIJFIY75PU3X
MFKFO5O\ @O\ 4XOAQ[OQ_P!(^C^JI)(I8WDG074JPN&4BC*;F<@B@!K\?<#"
M8#\?C\?3]'I22G5M;PVUO';PKQBB4(B^  H,F3:%3 KL52OS/?7-CHEQ<6S>
MG,."K+0,(^;A2Y!K7B#7[+8JP#S#K6@6=];Z<\176+V&>:QN!Z[2%8?[PR7%
M66NZGTY%_>?[[^QF)KIG'B-?5_=P_KSEP_U_Q_IH9)5'_8I!JMHNK!+=;:VU
MG2[BTG-W:O$SW:7?P^F42,!(E7XO4EDY2_8^/)2E&)CB._%'^+_=?C^FV8LT
M\4APDB9'\/U?S?\ /_WWI_S>?Z;Y,\CVOFO7%_0LM]81:E#$4DO'A^KP#3(;
MB1C&WQSR&9F7TW=?Y?CS*P=FQR\JJ'#'^KXLN#B_T_X_B<G4^U&?3D@SE>?B
MGZ!'U^!#U_[#_.>@Z/YBOM'T-FT:W6"+22MQ+8PE81<13UX@U4*K(W'CQ_=?
M\9/BY[?#V? #@/USX\?_  O-@KT?U,O]7C_S'E-1VO,S\3U<.+PLN3^.6;3Z
MJ/\ >_Q2X\,Y>K^'^EPO2/(]]9_5[FW5EC,MS)+;14"\D9%+%* *RA_4^QRX
MI_DYI_Q^/Q]3T(WY<F4XJ[%4B_PM*H"0:Q?PPJ.,<:M$0H H!5HV/$?YME1P
MQNZ_&Z;+O\,77?7-0H?!H!]U8C@\"'</Q^/QZ> V[_#-W_U?+_[X>IZ_[KZ?
MR_\ &V/@0[A^/Q^/X@2[_#%UM_N<U"G?XH:_C%]^/@1[OO\ \[K^/XN-;:'E
MB\VKKE^?IA[#_C'_ ,%_QKB,$.Y;_'X_']9O_#%U_P!7S4*?ZT'_ %2Z_P"?
M^5B,$>X?CX_C_=&PX>6;OOKE_P"]##^%8SB,$.X?C\2_V/\ -]3:"OM!UBW/
MJ+J>H7-J(SZJPO")P].J(8Z.H_EY^I_QDQ&" Z!%H_R]IVGPR7ES;WTUY<7!
M5;EYB!(A0%0K(%3@5'3FG/+(1$=@QD 4#I"VGEQ8]'U'U&MN<AL=4N2'B?U&
MY>DS'^YD%:<6^"7CS3XOW:[+/$ZC]Y'AX@ )8XCA_H?3_''_ '/%PNHTO#I!
MX,[X-_#RS/HGQWZ/]KE_1_C]4_YZSS[;:7-HMQ<WT;SQ"*MK*DH0(U"U5/)*
M,0.0?_B.:\[<]G=0QG)](XOZOK_']%'^16U!_)VC2:A<B\NY+2*1[H-ZG,.O
M)"7_ &VX%>3_ +3?%BQIC7YFW6DZ'JFD^9+G7$TB\C$EI'#)"]PMQ&2)& CB
M'J#@P4L_V/YLKR9HXQ<C3GZ#LW/JY\.&/&?XOX?]E+\?YJ?Z->^7-=T^TN[>
M[CUAIE=1>0_ 6],\F# $%.!>GIM]CGDH2C(6#LXVHTN3%+AR1..7]+\>I&VN
MG:%>1^I%&3P8I(I=PR.NQ1QRV*^&&FDA7.@Z4?\ =)ZU^VXZ?[+#UOJB@B;2
MRM;1&2WC$:NW-P"35J!:FM>RC%("MBKL5?_1]4XJ[%78J\F_.;\ZX/)KMHEC
MIIU+59;?UI&D8)#"K$A":AO5?;EQ^%?L_'F-GU,8>G^(N[[,["RZJ!R#^ZA]
M7\__ #4UT6VN_-6AZ;YW2&*VO[S3:6EG&3P1;OCS+R-QW$8Z<?@;!JN.6(\-
M<<O]]_I?YWU.EU4#$RC$\OXI>G_BN#_CTGCGYS>>//EEYVBTVWF:TL-%,2Z?
M8P!XA=1LD99FD_O&27BT:,K_  ?Z_+,.6I..0ATA7X_XZ]IV1[/0S:'Q 8RG
MD'#P?5]/^X_K?TO4]CU[\R- C\O7D%I:7=GJT5I.VFV<EL\!6]2$LENLBAHA
M<<FX\$9_VE7G]EMH34;'X_'])Y#%$'((DBC*/]7ZOXOQ%Y'^2_GK\U[Z^N_+
M\-XM[#<0W%ZU[) ))+9^!8%#7C223BB+*'7DWV/M9@:75F<N'_9?\4]9V_V!
M#2X?%XHQE_#CCZ?%Y?3]7T_5_2]3W'RQY4O]&U99X-4O+RRFA;Z]%?2RR\IC
MQX2*).7&39N?%O\ (?[*9L7C?Q^/Q%E^*NQ5V*NQ5V*NQ5V*NQ5V*NQ5AVK>
M8(YOTB;RX-KIEF\D,OQQQ1\(@!(\LDBN.)JWP_ G'^?EC^/Q]/\ OOXI>F,5
M _'X_'^FBP^]>[2.>#28Y=9EA#7.G6DTI:">-T#P5,2L%W7XI!\'!?\ *S!S
M^K+CATC^]E_F7"/%_I_]C+^'Z:I_4!_G?B7];_I%7AO-<EEO-3TRS:ZU:6T]
M6WMU9A')=!0C_O@ ?2]9?2:3@OPI_-AN]4/Z.(_]+)_\=]/\/\7"O/)O_-_3
M_N?ZC#?+GUVX_,S7Y+VS]'5KB_M%N;-6'P2R:/")%4OP+(';X99/[U5YHS<G
MS>Z29\+*;_AC+_29/?Z9?CTNL[2@#GP7UEDA_P K,9_K?Z5-[)UN9M!%[;-+
MP633I8Q\0E0,R0E3L'^,F.A;C\/^KF?J22<L8[2B8:K%_1C7KX?X?Z7I_P Z
M?\3J='P@8)3KAR1R:#/_ *:?A_YW^R]2>>5+J]/F"70/,%C))8Z/; Z<2)I)
MC)ZGPDQH#Z?"!45)%^%EY)_K:_7P!(R1 K/O_1\3^./]'U?T9?SG<=DSD(RP
M3WGICP?\D)"/@S_TO^=_L8IG$FM"XD@*6<\H!F$?U;45EX,SLBU'%>*']RK?
MM<.4GQOQS &_)VPW5[6SUL6\R74"&3@4AFA@O W,$$,X=>(Y+SXE(WX_!ZN-
M)X>C<5GK0U&)Y+>%K!6 ,)@OB_IU^WZG$?O@O)3\/%O]]+\/)6OQ^/3^/JX6
M3Z#$J2W;PQ30VCF/T8YO44U$8Y_#+N-SN1]K^;&T)OBKL5=BKL5=BKL505[I
M%G=N)B&ANE%$NX3PE&U*<A]H?Y+\EQ5A6L:E<WWF^X\LZS=_5=%2T@=4**K7
MK-4R/RI7BKA8^$7[?\V68\DH2$H[2:L^&&2!C,<49?C_ *0_Z18W^:/D[S-Y
MJ\I1Z5H47./0;YX&TWU2C2PK AA?E*?[R-9/A1F^R_[7PY1VMAGD$9 W+)'Q
M)\OKW_S7=^QG:>FTF3)'*/1C_P 'QS]4O#APQG_OH^J/%]*'_)W\M/.VA:'<
MQ>;F>?1YE/U+RV)O4-NQ8'DW"JCE3[,<C<.7V?M97IXSB*DCM;48,N0G#'A]
M1EQ?3Z>'\?YWT)+YU_*'S3K_ )?0:83!J=A=3OI>FW4B@C3)4!=2JUX5N4K;
MI_([KQ_DCJ< R -W8O:TM'.6_#&8_K_C\?5]3,_(OY0G2?*&GQV/F&\AU4AI
MKBY0K) LLM/5C6W;X55'15^UZO*/[?++,6(0C0_'\/X_G.#VAKYZK)QR^KZ?
M\WBXO]BS_P L>7H=!TOZDEQ)=RO(\UQ=3$<Y)9#\3&FP% %51]E5RUPDVQ5V
M*NQ5V*O_TO5.*NQ5V*L.\\_E1Y1\Z3Q7.KQ2I=Q((A<6SB-VC!+!'J'5E!9O
MV<Q\VEAD-GF[CL[MS4:2)AC(,)_5"?JBDB:5?>4[S1;72+XG29)1;WF@RE9+
M:WM*$S$$_'&(%^/U6?B_'_+RZ,0!7X_'\3JYRE.9)^J?JY?CABR"SBTADGU#
M3KNTUJRC)6QA!6X]"44_=0RIZS;_ !'A_P :9A8L$H68D2C_ ).'\$.?IXOZ
MLN%K&/+C) )%_P 'T)3^E-*UU_J<NG36T>D3BXOH@M9(WC?ZQ%&W]VR+(WQ)
M_-]G^?)?FY1E4H2'].X\/]'U?S?]FPA,F0C7#Q5'B_@YQCZI2_V7_'7F7EK_
M )R5EA\T+:WF@V<&FZK+QC6P'IW"2NU0\SL>$_4^HW"+*\&KLD&-?C^)[7MC
MV=&"$2,O&:_RO]7^#_8O:)/-MQ;>:M-T>X6"2WU=9#:RPLW-&2-I1RY#BZ.B
MTY+Q^/C\/\NQ.SQHW_'XX63DT!/AX;XJPV*UTRVT73YI-):[DFMPTGI(7D,@
MAY]J_%(:J&9E_P K-492,CZNO?\ C\<7\[U6"^M_C_??](M++I#I.Q\MW*"(
M*5#0 %^<A2BT/[/+E_Q'[./%+^=]OX_'%Q?7--'I^/\ CO\ N?J_K WUG0 Z
M1?X:O#/*SJ+?ZNG.JKS/P\_Y6#/_ *RX8\1_B^T_C\3_ )\U^[\?[[_3_P 2
M+FETN.*.0^6;MA*KLP2!2R<6=5Y -RY.%Y?#R^%DR(E+^=]OX_X]Z_YTUK\?
MC\?TE(7FF,5/^%+WTY A4B!.0Y<BP=>8X<.W^LN'BE_/^_\ 'J_WT_YTE _%
M_M_Z17S3Z9$_%_+-PRLB.KI#R6LB<BC="K!GX,*-_P %Q7$2E_./X_'\7\[^
MG- _'X_S?6OM)=%N;Q(#Y=N8$D?B;BXM^* D5J=V8 M\ -./^QXXF4_YWV_C
M\3_VR:Q\N?\ 9+_>(J"2RTGS1-&&2TL&L(Y'2O%#)ZS*#Q_GIMMF5I)&0-GB
M-_UOQ_TG+^)A(5]G_$II-YA@6"6>&VN)H8HWE>;TS%& @).\O MT_85\RKV0
M=N;"]6&E7%G-^F9EC;6_@:SG]+ZM-,T5/0%M(O[[X3Q91+ZK\O4_R4/X_'^E
M_P")^M('E^/]S_QV24VS:SI>AZA=V=HGZ0B18K>&Z86]JKQLH6&9HROU>-%X
MA?AX+QX<TS!TWJS9)_S:P_Z7UR_TV3_91_TU.,W(R[JC_-^C\?\ 2*-TMKZX
M?4+Z!8'NKI!,D4[NB-*\=5',*Q]/U/VOW?[O_9\3A%ZC)Y1QQ_'^^_WJ[')+
MW#\>KU?CUX_J8!Y-_3<WFO5]3U9;5=2_3.GVM];P,R1&X73TJ8S(*^DJ])'Y
M-S;^3CF\T.\<H[\4O]U'\2_TW\YUW:<^&>"7_01'_91G^)?3_FIYI&GZK)IF
MNI,R3W-E(+EKJOH-ZL1::J6ZF1D+ ?L_#_Q9\.9@R 9,,Y?3EQ^#/_IE_5]/
M[O\ H_Q.NEBD<&HQQ^O!F\;%_P!-_P#>2_WG\V2FG:UKBRZ=J&N+;-=S*;?5
MVM"T5H8)7#6[;F0A8U>,N_!T]3FB_9XY1@Q$QGIS]<+GB_KQ^J/\[UQ_A_G1
MXO5_%E:G.(2Q:L?1DC''F_X7E_NLG_)')_Q/\Z+,_*4.NP:U:#6[NTGN&2Z$
M,MB'CB:,NI2$QO\ $)(U7D7;^\X\_M<\U3O3^/Q_II,^PJMEECBB>65@D<:E
MG=M@% J23[8DH)2\>9-%*\A<U%.6R.=J _R^!R!R1',AD06_\0Z/6GUCO3[#
M^%?Y<?%CWA#7^(M'_P"6CP_8D[_['!XL.^/S5W^(M'_Y:/']B3M_L<?%AWQ^
M:M_XAT>M/K&]:?8?PK_+A&6)ZA6O\1:/_P M'A^Q)W_V.#Q8=\?FJZ/7](DE
M2);D!Y6X1AE9:L30"K "I/V?YL(R1/(A2@O,7FN+2+W3].BMGO-1U-G%O C!
M%"1\>;NYJ%%755VY.WV<FKPC\_\ \Q?-</FK3M+LK:XT:'3TD9[]#4S/=+Z?
MIK(NP3@-DY<I&_U%S!ULY 5&WJ?9O1X)3$\W 8GBX8SK^#^C/^MQ19?Y*U?\
MPY-+@UF>P?4;NJS7]E0132)+"$MKI49DC:0I#\:_ WQ*ZYLA*<]/BE+G4H_Z
M6?\ Q[\?4\SK\6'#VCJ<> _NO$QRA_GXOWO_ $LXL<?ZGU?S"#\[+/\ -2;R
MM;:LUL8=&MY));_3;:<M-$CM2$RQ !&2,?#QCEDX>I]CX&?-?K,4IC8U_OOQ
M_2_XZ]%[-Z[!I\O[R G*7T3_ )G]'U_SO3_-3S\JO+7G+6_R]L;^[UJYTN_=
MIH8/547+&P#4CCE1V#*Z/ZC15?X$;CP;X>-FE!$!?X_$G![=RXLFJG*$>#^=
M'^G^."7_ $EQ/6/+^C0Z+I%OIL4KSB ,7GEIS=Y',DCFE .3NS<5^%<R'4)A
MBKL5=BKL5=BK_]/U3BKL5=BKL58O^9OEJ]\R^2-3TBRN!;7,R*\;.>,;&)Q)
MZ<A&X1^/&O[/^K\.4:C&9P(!W=EV1K8:;4QRS''"/_$\/^Q^IXM^2OY;ZCH>
MMZSYDU&^>TN],(MH],T_C=,[2Q^H9)D7F.#!E6.G#DR/^\^',;%$X,?%/BV\
MN+\?[UV'M'VOBSSEX=>&>'U1_BW_ (>/^'U?YST_2= FCO9]:>[DD6Y>*ZU&
M:ZMS'"(X"6@6*,5+<6=Y'?GP^PWP8F4LQ@1Q0A&ISXP?\S^EQ1E_Q_C>6^NN
MD1Y?[G\?3_6]0+R/H_E>W_,K7S8V-I<7#6L;MJ4,07TRSLLD1ZJ#-RYLR']Y
MPS-ACC$^D5_Q3L-1K,N8 9)&?!Z?5^/^D?I9W:>5] M-5?5;>R1-0=60S_$2
M%<\F" DJG(_:X!<FXR:&M#3<]@=L58M;:0U_HVC.MY<6+P6\90P2!>?*-:JX
M(/)?AY*M<T\Y5([6V1%@(:/R9<1H[1^8=0:X>)$69Y0P+ 4#N%X<Z]J,F/B'
MN"3$EC^I>8?+]N;ZRO\ 5]8MY^0M3^[F!]6WEAC]>V:CKQ>0)]EN3^M\/VER
M8B:NHKS_ !_2_P"*_P!S]/\ . QZMHI4VT'FC7WENWM8Q-*C,(C'*0>(5(RG
MUAD*R,_J*O\ JO\ ',@CI';_ '/^R_'I^IC=_C\?SN)2OKKRY;^M9W/FWS*?
MJSW$,\])3&S11RA@9(X5C/$!G'#CS:/_ %<8\701OX?T9?C_ &7\Y)_'_2*>
M:3Y;MM;B;4K+S1K7&-FMX_4D*%7C15DI&Z\ZN59O]E^[X_::$I5M0_'I2!^/
MQ]"<3^1S-;P6L^O:I);PR-)*KSBL_-T;A(ZJIXAD^%$X\>?'['PY 9.M"_Q^
M/I6CLF$!/^-R345TQ1Q--CZ['MWS,T9])\C^O\<7^;ZOX82Y_C\?[%3\SW-S
M/?0:=#;O>6RHTM]!&I8'E\,:24*#BWQOPY_%P^)>/VLS;O\ Q^/QZ6(+ )(9
M;]Y&M].EEC\KWJA9M1M?0:)D12S6\\C R4BD5.2QHTG^KQDR.28A$R/\/J_T
MHXO][_I?Z442-"^[?\?C_3\*]AJMU=R6<5Q$VERVIAO;)X&6:.\EEY"X:X8>
MFD A8?N_YUY_R<<;08C'#'OEZY?\E?7+T_U9>K^M_$QPQ('G]7VC\?[E4-A<
M:@DEGIFK2VJVDT%W'<0NL;WD$((] LJO%Z,H^"3['/X/V?M0T8N60]#D_P"F
M</Z7]3\?2QQ<Y;]?Q_I9?Q?1_L6(:+#/<:EYO*720B3S)IS-/$LD<J.]C& Z
M"GPA/4/[.;WL_>4QWXLGX_WOT_YOK==VT:AC/\W/B_'_ !S^%E6GVO+7M>L+
MB]ELY;J R3W-NB!E<EE8P&4TX*LGP.R<OL\N/[3,\6E@1_!.4/\ E9^\_P![
M_LI^GA3C'#K\L?\ 5L<<G^D_=3_B_'^E7>7-!$@U"QGO%].V9],=WC:1I8N0
M,;@1LJ@JK.WVV_95,GK,A&6&://)&&7^K/?_ &7B?CBX^*GL_"):?)I9DUCE
M/#_R3R>O%+_9>C^JM\KI'I.GZK<^8]8O)9=*O))I9;JX$,=C&%"KP;C7T#OP
M67]K[/+EE6OQ@9.*/]WE_>0_SOKCZ?\ 4_HE_1<GLK/*6,PF?WN"7@Y/\W^[
ME_5GC_T_J>C>5]:.HQW$9D,ZP&)X+GX")8)XQ)&W)**QH?M*JKQX9A!V0^Q'
M:[_QP]1_YAIO^39^6"7)(YMPN?3CWJ>(J-ZG8;@D]J_Y6:8V"?>V ;;L(U"T
MM-&N!8OJVL[Q^H6B;FI!0HH#=F01]_\ JKE@E=T-OQ_O?Q_.:V_'^]_'^G=)
MJ%I=WL<<6K:O;O\ N80Q1T@!*A"TG.GV@O(_%\#OR?E]G)F1\NO7U?C_ #?Y
MR.7+\?C^E_64H[^&PNI5N-5UJ^EAEEBD$2?N@02AH#RY\*]>3<?VOV>(XC(=
M/Q_O?X?Z_&G:_P ?C^=_T[^E0N=1LHRZR:AK[*R\$MG5@9!*-OBV*FG]VQX+
M_.K_ !<39/=_Q/\ TA]/]:,?ZJ!^/XF3>68/51=3@U*^GMY1)'':WS"O($*:
MBFS(T;+_ ,U?M5SD>7X_'#_-]"0%7S8_^X^T/*@-_9\7-*?WRD&H*T';E7)Z
M8^L7^/X?Q_O?JB)!':YY7TW6+BSNIFEM[VP<O:W=N_IRJ&%&2M&#(W\I'VLV
MC6QKS%8>8?K=V\?F!]#TW3XD>U8B,FX<)RDEFDE!]6A^#TZ\?A7^? :_'X_'
M%_1]2(D[?4?Q_-_'\U,=/T_4K4Q^88K6*[U+4+2 :LGK>C5XT'Q0"CQ?'W5W
M1?A7X_MYGQS">,8YDQ$/HJ/%_I_IG_NG6STLL6:6;''C.2HSAQ<,O^2?\']?
MB_S92XD'YC\R37_E?4;FW@&GRZ9+%+-#JI2"":%'!_O6)A,<A!"MSXLR_%\+
MY1J<'A 'BC.,OXH'\?P_SOYW]%OT&J.ID8QA.,XGAX)#ZOZO\^*AY'\[MKYN
MM2A$'U:2-5L].MKB":6212QDD9(W80T(X_&?C_R?VL?BOS_'_23G3PRAM(&-
M>_\ ']7A_P!+ZF3>7O-%EK;7D$<4EK?:?((KVSG"B2,L"5;X2RE'HW%J_LX6
M%%.,5=BKL5=BKL5?_]3U3BKL5=BKL54[B-I(65>);JH< KR!J*U!VJ,5>>W6
M@:VOG!]=EN;"*Y5/1CM%DH%7XV^L3BB<@C%?37XFXR?:Y9@ZKBE*,8?4)<77
MBX?YW-KE?$!S]7^=P7_L?^D?YSQ7R;)^=5MYX?4[>ROKR."<Q>8S<L9+22.0
M R@@L$=D5E=?0Y,GP_#P^'*M+CS V;]7X_Z1_P!B][V[J>SLF.,(<(X8_5B_
MJRX?]EZ/^)X>)[[IOF"PL_-]MH.GK:2P:E%+<2&TC$1B>$"K-Q^&1'^R&_RE
MS9U^/Q_6>&WH?C\09GBKB*@BM/<8JQV/0_,MM"L%KJMNL,2JD(>UJW%11>1$
M@J>(X_\ #?Y.8QTL3^/Q^/\ 3,N+\?C\?P_TE3]&^;:[:K;4!-*VIW%32O[W
ML*8/RD/Q^/Q_27B6-H_F@MS.HVC.  '-H>6S<AOZAIN%_P T^,_E8^?X_'^Q
M1Q*AT[S9O34[;V_T8^__ !8?\G_5_P K -+'\?YO_'_]C]/U0)DU^C?-E/\
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MK7=U+8V"'S!/"LLUE,Y!>WD1*)R?E&DL+?"\9^%OM_MJN2P&'C2!_O?YV_\
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M1!'/\?C_ (M;[_?_ $?QQ<+!YKG1[>^\\KJTD2ZI>:O9'21R*\IOT9;RN(5
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M+R_'X_XZK3^5;VXB>*XUNYFCD!5XY(K5E())*D>E]D]_^%X8?R\.[\?C_?\
M^:3(_C\?C^'A6)Y/GC0I%J\R+5R +>RH#*Q>3804^,FI_P K'\O#\?C\?Z;B
M D?Q^/ZW]+^=*7JXGMY4O'J'UF<@\Z*8+,C]YNU0T)'Q'[5./+XOVFY8C3P[
MOQ^/ZW\'\WUD3+O\*WE6;],S\C7XOJ]G7J2*GT:G=W)_FYM_-@_+0KE^-_\
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MZW!Z8_S6;VGF=-8UV\N+*]D328?3AANE#.T_)BTMO"W%EE,:_%^UZ32<&?\
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M8F0X>+^9_F?S?]4\/T\/&A!I^GZ7H@NKJ%9[D\>IW9W!5%!'+X O[=/AX?\
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M9Y_\=5K+5-059--M;5IGB7B.=%"TV'(GX>@W^+_B/J9(CW_C_C_#^/H1+O\
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M+\[::&0S*%9 I9$5B!(LT3@_97G\38$>]D.@^;?+VOS7T.D7:W3Z=((;OBK
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M-\4')OWT7*5?Y<&R-D+Y1\Q:)KVJV^EZOY.AMKZ]@E)N?JD;0>G$0PC<R*)
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"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>18
<FILENAME>tsc03.jpg
<TEXT>
begin 644 tsc03.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0N44&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @ !
M.$))300"       $     #A"24T$"       $     $   )    "0      X
M0DE-!!0       0    ".$))300,      GF     0   '     ^   !4
M46    G* !@  ?_8_^  $$I&248  0(! $@ 2   _^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ /@!P P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M.VRO9?\ $I_XE<K_ ,/V?^><5>093V>Q@UV<SW_>W+V#_$M'_-;+C0?;[/\
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M! 8       < !     $! /_B#%A)0T-?4%)/1DE,10 ! 0  #$A,:6YO A
M &UN=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M                  #VU@ !     -,M2% @(
M                                        $6-P<G0   %0    ,V1E
M<V,   &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8
M%&=865H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
M    B'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,
M  0,    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)4
M4D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M
M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N
M,0              $G-21T(@245#-C$Y-C8M,BXQ
M                                              !865H@
M\U$  0    $6S%A96B                      6%E:(        &^B   X
M]0   Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/
M9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6
M245#(&AT=' Z+R]W=W<N:65C+F-H
M                             &1E<V,         +DE%0R V,3DV-BTR
M+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@                            !D97-C         "Q2969E<F5N8V4@
M5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L
M4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                                =FEE=P      $Z3^ !1?+@ 0SQ0
M ^W,  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S
M  $                        "CP    )S:6<@     $-25"!C=7)V
M    !      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!>
M &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X L@"W +P P0#& ,L
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M$0P,# P,$1$,# P,# P1# P,# P,# P,# P,# P,# P,# P,# P,# P,#/_
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M6&AXB)BHN,C8Z/@Y25EI>8F9J;G)V>GY*CI*6FIZBIJJNLK:ZOK_V@ , P$
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M2.F]?$?5_%^/Q'^%UV#6#+/AF."45DD'(AJT(ZCQH.V:X]DSS2B=L?\ %/\
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M1_O8</\ I?Q_%)A=QK]U-/-)QY"1F85K4 FHKUZ9N<?;.HCCX!7#^/\ CO\
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M+H-A_HL7;?\ E]L)W4[H_1_(WDO1;HW>D:%86%T1Q^L6]M%')0]?C50V_?\
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M2EU )_'_ !W_ $O];BM/(5B"H>[F:-37C\(/;]JA/45_V38C$.OX_P WZ?\
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MI98HHS)*ZQQKNSL0 /F3BKEDC9F56#,M.0!!(KN*_/#2 ;;=T12[L%4=68T
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M_P!5!!_/\MRJ!HX0RK+*?34QIR /HH6"EG4U]1N;_!]G@^'I^/Q_N&//EM^
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1%78J[%78J[%78J[%78J__]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>19
<FILENAME>tsc04.jpg
<TEXT>
begin 644 tsc04.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0Z84&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @ !
M.$))300"       $     #A"24T$"       $     $   )    "0      X
M0DE-!!0       0    ".$))300,      SJ     0   '    !.   !4
M9F    S. !@  ?_8_^  $$I&248  0(! $@ 2   _^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 3@!P P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M14,@<U)'0@                  ]M8  0    #3+4A0("
M                                                 !%C<')T   !
M4    #-D97-C   !A    &QW='!T   !\    !1B:W!T   "!    !1R6%E:
M   "&    !1G6%E:   "+    !1B6%E:   "0    !1D;6YD   "5    '!D
M;61D   "Q    (AV=65D   #3    (9V:65W   #U    "1L=6UI   #^
M !1M96%S   $#    "1T96-H   $,     QR5%)#   $/   " QG5%)#   $
M/   " QB5%)#   $/   " QT97AT     $-O<'ER:6=H=" H8RD@,3DY."!(
M97=L971T+5!A8VMA<F0@0V]M<&%N>0  9&5S8P         2<U)'0B!)14,V
M,3DV-BTR+C$              !)S4D="($E%0S8Q.38V+3(N,0
M                                                        6%E:
M(        /-1  $    !%LQ865H@                     %A96B
M  !OH@  ./4   .06%E:(        &*9  "WA0  &-I865H@        )*
M  ^$  "VSV1E<V,         %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M        %DE%0R!H='1P.B\O=W=W+FEE8RYC:
M                                      !D97-C         "Y)14,@
M-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C92 M('-21T(
M         "Y)14,@-C$Y-C8M,BXQ($1E9F%U;'0@4D="(&-O;&]U<B!S<&%C
M92 M('-21T(                             9&5S8P         L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M        +%)E9F5R96YC92!6:65W:6YG($-O;F1I=&EO;B!I;B!)14,V,3DV
M-BTR+C$                                  '9I97<      !.D_@ 4
M7RX $,\4  /MS  $$PL  UR>     5A96B       $P)5@!0    5Q_G;65A
M<P         !                         H\    "<VEG(     !#4E0@
M8W5R=@        0     !0 *  \ %  9 !X (P H "T ,@ W #L 0 !% $H
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M;?;[]XKX&?BH^3CYQ_I7^N?[=_P'_)C]*?VZ_DO^W/]M____[@ .061O8F4
M9      !_]L A  &! 0$!00&!04&"08%!@D+" 8&" L,"@H+"@H,$ P,# P,
M#! ,# P,# P,# P,# P,# P,# P,# P,# P,# P, 0<'!PT,#1@0$!@4#@X.
M%!0.#@X.%!$,# P,#!$1# P,# P,$0P,# P,# P,# P,# P,# P,# P,# P,
M# P,# S_P  1" #$ 1L# 1$  A$! Q$!_]T !  D_\0!H@    <! 0$! 0
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MTVUAFDFB>>26>4QJJ(ZI\*JKLY^+?$I*G]<\[$5&F60Z_";IZC8TW$1KN/\
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ME"?FSY2^IW-]+)<)9P2K$D@M+IF<.G-6],1>H!X_#\/[61B;-?CG^/\ 9,S
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M\5=BKL5=BKL5=BKL5=BKL5=BJ0^>*GRU<@ DEX:4K_OU?"GZ\5ND^Q5V*O\
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M,FXX"#'EZP6)XHVEC61/38I(P-"YD:GAS8_'3$K29(O%>/8=.M:>Y)-3C::
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M2:9;I;QZA< M=,P!]1_7!$PYL6;[?[60C",10'")'_9?SDDWS_$4O3\H)M+
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M85 9>C+X9$CYHKH4EN4CD\[0QR('1M-D1U85!5I14&O7[.,H<0WW']B]W?\
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M*CL)BX#JI*@HA:A-#N].*C_FG%:5].OH;^RBO(:^E,.2AMF&]"#_ )0(HV
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M&S%1TKB@BT7BE0N;"TNB#<1"2@916O1A0XC8VBNJI;V\-O"D$"".&,!4110
M#%+<D:2(R.*JX*L.FQV/3'K:J,.G64#%HH@C, "03T';K_P7\W[6(V1PA$8I
M0#Z%I#W1NVM4-R9$F,N_+G']DXVJ/Q5#W6GV=VT;7$0D:%N41)/PMXBAQ55A
MABAB6*)0D:"BJ,57XJ__U_5.*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*
JNQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>20
<FILENAME>tsc05.jpg
<TEXT>
begin 644 tsc05.jpg
M_]C_X  02D9)1@ ! @$ 2 !(  #_[0OZ4&AO=&]S:&]P(#,N,  X0DE- ^T
M     !  2     $  0!(     0 !.$))300-       $    >#A"24T#\P
M    "           .$))300*       !   X0DE-)Q        H  0
M   ".$))30/U      !( "]F9@ ! &QF9@ &       ! "]F9@ ! *&9F@ &
M       ! #(    ! %H    &       ! #4    ! "T    &       !.$))
M30/X      !P  #_____________________________ ^@     ________
M_____________________P/H     /____________________________\#
MZ     #_____________________________ ^@  #A"24T$         @ !
M.$))300"       $     #A"24T$"       $     $   )    "0      X
M0DE-!!0       0    ".$))300,      I,     0   '    !2   !4
M:Z    HP !@  ?_8_^  $$I&248  0(! $@ 2   _^X #D%D;V)E &2
M ?_; (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,
M# P,# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.
M#A01# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,
M_\  $0@ 4@!P P$B  (1 0,1 ?_=  0 !__$ 3\   $% 0$! 0$!
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MU.3TI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\
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M     $E%0R!S4D="                  #VU@ !     -,M2% @(
M                                                        $6-P
M<G0   %0    ,V1E<V,   &$    ;'=T<'0   'P    %&)K<'0   ($
M%')865H   (8    %&=865H   (L    %&)865H   )     %&1M;F0   )4
M    <&1M9&0   +$    B'9U960   -,    AG9I97<   /4    )&QU;6D
M  /X    %&UE87,   0,    )'1E8V@   0P    #')44D,   0\   (#&=4
M4D,   0\   (#&)44D,   0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q
M.3DX($AE=VQE='0M4&%C:V%R9"!#;VUP86YY  !D97-C         !)S4D="
M($E%0S8Q.38V+3(N,0              $G-21T(@245#-C$Y-C8M,BXQ
M
M  !865H@        \U$  0    $6S%A96B                      6%E:
M(        &^B   X]0   Y!865H@        8ID  +>%   8VEA96B
M   DH   #X0  +;/9&5S8P         6245#(&AT=' Z+R]W=W<N:65C+F-H
M               6245#(&AT=' Z+R]W=W<N:65C+F-H
M                                             &1E<V,
M+DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'
M0@              +DE%0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R
M('-P86-E("T@<U)'0@                            !D97-C
M "Q2969E<F5N8V4@5FEE=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ
M               L4F5F97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%
M0S8Q.38V+3(N,0                                  =FEE=P
M$Z3^ !1?+@ 0SQ0  ^W,  03"P #7)X    !6%E:(       3 E6 %    !7
M'^=M96%S          $                        "CP    )S:6<@
M $-25"!C=7)V        !      %  H #P 4 !D '@ C "@ +0 R #< .P!
M $4 2@!/ %0 60!> &, : !M '( =P!\ ($ A@"+ )  E0": )\ I "I *X
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M^L?Q_P":<EXND_F9/^5D?+^A_61PS[W?H3\[:'_G:-'K4T'Z-DZ;TW]?_/\
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M,;R?S?RX-O?7X_XZ@F_E^/Q_%]?]),-!UOR5I=J);139&^FX?5N,CMZA-=B
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MB@1_I?Q_5_K?YJ9H(OJ]M \SBY/(Q6Y#HLD:1LSE>21%'3[0D1O43^;C]C&
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MC1K1?I],$[\AUI_+EDN1KO/WR_Z1_P [_2UP'V?C_??T/3Z^&3%?R/T4ZO\
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MKL5=BKL5=BKL5=BKL5=BKL5=BJV2-)(VC<51P58>((H>F*OC[\O?*[V'YO\
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M\L>6K33[BWCN-:AFBFD0QP-"-R4>K%EY?%]G^3#C.WX_'X_Y5G(2?Q^/Y_\
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M "X-[W_X\K3O_L<?S>#_ %&/^GG^/Q_5X7PY?SG?X#\_5_\ )@7O7_EBM/\
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M3_FG'\W@_P!1C_IY_C\?U.%\.7\YW^ O/]/_ "8-[\_J5GX?ZN'\W@_U&/\
MIY_C\?U.%\.7\YW^ O/V_P#R$&]_Z0K3_FG!^;P?ZC'_ $\_Q^/ZJ^'+^<[_
M  %Y^_\ +@WO_2%:>/\ JX_F\'^HQ_T\_P ?C^KPOAR_G._P%Y^_\N#>_P#2
M%:>/^KC^;P?ZC'_3S_'X_J<+X<OYSO\  7G[;_D(-[_TA6G_ #3C^;P?ZC'_
M $\_Q^/ZG"^'+^<[_ 7G^G_DP;WY_4K/P_U</YO!_J,?]//\?C^IPOAR_G._
MP%Y^W_Y"#>_](5I_S3@_-X/]1C_IY_C\?U5\.7\YW^ O/W_EP;W_ *0K3Q_U
M<?S>#_48_P"GG^/Q_5X7PY?SG?X"\_?^7!O?^D*T\?\ 5Q_-X/\ 48_Z>?X_
M']3A?#E_.=_@+S]M_P A!O?^D*T_YIQ_-X/]1C_IY_C\?U.%\.7\YW^ O/\
M3_R8-[\_J5GX?ZN'\W@_U&/^GG^/Q_4X7PY?SG?X"\_;_P#(0;W_ *0K3_FG
M!^;P?ZC'_3S_ !^/ZJ^'+^<F_EGRSYGTN_DN-5\TW.MV[QE$M)K>WA57J#SY
M1#D>G3*<^?'.-1@,9_G<4F<8D<RR;,1F[%7_TO5.*NQ5V*NQ5V*NQ5V*NQ5V
M*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V*NQ5V
-*NQ5V*NQ5V*NQ5__V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388424017224">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document And Entity Information - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Mar. 14, 2022</div></th>
<th class="th"><div>Jun. 30, 2021</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentInformationLineItems', window );"><strong>Document Information [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001053691<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Diffusion Pharmaceuticals Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2021<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">000-24477<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">30-0645032<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">300 East Main Street, Suite 201<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Charlottesville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">VA<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">22902<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">434<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">220-0718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, par value $0.001 per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">DFFN<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 74,300,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">101,924,581<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">KPMG LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">McLean, Virginia<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">185<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentInformationLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentInformationLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423736104">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 37,313,558<span></span>
</td>
<td class="nump">$ 18,515,595<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PrepaidExpensesDepositsAndOtherAssets', window );">Prepaid expenses, deposits and other current assets</a></td>
<td class="nump">510,015<span></span>
</td>
<td class="nump">260,825<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">37,823,573<span></span>
</td>
<td class="nump">18,776,420<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">149,198<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill', window );">Intangible asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">8,639,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">149,162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">15,578<span></span>
</td>
<td class="nump">15,771<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">37,839,151<span></span>
</td>
<td class="nump">27,729,551<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">947,495<span></span>
</td>
<td class="nump">545,844<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">1,980,189<span></span>
</td>
<td class="nump">1,776,470<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Current operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">113,469<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">2,927,684<span></span>
</td>
<td class="nump">2,435,783<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilitiesNet', window );">Deferred income taxes</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">443,893<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Noncurrent operating lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">35,693<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">2,927,684<span></span>
</td>
<td class="nump">2,915,369<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingencies', window );">Commitments and Contingencies (Note 5)</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EquityAbstract', window );"><strong>Stockholders&#8217; Equity:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, $0.001 par value: 1,000,000,000 shares authorized; 101,914,280 and 64,015,441 shares issued and outstanding at December 31, 2021 and 2020, respectively</a></td>
<td class="nump">101,914<span></span>
</td>
<td class="nump">64,016<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapitalCommonStock', window );">Additional paid-in capital</a></td>
<td class="nump">164,814,664<span></span>
</td>
<td class="nump">130,659,550<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(130,005,111)<span></span>
</td>
<td class="num">(105,909,384)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">34,911,467<span></span>
</td>
<td class="nump">24,814,182<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 37,839,151<span></span>
</td>
<td class="nump">$ 27,729,551<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PrepaidExpensesDepositsAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PrepaidExpensesDepositsAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapitalCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapitalCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6801-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.9)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 15: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingencies">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.25)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03.(a),19)<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121557415&amp;loc=d3e14326-108349<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingencies</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilitiesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31917-109318<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilitiesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16323-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI http://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.17)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (g)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI http://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388430090264">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Balance Sheets (Parentheticals) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value (in dollars per share)</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, shares authorized (in shares)</a></td>
<td class="nump">1,000,000,000<span></span>
</td>
<td class="nump">1,000,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued (in shares)</a></td>
<td class="nump">101,914,280<span></span>
</td>
<td class="nump">64,015,441<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding (in shares)</a></td>
<td class="nump">101,914,280<span></span>
</td>
<td class="nump">64,015,441<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426649704">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Operations - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 8,499,414<span></span>
</td>
<td class="nump">$ 9,427,667<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Intangible asset impairment charge</a></td>
<td class="nump">8,639,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">7,445,277<span></span>
</td>
<td class="nump">6,444,109<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationNonproduction', window );">Depreciation</a></td>
<td class="nump">93,416<span></span>
</td>
<td class="nump">103,168<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(24,677,107)<span></span>
</td>
<td class="num">(15,974,944)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NonoperatingIncomeExpenseAbstract', window );"><strong>Other income:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_InterestIncomeExpenseNonoperatingNet', window );">Interest income</a></td>
<td class="nump">137,487<span></span>
</td>
<td class="nump">114,257<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest', window );">Loss before income taxes</a></td>
<td class="num">(24,539,620)<span></span>
</td>
<td class="num">(15,860,687)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income tax benefit</a></td>
<td class="nump">443,893<span></span>
</td>
<td class="nump">1,675,381<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">(24,095,727)<span></span>
</td>
<td class="num">(14,185,306)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeemedDividendFromWarrantExchange', window );">Deemed dividend arising from warrant exchange</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(1,950,378)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic', window );">Net loss applicable to common stockholders</a></td>
<td class="num">$ (24,095,727)<span></span>
</td>
<td class="num">$ (16,135,684)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Share information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Net loss per share of common stock, basic and diluted (in dollars per share)</a></td>
<td class="num">$ (0.25)<span></span>
</td>
<td class="num">$ (0.30)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Weighted average shares outstanding, basic and diluted (in dollars per share)</a></td>
<td class="nump">$ 97,626,748<span></span>
</td>
<td class="nump">$ 53,831,973<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeemedDividendFromWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend from the exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeemedDividendFromWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationNonproduction">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationNonproduction</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=125512782&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 20<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123384075&amp;loc=d3e41242-110953<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(10))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(8))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(15))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestIncomeExpenseNonoperatingNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net amount of nonoperating interest income (expense).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestIncomeExpenseNonoperatingNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1448-109256<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=d3e1377-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NonoperatingIncomeExpenseAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NonoperatingIncomeExpenseAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388424359080">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Consolidated Statements of Changes in Stockholders' Equity - USD ($)<br></strong></div></th>
<th class="th"><div>Common Stock [Member]</div></th>
<th class="th"><div>Additional Paid-in Capital [Member]</div></th>
<th class="th"><div>Retained Earnings [Member]</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2019</a></td>
<td class="nump">33,480,365<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2019</a></td>
<td class="nump">$ 33,481<span></span>
</td>
<td class="nump">$ 111,824,859<span></span>
</td>
<td class="num">$ (91,724,078)<span></span>
</td>
<td class="nump">$ 20,134,262<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)</a></td>
<td class="nump">11,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</a></td>
<td class="nump">$ 11,429<span></span>
</td>
<td class="nump">10,330,202<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">10,341,631<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">19,106,504<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 19,106<span></span>
</td>
<td class="nump">7,768,370<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">7,787,476<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">736,119<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">736,119<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(14,185,306)<span></span>
</td>
<td class="num">(14,185,306)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2020</a></td>
<td class="nump">64,015,441<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2020</a></td>
<td class="nump">$ 64,016<span></span>
</td>
<td class="nump">130,659,550<span></span>
</td>
<td class="num">(105,909,384)<span></span>
</td>
<td class="nump">24,814,182<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)</a></td>
<td class="nump">33,658,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts', window );">Issuance of common stock, pre-funded warrants and warrants, net of issuance costs</a></td>
<td class="nump">$ 33,658<span></span>
</td>
<td class="nump">31,060,644<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">31,094,302<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants (in shares)</a></td>
<td class="nump">4,230,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities', window );">Issuance of common stock upon exercise of warrants</a></td>
<td class="nump">$ 4,230<span></span>
</td>
<td class="nump">2,197,220<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">2,201,450<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock-based compensation expense</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">897,260<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">897,260<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="num">(24,095,727)<span></span>
</td>
<td class="num">(24,095,727)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross', window );">Vesting of restricted stock units (in shares)</a></td>
<td class="nump">10,301<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross', window );">Vesting of restricted stock units</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="num">(10)<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesOutstanding', window );">Balance (in shares) at Dec. 31, 2021</a></td>
<td class="nump">101,914,280<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest', window );">Balance at Dec. 31, 2021</a></td>
<td class="nump">$ 101,914<span></span>
</td>
<td class="nump">$ 164,814,664<span></span>
</td>
<td class="num">$ (130,005,111)<span></span>
</td>
<td class="nump">$ 34,911,467<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of shares and warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the value of common stock and warrants issued during the period, net of issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=122142933&amp;loc=d3e11178-113907<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123468992&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued which are neither cancelled nor held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-30)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The gross value of stock issued during the period upon the conversion of convertible securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Aggregate value of stock related to Restricted Stock Awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21930-107793<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 23<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21914-107793<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 5<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124442411-227067<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 10<br> -Section 65<br> -Paragraph 4<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=122640432&amp;loc=SL121648383-210437<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 105<br> -SubTopic 10<br> -Section 65<br> -Paragraph 6<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=124434974&amp;loc=SL124442142-165695<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568740-111683<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124436220&amp;loc=d3e21711-107793<br><br>Reference 13: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6450520&amp;loc=d3e32583-110901<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 17<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32136-110900<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 65<br> -Paragraph 8<br> -Subparagraph (d)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=123459177&amp;loc=SL121830611-158277<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4I<br> -URI http://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4590271-111686<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 30<br> -Section 45<br> -Paragraph 20<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=118261656&amp;loc=d3e32211-110900<br><br>Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123454820&amp;loc=SL4568447-111683<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (f)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 65<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121322162&amp;loc=SL121327923-165333<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Topic 848<br> -SubTopic 10<br> -Name Accounting Standards Codification<br> -Section 65<br> -Paragraph 2<br> -Publisher FASB<br> -Subparagraph (a)(3)(iii)(03)<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426661784">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Consolidated Statements of Cash Flows - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (24,095,727)<span></span>
</td>
<td class="num">$ (14,185,306)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization</a></td>
<td class="nump">93,416<span></span>
</td>
<td class="nump">103,168<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">51,782<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation expense</a></td>
<td class="nump">897,260<span></span>
</td>
<td class="nump">736,119<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentInProcess', window );">Abandonment of in-process research and development intangible asset</a></td>
<td class="nump">8,639,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxExpenseBenefit', window );">Change in deferred income taxes</a></td>
<td class="num">(443,893)<span></span>
</td>
<td class="num">(1,675,381)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses, deposits and other assets</a></td>
<td class="num">(248,997)<span></span>
</td>
<td class="nump">518,169<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities', window );">Accounts payable, accrued expenses and other liabilities</a></td>
<td class="nump">605,370<span></span>
</td>
<td class="nump">950,602<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(14,501,789)<span></span>
</td>
<td class="num">(13,552,629)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows provided by investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment', window );">Cash received from sale of property and equipment</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">4,000<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows provided by financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from the sale of common stock, net of issuance costs</a></td>
<td class="nump">31,094,302<span></span>
</td>
<td class="nump">10,827,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ProceedsFromSaleOfCommonStockWarrants', window );">Proceeds from the sale of common stock warrants</a></td>
<td class="nump">2,201,450<span></span>
</td>
<td class="nump">8,046,103<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PaymentsOfFinancingCosts', window );">Payment of offering costs</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(982,328)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">33,295,752<span></span>
</td>
<td class="nump">17,890,875<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase in cash and cash equivalents</a></td>
<td class="nump">18,797,963<span></span>
</td>
<td class="nump">4,338,246<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at beginning of year</a></td>
<td class="nump">18,515,595<span></span>
</td>
<td class="nump">14,177,349<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents at end of year</a></td>
<td class="nump">37,313,558<span></span>
</td>
<td class="nump">$ 18,515,595<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract', window );"><strong>Supplemental disclosure of non-cash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_RestrictedStockUnitsVestedAmount', window );">Vesting of restricted stock units</a></td>
<td class="nump">$ 10<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ProceedsFromSaleOfCommonStockWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of common stock, warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ProceedsFromSaleOfCommonStockWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_RestrictedStockUnitsVestedAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the amount related to restricted stock units vested.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_RestrictedStockUnitsVestedAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(1)(Note 1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI http://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123482062&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI http://asc.fasb.org/extlink&amp;oid=123367319&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI http://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=125511455&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI http://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=124509347&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI http://asc.fasb.org/extlink&amp;oid=124359900&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfFinancingCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for loan and debt issuance costs.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfFinancingCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3179-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentInProcess">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentInProcess</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426573352">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 1 - Organization and Description of Business<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NatureOfOperations', window );">Nature of Operations [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">1.</em> Organization and Description of Business</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Diffusion Pharmaceuticals Inc. ("the Company"), a Delaware corporation, is a biopharmaceutical company developing novel therapies that enhance the body&#8217;s ability to deliver oxygen to areas where it is needed most. The Company&#8217;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#8217;s most intractable and difficult-to-treat conditions. In <em style="font: inherit;"> November 2021, </em>based on the preclinical and clinical data accumulated to date and the significant unmet medical need, the Company announced that its near-term focus will be the design and execution of a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NatureOfOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -URI http://asc.fasb.org/topic&amp;trid=2134479<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NatureOfOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388429239560">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 2 - Liquidity<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_LiquidityDisclosureTextBlock', window );">Liquidity Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">2.</em> Liquidity</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has <em style="font: inherit;">not</em> generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. <em style="font: inherit;">No</em> assurance can be given that any such financing will be available when needed, or at all, or that the Company&#8217;s research and development efforts will be successful.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with <em style="font: inherit;">third</em> parties and other strategic alliances and business transactions. The Company does <em style="font: inherit;">not</em> have any commitments to obtain additional funds and <em style="font: inherit;"> may </em>be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with <em style="font: inherit;">third</em> parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it <em style="font: inherit;"> may </em>receive lower consideration upon commercialization of such products than if it had <em style="font: inherit;">not</em> entered such arrangements or if it entered into such arrangements at later stages in the product development process.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company&#8217;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#8217;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#8217;s financial condition and future operations. The Company expects that its existing cash and cash equivalents as of <em style="font: inherit;"> December 31, 2021 </em>will enable it to fund its operating expenses and capital expenditure requirements through <em style="font: inherit;">2023.</em></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_LiquidityDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the liquidity of the company.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_LiquidityDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426878472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Significant Accounting Policies [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">3.</em></b>&#160;<b>Basis of Presentation and Summary of Significant Accounting Policies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Basis of Presentation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying consolidated&#160;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash and Cash Equivalents</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company considers any highly-liquid investments, such as money market funds, with an original maturity of <em style="font: inherit;">three</em> months or less to be cash and cash equivalents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from 2 to 15 years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations. In <em style="font: inherit;"> November 2021, </em>the Company terminated the lease of its prior corporate headquarters and in connection with the termination the Company disposed of all of its related property and equipment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Intangible Asset</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021,</em> the Board of Directors made a determination to <em style="font: inherit;">no</em> longer dedicate financial resources to the Company's DFN-<em style="font: inherit;">529</em> intangible asset and any future internal development efforts were abandoned. In connection with this decision, the Company concluded that DFN-<em style="font: inherit;">529</em> was impaired in its entirety and as such, the Company recognized a non-cash impairment charge of $8.6 million during the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021.</em> The abandonment also resulted in an income tax benefit of $0.4 million due to the tax effect of the reduction in the deferred tax liability associated with the asset.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#160;</p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#8217;s behalf). Costs incurred for research and development are expensed as incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">At the end of the reporting period, the Company compares payments made to <em style="font: inherit;">third</em>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <em style="font: inherit;"> may </em>record net prepaid or accrued expenses relating to these costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Upfront payments made to <em style="font: inherit;">third</em> parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Patent Costs</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&#160;<em style="font: inherit;">not</em>&#160;that some portion or all of a deferred tax asset will&#160;<em style="font: inherit;">not</em>&#160;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&#160;<em style="font: inherit;">not</em>&#160;to be sustained.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">FASB ASC Subtopic <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> <i>Accounting for Uncertainty of Income Taxes</i>, (&#8220;ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10&#8221;</em>) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company <em style="font: inherit;"> may </em>recognize the tax benefit from an uncertain tax position only if it is more likely than <em style="font: inherit;">not</em> such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than <em style="font: inherit;">50%</em> likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> the Company&#8217;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Stock-based Compensation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the expected dividend yield and the fair value of the Company&#8217;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For certain stock option grants, the expected term was estimated using the &#8220;simplified method&#8221; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended <em style="font: inherit;"> December 31, 2020, </em>it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. 10 years) of the stock option and therefore the Company began to use the contractual life as the expected term.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <em style="font: inherit;">no</em> dividend yield because dividends are <em style="font: inherit;">not</em> expected to be paid in the near future, which is consistent with the Company&#8217;s history of <em style="font: inherit;">not</em> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Net Loss Per Common Share</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are <em style="font: inherit;">not</em> included in the calculation as the impact is anti-dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,499,469</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,100,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,240,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,401,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,493,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Recently Issued But <em style="font: inherit;">Not</em> Yet Adopted Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> Financial Instruments&#8212;<i>Credit Losses, Measurement of Credit Losses on Financial Instruments</i> (Topic <em style="font: inherit;">326</em>). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will <em style="font: inherit;">no</em> longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective for the Company as of <em style="font: inherit;"> January 1, 2022. </em>The Company is currently evaluating the impact of this ASU but&#160;does <em style="font: inherit;">not</em> expect that adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> &#8220;Income Taxes (Topic <em style="font: inherit;">740</em>): <i>Simplifying the Accounting for Income Taxes</i>.&#8221; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have <em style="font: inherit;">not</em> been issued and interim periods therein. The Company adopted this standard in <em style="font: inherit;"> January 2021 </em>and the adoption did <em style="font: inherit;">not</em> have a material impact on its related disclosures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b/></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123372394&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI http://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388429241592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses and Other Current Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock', window );">Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">4.</em></b>&#160;<b>Accrued Expenses and Other Current Liabilities</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Accrued expenses and other current liabilities consist of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom;">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">879,971</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">653,899</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">247,704</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,809</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">786,579</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,055,398</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65,935</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,364</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,980,189</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,776,470</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>

  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426891304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">5.</em></b>&#160;<b>Commitments and Contingencies</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Office Space Lease Commitment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">On <em style="font: inherit;"> November 8, 2021, </em>the Company entered into a Deed of Lease Termination Agreement with the Carlton Landlord providing for the early termination of the Carlton Lease related to the Company's prior corporate headquarters. The Carlton Lease was previously scheduled to expire on <em style="font: inherit;"> April 30, 2022. </em>In connection with the termination, the Company made a <em style="font: inherit;">one</em>-time payment to the Carlton Landlord of approximately $14,000, net of a security deposit subsequently returned in accordance with the Carlton Lease. In lieu of the fixed office and laboratory space previously available to us under the Carlton Lease, the Company has entered into short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Rent expense related to the Company's operating lease for both the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> was approximately $0.1 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development Arrangements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which <em style="font: inherit;"> may </em>require upfront payments and long-term commitments of cash.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Defined Contribution Retirement Plan</i></b>&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company has established a <em style="font: inherit;">401</em>(k)&#160;defined contribution plan that covers all employees who qualify under the terms of the plan. Eligible employees <em style="font: inherit;"> may </em>elect to contribute to the <em style="font: inherit;">401</em>(k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant&#8217;s compensation. The Company made matching contributions under the <em style="font: inherit;">401</em>(k) Plan of approximately $75,000 and $68,000 for the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:9pt;"><b><i>Legal Proceedings</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On <em style="font: inherit;"> August 7, 2014, </em>a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#8217;s legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case <em style="font: inherit;">No.</em> <em style="font: inherit;">BC553996</em>). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#8217; fees and costs. On <em style="font: inherit;"> December 30, 2014, </em>the Company filed a petition to compel arbitration and a motion to stay the action. On <em style="font: inherit;"> April 1, 2015, </em>the plaintiff filed a petition in opposition to the Company&#8217;s petition to compel arbitration and a motion to stay the action. After a related hearing on <em style="font: inherit;"> April 14, 2015, </em>the court granted the Company&#8217;s petition to compel arbitration and a motion to stay the action. On <em style="font: inherit;"> January 8, 2016, </em>the plaintiff filed an arbitration demand with the American Arbitration Association. On <em style="font: inherit;"> November 19, 2018 </em>at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds <em style="font: inherit;">not</em> to dismiss the case and an arbitration hearing was scheduled, originally for <em style="font: inherit;"> November 2020 </em>but later postponed due to the COVID-<em style="font: inherit;">19</em> pandemic and related restrictions on gatherings in the State of California. In addition, following the <em style="font: inherit;"> November 2018 </em>hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On <em style="font: inherit;"> October 22, 2021, </em>following a determination by the bankruptcy trustee <em style="font: inherit;">not</em> to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on <em style="font: inherit;"> February 23, 2022 </em>at which a trial date of <em style="font: inherit;"> May 24, 2023 </em>was set, and the parties have agreed to stipulate to mediation in advance of the trial.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">The Company believes the claims in this matter are without merit and intends to defend itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter <em style="font: inherit;"> may </em>have on the Company&#8217;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#8217;s financial position, results of operations and cash flows.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI http://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI http://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426866632">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity and Common Stock Warrants<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock', window );">Stockholders' Equity Note Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">6.</em></b>&#160;<b>Stockholders' Equity and Common Stock Warrants</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i><em style="font: inherit;">2021</em> Common Stock Offering</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> February 2021, </em>the Company completed the <em style="font: inherit;"> February 2021 </em>Offering in which it offered and sold 33,658,538 shares of its common stock in an underwritten, public offering for a purchase price to the public of $1.025 per share, inclusive of shares offered and sold pursuant to the exercise in full by the underwriter of its 30-day option to purchase additional shares. The <em style="font: inherit;"> February 2021 </em>Offering resulted in aggregate net proceeds to the Company of $31.1 million, after deducting underwriting commissions, discounts, and expenses. In addition, at the closings of the <em style="font: inherit;"> February 2021 </em>Offering, the Company issued to designees of the underwriter of the transaction warrants to purchase up to an aggregate of 1,682,927 shares of common stock to designees. The underwriter warrants have an exercise price of $1.28125 per share and a term of <span style="-sec-ix-hidden:c82208672">five</span> years from the date of issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i><em style="font: inherit;">2020</em> Common Stock Offering</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> May 2020, </em>the Company completed the <em style="font: inherit;"> May 2020 </em>Offering, a public offering of 11,428,572 shares of common stock for a purchase price of $1.05 per share for net proceeds of $10.3 million after deducting commissions, discounts, and other offering costs. In addition, at the closing of the <em style="font: inherit;"> May 2020 </em>Offering, the Company issued warrants to purchase up to 571,429 shares of common stock to designees of the placement agent for the <em style="font: inherit;"> May 2020 </em>Offering. The placement agent's warrants have an exercise price of $1.3125 per share and a term of <span style="-sec-ix-hidden:c82208679">five</span> years from the date of issuance.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Additionally, also in <em style="font: inherit;"> May 2020, </em>the Company entered into a warrant exercise agreement with an investor who held the Prior Warrant, a previously outstanding warrant to purchase up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $0.35 per share. In consideration for the exercise of the Prior Warrant for cash and an additional $0.125 per each share of common stock in the Prior Warrant being exercised, the exercising investor received new unregistered warrants to purchase up to an aggregate of 5,000,000 shares of common stock in a private placement. The warrants are exercisable immediately at an exercise price of $0.5263 per share and exercisable until <em style="font: inherit;"> November 8, 2025. </em>During the year ended <em style="font: inherit;"> December 31, 2020, </em>the Company recognized a deemed dividend of $2.0 million to reflect the consideration given as an inducement for the investor to exercise the warrants. This deemed dividend was recorded in the Company's consolidated statement of operations during the year ended <em style="font: inherit;"> December 31, 2020 </em>as an increase to the net loss applicable to common stockholders for purposes of computing net loss per share, basic and diluted.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">In connection with the <em style="font: inherit;"> May 2020 </em>Investor Warrant Exercise, the Company issued warrants to purchase up to 250,000 shares of common stock to the placement agent with an exercise price of $0.5938 per share and otherwise have identical terms to the warrants issued to the investor.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Common Stock Warrants</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">During its evaluation of equity classification for the Company's common stock warrants issued in <em style="font: inherit;">2020</em> and <em style="font: inherit;">2019,</em> the Company considered the conditions as prescribed within ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40,</em> <i>Derivatives and Hedging, Contracts in an Entity</i>&#8217;<i>s own Equity</i>. The conditions within ASC <em style="font: inherit;">815</em>-<em style="font: inherit;">40</em> are <em style="font: inherit;">not</em> subject to a probability assessment. The warrants do <em style="font: inherit;">not</em> fall under the liability criteria within ASC <em style="font: inherit;">480</em> <i>Distinguishing Liabilities from Equity </i>as they are <em style="font: inherit;">not</em> puttable and do <em style="font: inherit;">not</em> represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC <em style="font: inherit;">815,</em> but are eligible for the scope exception as they are indexed to the Company&#8217;s own stock and would be classified in permanent equity if freestanding.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> the Company had the following warrants outstanding to acquire shares of its common stock:</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#160;</p>

    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Outstanding</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Range of exercise </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price per share</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration dates</b></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">903,870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$33.30</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 2022</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the January 2018 common stock offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,181,421</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;">$12.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$15.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">January 2023</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,382,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;">$5.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$6.11875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">May and December 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the November 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">213,570</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$0.35</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">May 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the December 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">313,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$0.6981</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">571,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$1.3125</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Investor Warrant Exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$0.5938</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">November 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the February 2021 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,682,927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$1.28</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">February 2026</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,499,469</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#160;</em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 4%;"><em style="font: inherit;">&#160;</em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 16%;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">During the year ended <em style="font: inherit;"> December 31, 2021, </em>53,570 warrants expired and 4,230,000 warrants were exercised for proceeds of approximately $2.2 million. During the year ended <em style="font: inherit;"> December 31, 2020, </em>no warrants expired and 19,106,504 warrants were exercised for gross proceeds of $8.0 million.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"><b/></p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (g)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI http://asc.fasb.org/topic&amp;trid=2208762<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496171-112644<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496189-112644<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 16<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496180-112644<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=SL123496158-112644<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(e)(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426528120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Share-based Payment Arrangement [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:12pt;"><b><em style="font: inherit;">7.</em></b>&#160;<b>Stock-Based Compensation</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:9pt;"><b><i><em style="font: inherit;">2015</em> Equity Plan</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">The <em style="font: inherit;">2015</em> Equity Plan provides for increases to the number of shares reserved for issuance thereunder each <em style="font: inherit;"> January 1 </em>equal to 4.0% of the total shares of the Company&#8217;s common stock outstanding as of the immediately preceding <em style="font: inherit;"> December 31, </em>unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, 4,076,571 shares were added to the reserve as of &#160;<em style="font: inherit;"> January 1, 2022. </em>All such shares <em style="font: inherit;"> may </em>be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the <em style="font: inherit;">2015</em> Equity Plan. As of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there were 580,925 shares of common stock available for future issuance under the <em style="font: inherit;">2015</em> Equity Plan. Generally, the options have a <span style="-sec-ix-hidden:c82208765">ten</span> (<em style="font: inherit;">10</em>) year contractual term and vest in equal monthly installments over <span style="-sec-ix-hidden:c82208767">three</span> (<em style="font: inherit;">3</em>) years.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">154,041</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">164,791</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">743,219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">571,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">897,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">736,119</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following table summarizes the activity related to all stock options:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise price</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>per share</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>contractual life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">309,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,931,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,240,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">289,067</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,815,767</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(429,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,140,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.58</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The weighted average grant date fair value of stock option awards granted was $0.89 and $0.64 during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020,</em> respectively. The total fair value of options vested during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> were $0.8 million and $0.7 million, respectively. No options were exercised during any of the periods presented. At <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there was $1.1 million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&#160;1.7 years. During the year ended <em style="font: inherit;"> December 31, 2021, </em>the Company granted 385,267 performance-based stock options with an exercise price of $1.11 per share, subject to vesting based on the satisfaction of specified performance criteria. Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. The Company recorded stock-based compensation expense of approximately $0.1 million year ended <em style="font: inherit;"> December 31, 2021, </em>for service-based awards with performance conditions deemed probable of achievement and/or achieved. For performance-based awards containing performance conditions which were <em style="font: inherit;">not</em> deemed probable of achievement at <em style="font: inherit;"> December 31, 2021, </em><em style="font: inherit;">no</em> stock compensation expense was recognized and any previously recognized expense related to those awards originally deemed probable was reversed.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The grant date fair value of employee stock options is determined using the Black-Scholes Model. The following assumptions were used during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020:</em></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">5.31</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">1.3%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">0.4%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">122.6%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">125.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">113.4%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Restricted Stock Unit Awards</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of a RSU is equal to the fair market value price of the Company&#8217;s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;">The following table summarizes activity related to RSU stock-based payment awards:</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Units</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>grant date fair value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">153,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">138,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">275,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"><sup style="vertical-align:top;line-height:120%;font-size:pt">(<em style="font: inherit;">1</em>) The Company withheld 6,049 shares of common stock to cover the tax liability associated with the vesting of these units in <em style="font: inherit;">2021.</em> </sup></p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company recognized approximately $54,000 and $18,000 in expense related to these units during the years ended <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;"> December 2020, </em>respectively. At <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021,</em> there was approximately $0.1 million of unrecognized compensation cost that will be recognized over a weighted average period of 2.12 years.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI http://asc.fasb.org/topic&amp;trid=2228938<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426894104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DisclosureTextBlockAbstract', window );"><strong>Notes to Financial Statements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Tax Disclosure [Text Block]</a></td>
<td class="text">
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"><b><em style="font: inherit;">8.</em></b>&#160;<b> Income Taxes</b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. &#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,033,726</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,864,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,641,354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,571,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">647,937</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">541,384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,394</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,403,925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,709,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20,726,942</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,906,646</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,818,179</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,223,678</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(38,394</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,262,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(443,893</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The Company does <em style="font: inherit;">not</em> have unrecognized tax benefits as of <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> or <em style="font: inherit;"> December 31, 2020. </em>The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The Company had NOL carryforwards for federal and state income tax purposes at <em style="font: inherit;"> December&#160;</em><em style="font: inherit;">31,</em> <em style="font: inherit;">2021</em> and <em style="font: inherit;">2020</em> of approximately:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Combined NOL Carryforwards:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,442,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,013,388</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,436,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,007,966</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">The pre-<em style="font: inherit;">2018</em> net operating loss carryforwards begin expiring in <em style="font: inherit;">2021</em> for both federal and state income tax purposes. In <em style="font: inherit;"> November 2019, </em>the Company increased the number of shares outstanding resulting in a change of ownership, under the provisions of Internal Revenue Code Section <em style="font: inherit;">382</em> and similar state provisions. These provisions limit the Company&#8217;s ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation. The Company recorded a 100% valuation allowance of the deferred tax assets as of <em style="font: inherit;"> December 31, 2021 </em>because of the uncertainty of their realization.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Rate reconciliation:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total provision</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td></tr>
</tbody></table>

   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company&#8217;s 2018 to <em style="font: inherit;">2021</em> tax years remain open and subject to examination. All net operating losses and credits remain subject to review until utilized.</p>
  <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureTextBlockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureTextBlockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI http://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388424310536">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Accounting Policies [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Accounting, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Basis of Presentation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The accompanying consolidated&#160;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Use of Estimates</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Fair Value of Financial Instruments</i></b></p><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i/></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The carrying amounts of the Company&#8217;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration Risk, Credit Risk, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Concentration of Credit Risk</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Cash and Cash Equivalents</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company considers any highly-liquid investments, such as money market funds, with an original maturity of <em style="font: inherit;">three</em> months or less to be cash and cash equivalents.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property, Plant and Equipment, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Property and Equipment</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from 2 to 15 years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations. In <em style="font: inherit;"> November 2021, </em>the Company terminated the lease of its prior corporate headquarters and in connection with the termination the Company disposed of all of its related property and equipment.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock', window );">Goodwill and Intangible Assets, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Intangible Asset</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021,</em> the Board of Directors made a determination to <em style="font: inherit;">no</em> longer dedicate financial resources to the Company's DFN-<em style="font: inherit;">529</em> intangible asset and any future internal development efforts were abandoned. In connection with this decision, the Company concluded that DFN-<em style="font: inherit;">529</em> was impaired in its entirety and as such, the Company recognized a non-cash impairment charge of $8.6 million during the <em style="font: inherit;">third</em> quarter of <em style="font: inherit;">2021.</em> The abandonment also resulted in an income tax benefit of $0.4 million due to the tax effect of the reduction in the deferred tax liability associated with the asset.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Expense, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Research and Development</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#8217;s behalf). Costs incurred for research and development are expensed as incurred.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">At the end of the reporting period, the Company compares payments made to <em style="font: inherit;">third</em>-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company <em style="font: inherit;"> may </em>record net prepaid or accrued expenses relating to these costs.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">Upfront payments made to <em style="font: inherit;">third</em> parties who perform research and development services on the Company&#8217;s behalf are expensed as services are rendered.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_LegalCostsPolicyTextBlock', window );">Legal Costs, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Patent Costs</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Tax, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Income Taxes</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;">As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&#160;<em style="font: inherit;">not</em>&#160;that some portion or all of a deferred tax asset will&#160;<em style="font: inherit;">not</em>&#160;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&#160;<em style="font: inherit;">not</em>&#160;to be sustained.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: &quot;Times New Roman&quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">FASB ASC Subtopic <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> <i>Accounting for Uncertainty of Income Taxes</i>, (&#8220;ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10&#8221;</em>) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company <em style="font: inherit;"> may </em>recognize the tax benefit from an uncertain tax position only if it is more likely than <em style="font: inherit;">not</em> such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than <em style="font: inherit;">50%</em> likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC <em style="font: inherit;">740</em>-<em style="font: inherit;">10,</em> the Company&#8217;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Share-based Payment Arrangement [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Stock-based Compensation</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#8217;s common stock, the expected term of the Company&#8217;s stock options, the expected dividend yield and the fair value of the Company&#8217;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For certain stock option grants, the expected term was estimated using the &#8220;simplified method&#8221; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended <em style="font: inherit;"> December 31, 2020, </em>it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. 10 years) of the stock option and therefore the Company began to use the contractual life as the expected term.</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes <em style="font: inherit;">no</em> dividend yield because dividends are <em style="font: inherit;">not</em> expected to be paid in the near future, which is consistent with the Company&#8217;s history of <em style="font: inherit;">not</em> paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Earnings Per Share, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Net Loss Per Common Share</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are <em style="font: inherit;">not</em> included in the calculation as the impact is anti-dilutive.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>

    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,499,469</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,100,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,240,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,401,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,493,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>

   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">New Accounting Pronouncements, Policy [Policy Text Block]</a></td>
<td class="text"><p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"><b><i>Recently Issued But <em style="font: inherit;">Not</em> Yet Adopted Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;">In <em style="font: inherit;"> June 2016, </em>the FASB issued ASU <em style="font: inherit;">2016</em>-<em style="font: inherit;">13,</em> Financial Instruments&#8212;<i>Credit Losses, Measurement of Credit Losses on Financial Instruments</i> (Topic <em style="font: inherit;">326</em>). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#8217;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will <em style="font: inherit;">no</em> longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective for the Company as of <em style="font: inherit;"> January 1, 2022. </em>The Company is currently evaluating the impact of this ASU but&#160;does <em style="font: inherit;">not</em> expect that adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"><b><i>Recently Adopted Accounting Pronouncements</i></b></p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;">In <em style="font: inherit;"> December 2019, </em>the FASB issued ASU <em style="font: inherit;">No.</em> <em style="font: inherit;">2019</em>-<em style="font: inherit;">12,</em> &#8220;Income Taxes (Topic <em style="font: inherit;">740</em>): <i>Simplifying the Accounting for Income Taxes</i>.&#8221; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after <em style="font: inherit;"> December 15, 2020 </em>and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have <em style="font: inherit;">not</em> been issued and interim periods therein. The Company adopted this standard in <em style="font: inherit;"> January 2021 </em>and the adoption did <em style="font: inherit;">not</em> have a material impact on its related disclosures.</p>
   <p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;">&#160;</p>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123431023&amp;loc=d3e4273-108586<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123345438&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=121556970&amp;loc=d3e13816-109267<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LegalCostsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=27011672&amp;loc=d3e149975-122751<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LegalCostsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99779-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.13(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=120429125&amp;loc=d3e99893-112916<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b),(f)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426511240">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,499,469</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">9,100,112</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock options</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,240,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Unvested restricted stock units</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">275,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">153,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">10,401,142</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">11,493,316</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426591272">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses and Other Current Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock', window );">Other Current Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;">
     <tbody>
      <tr style="vertical-align: bottom;">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom;">
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
       <td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td>
       <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued payroll and payroll related expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">879,971</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">653,899</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued professional fees</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">247,704</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">31,809</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Accrued clinical studies expenses</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">786,579</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,055,398</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Other</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">65,935</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">35,364</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td>
      </tr>

      <tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);">
       <td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total</p> </td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,980,189</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td>
       <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">1,776,470</td>
       <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td>
      </tr>

     </tbody>
    </table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherCurrentLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of other current liabilities.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherCurrentLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426543144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity and Common Stock Warrants (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock', window );">Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]</a></td>
<td class="text">
    <table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &quot;Times New Roman&quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"><tbody><tr style="vertical-align: bottom; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td colspan="2" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Outstanding</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>Range of exercise </b></b></p> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b><b>price per share</b></b></p> </td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><b>Expiration dates</b></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2017 related to Series A convertible preferred stock offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">903,870</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$33.30</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 2022</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued in 2018 related to the January 2018 common stock offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,181,421</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;">$12.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$15.00</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">January 2023</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">1,382,913</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;">$5.00</td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">-</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">$6.11875</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">May and December 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the November 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">213,570</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$0.35</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">May 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the December 2019 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">313,339</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$0.6981</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">December 2024</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">571,429</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$1.3125</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">March 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the May 2020 Investor Warrant Exercise</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">250,000</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$0.5938</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">November 2025</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Common stock warrants issued related to the February 2021 Offering</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,682,927</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 4%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;">$1.28</td><td style="width: 5%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt;">&#160;</td><td style="text-align: center; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"> <p style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"><em style="font: inherit;">February 2026</em></p> </td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;"><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 53%;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">6,499,469</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#160;</em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 4%;"><em style="font: inherit;">&#160;</em></td><td style="text-align: right; font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 5%;"><em style="font: inherit;">&#160;</em></td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 1%;">&#160;</td><td style="font-family: &quot;Times New Roman&quot;, Times, serif; font-size: 9pt; width: 16%;"><em style="font: inherit;">&#160;</em></td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 50<br> -Section S99<br> -Paragraph 1<br> -URI http://asc.fasb.org/extlink&amp;oid=6784392&amp;loc=d3e188667-122775<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388424016216">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Year ended</b> </b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31,</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Research and development</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">154,041</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">164,791</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">General and administrative</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">743,219</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">571,328</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Total stock-based compensation expense</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">897,260</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">736,119</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Share-based Payment Arrangement, Option, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Options</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>exercise price</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>per share</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>remaining</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>contractual life</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>(in years)</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Aggregate</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Intrinsic</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Value</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">309,276</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">55.78</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,931,100</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.68</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expired</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(172</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">142.50</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at December 31, 2020</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">2,240,204</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">8.28</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">289,067</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,815,767</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.89</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Forfeited</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(429,748</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1.37</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Exercisable at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,140,524</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">8.58</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.09</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested and expected to vest at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">3,626,223</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">5.40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">8.52</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 9%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"><em style="font: inherit;">&#8212;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt; width: 1%;">&#160;</td><td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected term (in years)</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;">10</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">5.31</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">10</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Risk-free interest rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">1.3%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">0.4%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1.7%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Expected volatility</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">122.6%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">125.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;">113.4%</td><td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"><em style="font: inherit;">&#8212;</em></td><td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">124.8%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Dividend yield</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; text-align: right;"><em style="font: inherit;">&#160;</em></td><td style="width: 3%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: center;">0%</td><td style="width: 5%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;"><em style="font: inherit;">&#160;</em></td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock', window );">Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Number of</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Units</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>Weighted</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>average</b></b></p> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>grant date fair value</b> </b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Balance at January 1, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">153,000</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.65</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Granted</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">138,800</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">0.72</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Vested<sup style="vertical-align:top;line-height:120%;font-size:pt">(1)</sup></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(16,350</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">0.51</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Outstanding at December 31, 2021</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">275,450</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">0.70</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388510626472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_TableTextBlock', window );"><strong>Notes Tables</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax assets</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net operating loss carryforwards</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">6,033,726</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">3,864,189</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Stock option compensation</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,641,354</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">1,571,227</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan Drug credits</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">647,937</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">541,384</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Lease liability</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">38,394</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Capitalized start-up costs and other</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">12,403,925</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">10,709,631</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Valuation allowance</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(20,726,942</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(14,906,646</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">1,818,179</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td><td>&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Deferred tax liabilities</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td><td style="font-family: Times New Roman; font-size: 10pt;"><b>&#160;</b></td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Intangible assets</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2,223,678</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Right of use asset</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(38,394</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Deferred tax liabilities</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;">&#8212;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(2,262,072</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td>&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="padding-bottom: 1px;">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Net deferred tax liability</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">&#8212;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(443,893</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock', window );">Summary of Operating Loss Carryforwards [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Combined NOL Carryforwards:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,442,045</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,013,388</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">23,436,624</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">15,007,966</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">&#160;</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</a></td>
<td class="text">
    <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="vertical-align: bottom;"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Rate reconciliation:</b></p> </td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2021</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="font-family: Times New Roman; font-size: 10pt;">&#160;</td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> <p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"><b><b>December 31, 2020</b></b></p> </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;">&#160;</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Federal tax benefit at statutory rate</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(21.0</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">State tax, net of Federal benefit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(4.7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Orphan drug credit</p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(0.4</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">(2.9</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">)%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;">Change in valuation allowance</p> </td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">24.3</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; padding-bottom: 1px;">&#160;</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">18.1</td><td style="width: 1%; font-family: &quot;Times New Roman&quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">%</td></tr>
<tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"><td style="font-family: Times New Roman; font-size: 10pt;"> <p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"><b>Total provision</b></p> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(1.8</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;">&#160;</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);">&#160;</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">(10.5</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;">)%</td></tr>
</tbody></table>
   <span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_TableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_TableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388424041464">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">3 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill', window );">Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)</a></td>
<td class="nump">$ 8,600,000<span></span>
</td>
<td class="nump">$ 8,639,000<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxExpenseBenefit', window );">Income Tax Expense (Benefit), Total</a></td>
<td class="num">$ (400,000)<span></span>
</td>
<td class="num">$ (443,893)<span></span>
</td>
<td class="num">$ (1,675,381)<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentUsefulLife', window );">Property, Plant and Equipment, Useful Life (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">15 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum [Member] | Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16373-109275<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxExpenseBenefit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.7)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32672-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (h)<br> -URI http://asc.fasb.org/extlink&amp;oid=123359005&amp;loc=d3e8736-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123586238&amp;loc=d3e38679-109324<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(9))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxExpenseBenefit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentUsefulLife">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentUsefulLife</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423471320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">10,401,142<span></span>
</td>
<td class="nump">11,493,316<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember', window );">Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">6,499,469<span></span>
</td>
<td class="nump">9,100,112<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">3,626,223<span></span>
</td>
<td class="nump">2,240,204<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_UnvestedRestrictedStockUnitsMember', window );">Unvested Restricted Stock Units [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Anti-dilutive securities (in shares)</a></td>
<td class="nump">275,450<span></span>
</td>
<td class="nump">153,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_WarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_UnvestedRestrictedStockUnitsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=dffn_UnvestedRestrictedStockUnitsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423869016">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedSalariesCurrent', window );">Accrued payroll and payroll related expenses</a></td>
<td class="nump">$ 879,971<span></span>
</td>
<td class="nump">$ 653,899<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AccruedProfessionalFeesCurrent', window );">Accrued professional fees</a></td>
<td class="nump">247,704<span></span>
</td>
<td class="nump">31,809<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_AccruedClinicalStudiesExpensesCurrent', window );">Accrued clinical studies expenses</a></td>
<td class="nump">786,579<span></span>
</td>
<td class="nump">1,055,398<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherSundryLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">65,935<span></span>
</td>
<td class="nump">35,364<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OtherAccruedLiabilitiesCurrent', window );">Total</a></td>
<td class="nump">$ 1,980,189<span></span>
</td>
<td class="nump">$ 1,776,470<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_AccruedClinicalStudiesExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_AccruedClinicalStudiesExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedProfessionalFeesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedProfessionalFeesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedSalariesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedSalariesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAccruedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6911-107765<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 9<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e7018-107765<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6935-107765<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAccruedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherSundryLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI http://asc.fasb.org/extlink&amp;oid=99376301&amp;loc=d3e1243-112600<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherSundryLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423942520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 5 - Commitments and Contingencies (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Nov. 08, 2021</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating Lease, Payments</a></td>
<td class="nump">$ 14,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating Lease, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent', window );">Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">90.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent', window );">Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Defined Contribution Plan, Employer Discretionary Contribution Amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 75,000<span></span>
</td>
<td class="nump">$ 68,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=123408670&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388425017800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity and Common Stock Warrants (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">1 Months Ended</th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 31,094,302<span></span>
</td>
<td class="nump">$ 10,827,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeemedDividendFromWarrantExchange', window );">Deemed Dividend From Warrant Exchange</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,000,000.0<span></span>
</td>
<td class="nump">$ (0)<span></span>
</td>
<td class="nump">$ 1,950,378<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightsExpired', window );">Class of Warrant or Rights, Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">53,570<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod', window );">Class of Warrant or Right, Exercised During Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,230,000<span></span>
</td>
<td class="nump">19,106,504<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromWarrantExercises', window );">Proceeds from Warrant Exercises</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,200,000<span></span>
</td>
<td class="nump">$ 8,000,000.0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember', window );">Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="nump">1,682,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="nump">$ 1.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember', window );">The May 2020 Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3125<span></span>
</td>
<td class="nump">$ 1.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_WarrantsAndRightsOutstandingTerm', window );">Warrants and Rights Outstanding, Term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_PriorWarrantMember', window );">Prior Warrant [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare', window );">Class of Warrant or Right, Exchange, Additional Consideration Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_NewWarrantsIssuedMay82020Member', window );">New Warrants Issued May 8, 2020 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5263<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020PAWarrantsMember', window );">The May 2020 PA Warrants [Member] | H.C Wainwright &amp; Co., LLC [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights', window );">Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.5938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_PublicOfferingInclusiveOfUnderwriterSharesMember', window );">Public Offering, Inclusive of Underwriter Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="nump">33,658,538<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="nump">$ 1.025<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm', window );">Underwriter Option to Purchase Additional Shares, Term (Day)</a></td>
<td class="text">30 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="nump">$ 31,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_TheMay2020OfferingMember', window );">The May 2020 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Stock Issued During Period, Shares, New Issues (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11,428,572<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesIssuedPricePerShare', window );">Shares Issued, Price Per Share (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.05<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfCommonStock', window );">Proceeds from Issuance of Common Stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 10,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>the amount of additional consideration per share given in the exchange of a class of warrant or right.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightExercisedDuringPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of warrants or rights exercised during period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightExercisedDuringPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_ClassOfWarrantOrRightsExpired">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_ClassOfWarrantOrRightsExpired</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeemedDividendFromWarrantExchange">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The amount of deemed dividend from the exchange of warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeemedDividendFromWarrantExchange</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Represents the term of the underwiter's option to purchase additional shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfCommonStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the additional capital contribution to the entity.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfCommonStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromWarrantExercises">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from holders exercising their stock warrants.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=123570139&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromWarrantExercises</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (bbb)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=123874694&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_PriorWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_PriorWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_NewWarrantsIssuedMay82020Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_NewWarrantsIssuedMay82020Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020PAWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020PAWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=dffn_HCWainwrightAndCoLLCMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_PublicOfferingInclusiveOfUnderwriterSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_PublicOfferingInclusiveOfUnderwriterSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=dffn_TheMay2020OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=dffn_TheMay2020OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423318952">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Feb. 28, 2021</div></th>
<th class="th"><div>May 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">6,499,469<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember', window );">Warrants Attached to Series A Convertible Preferred Stock [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">903,870<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 33.30<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember', window );">Warrants Issued in Connection with the January 2018 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">1,181,421<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember', window );">Warrants Issued in Connection with the January 2018 Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 12.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember', window );">Warrants Issued in Connection with the January 2018 Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">1,382,913<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member] | Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember', window );">Warrants Issued in Connection with May 2019 Public Offering [Member] | Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 6.11875<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember', window );">Warrants Issued in Connection with the November 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">213,570<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.35<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember', window );">Warrants Issued in Connection with the December 2019 Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">313,339<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.6981<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember', window );">The May 2020 Offering Warrants [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">571,429<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.3125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.3125<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember', window );">The May 2020 Investor Warrant Exercise [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">250,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.5938<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember', window );">Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightOutstanding', window );">Common stock warrants, outstanding (in shares)</a></td>
<td class="nump">1,682,927<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1', window );">Range of exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.28<span></span>
</td>
<td class="nump">$ 1.28125<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21475-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020OfferingWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_TheMay2020InvestorWarrantExerciseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ClassOfWarrantOrRightAxis=dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426765848">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation (Details Textual) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jan. 01, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.64<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 800,000<span></span>
</td>
<td class="nump">$ 700,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,815,767<span></span>
</td>
<td class="nump">1,931,100<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 897,260<span></span>
</td>
<td class="nump">$ 736,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Share-based Payment Arrangement, Option [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod', window );">Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">3 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">1 year 8 months 12 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember', window );">Performance Shares [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">385,267<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.11<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation', window );">Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,049<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember', window );">Restricted Stock Units (RSUs) [Member] | Director [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">18 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 1 month 13 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Share-based Payment Arrangement, Expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 54,000<span></span>
</td>
<td class="nump">$ 18,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member', window );">Equity Incentive Plan 2015 [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis', window );">Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">580,925<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member', window );">Equity Incentive Plan 2015 [Member] | Subsequent Event [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized', window );">Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)</a></td>
<td class="nump">4,076,571<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of additional shares authorized for issuance under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI http://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=123467817&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_PerformanceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_TitleOfIndividualAxis=srt_DirectorMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_TitleOfIndividualAxis=srt_DirectorMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=dffn_EquityIncentivePlan2015Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventTypeAxis=us-gaap_SubsequentEventMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423826472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 897,260<span></span>
</td>
<td class="nump">$ 736,119<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and Development Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">154,041<span></span>
</td>
<td class="nump">164,791<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and Administrative Expense [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Stock-based compensation expense</a></td>
<td class="nump">$ 743,219<span></span>
</td>
<td class="nump">$ 571,328<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5047-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.F)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423298600">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation - Stock Option Activity (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="nump">2,240,204<span></span>
</td>
<td class="nump">309,276<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.28<span></span>
</td>
<td class="nump">$ 55.78<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="nump">1,815,767<span></span>
</td>
<td class="nump">1,931,100<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 0.89<span></span>
</td>
<td class="nump">$ 0.68<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod', window );">Expired (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(172)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice', window );">Expired, weighted-average exercise price (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 142.50<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="nump">3,626,223<span></span>
</td>
<td class="nump">2,240,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Options outstanding, aggregate intrinsic value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 289,067<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeited (in shares)</a></td>
<td class="num">(429,748)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 1.37<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Options outstanding, number (in shares)</a></td>
<td class="nump">3,626,223<span></span>
</td>
<td class="nump">2,240,204<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Options outstanding, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.40<span></span>
</td>
<td class="nump">$ 8.28<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Options outstanding, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber', window );">Exercisable (in shares)</a></td>
<td class="nump">2,140,524<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice', window );">Exercisable, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 8.58<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 1 month 2 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber', window );">Vested and expected to vest (in shares)</a></td>
<td class="nump">3,626,223<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice', window );">Vested and expected to vest, weighted-average exercise price (in dollars per share)</a></td>
<td class="nump">$ 5.40<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1', window );">Vested and expected to vest, weighted-average remaining contractual life (Year)</a></td>
<td class="text">8 years 6 months 7 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(4)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(3)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388423518200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation - Fair Value Assumptions (Details) - Share-based Payment Arrangement, Option [Member]<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">10 years<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate', window );">Dividend yield</a></td>
<td class="nump">0.00%<span></span>
</td>
<td class="nump">0.00%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Minimum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">5 years 3 months 21 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.30%<span></span>
</td>
<td class="nump">0.40%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">122.60%<span></span>
</td>
<td class="nump">113.40%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember', window );">Maximum [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term (Year)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk-free interest rate</a></td>
<td class="nump">1.70%<span></span>
</td>
<td class="nump">1.70%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">125.80%<span></span>
</td>
<td class="nump">124.80%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2)<br> -URI http://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388425214872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details) - Restricted Stock Units (RSUs) [Member]<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th></tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, shares (in shares) | shares</a></td>
<td class="nump">153,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.65<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod', window );">Granted, shares (in shares) | shares</a></td>
<td class="nump">138,800<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Granted, Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.72<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod', window );">Vested, shars (in shares) | shares</a></td>
<td class="num">(16,350)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue', window );">Vested, Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.51<span></span>
</td>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber', window );">Unvested, shares (in shares) | shares</a></td>
<td class="nump">275,450<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue', window );">Unvested, Weighted-average grant date fair value (in dollars per share) | $ / shares</a></td>
<td class="nump">$ 0.70<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(1)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(i)-(ii)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(2)(iii)(2)<br> -URI http://asc.fasb.org/extlink&amp;oid=120381028&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426595400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes (Details Textual)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2021</div></th></tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsValuationAllowancePercentage', window );">Deferred Tax Assets, Valuation Allowance, Percentage</a></td>
<td class="nump">100.00%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OpenTaxYear', window );">Open Tax Year</a></td>
<td class="text">2018<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsValuationAllowancePercentage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Deferred tax Assets' percentage related to net of valuation allowance.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsValuationAllowancePercentage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OpenTaxYear">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Tax year that remains open to examination under enacted tax laws, in YYYY format.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (e)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OpenTaxYear</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:gYearListItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388426843176">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Net operating loss carryforwards</a></td>
<td class="nump">$ 6,033,726<span></span>
</td>
<td class="nump">$ 3,864,189<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Stock option compensation</a></td>
<td class="nump">1,641,354<span></span>
</td>
<td class="nump">1,571,227<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsOrphanDrugCredits', window );">Orphan Drug credits</a></td>
<td class="nump">647,937<span></span>
</td>
<td class="nump">541,384<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsLeaseLiability', window );">Lease liability</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">38,394<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxAssetsCapitalizedCostsAndOther', window );">Capitalized start-up costs and other</a></td>
<td class="nump">12,403,925<span></span>
</td>
<td class="nump">10,709,631<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Valuation allowance</a></td>
<td class="num">(20,726,942)<span></span>
</td>
<td class="num">(14,906,646)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Deferred tax assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">1,818,179<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets', window );">Intangible assets</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,223,678)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_DeferredTaxLiabilitiesRightOfUseAsset', window );">Right of use asset</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(38,394)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Deferred tax liabilities</a></td>
<td class="nump">0<span></span>
</td>
<td class="num">(2,262,072)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilities', window );">Net deferred tax liability</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="num">$ (443,893)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsCapitalizedCostsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsCapitalizedCostsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxAssetsOrphanDrugCredits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxAssetsOrphanDrugCredits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_DeferredTaxLiabilitiesRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_DeferredTaxLiabilitiesRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120400017&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120398452&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI http://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e31931-109318<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388424344632">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Operating Loss Carryforwards (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember', window );">Domestic Tax Authority [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 23,442,045<span></span>
</td>
<td class="nump">$ 15,013,388<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember', window );">State and Local Jurisdiction [Member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_OperatingLossCarryforwards', window );">Operating loss carryforwards</a></td>
<td class="nump">$ 23,436,624<span></span>
</td>
<td class="nump">$ 15,007,966<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_DomesticCountryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxAuthorityAxis=us-gaap_StateAndLocalJurisdictionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.0.1</span><table class="report" border="0" cellspacing="2" id="idm140388429958392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Federal tax benefit at statutory rate</a></td>
<td class="num">(21.00%)<span></span>
</td>
<td class="num">(21.00%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State tax, net of Federal benefit</a></td>
<td class="num">(4.70%)<span></span>
</td>
<td class="num">(4.70%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent', window );">Orphan drug credit</a></td>
<td class="num">(0.40%)<span></span>
</td>
<td class="num">(2.90%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance</a></td>
<td class="nump">24.30%<span></span>
</td>
<td class="nump">18.10%<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl " style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="top.Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations', window );">Total provision</a></td>
<td class="num">(1.80%)<span></span>
</td>
<td class="num">(10.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dffn_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI http://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="top.Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI http://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI http://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="top.Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>dffn20211231_10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:dffn="http://www.diffusionpharma.com/20211231"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:thunderdome="http://www.RDGFilings.com"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="dffn-20211231.xsd" xlink:type="simple"/>
    <context id="d_2021-01-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-06-30">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2021-06-30</instant>
        </period>
    </context>
    <context id="i_2022-03-14">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2022-03-14</instant>
        </period>
    </context>
    <context id="i_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="i_2019-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <instant>2019-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-10-01_2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2021-10-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">dffn:UnvestedRestrictedStockUnitsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-11-08_2021-11-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2021-11-08</startDate>
            <endDate>2021-11-08</endDate>
        </period>
    </context>
    <context id="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:PublicOfferingInclusiveOfUnderwriterSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-02-01</startDate>
            <endDate>2021-02-28</endDate>
        </period>
    </context>
    <context id="i_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:PublicOfferingInclusiveOfUnderwriterSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-02-28</instant>
        </period>
    </context>
    <context id="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:TheMay2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">dffn:TheMay2020OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PriorWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="d_2020-05-01_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:PriorWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:NewWarrantsIssuedMay82020Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="d_2020-05-01_2020-05-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
        </entity>
        <period>
            <startDate>2020-05-01</startDate>
            <endDate>2020-05-31</endDate>
        </period>
    </context>
    <context id="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">dffn:HCWainwrightAndCoLLCMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020PAWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-05-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsAttachedToSeriesAConvertiblePreferredStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithMay2019PublicOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheNovember2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:WarrantsIssuedInConnectionWithTheDecember2019OfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020OfferingWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:TheMay2020InvestorWarrantExerciseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">dffn:UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2022-01-01_2022-01-01_PlanNameAxis-EquityIncentivePlan2015Member_SubsequentEventTypeAxis-SubsequentEventMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:SubsequentEventTypeAxis">us-gaap:SubsequentEventMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-01-01</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">dffn:EquityIncentivePlan2015Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:PerformanceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">srt:DirectorMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:AwardTypeAxis">us-gaap:RestrictedStockUnitsRSUMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:DomesticCountryMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001053691</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:StateAndLocalJurisdictionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Share">
        <measure>shares</measure>
    </unit>
    <unit id="NonApplicable">
        <measure>thunderdome:item</measure>
    </unit>
    <unit id="USDPerShare">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Year">
        <measure>utr:Y</measure>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Day">
        <measure>utr:D</measure>
    </unit>
    <unit id="Month">
        <measure>utr:M</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityCentralIndexKey">0001053691</dei:EntityCentralIndexKey>
    <dei:EntityRegistrantName
      contextRef="d_2021-01-01_2021-12-31"
      id="thunderdome-EntityRegistrantName">Diffusion Pharmaceuticals Inc.</dei:EntityRegistrantName>
    <dei:AmendmentFlag contextRef="d_2021-01-01_2021-12-31">false</dei:AmendmentFlag>
    <dei:CurrentFiscalYearEndDate contextRef="d_2021-01-01_2021-12-31">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalPeriodFocus contextRef="d_2021-01-01_2021-12-31">FY</dei:DocumentFiscalPeriodFocus>
    <dei:DocumentFiscalYearFocus contextRef="d_2021-01-01_2021-12-31">2021</dei:DocumentFiscalYearFocus>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2021-12-31"
      id="c82208380"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommitmentsAndContingencies
      contextRef="i_2020-12-31"
      id="c82208381"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208385"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208386"
      unitRef="USDPerShare">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208387"
      unitRef="Share">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208388"
      unitRef="Share">1000000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208389"
      unitRef="Share">101914280</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208391"
      unitRef="Share">101914280</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208390"
      unitRef="Share">64015441</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208392"
      unitRef="Share">64015441</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c82208642"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      id="c82208672">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:WarrantsAndRightsOutstandingTerm
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      id="c82208679">P5Y</us-gaap:WarrantsAndRightsOutstandingTerm>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c82208765">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c82208767">P3Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c82208780"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <dei:DocumentType contextRef="d_2021-01-01_2021-12-31">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport contextRef="d_2021-01-01_2021-12-31">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate contextRef="d_2021-01-01_2021-12-31">2021-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="d_2021-01-01_2021-12-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="d_2021-01-01_2021-12-31">000-24477</dei:EntityFileNumber>
    <dei:EntityIncorporationStateCountryCode contextRef="d_2021-01-01_2021-12-31">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="d_2021-01-01_2021-12-31">30-0645032</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="d_2021-01-01_2021-12-31">300 East Main Street, Suite 201</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="d_2021-01-01_2021-12-31">Charlottesville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="d_2021-01-01_2021-12-31">VA</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="d_2021-01-01_2021-12-31">22902</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="d_2021-01-01_2021-12-31">434</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="d_2021-01-01_2021-12-31">220-0718</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="d_2021-01-01_2021-12-31">Common Stock, par value $0.001 per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="d_2021-01-01_2021-12-31">DFFN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="d_2021-01-01_2021-12-31">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer contextRef="d_2021-01-01_2021-12-31">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers contextRef="d_2021-01-01_2021-12-31">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="d_2021-01-01_2021-12-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="d_2021-01-01_2021-12-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="d_2021-01-01_2021-12-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityEmergingGrowthCompany>
    <dei:IcfrAuditorAttestationFlag contextRef="d_2021-01-01_2021-12-31">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany contextRef="d_2021-01-01_2021-12-31">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat contextRef="i_2021-06-30" decimals="1" unitRef="USD">74300000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding contextRef="i_2022-03-14" decimals="INF" unitRef="Share">101924581</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorName contextRef="d_2021-01-01_2021-12-31">KPMG LLP</dei:AuditorName>
    <dei:AuditorLocation contextRef="d_2021-01-01_2021-12-31">McLean, Virginia</dei:AuditorLocation>
    <dei:AuditorFirmId contextRef="d_2021-01-01_2021-12-31">185</dei:AuditorFirmId>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208347"
      unitRef="USD">37313558</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208348"
      unitRef="USD">18515595</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <dffn:PrepaidExpensesDepositsAndOtherAssets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208349"
      unitRef="USD">510015</dffn:PrepaidExpensesDepositsAndOtherAssets>
    <dffn:PrepaidExpensesDepositsAndOtherAssets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208350"
      unitRef="USD">260825</dffn:PrepaidExpensesDepositsAndOtherAssets>
    <us-gaap:AssetsCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208351"
      unitRef="USD">37823573</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208352"
      unitRef="USD">18776420</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208353"
      unitRef="USD">0</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208354"
      unitRef="USD">149198</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208355"
      unitRef="USD">0</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208356"
      unitRef="USD">8639000</us-gaap:IndefiniteLivedIntangibleAssetsExcludingGoodwill>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208357"
      unitRef="USD">0</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208358"
      unitRef="USD">149162</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208359"
      unitRef="USD">15578</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208360"
      unitRef="USD">15771</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208361"
      unitRef="USD">37839151</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208362"
      unitRef="USD">27729551</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208365"
      unitRef="USD">947495</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208366"
      unitRef="USD">545844</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208367"
      unitRef="USD">1980189</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208368"
      unitRef="USD">1776470</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208369"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208370"
      unitRef="USD">113469</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208371"
      unitRef="USD">2927684</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208372"
      unitRef="USD">2435783</us-gaap:LiabilitiesCurrent>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208373"
      unitRef="USD">0</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:DeferredIncomeTaxLiabilitiesNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208374"
      unitRef="USD">443893</us-gaap:DeferredIncomeTaxLiabilitiesNet>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208375"
      unitRef="USD">0</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208376"
      unitRef="USD">35693</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:Liabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208377"
      unitRef="USD">2927684</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208378"
      unitRef="USD">2915369</us-gaap:Liabilities>
    <us-gaap:CommonStockValue
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208383"
      unitRef="USD">101914</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208384"
      unitRef="USD">64016</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208393"
      unitRef="USD">164814664</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208394"
      unitRef="USD">130659550</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208395"
      unitRef="USD">-130005111</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208396"
      unitRef="USD">-105909384</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208397"
      unitRef="USD">34911467</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208398"
      unitRef="USD">24814182</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208399"
      unitRef="USD">37839151</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208400"
      unitRef="USD">27729551</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208402"
      unitRef="USD">8499414</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208403"
      unitRef="USD">9427667</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208404"
      unitRef="USD">8639000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208405"
      unitRef="USD">0</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208406"
      unitRef="USD">7445277</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208407"
      unitRef="USD">6444109</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:DepreciationNonproduction
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208408"
      unitRef="USD">93416</us-gaap:DepreciationNonproduction>
    <us-gaap:DepreciationNonproduction
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208409"
      unitRef="USD">103168</us-gaap:DepreciationNonproduction>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208410"
      unitRef="USD">-24677107</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208411"
      unitRef="USD">-15974944</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208413"
      unitRef="USD">137487</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:InterestIncomeExpenseNonoperatingNet
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208414"
      unitRef="USD">114257</us-gaap:InterestIncomeExpenseNonoperatingNet>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208415"
      unitRef="USD">-24539620</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208416"
      unitRef="USD">-15860687</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208417"
      unitRef="USD">-443893</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208418"
      unitRef="USD">-1675381</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208419"
      unitRef="USD">-24095727</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208420"
      unitRef="USD">-14185306</us-gaap:NetIncomeLoss>
    <dffn:DeemedDividendFromWarrantExchange
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208421"
      unitRef="USD">-0</dffn:DeemedDividendFromWarrantExchange>
    <dffn:DeemedDividendFromWarrantExchange
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208422"
      unitRef="USD">1950378</dffn:DeemedDividendFromWarrantExchange>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208423"
      unitRef="USD">-24095727</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208424"
      unitRef="USD">-16135684</us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208426"
      unitRef="USDPerShare">-0.25</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208427"
      unitRef="USDPerShare">-0.30</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208428"
      unitRef="USDPerShare">97626748</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208429"
      unitRef="USDPerShare">53831973</us-gaap:EarningsPerShareDiluted>
    <us-gaap:SharesOutstanding
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208430"
      unitRef="Share">33480365</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208431"
      unitRef="USD">33481</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208432"
      unitRef="USD">111824859</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208433"
      unitRef="USD">-91724078</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c82208434"
      unitRef="USD">20134262</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208435"
      unitRef="Share">11428572</dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208436"
      unitRef="USD">11429</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208437"
      unitRef="USD">10330202</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208438"
      unitRef="USD">0</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208439"
      unitRef="USD">10341631</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208440"
      unitRef="Share">19106504</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208441"
      unitRef="USD">19106</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208442"
      unitRef="USD">7768370</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208443"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208444"
      unitRef="USD">7787476</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208446"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208447"
      unitRef="USD">736119</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208448"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208449"
      unitRef="USD">736119</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208451"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208452"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208453"
      unitRef="USD">-14185306</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208454"
      unitRef="USD">-14185306</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208455"
      unitRef="Share">64015441</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208456"
      unitRef="USD">64016</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208457"
      unitRef="USD">130659550</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208458"
      unitRef="USD">-105909384</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208459"
      unitRef="USD">24814182</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208460"
      unitRef="Share">33658538</dffn:StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208461"
      unitRef="USD">33658</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208462"
      unitRef="USD">31060644</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208463"
      unitRef="USD">0</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208464"
      unitRef="USD">31094302</dffn:StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts>
    <us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208465"
      unitRef="Share">4230000</us-gaap:StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208466"
      unitRef="USD">4230</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208467"
      unitRef="USD">2197220</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208468"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208469"
      unitRef="USD">2201450</us-gaap:StockIssuedDuringPeriodValueConversionOfConvertibleSecurities>
    <us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208470"
      unitRef="Share">10301</us-gaap:StockIssuedDuringPeriodSharesRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208471"
      unitRef="USD">10</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208472"
      unitRef="USD">-10</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208473"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208474"
      unitRef="USD">0</us-gaap:StockIssuedDuringPeriodValueRestrictedStockAwardGross>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208476"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208477"
      unitRef="USD">897260</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208478"
      unitRef="USD">0</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208479"
      unitRef="USD">897260</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208481"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208482"
      unitRef="USD">0</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208483"
      unitRef="USD">-24095727</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208484"
      unitRef="USD">-24095727</us-gaap:NetIncomeLoss>
    <us-gaap:SharesOutstanding
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208485"
      unitRef="Share">101914280</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember"
      decimals="INF"
      id="c82208486"
      unitRef="USD">101914</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-AdditionalPaidInCapitalMember"
      decimals="INF"
      id="c82208487"
      unitRef="USD">164814664</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31_StatementEquityComponentsAxis-RetainedEarningsMember"
      decimals="INF"
      id="c82208488"
      unitRef="USD">-130005111</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208489"
      unitRef="USD">34911467</us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest>
    <us-gaap:NetIncomeLoss
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208491"
      unitRef="USD">-24095727</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208492"
      unitRef="USD">-14185306</us-gaap:NetIncomeLoss>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208494"
      unitRef="USD">93416</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208495"
      unitRef="USD">103168</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208496"
      unitRef="USD">-51782</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208497"
      unitRef="USD">-0</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208498"
      unitRef="USD">897260</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208499"
      unitRef="USD">736119</us-gaap:ShareBasedCompensation>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208500"
      unitRef="USD">8639000</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:ResearchAndDevelopmentInProcess
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208501"
      unitRef="USD">0</us-gaap:ResearchAndDevelopmentInProcess>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208502"
      unitRef="USD">-443893</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:DeferredIncomeTaxExpenseBenefit
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208503"
      unitRef="USD">-1675381</us-gaap:DeferredIncomeTaxExpenseBenefit>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208505"
      unitRef="USD">248997</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208506"
      unitRef="USD">-518169</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208507"
      unitRef="USD">605370</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208508"
      unitRef="USD">950602</us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208509"
      unitRef="USD">-14501789</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208510"
      unitRef="USD">-13552629</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208512"
      unitRef="USD">4000</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208513"
      unitRef="USD">0</us-gaap:ProceedsFromSaleOfPropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208514"
      unitRef="USD">4000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208515"
      unitRef="USD">0</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208517"
      unitRef="USD">31094302</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208518"
      unitRef="USD">10827100</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <dffn:ProceedsFromSaleOfCommonStockWarrants
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208519"
      unitRef="USD">2201450</dffn:ProceedsFromSaleOfCommonStockWarrants>
    <dffn:ProceedsFromSaleOfCommonStockWarrants
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208520"
      unitRef="USD">8046103</dffn:ProceedsFromSaleOfCommonStockWarrants>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208521"
      unitRef="USD">-0</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:PaymentsOfFinancingCosts
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208522"
      unitRef="USD">982328</us-gaap:PaymentsOfFinancingCosts>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208523"
      unitRef="USD">33295752</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208524"
      unitRef="USD">17890875</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208525"
      unitRef="USD">18797963</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208526"
      unitRef="USD">4338246</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208527"
      unitRef="USD">18515595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c82208528"
      unitRef="USD">14177349</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208529"
      unitRef="USD">37313558</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208530"
      unitRef="USD">18515595</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <dffn:RestrictedStockUnitsVestedAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208532"
      unitRef="USD">10</dffn:RestrictedStockUnitsVestedAmount>
    <us-gaap:NatureOfOperations contextRef="d_2021-01-01_2021-12-31" id="c2066658">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;1.&lt;/em&gt; Organization and Description of Business&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Diffusion Pharmaceuticals Inc. ("the Company"), a Delaware corporation, is a biopharmaceutical company developing novel therapies that enhance the body&#x2019;s ability to deliver oxygen to areas where it is needed most. The Company&#x2019;s lead product candidate, TSC, is being developed to enhance the diffusion of oxygen to tissues with low oxygen levels, also known as hypoxia, a serious complication of many of medicine&#x2019;s most intractable and difficult-to-treat conditions. In &lt;em style="font: inherit;"&gt; November 2021, &lt;/em&gt;based on the preclinical and clinical data accumulated to date and the significant unmet medical need, the Company announced that its near-term focus will be the design and execution of a clinical program to support the use of intravenously administered TSC as an adjunctive treatment for hypoxic solid tumors.&lt;/p&gt;
  </us-gaap:NatureOfOperations>
    <dffn:LiquidityDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066659">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;2.&lt;/em&gt; Liquidity&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has &lt;em style="font: inherit;"&gt;not&lt;/em&gt; generated any revenues from product sales and has funded operations primarily from the proceeds of public and private offerings of equity, convertible debt and convertible preferred stock. Substantial additional financing will be required by the Company to continue to fund its research and development activities. &lt;em style="font: inherit;"&gt;No&lt;/em&gt; assurance can be given that any such financing will be available when needed, or at all, or that the Company&#x2019;s research and development efforts will be successful.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company regularly explores alternative means of financing its operations and seeks funding through various sources, including public and private securities offerings, collaborative arrangements with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties and other strategic alliances and business transactions. The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have any commitments to obtain additional funds and &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be unable to obtain sufficient funding in the future on acceptable terms, if at all. If the Company cannot obtain the necessary funding, it will need to delay, scale back or eliminate some or all of its research and development programs or enter into collaborations with &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties to commercialize potential products or technologies that it might otherwise seek to develop or commercialize independently; consider other various strategic alternatives, including a merger or sale of the Company; or cease operations. If the Company engages in collaborations, it &lt;em style="font: inherit;"&gt; may &lt;/em&gt;receive lower consideration upon commercialization of such products than if it had &lt;em style="font: inherit;"&gt;not&lt;/em&gt; entered such arrangements or if it entered into such arrangements at later stages in the product development process.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Operations of the Company are subject to certain risks and uncertainties including various internal and external factors that will affect whether and when the Company&#x2019;s product candidates become approved drugs and how significant their market share will be, some of which are outside of the Company&#x2019;s control. The length of time and cost of developing and commercializing these product candidates and/or failure of them at any stage of the drug approval process will materially affect the Company&#x2019;s financial condition and future operations. The Company expects that its existing cash and cash equivalents as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;will enable it to fund its operating expenses and capital expenditure requirements through &lt;em style="font: inherit;"&gt;2023.&lt;/em&gt;&lt;/p&gt;
  </dffn:LiquidityDisclosureTextBlock>
    <us-gaap:SignificantAccountingPoliciesTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066660">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;3.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt;Basis of Presentation and Summary of Significant Accounting Policies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The accompanying consolidated&#160;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company considers any highly-liquid investments, such as money market funds, with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash and cash equivalents.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from 2 to 15 years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations. In &lt;em style="font: inherit;"&gt; November 2021, &lt;/em&gt;the Company terminated the lease of its prior corporate headquarters and in connection with the termination the Company disposed of all of its related property and equipment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible Asset&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Board of Directors made a determination to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer dedicate financial resources to the Company's DFN-&lt;em style="font: inherit;"&gt;529&lt;/em&gt; intangible asset and any future internal development efforts were abandoned. In connection with this decision, the Company concluded that DFN-&lt;em style="font: inherit;"&gt;529&lt;/em&gt; was impaired in its entirety and as such, the Company recognized a non-cash impairment charge of $8.6 million during the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The abandonment also resulted in an income tax benefit of $0.4 million due to the tax effect of the reduction in the deferred tax liability associated with the asset.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;At the end of the reporting period, the Company compares payments made to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;record net prepaid or accrued expenses relating to these costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Upfront payments made to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;that some portion or all of a deferred tax asset will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;to be sustained.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;FASB ASC Subtopic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Accounting for Uncertainty of Income Taxes&lt;/i&gt;, (&#x201c;ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&#x201d;&lt;/em&gt;) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;recognize the tax benefit from an uncertain tax position only if it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; the Company&#x2019;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. 10 years) of the stock option and therefore the Company began to use the contractual life as the expected term.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes &lt;em style="font: inherit;"&gt;no&lt;/em&gt; dividend yield because dividends are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be paid in the near future, which is consistent with the Company&#x2019;s history of &lt;em style="font: inherit;"&gt;not&lt;/em&gt; paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculation as the impact is anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,499,469&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,100,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,240,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;275,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;153,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,401,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,493,316&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Issued But &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Yet Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; Financial Instruments&#x2014;&lt;i&gt;Credit Losses, Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective for the Company as of &lt;em style="font: inherit;"&gt; January 1, 2022. &lt;/em&gt;The Company is currently evaluating the impact of this ASU but&#160;does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect that adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12,&lt;/em&gt; &#x201c;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;.&#x201d; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2020 &lt;/em&gt;and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been issued and interim periods therein. The Company adopted this standard in &lt;em style="font: inherit;"&gt; January 2021 &lt;/em&gt;and the adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on its related disclosures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;b/&gt;&lt;/p&gt;
  </us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209484">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Basis of Presentation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The accompanying consolidated&#160;financial statements of the Company have been prepared in accordance with GAAP. Any reference in these notes to applicable guidance is meant to refer to GAAP as found in the Accounting Standards Codification and Accounting Standards Updates of the Financial Accounting Standards Board.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates contextRef="d_2021-01-01_2021-12-31" id="c82209486">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Use of Estimates&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The preparation of financial statements in conformity with GAAP requires the Company to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On an ongoing basis, the Company evaluates its estimates using historical experience and other factors, including the current economic environment. Significant items subject to such estimates are assumptions used for purposes of determining stock-based compensation and accounting for research and development activities. Management believes its estimates to be reasonable under the circumstances. Actual results could differ significantly from those estimates.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy contextRef="d_2021-01-01_2021-12-31" id="c82209487">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Fair Value of Financial Instruments&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i/&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The carrying amounts of the Company&#x2019;s financial instruments, including cash equivalents and accounts payable approximate fair value due to the short-term nature of those instruments.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:ConcentrationRiskCreditRisk contextRef="d_2021-01-01_2021-12-31" id="c82209488">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Concentration of Credit Risk&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk consist principally of cash on deposit with multiple financial institutions, the balances of which frequently exceed federally insured limits.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209489">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Cash and Cash Equivalents&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company considers any highly-liquid investments, such as money market funds, with an original maturity of &lt;em style="font: inherit;"&gt;three&lt;/em&gt; months or less to be cash and cash equivalents.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209490">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Property and Equipment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company records property and equipment at cost less accumulated depreciation and amortization. Costs of renewals and improvements that extend the useful lives of the assets are capitalized. Maintenance and repairs are expensed as incurred. Depreciation is recognized on a straight-line basis over the estimated useful lives of the assets, which generally range from 2 to 15 years. The Company amortizes leasehold improvements over the shorter of the estimated useful life of the asset or the term of the related lease. Upon retirement or disposition of assets, the costs and related accumulated depreciation and amortization are removed from the accounts with the resulting gains or losses, if any, reflected in results of operations. In &lt;em style="font: inherit;"&gt; November 2021, &lt;/em&gt;the Company terminated the lease of its prior corporate headquarters and in connection with the termination the Company disposed of all of its related property and equipment.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MinimumMember"
      id="c82208549">P2Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:PropertyPlantAndEquipmentUsefulLife
      contextRef="d_2021-01-01_2021-12-31_RangeAxis-MaximumMember"
      id="c82208551">P15Y</us-gaap:PropertyPlantAndEquipmentUsefulLife>
    <us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209491">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Intangible Asset&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Board of Directors made a determination to &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer dedicate financial resources to the Company's DFN-&lt;em style="font: inherit;"&gt;529&lt;/em&gt; intangible asset and any future internal development efforts were abandoned. In connection with this decision, the Company concluded that DFN-&lt;em style="font: inherit;"&gt;529&lt;/em&gt; was impaired in its entirety and as such, the Company recognized a non-cash impairment charge of $8.6 million during the &lt;em style="font: inherit;"&gt;third&lt;/em&gt; quarter of &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; The abandonment also resulted in an income tax benefit of $0.4 million due to the tax effect of the reduction in the deferred tax liability associated with the asset.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:45pt;"&gt;&#160;&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock>
    <us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill
      contextRef="d_2021-10-01_2021-12-31"
      decimals="-5"
      id="c82208563"
      unitRef="USD">8600000</us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="d_2021-10-01_2021-12-31"
      decimals="-5"
      id="c82208570"
      unitRef="USD">-400000</us-gaap:IncomeTaxExpenseBenefit>
    <us-gaap:ResearchAndDevelopmentExpensePolicy contextRef="d_2021-01-01_2021-12-31" id="c82209492">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Major components of research and development costs include internal research and development (such as salaries and related employee benefits, equity-based compensation, supplies and allocated facility costs) and contracted services (research and development activities performed on the Company&#x2019;s behalf). Costs incurred for research and development are expensed as incurred.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;At the end of the reporting period, the Company compares payments made to &lt;em style="font: inherit;"&gt;third&lt;/em&gt;-party service providers to the estimated progress toward completion of the research or development objectives. Such estimates are subject to change as additional information becomes available. Depending on the timing of payments to the service providers and the progress that the Company estimates has been made as a result of the services provided, the Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;record net prepaid or accrued expenses relating to these costs.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Upfront payments made to &lt;em style="font: inherit;"&gt;third&lt;/em&gt; parties who perform research and development services on the Company&#x2019;s behalf are expensed as services are rendered.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:LegalCostsPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209493">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Patent Costs&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Patent costs, including related legal costs, are expensed as incurred and are recorded within general and administrative expenses in the consolidated statements of operations.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:LegalCostsPolicyTextBlock>
    <us-gaap:IncomeTaxPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209494">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Income Taxes&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;As a corporation, the Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases and operating loss and credit carryforwards. Deferred tax assets and liabilities are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. A valuation allowance is provided when it is more likely than&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;that some portion or all of a deferred tax asset will&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;be realized. The Company recognizes the benefit of an uncertain tax position that it has taken or expects to take on its income tax return it files, if such a position is more likely than&#160;&lt;em style="font: inherit;"&gt;not&lt;/em&gt;&#160;to be sustained.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;FASB ASC Subtopic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; &lt;i&gt;Accounting for Uncertainty of Income Taxes&lt;/i&gt;, (&#x201c;ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10&#x201d;&lt;/em&gt;) defines the criterion an individual tax position must meet for any part of the benefit of the tax position to be recognized in financial statements prepared in conformity with GAAP. The Company &lt;em style="font: inherit;"&gt; may &lt;/em&gt;recognize the tax benefit from an uncertain tax position only if it is more likely than &lt;em style="font: inherit;"&gt;not&lt;/em&gt; such tax position will be sustained on examination by the taxing authorities, based solely on the technical merits of the respective tax position. The tax benefits recognized in the financial statements from such a tax position should be measured based on the largest benefit having a greater than &lt;em style="font: inherit;"&gt;50%&lt;/em&gt; likelihood of being realized upon ultimate settlement with the tax authority. In accordance with the disclosure requirements of ASC &lt;em style="font: inherit;"&gt;740&lt;/em&gt;-&lt;em style="font: inherit;"&gt;10,&lt;/em&gt; the Company&#x2019;s policy on income statement classification of interest and penalties related to income tax obligations is to include such items as part of total interest expense and other expense, respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy contextRef="d_2021-01-01_2021-12-31" id="c82209495">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Stock-based Compensation&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company measures stock-based awards at grant-date fair value and records compensation expense on a straight-line basis over the vesting period of the award. The Company uses the Black-Scholes Model to value its stock option awards. Estimating the fair value of stock option awards requires management to apply judgment and make estimates, including the volatility of the Company&#x2019;s common stock, the expected term of the Company&#x2019;s stock options, the expected dividend yield and the fair value of the Company&#x2019;s common stock on the measurement date. As a result, if factors change and management uses different assumptions, stock-based compensation expense could be materially different for future awards.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For certain stock option grants, the expected term was estimated using the &#x201c;simplified method&#x201d; for employee options as the Company has limited historical information to develop reasonable expectations about future exercise patterns and post vesting employment termination behavior for its stock option grants. The simplified method is based on the average of the vesting tranches and the contractual life of each grant. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;it became apparent that the expected term of the Company's stock options was commensurate with the contractual life (i.e. 10 years) of the stock option and therefore the Company began to use the contractual life as the expected term.&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;For stock price volatility, the Company uses a combination of its own historical stock price and comparable public companies as a basis for its expected volatility to calculate the fair value of option grants. The Company assumes &lt;em style="font: inherit;"&gt;no&lt;/em&gt; dividend yield because dividends are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expected to be paid in the near future, which is consistent with the Company&#x2019;s history of &lt;em style="font: inherit;"&gt;not&lt;/em&gt; paying dividends. The risk-free interest rate is based on U.S. Treasury notes with a term approximating the expected term of the option. The Company accounts for forfeitures in the periods they occur.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c82208586">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209496">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Net Loss Per Common Share&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Basic net loss per share is computed by dividing net loss applicable to common stockholders by the weighted average number of shares of common stock outstanding during each period. Diluted net loss per share includes the effect, if any, from the potential exercise or conversion of securities, such as convertible debt, convertible preferred stock, common stock warrants, stock options and unvested restricted stock that would result in the issuance of incremental shares of common stock. In computing the basic and diluted net loss per share applicable to common stockholders, the weighted average number of shares remains the same for both calculations due to the fact that when a net loss exists, dilutive shares are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; included in the calculation as the impact is anti-dilutive.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following potentially dilutive securities outstanding have been excluded from the computation of diluted weighted average shares outstanding, as they would be anti-dilutive:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,499,469&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,100,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,240,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;275,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;153,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,401,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,493,316&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066661">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,499,469&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;9,100,112&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock options&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,240,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Unvested restricted stock units&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;275,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;153,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;10,401,142&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;11,493,316&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c82208616"
      unitRef="Share">6499469</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-WarrantMember"
      decimals="INF"
      id="c82208617"
      unitRef="Share">9100112</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c82208618"
      unitRef="Share">3626223</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-EmployeeStockOptionMember"
      decimals="INF"
      id="c82208619"
      unitRef="Share">2240204</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      id="c82208620"
      unitRef="Share">275450</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis-UnvestedRestrictedStockUnitsMember"
      decimals="INF"
      id="c82208621"
      unitRef="Share">153000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208622"
      unitRef="Share">10401142</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208623"
      unitRef="Share">11493316</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock contextRef="d_2021-01-01_2021-12-31" id="c82209497">&lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Issued But &lt;em style="font: inherit;"&gt;Not&lt;/em&gt; Yet Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;In &lt;em style="font: inherit;"&gt; June 2016, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;2016&lt;/em&gt;-&lt;em style="font: inherit;"&gt;13,&lt;/em&gt; Financial Instruments&#x2014;&lt;i&gt;Credit Losses, Measurement of Credit Losses on Financial Instruments&lt;/i&gt; (Topic &lt;em style="font: inherit;"&gt;326&lt;/em&gt;). The standard amends the impairment model by requiring entities to use a forward-looking approach based on expected losses to estimate credit losses for most financial assets and certain other instruments that aren&#x2019;t measured at fair value through net income. For available-for-sale debt securities, entities will be required to recognize an allowance for credit losses rather than a reduction in carrying value of the asset. Entities will &lt;em style="font: inherit;"&gt;no&lt;/em&gt; longer be permitted to consider the length of time that fair value has been less than amortized cost when evaluating when credit losses should be recognized. This new guidance is effective for the Company as of &lt;em style="font: inherit;"&gt; January 1, 2022. &lt;/em&gt;The Company is currently evaluating the impact of this ASU but&#160;does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; expect that adoption of this standard will have a material impact on its consolidated financial statements and related disclosures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Recently Adopted Accounting Pronouncements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; December 2019, &lt;/em&gt;the FASB issued ASU &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;2019&lt;/em&gt;-&lt;em style="font: inherit;"&gt;12,&lt;/em&gt; &#x201c;Income Taxes (Topic &lt;em style="font: inherit;"&gt;740&lt;/em&gt;): &lt;i&gt;Simplifying the Accounting for Income Taxes&lt;/i&gt;.&#x201d; This guidance applies to all entities and aims to reduce the complexity of tax accounting standards while enhancing reporting disclosures. This guidance is effective for fiscal years beginning after &lt;em style="font: inherit;"&gt; December 15, 2020 &lt;/em&gt;and interim periods therein. Early adoption is permitted for any annual periods for which financial statements have &lt;em style="font: inherit;"&gt;not&lt;/em&gt; been issued and interim periods therein. The Company adopted this standard in &lt;em style="font: inherit;"&gt; January 2021 &lt;/em&gt;and the adoption did &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have a material impact on its related disclosures.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   </us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066662">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;4.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt;Accrued Expenses and Other Current Liabilities&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;Accrued expenses and other current liabilities consist of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;879,971&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;653,899&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional fees&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;247,704&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,809&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical studies expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;786,579&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,055,398&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;65,935&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,364&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,980,189&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,776,470&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;

  </us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:OtherCurrentLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066663">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;
     &lt;tbody&gt;
      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom;"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued payroll and payroll related expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;879,971&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;653,899&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued professional fees&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;247,704&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;31,809&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Accrued clinical studies expenses&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;786,579&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,055,398&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Other&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;65,935&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;35,364&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

      &lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;
       &lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total&lt;/p&gt; &lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,980,189&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;
       &lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;1,776,470&lt;/td&gt;
       &lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;
      &lt;/tr&gt;

     &lt;/tbody&gt;
    &lt;/table&gt;
   </us-gaap:OtherCurrentLiabilitiesTableTextBlock>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208625"
      unitRef="USD">879971</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedSalariesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208626"
      unitRef="USD">653899</us-gaap:AccruedSalariesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208627"
      unitRef="USD">247704</us-gaap:AccruedProfessionalFeesCurrent>
    <us-gaap:AccruedProfessionalFeesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208628"
      unitRef="USD">31809</us-gaap:AccruedProfessionalFeesCurrent>
    <dffn:AccruedClinicalStudiesExpensesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208629"
      unitRef="USD">786579</dffn:AccruedClinicalStudiesExpensesCurrent>
    <dffn:AccruedClinicalStudiesExpensesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208630"
      unitRef="USD">1055398</dffn:AccruedClinicalStudiesExpensesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208631"
      unitRef="USD">65935</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherSundryLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208632"
      unitRef="USD">35364</us-gaap:OtherSundryLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208633"
      unitRef="USD">1980189</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208634"
      unitRef="USD">1776470</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066664">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;5.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt;Commitments and Contingencies&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Office Space Lease Commitment&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;On &lt;em style="font: inherit;"&gt; November 8, 2021, &lt;/em&gt;the Company entered into a Deed of Lease Termination Agreement with the Carlton Landlord providing for the early termination of the Carlton Lease related to the Company's prior corporate headquarters. The Carlton Lease was previously scheduled to expire on &lt;em style="font: inherit;"&gt; April 30, 2022. &lt;/em&gt;In connection with the termination, the Company made a &lt;em style="font: inherit;"&gt;one&lt;/em&gt;-time payment to the Carlton Landlord of approximately $14,000, net of a security deposit subsequently returned in accordance with the Carlton Lease. In lieu of the fixed office and laboratory space previously available to us under the Carlton Lease, the Company has entered into short term agreements to utilize membership-based co-working space in both Charlottesville, Virginia and Philadelphia, Pennsylvania.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Rent expense related to the Company's operating lease for both the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; was approximately $0.1 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Research and Development Arrangements&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In the course of normal business operations, the Company enters into agreements with universities and contract research organizations, or CROs, to assist in the performance of research and development activities and contract manufacturers to assist with chemistry, manufacturing, and controls related expenses. Expenditures to CROs represent a significant cost in clinical development for the Company. The Company could also enter into additional collaborative research, contract research, manufacturing, and supplier agreements in the future, which &lt;em style="font: inherit;"&gt; may &lt;/em&gt;require upfront payments and long-term commitments of cash.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Defined Contribution Retirement Plan&lt;/i&gt;&lt;/b&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company has established a &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k)&#160;defined contribution plan that covers all employees who qualify under the terms of the plan. Eligible employees &lt;em style="font: inherit;"&gt; may &lt;/em&gt;elect to contribute to the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan up to 90% of their compensation, limited by the IRS-imposed maximum. The Company provides a safe harbor match with a maximum amount of 4% of the participant&#x2019;s compensation. The Company made matching contributions under the &lt;em style="font: inherit;"&gt;401&lt;/em&gt;(k) Plan of approximately $75,000 and $68,000 for the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;i&gt;Legal Proceedings&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;On &lt;em style="font: inherit;"&gt; August 7, 2014, &lt;/em&gt;a complaint was filed in the Superior Court of Los Angeles County, California by Paul Feller, the former Chief Executive Officer of the Company&#x2019;s legal predecessor under the caption Paul Feller v. RestorGenex Corporation, Pro Sports &amp;amp; Entertainment, Inc., ProElite, Inc. and Stratus Media Group, GmbH (Case &lt;em style="font: inherit;"&gt;No.&lt;/em&gt; &lt;em style="font: inherit;"&gt;BC553996&lt;/em&gt;). The complaint asserts various causes of action, including, among other things, promissory fraud, negligent misrepresentation, breach of contract, breach of employment agreement, breach of the covenant of good faith and fair dealing, violations of the California Labor Code and common counts. The plaintiff is seeking, among other things, compensatory damages in an undetermined amount, punitive damages, accrued interest and an award of attorneys&#x2019; fees and costs. On &lt;em style="font: inherit;"&gt; December 30, 2014, &lt;/em&gt;the Company filed a petition to compel arbitration and a motion to stay the action. On &lt;em style="font: inherit;"&gt; April 1, 2015, &lt;/em&gt;the plaintiff filed a petition in opposition to the Company&#x2019;s petition to compel arbitration and a motion to stay the action. After a related hearing on &lt;em style="font: inherit;"&gt; April 14, 2015, &lt;/em&gt;the court granted the Company&#x2019;s petition to compel arbitration and a motion to stay the action. On &lt;em style="font: inherit;"&gt; January 8, 2016, &lt;/em&gt;the plaintiff filed an arbitration demand with the American Arbitration Association. On &lt;em style="font: inherit;"&gt; November 19, 2018 &lt;/em&gt;at an Order to Show Cause Re Dismissal Hearing, the court found sufficient grounds &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to dismiss the case and an arbitration hearing was scheduled, originally for &lt;em style="font: inherit;"&gt; November 2020 &lt;/em&gt;but later postponed due to the COVID-&lt;em style="font: inherit;"&gt;19&lt;/em&gt; pandemic and related restrictions on gatherings in the State of California. In addition, following the &lt;em style="font: inherit;"&gt; November 2018 &lt;/em&gt;hearing, an automatic stay was placed on the arbitration in connection with the plaintiff filing for personal bankruptcy protection. On &lt;em style="font: inherit;"&gt; October 22, 2021, &lt;/em&gt;following a determination by the bankruptcy trustee &lt;em style="font: inherit;"&gt;not&lt;/em&gt; to pursue the claims and release them back to the plaintiff, the parties entered into a stipulation to abandon arbitration and return the matter to state court. A case management conference was held on &lt;em style="font: inherit;"&gt; February 23, 2022 &lt;/em&gt;at which a trial date of &lt;em style="font: inherit;"&gt; May 24, 2023 &lt;/em&gt;was set, and the parties have agreed to stipulate to mediation in advance of the trial.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;The Company believes the claims in this matter are without merit and intends to defend itself vigorously. However, at this stage, the Company is unable to predict the outcome and possible loss or range of loss, if any, associated with its resolution or any potential effect the matter &lt;em style="font: inherit;"&gt; may &lt;/em&gt;have on the Company&#x2019;s financial position. Depending on the outcome or resolution of this matter, it could have a material effect on the Company&#x2019;s financial position, results of operations and cash flows.&lt;/p&gt;
  </us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="d_2021-11-08_2021-11-08"
      decimals="INF"
      id="c82208637"
      unitRef="USD">14000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c82208641"
      unitRef="USD">100000</us-gaap:OperatingLeaseExpense>
    <us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent
      contextRef="d_2021-01-01_2021-12-31"
      decimals="1"
      id="c82208645"
      unitRef="Pure">0.90</us-gaap:DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent>
    <us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent
      contextRef="d_2021-01-01_2021-12-31"
      decimals="2"
      id="c82208646"
      unitRef="Pure">0.04</us-gaap:DefinedContributionPlanEmployerMatchingContributionPercent>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208648"
      unitRef="USD">75000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208649"
      unitRef="USD">68000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066665">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;6.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt;Stockholders' Equity and Common Stock Warrants&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2021&lt;/em&gt; Common Stock Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; February 2021, &lt;/em&gt;the Company completed the &lt;em style="font: inherit;"&gt; February 2021 &lt;/em&gt;Offering in which it offered and sold 33,658,538 shares of its common stock in an underwritten, public offering for a purchase price to the public of $1.025 per share, inclusive of shares offered and sold pursuant to the exercise in full by the underwriter of its 30-day option to purchase additional shares. The &lt;em style="font: inherit;"&gt; February 2021 &lt;/em&gt;Offering resulted in aggregate net proceeds to the Company of $31.1 million, after deducting underwriting commissions, discounts, and expenses. In addition, at the closings of the &lt;em style="font: inherit;"&gt; February 2021 &lt;/em&gt;Offering, the Company issued to designees of the underwriter of the transaction warrants to purchase up to an aggregate of 1,682,927 shares of common stock to designees. The underwriter warrants have an exercise price of $1.28125 per share and a term of &lt;span style="-sec-ix-hidden:c82208672"&gt;five&lt;/span&gt; years from the date of issuance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2020&lt;/em&gt; Common Stock Offering&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;In &lt;em style="font: inherit;"&gt; May 2020, &lt;/em&gt;the Company completed the &lt;em style="font: inherit;"&gt; May 2020 &lt;/em&gt;Offering, a public offering of 11,428,572 shares of common stock for a purchase price of $1.05 per share for net proceeds of $10.3 million after deducting commissions, discounts, and other offering costs. In addition, at the closing of the &lt;em style="font: inherit;"&gt; May 2020 &lt;/em&gt;Offering, the Company issued warrants to purchase up to 571,429 shares of common stock to designees of the placement agent for the &lt;em style="font: inherit;"&gt; May 2020 &lt;/em&gt;Offering. The placement agent's warrants have an exercise price of $1.3125 per share and a term of &lt;span style="-sec-ix-hidden:c82208679"&gt;five&lt;/span&gt; years from the date of issuance.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;Additionally, also in &lt;em style="font: inherit;"&gt; May 2020, &lt;/em&gt;the Company entered into a warrant exercise agreement with an investor who held the Prior Warrant, a previously outstanding warrant to purchase up to an aggregate of 5,000,000 shares of our common stock at an exercise price of $0.35 per share. In consideration for the exercise of the Prior Warrant for cash and an additional $0.125 per each share of common stock in the Prior Warrant being exercised, the exercising investor received new unregistered warrants to purchase up to an aggregate of 5,000,000 shares of common stock in a private placement. The warrants are exercisable immediately at an exercise price of $0.5263 per share and exercisable until &lt;em style="font: inherit;"&gt; November 8, 2025. &lt;/em&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;the Company recognized a deemed dividend of $2.0 million to reflect the consideration given as an inducement for the investor to exercise the warrants. This deemed dividend was recorded in the Company's consolidated statement of operations during the year ended &lt;em style="font: inherit;"&gt; December 31, 2020 &lt;/em&gt;as an increase to the net loss applicable to common stockholders for purposes of computing net loss per share, basic and diluted.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:36pt;"&gt;In connection with the &lt;em style="font: inherit;"&gt; May 2020 &lt;/em&gt;Investor Warrant Exercise, the Company issued warrants to purchase up to 250,000 shares of common stock to the placement agent with an exercise price of $0.5938 per share and otherwise have identical terms to the warrants issued to the investor.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Common Stock Warrants&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;During its evaluation of equity classification for the Company's common stock warrants issued in &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2019,&lt;/em&gt; the Company considered the conditions as prescribed within ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40,&lt;/em&gt; &lt;i&gt;Derivatives and Hedging, Contracts in an Entity&lt;/i&gt;&#x2019;&lt;i&gt;s own Equity&lt;/i&gt;. The conditions within ASC &lt;em style="font: inherit;"&gt;815&lt;/em&gt;-&lt;em style="font: inherit;"&gt;40&lt;/em&gt; are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; subject to a probability assessment. The warrants do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; fall under the liability criteria within ASC &lt;em style="font: inherit;"&gt;480&lt;/em&gt; &lt;i&gt;Distinguishing Liabilities from Equity &lt;/i&gt;as they are &lt;em style="font: inherit;"&gt;not&lt;/em&gt; puttable and do &lt;em style="font: inherit;"&gt;not&lt;/em&gt; represent an instrument that has a redeemable underlying security. The warrants do meet the definition of a derivative instrument under ASC &lt;em style="font: inherit;"&gt;815,&lt;/em&gt; but are eligible for the scope exception as they are indexed to the Company&#x2019;s own stock and would be classified in permanent equity if freestanding.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; the Company had the following warrants outstanding to acquire shares of its common stock:&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;&#160;&lt;/p&gt;

    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Range of exercise &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;price per share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiration dates&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2017 related to Series A convertible preferred stock offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;903,870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$33.30&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;March 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2018 related to the January 2018 common stock offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,181,421&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;$12.00&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$15.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;January 2023&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2019 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,382,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;$5.00&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$6.11875&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;May and December 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the November 2019 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;213,570&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$0.35&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;May 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the December 2019 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;313,339&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$0.6981&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;571,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$1.3125&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;March 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Investor Warrant Exercise&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$0.5938&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;November 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the February 2021 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,682,927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$1.28&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;February 2026&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,499,469&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 4%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 16%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;53,570 warrants expired and 4,230,000 warrants were exercised for proceeds of approximately $2.2 million. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2020, &lt;/em&gt;no warrants expired and 19,106,504 warrants were exercised for gross proceeds of $8.0 million.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt 0pt 0pt 8pt;text-indent:9pt;"&gt;&lt;b/&gt;&lt;/p&gt;
  </us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember"
      decimals="INF"
      id="c82208666"
      unitRef="Share">33658538</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember"
      decimals="INF"
      id="c82208667"
      unitRef="USDPerShare">1.025</us-gaap:SharesIssuedPricePerShare>
    <dffn:UnderwriterOptionToPurchaseAdditionalSharesTerm
      contextRef="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember"
      id="c82208668">P30D</dffn:UnderwriterOptionToPurchaseAdditionalSharesTerm>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2021-02-01_2021-02-28_SubsidiarySaleOfStockAxis-PublicOfferingInclusiveOfUnderwriterSharesMember"
      decimals="-5"
      id="c82208669"
      unitRef="USD">31100000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      decimals="INF"
      id="c82208670"
      unitRef="Share">1682927</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-02-28_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      decimals="INF"
      id="c82208671"
      unitRef="USDPerShare">1.28125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember"
      decimals="INF"
      id="c82208674"
      unitRef="Share">11428572</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharesIssuedPricePerShare
      contextRef="i_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember"
      decimals="INF"
      id="c82208675"
      unitRef="USDPerShare">1.05</us-gaap:SharesIssuedPricePerShare>
    <us-gaap:ProceedsFromIssuanceOfCommonStock
      contextRef="d_2020-05-01_2020-05-31_SubsidiarySaleOfStockAxis-TheMay2020OfferingMember"
      decimals="-5"
      id="c82208676"
      unitRef="USD">10300000</us-gaap:ProceedsFromIssuanceOfCommonStock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      decimals="INF"
      id="c82208677"
      unitRef="Share">571429</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      decimals="INF"
      id="c82208678"
      unitRef="USDPerShare">1.3125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember"
      decimals="INF"
      id="c82208680"
      unitRef="Share">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember"
      decimals="INF"
      id="c82208681"
      unitRef="USDPerShare">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dffn:ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare
      contextRef="d_2020-05-01_2020-05-31_ClassOfWarrantOrRightAxis-PriorWarrantMember"
      decimals="INF"
      id="c82208682"
      unitRef="USDPerShare">0.125</dffn:ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member"
      decimals="INF"
      id="c82208683"
      unitRef="Share">5000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-NewWarrantsIssuedMay82020Member"
      decimals="INF"
      id="c82208684"
      unitRef="USDPerShare">0.5263</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <dffn:DeemedDividendFromWarrantExchange
      contextRef="d_2020-05-01_2020-05-31"
      decimals="-6"
      id="c82208685"
      unitRef="USD">2000000.0</dffn:DeemedDividendFromWarrantExchange>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="c82208687"
      unitRef="Share">250000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2020-05-31_ClassOfWarrantOrRightAxis-TheMay2020PAWarrantsMember_CounterpartyNameAxis-HCWainwrightAndCoLLCMember"
      decimals="INF"
      id="c82208688"
      unitRef="USDPerShare">0.5938</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066666">
    &lt;table cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 9pt; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; text-indent: 0px; margin-left: 0pt; margin-right: 0pt;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Outstanding&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;Range of exercise &lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;&lt;b&gt;price per share&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;b&gt;Expiration dates&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2017 related to Series A convertible preferred stock offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;903,870&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$33.30&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;March 2022&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued in 2018 related to the January 2018 common stock offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,181,421&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;$12.00&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$15.00&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;January 2023&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2019 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;1,382,913&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: right;"&gt;$5.00&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;-&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;$6.11875&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;May and December 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the November 2019 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;213,570&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$0.35&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;May 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the December 2019 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;313,339&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$0.6981&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;December 2024&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;571,429&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$1.3125&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;March 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the May 2020 Investor Warrant Exercise&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;250,000&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$0.5938&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;November 2025&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Common stock warrants issued related to the February 2021 Offering&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,682,927&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 4%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; text-align: center;"&gt;$1.28&lt;/td&gt;&lt;td style="width: 5%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; width: 16%;"&gt; &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; font-variant: normal; text-align: center; margin: 0pt;"&gt;&lt;em style="font: inherit;"&gt;February 2026&lt;/em&gt;&lt;/p&gt; &lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255); font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 53%;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;6,499,469&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 4%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 5%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: &amp;quot;Times New Roman&amp;quot;, Times, serif; font-size: 9pt; width: 16%;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c82208710"
      unitRef="Share">903870</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsAttachedToSeriesAConvertiblePreferredStockMember"
      decimals="INF"
      id="c82208712"
      unitRef="USDPerShare">33.30</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember"
      decimals="INF"
      id="c82208715"
      unitRef="Share">1181421</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c82208716"
      unitRef="USDPerShare">12.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c82208718"
      unitRef="USDPerShare">15.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember"
      decimals="INF"
      id="c82208720"
      unitRef="Share">1382913</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MinimumMember"
      decimals="INF"
      id="c82208721"
      unitRef="USDPerShare">5.00</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithMay2019PublicOfferingMember_RangeAxis-MaximumMember"
      decimals="INF"
      id="c82208723"
      unitRef="USDPerShare">6.11875</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember"
      decimals="INF"
      id="c82208725"
      unitRef="Share">213570</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheNovember2019OfferingMember"
      decimals="INF"
      id="c82208727"
      unitRef="USDPerShare">0.35</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember"
      decimals="INF"
      id="c82208730"
      unitRef="Share">313339</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-WarrantsIssuedInConnectionWithTheDecember2019OfferingMember"
      decimals="INF"
      id="c82208732"
      unitRef="USDPerShare">0.6981</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      decimals="INF"
      id="c82208735"
      unitRef="Share">571429</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020OfferingWarrantsMember"
      decimals="INF"
      id="c82208737"
      unitRef="USDPerShare">1.3125</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember"
      decimals="INF"
      id="c82208740"
      unitRef="Share">250000</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-TheMay2020InvestorWarrantExerciseMember"
      decimals="INF"
      id="c82208742"
      unitRef="USDPerShare">0.5938</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      decimals="INF"
      id="c82208745"
      unitRef="Share">1682927</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="i_2021-12-31_ClassOfWarrantOrRightAxis-UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember"
      decimals="INF"
      id="c82208747"
      unitRef="USDPerShare">1.28</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208750"
      unitRef="Share">6499469</us-gaap:ClassOfWarrantOrRightOutstanding>
    <dffn:ClassOfWarrantOrRightsExpired
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208703"
      unitRef="Share">53570</dffn:ClassOfWarrantOrRightsExpired>
    <dffn:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208704"
      unitRef="Share">4230000</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c82208705"
      unitRef="USD">2200000</us-gaap:ProceedsFromWarrantExercises>
    <dffn:ClassOfWarrantOrRightsExpired
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-3"
      id="c82208706"
      unitRef="Share">0</dffn:ClassOfWarrantOrRightsExpired>
    <dffn:ClassOfWarrantOrRightExercisedDuringPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208707"
      unitRef="Share">19106504</dffn:ClassOfWarrantOrRightExercisedDuringPeriod>
    <us-gaap:ProceedsFromWarrantExercises
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-6"
      id="c82208708"
      unitRef="USD">8000000.0</us-gaap:ProceedsFromWarrantExercises>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066667">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:12pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;7.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt;Stock-Based Compensation&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt 0pt 0pt 36pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;i&gt;&lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Equity Plan&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;The &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Equity Plan provides for increases to the number of shares reserved for issuance thereunder each &lt;em style="font: inherit;"&gt; January 1 &lt;/em&gt;equal to 4.0% of the total shares of the Company&#x2019;s common stock outstanding as of the immediately preceding &lt;em style="font: inherit;"&gt; December 31, &lt;/em&gt;unless a lesser amount is stipulated by the Compensation Committee of the Company's board of directors. Accordingly, 4,076,571 shares were added to the reserve as of &#160;&lt;em style="font: inherit;"&gt; January 1, 2022. &lt;/em&gt;All such shares &lt;em style="font: inherit;"&gt; may &lt;/em&gt;be issued in connection with the grant of stock-based awards, including stock options, restricted stock, restricted stock units, stock appreciation rights and other types of awards as deemed appropriate, in each case, in accordance with the terms of the &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Equity Plan. As of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there were 580,925 shares of common stock available for future issuance under the &lt;em style="font: inherit;"&gt;2015&lt;/em&gt; Equity Plan. Generally, the options have a &lt;span style="-sec-ix-hidden:c82208765"&gt;ten&lt;/span&gt; (&lt;em style="font: inherit;"&gt;10&lt;/em&gt;) year contractual term and vest in equal monthly installments over &lt;span style="-sec-ix-hidden:c82208767"&gt;three&lt;/span&gt; (&lt;em style="font: inherit;"&gt;3&lt;/em&gt;) years.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company recorded stock-based compensation expense in the following expense categories of its consolidated statements of operations for the periods indicated:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;154,041&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;164,791&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;743,219&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;571,328&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;897,260&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;736,119&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The following table summarizes the activity related to all stock options:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;per share&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;contractual life&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(in years)&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;309,276&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;55.78&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,931,100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.68&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(172&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;142.50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,240,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;289,067&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,815,767&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.89&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(429,748&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1.37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8.52&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,140,524&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8.58&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8.52&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The weighted average grant date fair value of stock option awards granted was $0.89 and $0.64 during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020,&lt;/em&gt; respectively. The total fair value of options vested during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; were $0.8 million and $0.7 million, respectively. No options were exercised during any of the periods presented. At &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there was $1.1 million of unrecognized compensation cost related to unvested options that will be recognized as expense over a weighted-average period of&#160;1.7 years. During the year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;the Company granted 385,267 performance-based stock options with an exercise price of $1.11 per share, subject to vesting based on the satisfaction of specified performance criteria. Compensation expense for the performance-based awards is recorded over the estimated service period for each milestone when the performance conditions are deemed probable of achievement. The Company recorded stock-based compensation expense of approximately $0.1 million year ended &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;for service-based awards with performance conditions deemed probable of achievement and/or achieved. For performance-based awards containing performance conditions which were &lt;em style="font: inherit;"&gt;not&lt;/em&gt; deemed probable of achievement at &lt;em style="font: inherit;"&gt; December 31, 2021, &lt;/em&gt;&lt;em style="font: inherit;"&gt;no&lt;/em&gt; stock compensation expense was recognized and any previously recognized expense related to those awards originally deemed probable was reversed.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The grant date fair value of employee stock options is determined using the Black-Scholes Model. The following assumptions were used during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020:&lt;/em&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;10&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;5.31&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;1.3%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.7%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;0.4%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.7%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;122.6%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;125.8%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;113.4%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;124.8%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&lt;b&gt;&lt;i&gt;Restricted Stock Unit Awards&lt;/i&gt;&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;The Company issues restricted stock ("RSU") to newly elected, non-executive members of the board of directors that vest in six, tri-monthly installments beginning 18 months after the respective grant date. The fair value of a RSU is equal to the fair market value price of the Company&#x2019;s common stock on the date of grant. RSU expense is recorded on a straight-line basis over the service period.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify;"&gt;The following table summarizes activity related to RSU stock-based payment awards:&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-align: justify; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Units&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;grant date fair value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;153,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.65&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;138,800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.72&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,350&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;275,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;"&gt;&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(&lt;em style="font: inherit;"&gt;1&lt;/em&gt;) The Company withheld 6,049 shares of common stock to cover the tax liability associated with the vesting of these units in &lt;em style="font: inherit;"&gt;2021.&lt;/em&gt; &lt;/sup&gt;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company recognized approximately $54,000 and $18,000 in expense related to these units during the years ended &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt; December 2020, &lt;/em&gt;respectively. At &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021,&lt;/em&gt; there was approximately $0.1 million of unrecognized compensation cost that will be recognized over a weighted average period of 2.12 years.&lt;/p&gt;
  </us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis
      contextRef="d_2021-01-01_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="2"
      id="c82208758"
      unitRef="Pure">0.040</dffn:PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized
      contextRef="d_2022-01-01_2022-01-01_PlanNameAxis-EquityIncentivePlan2015Member_SubsequentEventTypeAxis-SubsequentEventMember"
      decimals="INF"
      id="c82208759"
      unitRef="Share">4076571</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant
      contextRef="i_2021-12-31_PlanNameAxis-EquityIncentivePlan2015Member"
      decimals="INF"
      id="c82208763"
      unitRef="Share">580925</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066668">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Year ended&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31,&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Research and development&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;154,041&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;164,791&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;General and administrative&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;743,219&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;571,328&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Total stock-based compensation expense&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;897,260&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;736,119&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c82208812"
      unitRef="USD">154041</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember"
      decimals="INF"
      id="c82208813"
      unitRef="USD">164791</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c82208814"
      unitRef="USD">743219</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember"
      decimals="INF"
      id="c82208815"
      unitRef="USD">571328</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208816"
      unitRef="USD">897260</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208817"
      unitRef="USD">736119</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066669">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Options&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;exercise price&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;per share&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;remaining&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;contractual life&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;(in years)&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Aggregate&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Intrinsic&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Value&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 52%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;309,276&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;55.78&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,931,100&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.68&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expired&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(172&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;142.50&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at December 31, 2020&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;2,240,204&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;8.28&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;289,067&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,815,767&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.89&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Forfeited&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(429,748&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1.37&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8.52&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Exercisable at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;2,140,524&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;8.58&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8.09&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested and expected to vest at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;3,626,223&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 9%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;5.40&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;8.52&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 9%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c82208818"
      unitRef="Share">309276</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2019-12-31"
      decimals="INF"
      id="c82208819"
      unitRef="USDPerShare">55.78</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208822"
      unitRef="Share">1931100</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208823"
      unitRef="USDPerShare">0.68</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208826"
      unitRef="Share">172</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208827"
      unitRef="USDPerShare">142.50</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208830"
      unitRef="Share">2240204</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208831"
      unitRef="USDPerShare">8.28</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208833"
      unitRef="USD">289067</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208834"
      unitRef="Share">1815767</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208835"
      unitRef="USDPerShare">0.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208838"
      unitRef="Share">429748</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208839"
      unitRef="USDPerShare">1.37</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208842"
      unitRef="Share">3626223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208843"
      unitRef="USDPerShare">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2 contextRef="d_2021-01-01_2021-12-31" id="c82208844">P8Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208846"
      unitRef="Share">2140524</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208847"
      unitRef="USDPerShare">8.58</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1 contextRef="d_2021-01-01_2021-12-31" id="c82208848">P8Y1M2D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208850"
      unitRef="Share">3626223</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208851"
      unitRef="USDPerShare">5.40</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1 contextRef="d_2021-01-01_2021-12-31" id="c82208852">P8Y6M7D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31"
      decimals="INF"
      id="c82208769"
      unitRef="USDPerShare">0.89</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2020-01-01_2020-12-31"
      decimals="INF"
      id="c82208770"
      unitRef="USDPerShare">0.64</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-5"
      id="c82208777"
      unitRef="USD">800000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="d_2020-01-01_2020-12-31"
      decimals="-5"
      id="c82208778"
      unitRef="USD">700000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="d_2021-01-01_2021-12-31"
      decimals="-3"
      id="c82208779"
      unitRef="Share">0</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c82208783"
      unitRef="USD">1100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c82208784">P1Y8M12D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c82208785"
      unitRef="Share">385267</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-PerformanceSharesMember"
      decimals="INF"
      id="c82208786"
      unitRef="USDPerShare">1.11</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-5"
      id="c82208787"
      unitRef="USD">100000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066670">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;td colspan="3" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 8%;"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; width: 1%;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected term (in years)&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;10&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;5.31&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;10&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Risk-free interest rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;1.3%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.7%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;0.4%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1.7%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Expected volatility&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;122.6%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;125.8%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; text-align: right;"&gt;113.4%&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;&lt;em style="font: inherit;"&gt;&#x2014;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 5%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;124.8%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Dividend yield&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; text-align: right;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 3%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: center;"&gt;0%&lt;/td&gt;&lt;td style="width: 5%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&lt;em style="font: inherit;"&gt;&#160;&lt;/em&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      id="c82208855">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      id="c82208857">P5Y3M21D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      id="c82208859">P10Y</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c82208860"
      unitRef="Pure">0.013</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c82208862"
      unitRef="Pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c82208863"
      unitRef="Pure">0.004</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c82208865"
      unitRef="Pure">0.017</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c82208866"
      unitRef="Pure">1.226</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c82208868"
      unitRef="Pure">1.258</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MinimumMember"
      decimals="3"
      id="c82208869"
      unitRef="Pure">1.134</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember_RangeAxis-MaximumMember"
      decimals="3"
      id="c82208871"
      unitRef="Pure">1.248</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c82208873"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-EmployeeStockOptionMember"
      decimals="-3"
      id="c82208876"
      unitRef="Pure">0</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      id="c82208794">P18M</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066671">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Number of&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Units&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;Weighted&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;average&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;grant date fair value&lt;/b&gt; &lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Balance at January 1, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;153,000&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.65&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Granted&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;138,800&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;0.72&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Vested&lt;sup style="vertical-align:top;line-height:120%;font-size:pt"&gt;(1)&lt;/sup&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(16,350&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;0.51&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Outstanding at December 31, 2021&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;275,450&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;0.70&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208878"
      unitRef="Share">153000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208879"
      unitRef="USDPerShare">0.65</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208880"
      unitRef="Share">138800</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208881"
      unitRef="USDPerShare">0.72</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208882"
      unitRef="Share">16350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208883"
      unitRef="USDPerShare">0.51</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208884"
      unitRef="Share">275450</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208885"
      unitRef="USDPerShare">0.70</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue>
    <us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember"
      decimals="INF"
      id="c82208796"
      unitRef="Share">6049</us-gaap:SharesPaidForTaxWithholdingForShareBasedCompensation>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c82208798"
      unitRef="USD">54000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="d_2020-01-01_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="INF"
      id="c82208799"
      unitRef="USD">18000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="i_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      decimals="-5"
      id="c82208804"
      unitRef="USD">100000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="d_2021-01-01_2021-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember_TitleOfIndividualAxis-DirectorMember"
      id="c82208805">P2Y1M13D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066672">
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&lt;b&gt;&lt;em style="font: inherit;"&gt;8.&lt;/em&gt;&lt;/b&gt;&#160;&lt;b&gt; Income Taxes&lt;/b&gt;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Deferred tax assets and liabilities are determined based on the differences between the financial statement carrying amounts and tax bases of assets and liabilities using enacted tax rates in effect for years in which differences are expected to reverse. &#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;Significant components of the Company's deferred tax assets for federal income taxes consisted of the following:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,033,726&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,864,189&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock option compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,641,354&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,571,227&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan Drug credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;647,937&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;541,384&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;38,394&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Capitalized start-up costs and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,403,925&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;10,709,631&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20,726,942&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14,906,646&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,818,179&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2,223,678&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Right of use asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(38,394&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,262,072&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(443,893&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;The Company does &lt;em style="font: inherit;"&gt;not&lt;/em&gt; have unrecognized tax benefits as of &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; or &lt;em style="font: inherit;"&gt; December 31, 2020. &lt;/em&gt;The Company recognizes interest and penalties accrued on any unrecognized tax benefits as a component of income tax expense.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;The Company had NOL carryforwards for federal and state income tax purposes at &lt;em style="font: inherit;"&gt; December&#160;&lt;/em&gt;&lt;em style="font: inherit;"&gt;31,&lt;/em&gt; &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; and &lt;em style="font: inherit;"&gt;2020&lt;/em&gt; of approximately:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Combined NOL Carryforwards:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;23,442,045&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,013,388&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;23,436,624&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,007,966&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:justify;margin:0pt;text-indent:45pt;"&gt;The pre-&lt;em style="font: inherit;"&gt;2018&lt;/em&gt; net operating loss carryforwards begin expiring in &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; for both federal and state income tax purposes. In &lt;em style="font: inherit;"&gt; November 2019, &lt;/em&gt;the Company increased the number of shares outstanding resulting in a change of ownership, under the provisions of Internal Revenue Code Section &lt;em style="font: inherit;"&gt;382&lt;/em&gt; and similar state provisions. These provisions limit the Company&#x2019;s ability to utilize these net operating loss carryforwards to offset future income. The amounts above reflect the amount of NOLs that the Company expects to be able to utilize as a result of the limitation. The Company recorded a 100% valuation allowance of the deferred tax assets as of &lt;em style="font: inherit;"&gt; December 31, 2021 &lt;/em&gt;because of the uncertainty of their realization.&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; margin: 0pt; text-align: left"/&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; text-align: justify; margin: 0pt; text-indent: 36pt;"&gt;A reconciliation of income tax benefit at the statutory federal income tax rate and income taxes as reflected in the consolidated financial statements is as follows:&lt;/p&gt;
   &lt;p style="font-family:'Times New Roman';font-size:10pt;font-variant:normal;margin:0pt;"&gt;&#160;&lt;/p&gt;

    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Rate reconciliation:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax, net of Federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(4.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(4.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan drug credit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;24.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total provision&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(10.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;

   &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;margin:0pt;text-indent:9pt;"&gt;&#160;&lt;/p&gt;
   &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin: 0pt; text-indent: 36pt; text-align: justify;"&gt;The Company files income tax returns in the U.S. federal jurisdiction and various state jurisdictions. The Company&#x2019;s 2018 to &lt;em style="font: inherit;"&gt;2021&lt;/em&gt; tax years remain open and subject to examination. All net operating losses and credits remain subject to review until utilized.&lt;/p&gt;
  </us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066673">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Deferred tax assets&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net operating loss carryforwards&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;6,033,726&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;3,864,189&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Stock option compensation&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,641,354&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;1,571,227&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan Drug credits&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;647,937&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;541,384&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Lease liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;38,394&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Capitalized start-up costs and other&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;12,403,925&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;10,709,631&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(20,726,942&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(14,906,646&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;1,818,179&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Deferred tax liabilities&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Intangible assets&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2,223,678&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Right of use asset&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(38,394&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Deferred tax liabilities&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); text-align: right;"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;(2,262,072&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Net deferred tax liability&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#x2014;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(443,893&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208901"
      unitRef="USD">6033726</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208902"
      unitRef="USD">3864189</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208903"
      unitRef="USD">1641354</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208904"
      unitRef="USD">1571227</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <dffn:DeferredTaxAssetsOrphanDrugCredits
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208905"
      unitRef="USD">647937</dffn:DeferredTaxAssetsOrphanDrugCredits>
    <dffn:DeferredTaxAssetsOrphanDrugCredits
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208906"
      unitRef="USD">541384</dffn:DeferredTaxAssetsOrphanDrugCredits>
    <dffn:DeferredTaxAssetsLeaseLiability
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208907"
      unitRef="USD">0</dffn:DeferredTaxAssetsLeaseLiability>
    <dffn:DeferredTaxAssetsLeaseLiability
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208908"
      unitRef="USD">38394</dffn:DeferredTaxAssetsLeaseLiability>
    <dffn:DeferredTaxAssetsCapitalizedCostsAndOther
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208909"
      unitRef="USD">12403925</dffn:DeferredTaxAssetsCapitalizedCostsAndOther>
    <dffn:DeferredTaxAssetsCapitalizedCostsAndOther
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208910"
      unitRef="USD">10709631</dffn:DeferredTaxAssetsCapitalizedCostsAndOther>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208911"
      unitRef="USD">20726942</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208912"
      unitRef="USD">14906646</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208913"
      unitRef="USD">0</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208914"
      unitRef="USD">1818179</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208916"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208917"
      unitRef="USD">2223678</us-gaap:DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets>
    <dffn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208918"
      unitRef="USD">-0</dffn:DeferredTaxLiabilitiesRightOfUseAsset>
    <dffn:DeferredTaxLiabilitiesRightOfUseAsset
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208919"
      unitRef="USD">38394</dffn:DeferredTaxLiabilitiesRightOfUseAsset>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208920"
      unitRef="USD">-0</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208921"
      unitRef="USD">2262072</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2021-12-31"
      decimals="INF"
      id="c82208922"
      unitRef="USD">-0</us-gaap:DeferredTaxLiabilities>
    <us-gaap:DeferredTaxLiabilities
      contextRef="i_2020-12-31"
      decimals="INF"
      id="c82208923"
      unitRef="USD">443893</us-gaap:DeferredTaxLiabilities>
    <us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066674">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Combined NOL Carryforwards:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;23,442,045&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,013,388&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;23,436,624&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;15,007,966&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="INF"
      id="c82208924"
      unitRef="USD">23442045</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember"
      decimals="INF"
      id="c82208925"
      unitRef="USD">15013388</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2021-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="INF"
      id="c82208926"
      unitRef="USD">23436624</us-gaap:OperatingLossCarryforwards>
    <us-gaap:OperatingLossCarryforwards
      contextRef="i_2020-12-31_IncomeTaxAuthorityAxis-StateAndLocalJurisdictionMember"
      decimals="INF"
      id="c82208927"
      unitRef="USD">15007966</us-gaap:OperatingLossCarryforwards>
    <dffn:DeferredTaxAssetsValuationAllowancePercentage
      contextRef="d_2021-01-01_2021-12-31"
      decimals="0"
      id="c82208897"
      unitRef="Pure">1</dffn:DeferredTaxAssetsValuationAllowancePercentage>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock contextRef="d_2021-01-01_2021-12-31" id="c2066675">
    &lt;table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"&gt;&lt;tbody&gt;&lt;tr style="vertical-align: bottom;"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Rate reconciliation:&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt; &lt;p style="font-family:Times New Roman;font-size:10pt;font-variant:normal;text-align:center;margin:0pt;"&gt;&lt;b&gt;&lt;b&gt;December 31, 2020&lt;/b&gt;&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Federal tax benefit at statutory rate&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(21.0&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;State tax, net of Federal benefit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(4.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(4.7&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Orphan drug credit&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(0.4&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;(2.9&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(255, 255, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;Change in valuation allowance&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;24.3&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;%&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; padding-bottom: 1px;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"&gt;18.1&lt;/td&gt;&lt;td style="width: 1%; font-family: &amp;quot;Times New Roman&amp;quot;; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;"&gt;%&lt;/td&gt;&lt;/tr&gt;
&lt;tr style="vertical-align: bottom; background-color: rgb(204, 238, 255);"&gt;&lt;td style="font-family: Times New Roman; font-size: 10pt;"&gt; &lt;p style="font-family: Times New Roman; font-size: 10pt; font-variant: normal; margin-top: 0pt; margin-bottom: 0pt;"&gt;&lt;b&gt;Total provision&lt;/b&gt;&lt;/p&gt; &lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(1.8&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"&gt;&#160;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;&#160;&lt;/td&gt;&lt;td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);"&gt;(10.5&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"&gt;)%&lt;/td&gt;&lt;/tr&gt;
&lt;/tbody&gt;&lt;/table&gt;
   </us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2021-01-01_2021-12-31"
      decimals="2"
      id="c82208928"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="d_2020-01-01_2020-12-31"
      decimals="2"
      id="c82208929"
      unitRef="Pure">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c82208930"
      unitRef="Pure">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="d_2020-01-01_2020-12-31"
      decimals="3"
      id="c82208931"
      unitRef="Pure">0.047</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c82208932"
      unitRef="Pure">0.004</dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent>
    <dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent
      contextRef="d_2020-01-01_2020-12-31"
      decimals="3"
      id="c82208933"
      unitRef="Pure">0.029</dffn:EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c82208934"
      unitRef="Pure">0.243</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="d_2020-01-01_2020-12-31"
      decimals="3"
      id="c82208935"
      unitRef="Pure">0.181</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2021-01-01_2021-12-31"
      decimals="3"
      id="c82208936"
      unitRef="Pure">-0.018</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:EffectiveIncomeTaxRateContinuingOperations
      contextRef="d_2020-01-01_2020-12-31"
      decimals="3"
      id="c82208937"
      unitRef="Pure">-0.105</us-gaap:EffectiveIncomeTaxRateContinuingOperations>
    <us-gaap:OpenTaxYear contextRef="d_2021-01-01_2021-12-31" id="c82208899">2018</us-gaap:OpenTaxYear>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>57
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M?!^2!F.,6_0T7X\48JVFL:W&VC$,>8!8\PRA9CC?AT6:&C/5BZPYC0IO0=5
MY3_;U UH]@TT')$%7C&9MC:CY$X*/-S^[PVPPL2.X>V+OP%02P,$%     @
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M*%N ]S=2FL/$]IK^U9+^!U!+ P04    " "G@G)4A N8P6($   W#@  &
M 'AL+W=O<FMS:&5E=',O<VAE970T+GAM;*6766_C-A" _PIA]&$+;")1HJ[
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MJ]9$&6O%@*X6(3$>0TG5_L<?;HKYNU\%M#36\#Z*7:&5AO1 N_T673P1%BI
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M<-S1J$3C!>A_HZF*AHLW<!J^\S]02P,$%     @ IX)R5(:."6N7 @  =@4
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M<#1-/%#=<]5-C-RY)V(M#3TX;EC2"X_*&M#^1M(5U4\LP>D_P^)O4$L#!!0
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MF. #^L(^^M#K"P>B-] &.* NZM5%7EWT%7772ZFQR^&E?"3L6CC76M8+=.L
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MJ)T O9\W-')T&V>@G[YG_P)02P,$%     @ IX)R5-4*4:8@!   M0D  !D
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M\[X\YV .LQWCSZ("D.BUIHV86Y64[8UMB[R"&HMKUD*C=DK&:RS5E&]LT7+
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M2OU]@.L M5\RU9'ZB6YPP_\L^P]02P,$%     @ IX)R5*-2<G.@ @  >@<
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MA L:Y<$2013$V2]^S@?B*$#FJ0] >0 Z#>@U!-AY@'T:T&\(Z.4!O4M[</*
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MY$%57ZA&7_-JN^&)#DN(AP7BH1'Q%UDFV8X%@C!=TN4@NS2.<P??!6(#Q(8
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MN"S[W)*="+I-OR<LJ1 T2@\W!,MZH!K(^RM*Q>%$=5!\])K\#U!+ P04
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M=(XAE3.T<>1^0*+"[CN>.:[>'R*KR#_(\]MZ?QP/>G'<&\2CX/$ ,%H"HXW
M2J'/M6;&=V96Y7N0W*A[;H3-'D%J/DD W9J:!2G-B$+GOVX@G8#\NX&=7@FB
M=V)V>GOLQ"&-AN%A<OHEKGXCKCN6+<!N<G@".>4*T$KR*>1@9B))F%1H!;(
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M8HE[7<[6@&MK-9H^,&0:;P6?ACKO8\G57:K\9.^&20(<\ &,)9L^?= 4>F#
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M(/4C@&H&J#JCJ3)G:T@U[;:EV"!I3QLV.W"Q<6CCAB4VC4]:FEUF<+K[56A
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M*KN YN>2JEO5L1O4WSK#OU!+ P04    " "G@G)4^BDZDA4"  "G!   &0
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M5O8F >T2['FIK!W[P!48[J;L+U!+ P04    " "G@G)4JE-W/EP#  "S"@
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M!=Z!G GR9:.X+G@W?P<8DPQUDO]J3+++F&@T"N,7QKQ.1&/\TX^CT0MCZ-8
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MNFC+[=$$LJ8H&ER#H8SK3[/ X$:L79#4BRZK1>..1:.8W$EA,DV^BA324X,
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M D\CCF .P .&1%%S#NZ<1^'ZG HW_XD:_P)02P,$%     @ IX)R5)>*NQS
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M\28%>C/JS0KT9M2;%>C-DY]M!7HSZLT*]&;4FQ7HS:@W*]";46]6H#>CWJQ
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M4$L! A0#%     @ IX)R5)+N309/ @  9@8  !@              ("!WA,
M 'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+ 0(4 Q0    ( *>"<E2$"YC!
M8@0  #<.   8              " @6,6  !X;"]W;W)K<VAE971S+W-H965T
M-"YX;6Q02P$"% ,4    " "G@G)4$PIN"/X$  #K%0  &
M@('[&@  >&PO=V]R:W-H965T<R]S:&5E=#4N>&UL4$L! A0#%     @ IX)R
M5&.T&\ZU!0  GQ0  !@              ("!+R   'AL+W=O<FMS:&5E=',O
M<VAE970V+GAM;%!+ 0(4 Q0    ( *>"<E00_:'_+0,  '\&   8
M      " @1HF  !X;"]W;W)K<VAE971S+W-H965T-RYX;6Q02P$"% ,4
M" "G@G)4P9G0V[4#  #@!P  &               @(%]*0  >&PO=V]R:W-H
M965T<R]S:&5E=#@N>&UL4$L! A0#%     @ IX)R5(!(S]%M#   +"   !@
M             ("!:"T  'AL+W=O<FMS:&5E=',O<VAE970Y+GAM;%!+ 0(4
M Q0    ( *>"<E3:\<CFV (  "H&   9              " @0LZ  !X;"]W
M;W)K<VAE971S+W-H965T,3 N>&UL4$L! A0#%     @ IX)R5("=J5:7!
M& H  !D              ("!&CT  'AL+W=O<FMS:&5E=',O<VAE970Q,2YX
M;6Q02P$"% ,4    " "G@G)4D6G]Q3<$  "P"@  &0              @('H
M00  >&PO=V]R:W-H965T<R]S:&5E=#$R+GAM;%!+ 0(4 Q0    ( *>"<E0$
MF#,W/P8  (L.   9              " @59&  !X;"]W;W)K<VAE971S+W-H
M965T,3,N>&UL4$L! A0#%     @ IX)R5'O*EM04!0  I L  !D
M     ("!S$P  'AL+W=O<FMS:&5E=',O<VAE970Q-"YX;6Q02P$"% ,4
M" "G@G)4"HS+]Z,-  #$*   &0              @($74@  >&PO=V]R:W-H
M965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    ( *>"<E26O 0>M@(  (@%   9
M              " @?%?  !X;"]W;W)K<VAE971S+W-H965T,38N>&UL4$L!
M A0#%     @ IX)R5(:."6N7 @  =@4  !D              ("!WF(  'AL
M+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"% ,4    " "G@G)4W%>-^6(#
M   _"   &0              @(&L90  >&PO=V]R:W-H965T<R]S:&5E=#$X
M+GAM;%!+ 0(4 Q0    ( *>"<E14?9N<GP0  (D+   9              "
M@45I  !X;"]W;W)K<VAE971S+W-H965T,3DN>&UL4$L! A0#%     @ IX)R
M5-4*4:8@!   M0D  !D              ("!&VX  'AL+W=O<FMS:&5E=',O
M<VAE970R,"YX;6Q02P$"% ,4    " "G@G)4#/6U9L0#  !A#0  &0
M        @(%R<@  >&PO=V]R:W-H965T<R]S:&5E=#(Q+GAM;%!+ 0(4 Q0
M   ( *>"<E0L%^U2\@(  &$(   9              " @6UV  !X;"]W;W)K
M<VAE971S+W-H965T,C(N>&UL4$L! A0#%     @ IX)R5,E+DLF. @  VP8
M !D              ("!EGD  'AL+W=O<FMS:&5E=',O<VAE970R,RYX;6Q0
M2P$"% ,4    " "G@G)4HU)R<Z "  !Z!P  &0              @(%;?
M>&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+ 0(4 Q0    ( *>"<E24*K,G
M^@4    ;   9              " @3)_  !X;"]W;W)K<VAE971S+W-H965T
M,C4N>&UL4$L! A0#%     @ IX)R5-N+VO.O!   AA8  !D
M ("!8X4  'AL+W=O<FMS:&5E=',O<VAE970R-BYX;6Q02P$"% ,4    " "G
M@G)4O-QQ.#T%  #[&   &0              @(%)B@  >&PO=V]R:W-H965T
M<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( *>"<E38/'>HE (  !<'   9
M          " @;V/  !X;"]W;W)K<VAE971S+W-H965T,C@N>&UL4$L! A0#
M%     @ IX)R5&'>KYTH!   A!$  !D              ("!B)(  'AL+W=O
M<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4    " "G@G)4V E* @H#  #7
M"@  &0              @('GE@  >&PO=V]R:W-H965T<R]S:&5E=#,P+GAM
M;%!+ 0(4 Q0    ( *>"<E2>-ZK4UP(  /<(   9              " @2B:
M  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL4$L! A0#%     @ IX)R5/HI
M.I(5 @  IP0  !D              ("!-IT  'AL+W=O<FMS:&5E=',O<VAE
M970S,BYX;6Q02P$"% ,4    " "G@G)4JE-W/EP#  "S"@  &0
M    @(&"GP  >&PO=V]R:W-H965T<R]S:&5E=#,S+GAM;%!+ 0(4 Q0    (
M *>"<E1.LPSX3P(  *$%   9              " @16C  !X;"]W;W)K<VAE
M971S+W-H965T,S0N>&UL4$L! A0#%     @ IX)R5,(YXIFV @  (P@  !D
M             ("!FZ4  'AL+W=O<FMS:&5E=',O<VAE970S-2YX;6Q02P$"
M% ,4    " "G@G)4U-P!,"0#  "6$@  #0              @ &(J   >&PO
M<W1Y;&5S+GAM;%!+ 0(4 Q0    ( *>"<E27BKL<P    !,"   +
M      "  =>K  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( *>"<E1W, #!:0,
M #X8   /              "  <"L  !X;"]W;W)K8F]O:RYX;6Q02P$"% ,4
M    " "G@G)42XJ@"W,!  !P%0  &@              @ %6L   >&PO7W)E
M;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " "G@G)4WR$G&Y(!  #Y
M%0  $P              @ $!L@  6T-O;G1E;G1?5'EP97-=+GAM;%!+!08
1    *P K *0+  #$LP     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.0.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>296</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>32</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>8</UnitCount>
  <MyReports>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>000 - Document - Document And Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information</Role>
      <ShortName>Document And Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>001 - Statement - Consolidated Balance Sheets</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-</Role>
      <ShortName>Consolidated Balance Sheets</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>002 - Statement - Consolidated Balance Sheets (Parentheticals)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals</Role>
      <ShortName>Consolidated Balance Sheets (Parentheticals)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>003 - Statement - Consolidated Statements of Operations</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-</Role>
      <ShortName>Consolidated Statements of Operations</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>004 - Statement - Consolidated Statements of Changes in Stockholders' Equity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-</Role>
      <ShortName>Consolidated Statements of Changes in Stockholders' Equity</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>005 - Statement - Consolidated Statements of Cash Flows</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-</Role>
      <ShortName>Consolidated Statements of Cash Flows</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>006 - Disclosure - Note 1 - Organization and Description of Business</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business</Role>
      <ShortName>Note 1 - Organization and Description of Business</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>007 - Disclosure - Note 2 - Liquidity</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity</Role>
      <ShortName>Note 2 - Liquidity</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>009 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities</Role>
      <ShortName>Note 4 - Accrued Expenses and Other Current Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>010 - Disclosure - Note 5 - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-</Role>
      <ShortName>Note 5 - Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>011 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants</Role>
      <ShortName>Note 6 - Stockholders' Equity and Common Stock Warrants</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>012 - Disclosure - Note 7 - Stock-based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation</Role>
      <ShortName>Note 7 - Stock-based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>013 - Disclosure - Note 8 - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes</Role>
      <ShortName>Note 8 - Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>014 - Disclosure - Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies</Role>
      <ShortName>Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>15</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>015 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies</ParentRole>
      <Position>16</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>016 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables</Role>
      <ShortName>Note 4 - Accrued Expenses and Other Current Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities</ParentRole>
      <Position>17</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>017 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables</Role>
      <ShortName>Note 6 - Stockholders' Equity and Common Stock Warrants (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>018 - Disclosure - Note 7 - Stock-based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables</Role>
      <ShortName>Note 7 - Stock-based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>019 - Disclosure - Note 8 - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables</Role>
      <ShortName>Note 8 - Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>020 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>021 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details</Role>
      <ShortName>Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>022 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details</Role>
      <ShortName>Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>23</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>023 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual</Role>
      <ShortName>Note 5 - Commitments and Contingencies (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>024 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual</Role>
      <ShortName>Note 6 - Stockholders' Equity and Common Stock Warrants (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>025 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details</Role>
      <ShortName>Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>26</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>026 - Disclosure - Note 7 - Stock-based Compensation (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual</Role>
      <ShortName>Note 7 - Stock-based Compensation (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>027 - Disclosure - Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details</Role>
      <ShortName>Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>28</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>028 - Disclosure - Note 7 - Stock-based Compensation - Stock Option Activity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details</Role>
      <ShortName>Note 7 - Stock-based Compensation - Stock Option Activity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>29</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>029 - Disclosure - Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details</Role>
      <ShortName>Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>30</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>030 - Disclosure - Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details</Role>
      <ShortName>Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>31</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>031 - Disclosure - Note 8 - Income Taxes (Details Textual)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual</Role>
      <ShortName>Note 8 - Income Taxes (Details Textual)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>032 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details</Role>
      <ShortName>Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>033 - Disclosure - Note 8 - Income Taxes - Operating Loss Carryforwards (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details</Role>
      <ShortName>Note 8 - Income Taxes - Operating Loss Carryforwards (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>34</Position>
    </Report>
    <Report instance="dffn20211231_10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>034 - Disclosure - Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details</Role>
      <ShortName>Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="10-K" original="dffn20211231_10k.htm">dffn20211231_10k.htm</File>
    <File>dffn-20211231.xsd</File>
    <File>dffn-20211231_cal.xml</File>
    <File>dffn-20211231_def.xml</File>
    <File>dffn-20211231_lab.xml</File>
    <File>dffn-20211231_pre.xml</File>
    <File>ex_346478.htm</File>
    <File>ex_346479.htm</File>
    <File>ex_346480.htm</File>
    <File>ex_348717.htm</File>
    <File>ex_348718.htm</File>
    <File>ex_348719.htm</File>
    <File>ex_348951.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>logo.jpg</File>
    <File>tsc01.jpg</File>
    <File>tsc02.jpg</File>
    <File>tsc03.jpg</File>
    <File>tsc04.jpg</File>
    <File>tsc05.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="346">http://fasb.org/us-gaap/2021-01-31</BaseTaxonomy>
    <BaseTaxonomy items="36">http://xbrl.sec.gov/dei/2021q4</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>63
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "dffn20211231_10k.htm": {
   "axisCustom": 0,
   "axisStandard": 12,
   "contextCount": 80,
   "dts": {
    "calculationLink": {
     "local": [
      "dffn-20211231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "dffn-20211231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "dffn20211231_10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "dffn-20211231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "dffn-20211231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "dffn-20211231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/srt/2021/elts/srt-types-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-gaap-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-roles-2021-01-31.xsd",
      "https://xbrl.fasb.org/us-gaap/2021/elts/us-types-2021-01-31.xsd",
      "https://xbrl.sec.gov/country/2021/country-2021.xsd",
      "https://xbrl.sec.gov/currency/2021/currency-2021.xsd",
      "https://xbrl.sec.gov/dei/2021q4/dei-2021q4.xsd",
      "https://xbrl.sec.gov/exch/2021/exch-2021.xsd",
      "https://xbrl.sec.gov/naics/2021/naics-2021.xsd",
      "https://xbrl.sec.gov/sic/2021/sic-2021.xsd",
      "https://xbrl.sec.gov/stpr/2021/stpr-2021.xsd"
     ]
    }
   },
   "elementCount": 309,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2021-01-31": 16,
    "http://xbrl.sec.gov/dei/2021q4": 6,
    "total": 22
   },
   "keyCustom": 19,
   "keyStandard": 277,
   "memberCustom": 16,
   "memberStandard": 15,
   "nsprefix": "dffn",
   "nsuri": "http://www.diffusionpharma.com/20211231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "000 - Document - Document And Entity Information",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information",
     "shortName": "Document And Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "b",
       "p",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "009 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities",
     "shortName": "Note 4 - Accrued Expenses and Other Current Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "010 - Disclosure - Note 5 - Commitments and Contingencies",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-",
     "shortName": "Note 5 - Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "011 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
     "shortName": "Note 6 - Stockholders' Equity and Common Stock Warrants",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "012 - Disclosure - Note 7 - Stock-based Compensation",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
     "shortName": "Note 7 - Stock-based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "013 - Disclosure - Note 8 - Income Taxes",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes",
     "shortName": "Note 8 - Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "014 - Disclosure - Significant Accounting Policies (Policies)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies",
     "shortName": "Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "015 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "016 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities (Tables)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
     "shortName": "Note 4 - Accrued Expenses and Other Current Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "017 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants (Tables)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
     "shortName": "Note 6 - Stockholders' Equity and Common Stock Warrants (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "018 - Disclosure - Note 7 - Stock-based Compensation (Tables)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables",
     "shortName": "Note 7 - Stock-based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "001 - Statement - Consolidated Balance Sheets",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-",
     "shortName": "Consolidated Balance Sheets",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "019 - Disclosure - Note 8 - Income Taxes (Tables)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables",
     "shortName": "Note 8 - Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-10-01_2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "020 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:GoodwillAndIntangibleAssetsPolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-10-01_2021-12-31",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "021 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerSharePolicyTextBlock",
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "022 - Disclosure - Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
     "shortName": "Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:OtherCurrentLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AccruedSalariesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-11-08_2021-11-08",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "023 - Disclosure - Note 5 - Commitments and Contingencies (Details Textual)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual",
     "shortName": "Note 5 - Commitments and Contingencies (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-11-08_2021-11-08",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLeasePayments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromIssuanceOfCommonStock",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "024 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
     "shortName": "Note 6 - Stockholders' Equity and Common Stock Warrants (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2020-05-01_2020-05-31",
      "decimals": "-6",
      "lang": null,
      "name": "dffn:DeemedDividendFromWarrantExchange",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "025 - Disclosure - Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
     "shortName": "Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
       "us-gaap:StockholdersEquityNoteDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ClassOfWarrantOrRightOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "026 - Disclosure - Note 7 - Stock-based Compensation (Details Textual)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
     "shortName": "Note 7 - Stock-based Compensation (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USDPerShare",
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "027 - Disclosure - Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details",
     "shortName": "Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_IncomeStatementLocationAxis-ResearchAndDevelopmentExpenseMember",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2020-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "028 - Disclosure - Note 7 - Stock-based Compensation - Stock Option Activity (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details",
     "shortName": "Note 7 - Stock-based Compensation - Stock Option Activity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2019-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": null,
     "groupType": "statement",
     "isDefault": "false",
     "longName": "002 - Statement - Consolidated Balance Sheets (Parentheticals)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
     "shortName": "Consolidated Balance Sheets (Parentheticals)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "029 - Disclosure - Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
     "shortName": "Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31_AwardTypeAxis-EmployeeStockOptionMember",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "030 - Disclosure - Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details",
     "shortName": "Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
       "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2020-12-31_AwardTypeAxis-RestrictedStockUnitsRSUMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dffn:DeferredTaxAssetsValuationAllowancePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "031 - Disclosure - Note 8 - Income Taxes (Details Textual)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
     "shortName": "Note 8 - Income Taxes (Details Textual)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "dffn:DeferredTaxAssetsValuationAllowancePercentage",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "032 - Disclosure - Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details",
     "shortName": "Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "033 - Disclosure - Note 8 - Income Taxes - Operating Loss Carryforwards (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details",
     "shortName": "Note 8 - Income Taxes - Operating Loss Carryforwards (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:SummaryOfOperatingLossCarryforwardsTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2021-12-31_IncomeTaxAuthorityAxis-DomesticCountryMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:OperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "034 - Disclosure - Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details",
     "shortName": "Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "2",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Pure",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "003 - Statement - Consolidated Statements of Operations",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
     "shortName": "Consolidated Statements of Operations",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "004 - Statement - Consolidated Statements of Changes in Stockholders' Equity",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-",
     "shortName": "Consolidated Statements of Changes in Stockholders' Equity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "i_2019-12-31_StatementEquityComponentsAxis-CommonStockMember",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:SharesOutstanding",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Share",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NetIncomeLoss",
      "reportCount": 1,
      "unitRef": "USD",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "005 - Statement - Consolidated Statements of Cash Flows",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
     "shortName": "Consolidated Statements of Cash Flows",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "td",
       "tr",
       "tbody",
       "table",
       "div",
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": "INF",
      "lang": null,
      "name": "us-gaap:DepreciationDepletionAndAmortization",
      "reportCount": 1,
      "unique": true,
      "unitRef": "USD",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "006 - Disclosure - Note 1 - Organization and Description of Business",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business",
     "shortName": "Note 1 - Organization and Description of Business",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:NatureOfOperations",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dffn:LiquidityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "007 - Disclosure - Note 2 - Liquidity",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity",
     "shortName": "Note 2 - Liquidity",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dffn:LiquidityDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "008 - Disclosure - Note 3 - Basis of Presentation and Summary of Significant Accounting Policies",
     "role": "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
     "shortName": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "body",
       "html"
      ],
      "baseRef": "dffn20211231_10k.htm",
      "contextRef": "d_2021-01-01_2021-12-31",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 32,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentInformationLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Document Information [Line Items]"
       }
      }
     },
     "localname": "DocumentInformationLineItems",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_DocumentInformationTable": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.",
        "label": "Document Information [Table]"
       }
      }
     },
     "localname": "DocumentInformationTable",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "xbrltype": "stringItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r325"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.",
        "label": "Entity [Domain]"
       }
      }
     },
     "localname": "EntityDomain",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information",
      "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "domainItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r326"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r320"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r322",
      "r323",
      "r324"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LegalEntityAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The set of legal entities associated with a report.",
        "label": "Legal Entity [Axis]"
       }
      }
     },
     "localname": "LegalEntityAxis",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information",
      "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r319"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r321"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2021q4",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-document-and-entity-information"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "dffn_AccruedClinicalStudiesExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 1.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical studies.",
        "label": "dffn_AccruedClinicalStudiesExpensesCurrent",
        "terseLabel": "Accrued clinical studies expenses"
       }
      }
     },
     "localname": "AccruedClinicalStudiesExpensesCurrent",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "the amount of additional consideration per share given in the exchange of a class of warrant or right.",
        "label": "dffn_ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare",
        "terseLabel": "Class of Warrant or Right, Exchange, Additional Consideration Per Share (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExchangeAdditionalConsiderationPerShare",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "dffn_ClassOfWarrantOrRightExercisedDuringPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of warrants or rights exercised during period.",
        "label": "dffn_ClassOfWarrantOrRightExercisedDuringPeriod",
        "terseLabel": "Class of Warrant or Right, Exercised During Period (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisedDuringPeriod",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "dffn_ClassOfWarrantOrRightsExpired": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights expired.",
        "label": "dffn_ClassOfWarrantOrRightsExpired",
        "terseLabel": "Class of Warrant or Rights, Expired (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightsExpired",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "dffn_DeemedDividendFromWarrantExchange": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of deemed dividend from the exchange of warrants.",
        "label": "dffn_DeemedDividendFromWarrantExchange",
        "negatedLabel": "Deemed dividend arising from warrant exchange",
        "terseLabel": "Deemed Dividend From Warrant Exchange"
       }
      }
     },
     "localname": "DeemedDividendFromWarrantExchange",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_DeferredTaxAssetsCapitalizedCostsAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to capitalized costs and other.",
        "label": "Capitalized start-up costs and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedCostsAndOther",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_DeferredTaxAssetsLeaseLiability": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from lease liability.",
        "label": "Lease liability"
       }
      }
     },
     "localname": "DeferredTaxAssetsLeaseLiability",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_DeferredTaxAssetsOrphanDrugCredits": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to the orphan drug credits.",
        "label": "Orphan Drug credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsOrphanDrugCredits",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_DeferredTaxAssetsValuationAllowancePercentage": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Deferred tax Assets' percentage related to net of valuation allowance.",
        "label": "dffn_DeferredTaxAssetsValuationAllowancePercentage",
        "terseLabel": "Deferred Tax Assets, Valuation Allowance, Percentage"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowancePercentage",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dffn_DeferredTaxLiabilitiesRightOfUseAsset": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from right-of-use asset.",
        "label": "dffn_DeferredTaxLiabilitiesRightOfUseAsset",
        "negatedLabel": "Right of use asset"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesRightOfUseAsset",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to orphan drug credits.",
        "label": "dffn_EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent",
        "negatedLabel": "Orphan drug credit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationOrphanDrugCreditsPercent",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details"
     ],
     "xbrltype": "percentItemType"
    },
    "dffn_EquityIncentivePlan2015Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the 2015 equity incentive plan.",
        "label": "Equity Incentive Plan 2015 [Member]"
       }
      }
     },
     "localname": "EquityIncentivePlan2015Member",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_HCWainwrightAndCoLLCMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to H.C. Wainwright &amp; Co., LLC.",
        "label": "H.C Wainwright &amp; Co., LLC [Member]"
       }
      }
     },
     "localname": "HCWainwrightAndCoLLCMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_LiquidityDisclosureTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the liquidity of the company.",
        "label": "Liquidity Disclosure [Text Block]"
       }
      }
     },
     "localname": "LiquidityDisclosureTextBlock",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity"
     ],
     "xbrltype": "textBlockItemType"
    },
    "dffn_NewWarrantsIssuedMay82020Member": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents new unregistered warrants (the \"New Warrants\") issued May 8, 2020.",
        "label": "New Warrants Issued May 8, 2020 [Member]"
       }
      }
     },
     "localname": "NewWarrantsIssuedMay82020Member",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_NoteToFinancialStatementDetailsTextual": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note To Financial Statement Details Textual"
       }
      }
     },
     "localname": "NoteToFinancialStatementDetailsTextual",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_NotesToFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Notes To Financial Statements [Abstract]"
       }
      }
     },
     "localname": "NotesToFinancialStatementsAbstract",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The percentage of total shares within the plan that may be added to the plan reserve, occurring on an annual basis.",
        "label": "dffn_PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
        "terseLabel": "Percentage of Total Shares Eligible for Plan Reserve, On an Annual Basis"
       }
      }
     },
     "localname": "PercentageOfTotalSharesEligibleForPlanReserveOnAnAnnualBasis",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "dffn_PrepaidExpensesDepositsAndOtherAssets": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 0.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying amount as of the balance sheet date of consideration paid in advance for costs that provide economic benefits within a future period, amounts transferred third parties for security purposes that are expected to be returned or applied towards payment, and assets not separately disclosed in the balance sheet that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid expenses, deposits and other current assets"
       }
      }
     },
     "localname": "PrepaidExpensesDepositsAndOtherAssets",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_PriorWarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the prior warrant.",
        "label": "Prior Warrant [Member]"
       }
      }
     },
     "localname": "PriorWarrantMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_ProceedsFromSaleOfCommonStockWarrants": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of common stock, warrants.",
        "label": "Proceeds from the sale of common stock warrants"
       }
      }
     },
     "localname": "ProceedsFromSaleOfCommonStockWarrants",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_PublicOfferingInclusiveOfUnderwriterSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information regarding a public offering, inclusive of shares offered and sold pursuant to the exercise-in-full by the underwriter of its option to purchase additional shares.",
        "label": "Public Offering, Inclusive of Underwriter Shares [Member]"
       }
      }
     },
     "localname": "PublicOfferingInclusiveOfUnderwriterSharesMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_RestrictedStockUnitsVestedAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount related to restricted stock units vested.",
        "label": "dffn_RestrictedStockUnitsVestedAmount",
        "terseLabel": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "RestrictedStockUnitsVestedAmount",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of shares and warrants issued during the period.",
        "label": "Issuance of common stock, pre-funded warrants and warrants, net of issuance costs (in shares)"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodSharesNetIssuanceCosts",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "sharesItemType"
    },
    "dffn_StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the value of common stock and warrants issued during the period, net of issuance costs.",
        "label": "Issuance of common stock, pre-funded warrants and warrants, net of issuance costs"
       }
      }
     },
     "localname": "StockAndWarrantsIssuedDuringPeriodValueNetIssuanceCosts",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dffn_TheMay2020InvestorWarrantExerciseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the May 2020 Investor Warrant Exercise.",
        "label": "The May 2020 Investor Warrant Exercise [Member]"
       }
      }
     },
     "localname": "TheMay2020InvestorWarrantExerciseMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_TheMay2020OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the May 2020 offering.",
        "label": "The May 2020 Offering [Member]"
       }
      }
     },
     "localname": "TheMay2020OfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_TheMay2020OfferingWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Related to the May 2020 offering warrants.",
        "label": "The May 2020 Offering Warrants [Member]"
       }
      }
     },
     "localname": "TheMay2020OfferingWarrantsMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_TheMay2020PAWarrantsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the May 2020 PA Warrants.",
        "label": "The May 2020 PA Warrants [Member]"
       }
      }
     },
     "localname": "TheMay2020PAWarrantsMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the term of the underwiter's option to purchase additional shares.",
        "label": "dffn_UnderwriterOptionToPurchaseAdditionalSharesTerm",
        "terseLabel": "Underwriter Option to Purchase Additional Shares, Term (Day)"
       }
      }
     },
     "localname": "UnderwriterOptionToPurchaseAdditionalSharesTerm",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "dffn_UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to warrants issued to designees of the underwriter in connection with the February 2021 common stock offering.",
        "label": "Underwriter Warrants in Connection with the February 2021 Common Stock Offering [Member]"
       }
      }
     },
     "localname": "UnderwriterWarrantsInConnectionWithTheFebruary2021CommonStockOfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_UnvestedRestrictedStockUnitsMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents unvested restricted stock units.",
        "label": "Unvested Restricted Stock Units [Member]"
       }
      }
     },
     "localname": "UnvestedRestrictedStockUnitsMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsAttachedToSeriesAConvertiblePreferredStockMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents warrants that are attached to Series A Convertible Preferred Stock.",
        "label": "Warrants Attached to Series A Convertible Preferred Stock [Member]"
       }
      }
     },
     "localname": "WarrantsAttachedToSeriesAConvertiblePreferredStockMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithMay2019PublicOfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information pertaining to warrants issued in connection with May 2019 public offering.",
        "label": "Warrants Issued in Connection with May 2019 Public Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithMay2019PublicOfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithTheDecember2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the warrants issued in connection to the December 2019 public offering.",
        "label": "Warrants Issued in Connection with the December 2019 Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithTheDecember2019OfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the warrants issued in connection to the January 2018 public offering.",
        "label": "Warrants Issued in Connection with the January 2018 Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithTheJanuary2018OfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_WarrantsIssuedInConnectionWithTheNovember2019OfferingMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to the warrants issued in connection to the November 2019 public offering.",
        "label": "Warrants Issued in Connection with the November 2019 Offering [Member]"
       }
      }
     },
     "localname": "WarrantsIssuedInConnectionWithTheNovember2019OfferingMember",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies - Outstanding Dilutive Securities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 3 - Basis of Presentation and Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Accrued Expenses and Other Current Liabilities - Summary of Accrued Expenses (Details)"
       }
      }
     },
     "localname": "statement-statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 4 - Accrued Expenses and Other Current Liabilities"
       }
      }
     },
     "localname": "statement-statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Stockholders' Equity and Common Stock Warrants"
       }
      }
     },
     "localname": "statement-statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 6 - Stockholders' Equity and Common Stock Warrants - Warrants Outstanding to Acquire Shares of Its Common Stock (Details)"
       }
      }
     },
     "localname": "statement-statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stock-based Compensation - Fair Value Assumptions (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockbased-compensation-fair-value-assumptions-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stock-based Compensation - RSU Stock-based Payment Awards (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockbased-compensation-stock-option-activity-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stock-based Compensation - Stock Option Activity (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockbased-compensation-stock-option-activity-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stock-based Compensation - Stock-based Compensation Expense (Details)"
       }
      }
     },
     "localname": "statement-statement-note-7-stockbased-compensation-stockbased-compensation-expense-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-7-stockbased-compensation-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 7 - Stock-based Compensation"
       }
      }
     },
     "localname": "statement-statement-note-7-stockbased-compensation-tables",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Deferred Tax Assets and Liabilities (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-income-taxes-operating-loss-carryforwards-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Operating Loss Carryforwards (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-operating-loss-carryforwards-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes - Reconciliation of Income Tax Rate (Details)"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-note-8-income-taxes-tables": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Note 8 - Income Taxes"
       }
      }
     },
     "localname": "statement-statement-note-8-income-taxes-tables",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "dffn_statement-statement-significant-accounting-policies-policies": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant Accounting Policies"
       }
      }
     },
     "localname": "statement-statement-significant-accounting-policies-policies",
     "nsuri": "http://www.diffusionpharma.com/20211231",
     "xbrltype": "stringItemType"
    },
    "srt_CounterpartyNameAxis": {
     "auth_ref": [
      "r32",
      "r34",
      "r63",
      "r64",
      "r143",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "localname": "CounterpartyNameAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_DirectorMember": {
     "auth_ref": [
      "r112"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Director [Member]"
       }
      }
     },
     "localname": "DirectorMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r142",
      "r146",
      "r165",
      "r166",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r306",
      "r307",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum [Member]"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r142",
      "r146",
      "r165",
      "r166",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r306",
      "r307",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum [Member]"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r142",
      "r146",
      "r164",
      "r165",
      "r166",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r306",
      "r307",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r142",
      "r146",
      "r164",
      "r165",
      "r166",
      "r276",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r306",
      "r307",
      "r316",
      "r317"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statistical Measurement [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "auth_ref": [
      "r33",
      "r34",
      "r63",
      "r64",
      "r143",
      "r147"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_TitleOfIndividualAxis": {
     "auth_ref": [
      "r112",
      "r271"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Axis]"
       }
      }
     },
     "localname": "TitleOfIndividualAxis",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_TitleOfIndividualWithRelationshipToEntityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Title of Individual [Domain]"
       }
      }
     },
     "localname": "TitleOfIndividualWithRelationshipToEntityDomain",
     "nsuri": "http://fasb.org/srt/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accounting Policies [Abstract]"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable, accrued expenses, and other liabilities that are classified as current at the end of the reporting period.",
        "label": "Accounts Payable, Accrued Liabilities, and Other Liabilities Disclosure, Current [Text Block]"
       }
      }
     },
     "localname": "AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r24",
      "r274"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedProfessionalFeesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r26"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 2.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for professional fees, such as for legal and accounting services received. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_AccruedProfessionalFeesCurrent",
        "terseLabel": "Accrued professional fees"
       }
      }
     },
     "localname": "AccruedProfessionalFeesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedSalariesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r26"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 3.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of the obligations incurred through that date and payable for employees' services provided. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "us-gaap_AccruedSalariesCurrent",
        "terseLabel": "Accrued payroll and payroll related expenses"
       }
      }
     },
     "localname": "AccruedSalariesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalCommonStock": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.",
        "label": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r200",
      "r201",
      "r202",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital [Member]"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r167",
      "r169",
      "r206",
      "r207"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r169",
      "r197",
      "r205"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "us-gaap_AllocatedShareBasedCompensationExpense",
        "terseLabel": "Share-based Payment Arrangement, Expense",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Anti-dilutive securities (in shares)"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r59",
      "r104",
      "r106",
      "r110",
      "r114",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r246",
      "r248",
      "r257",
      "r272",
      "r274",
      "r286",
      "r297"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r4",
      "r5",
      "r31",
      "r59",
      "r114",
      "r131",
      "r132",
      "r133",
      "r134",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r246",
      "r248",
      "r257",
      "r272",
      "r274"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "us-gaap_AssetsCurrent",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AwardTypeAxis": {
     "auth_ref": [
      "r170",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of award under share-based payment arrangement.",
        "label": "Award Type [Axis]"
       }
      }
     },
     "localname": "AwardTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r3",
      "r21",
      "r54"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r9",
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r49",
      "r54",
      "r56"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
        "periodEndLabel": "Cash and cash equivalents at end of year",
        "periodStartLabel": "Cash and cash equivalents at beginning of year"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r49",
      "r258"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
        "totalLabel": "Net increase in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental disclosure of non-cash investing and financing activities:"
       }
      }
     },
     "localname": "CashFlowNoncashInvestingAndFinancingActivitiesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightAxis": {
     "auth_ref": [
      "r162",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of warrant or right issued.",
        "label": "Class of Warrant or Right [Axis]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ClassOfWarrantOrRightDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.",
        "label": "Class of Warrant or Right [Domain]"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Range of exercise price (in dollars per share)",
        "terseLabel": "Class of Warrant or Right, Exercise Price of Warrants or Rights (in dollars per share)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights": {
     "auth_ref": [
      "r160"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.",
        "label": "us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
        "terseLabel": "Class of Warrant or Right, Number of Securities Called by Warrants or Rights (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ClassOfWarrantOrRightOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of warrants or rights outstanding.",
        "label": "Common stock warrants, outstanding (in shares)"
       }
      }
     },
     "localname": "ClassOfWarrantOrRightOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommitmentsAndContingencies": {
     "auth_ref": [
      "r28",
      "r127",
      "r289",
      "r301"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.",
        "label": "Commitments and Contingencies (Note 5)"
       }
      }
     },
     "localname": "CommitmentsAndContingencies",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r124",
      "r125",
      "r126",
      "r129",
      "r313"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r66",
      "r67",
      "r251"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock [Member]"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common stock, par value (in dollars per share)"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common stock, shares authorized (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r15"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common stock, shares issued (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r15",
      "r159"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common stock, shares outstanding (in shares)"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r15",
      "r274"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 0.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common stock, $0.001 par value: 1,000,000,000 shares authorized; 101,914,280 and 64,015,441 shares issued and outstanding at December 31, 2021 and 2020, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r95",
      "r295"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DeferredIncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r52",
      "r60",
      "r229",
      "r235",
      "r236",
      "r237"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred income tax expense (benefit) pertaining to income (loss) from continuing operations.",
        "label": "Change in deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r12",
      "r13",
      "r220",
      "r287",
      "r296"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "us-gaap_DeferredIncomeTaxLiabilities",
        "negatedTotalLabel": "Deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilitiesNet": {
     "auth_ref": [
      "r212",
      "r213"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences with jurisdictional netting.",
        "label": "Deferred income taxes"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r222"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxLiabilities",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "us-gaap_DeferredTaxAssetsNet",
        "totalLabel": "Deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 0.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Stock option compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r221"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "us-gaap_DeferredTaxAssetsValuationAllowance",
        "negatedLabel": "Valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilities": {
     "auth_ref": [
      "r213",
      "r222"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deferred tax asset, of deferred tax liability attributable to taxable differences without jurisdictional netting.",
        "label": "us-gaap_DeferredTaxLiabilities",
        "negatedTotalLabel": "Net deferred tax liability"
       }
      }
     },
     "localname": "DeferredTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets": {
     "auth_ref": [
      "r227",
      "r228"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from intangible assets other than goodwill.",
        "label": "us-gaap_DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
        "negatedLabel": "Intangible assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesGoodwillAndIntangibleAssetsIntangibleAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount",
        "terseLabel": "Defined Contribution Plan, Employer Discretionary Contribution Amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of employees' gross pay for which the employer contributes a matching contribution to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanEmployerMatchingContributionPercent",
        "terseLabel": "Defined Contribution Plan, Employer Matching Contribution, Percent of Employees' Gross Pay"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerMatchingContributionPercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Maximum percentage of employee gross pay the employee may contribute to a defined contribution plan.",
        "label": "us-gaap_DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
        "terseLabel": "Defined Contribution Plan, Maximum Annual Contributions Per Employee, Percent"
       }
      }
     },
     "localname": "DefinedContributionPlanMaximumAnnualContributionsPerEmployeePercent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r52",
      "r102"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationNonproduction": {
     "auth_ref": [
      "r52",
      "r120"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 3.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The expense recognized in the current period that allocates the cost of nonproduction tangible assets over their useful lives.",
        "label": "us-gaap_DepreciationNonproduction",
        "terseLabel": "Depreciation"
       }
      }
     },
     "localname": "DepreciationNonproduction",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r208"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Share-based Payment Arrangement [Text Block]"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_DisclosureTextBlockAbstract",
        "terseLabel": "Notes to Financial Statements"
       }
      }
     },
     "localname": "DisclosureTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DomesticCountryMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of the government that is entitled to levy and collect income taxes from the entity in its country of domicile.",
        "label": "Domestic Tax Authority [Member]"
       }
      }
     },
     "localname": "DomesticCountryMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share information:"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r43",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r79",
      "r81",
      "r84",
      "r85",
      "r86",
      "r89",
      "r90",
      "r252",
      "r253",
      "r292",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Net loss per share of common stock, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r43",
      "r71",
      "r72",
      "r73",
      "r74",
      "r75",
      "r81",
      "r84",
      "r85",
      "r86",
      "r89",
      "r90",
      "r252",
      "r253",
      "r292",
      "r303"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Weighted average shares outstanding, basic and diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r87",
      "r88"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r215"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
        "totalLabel": "Total provision"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r61",
      "r215",
      "r238"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
        "negatedLabel": "Federal tax benefit at statutory rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r215",
      "r238"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details": {
       "order": 0.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
        "terseLabel": "Change in valuation allowance"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r215",
      "r238"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
        "negatedLabel": "State tax, net of Federal benefit"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r198"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount, Total"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r198"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
        "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Period for Recognition (Year)"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [
      "r195"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Share-based Payment Arrangement, Option [Member]"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders\u2019 Equity:"
       }
      }
     },
     "localname": "EquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r0",
      "r38",
      "r39",
      "r40",
      "r66",
      "r67",
      "r68",
      "r70",
      "r76",
      "r78",
      "r91",
      "r115",
      "r159",
      "r161",
      "r200",
      "r201",
      "r202",
      "r231",
      "r232",
      "r251",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r308",
      "r309",
      "r310",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r255",
      "r256"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r52"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "us-gaap_GainLossOnSaleOfPropertyPlantEquipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r45"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 0.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and Administrative Expense [Member]"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsPolicyTextBlock": {
     "auth_ref": [
      "r116",
      "r117"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for goodwill and intangible assets. This accounting policy also may address how an entity assesses and measures impairment of goodwill and intangible assets.",
        "label": "Goodwill and Intangible Assets, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill": {
     "auth_ref": [
      "r52",
      "r119"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of impairment loss resulting from write-down of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit to fair value.",
        "label": "us-gaap_ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
        "terseLabel": "Impairment of Intangible Assets, Indefinite-lived (Excluding Goodwill)",
        "verboseLabel": "Intangible asset impairment charge"
       }
      }
     },
     "localname": "ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest": {
     "auth_ref": [
      "r41",
      "r104",
      "r105",
      "r108",
      "r109",
      "r111",
      "r285",
      "r290",
      "r293",
      "r304"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.",
        "label": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
        "totalLabel": "Loss before income taxes"
       }
      }
     },
     "localname": "IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Statement [Abstract]"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r122",
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r123"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxAuthorityAxis": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by tax jurisdiction.",
        "label": "Income Tax Authority [Axis]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxAuthorityDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Agency, division or body classification that levies income taxes, examines tax returns for compliance, or grants exemptions from or makes other decisions pertaining to income taxes.",
        "label": "Income Tax Authority [Domain]"
       }
      }
     },
     "localname": "IncomeTaxAuthorityDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r216",
      "r218",
      "r224",
      "r233",
      "r239",
      "r241",
      "r242",
      "r243"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxExpenseBenefit": {
     "auth_ref": [
      "r62",
      "r77",
      "r78",
      "r103",
      "r214",
      "r234",
      "r240",
      "r305"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "us-gaap_IncomeTaxExpenseBenefit",
        "negatedLabel": "Income tax benefit",
        "terseLabel": "Income Tax Expense (Benefit), Total"
       }
      }
     },
     "localname": "IncomeTaxExpenseBenefit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r37",
      "r210",
      "r211",
      "r218",
      "r219",
      "r223",
      "r230"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayableAndAccruedLiabilities": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the amounts payable to vendors for goods and services received and the amount of obligations and expenses incurred but not paid.",
        "label": "Accounts payable, accrued expenses and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayableAndAccruedLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
        "negatedTerseLabel": "Prepaid expenses, deposits and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IndefiniteLivedIntangibleAssetsExcludingGoodwill": {
     "auth_ref": [
      "r118"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of assets, excluding financial assets and goodwill, lacking physical substance and having a projected indefinite period of benefit.",
        "label": "Intangible asset"
       }
      }
     },
     "localname": "IndefiniteLivedIntangibleAssetsExcludingGoodwill",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InterestIncomeExpenseNonoperatingNet": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 0.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net amount of nonoperating interest income (expense).",
        "label": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeExpenseNonoperatingNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LegalCostsPolicyTextBlock": {
     "auth_ref": [
      "r128"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for legal costs incurred to protect or defend the entity's assets and rights, or to obtain assets, including monetary damages, or to obtain rights.",
        "label": "Legal Costs, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "LegalCostsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r25",
      "r59",
      "r107",
      "r114",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r247",
      "r248",
      "r249",
      "r257",
      "r272",
      "r273"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "us-gaap_Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r20",
      "r59",
      "r114",
      "r257",
      "r274",
      "r288",
      "r299"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "us-gaap_LiabilitiesAndStockholdersEquity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r27",
      "r59",
      "r114",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r247",
      "r248",
      "r249",
      "r257",
      "r272",
      "r273",
      "r274"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "us-gaap_LiabilitiesCurrent",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NatureOfOperations": {
     "auth_ref": [
      "r92",
      "r101"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.",
        "label": "Nature of Operations [Text Block]"
       }
      }
     },
     "localname": "NatureOfOperations",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
        "totalLabel": "Net cash provided by financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows provided by investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r49",
      "r50",
      "r53"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r2",
      "r35",
      "r36",
      "r40",
      "r42",
      "r53",
      "r59",
      "r69",
      "r71",
      "r72",
      "r73",
      "r74",
      "r77",
      "r78",
      "r82",
      "r104",
      "r105",
      "r108",
      "r109",
      "r111",
      "r114",
      "r131",
      "r132",
      "r133",
      "r135",
      "r136",
      "r137",
      "r138",
      "r139",
      "r140",
      "r141",
      "r253",
      "r257",
      "r291",
      "r302"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      },
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net loss",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic": {
     "auth_ref": [
      "r71",
      "r72",
      "r73",
      "r74",
      "r79",
      "r80",
      "r83",
      "r86",
      "r104",
      "r105",
      "r108",
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.",
        "label": "us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic",
        "totalLabel": "Net loss applicable to common stockholders"
       }
      }
     },
     "localname": "NetIncomeLossAvailableToCommonStockholdersBasic",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NonoperatingIncomeExpenseAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other income:"
       }
      }
     },
     "localname": "NonoperatingIncomeExpenseAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OpenTaxYear": {
     "auth_ref": [
      "r217"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tax year that remains open to examination under enacted tax laws, in YYYY format.",
        "label": "us-gaap_OpenTaxYear",
        "terseLabel": "Open Tax Year"
       }
      }
     },
     "localname": "OpenTaxYear",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual"
     ],
     "xbrltype": "gYearListItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r104",
      "r105",
      "r108",
      "r109",
      "r111"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 1.0,
       "parentTag": "us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "us-gaap_OperatingIncomeLoss",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r268"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "us-gaap_OperatingLeaseExpense",
        "terseLabel": "Operating Lease, Expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 0.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Current operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r267"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 0.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Noncurrent operating lease liability"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r269",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "us-gaap_OperatingLeasePayments",
        "terseLabel": "Operating Lease, Payments"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r266"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Right of use asset"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLossCarryforwards": {
     "auth_ref": [
      "r225"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating loss carryforward, before tax effects, available to reduce future taxable income under enacted tax laws.",
        "label": "Operating loss carryforwards"
       }
      }
     },
     "localname": "OperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAccruedLiabilitiesCurrent": {
     "auth_ref": [
      "r6",
      "r7",
      "r8",
      "r26"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      },
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expenses incurred but not yet paid classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued expenses and other current liabilities",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "OtherAccruedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r23"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 0.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherCurrentLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of other current liabilities.",
        "label": "Other Current Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "OtherCurrentLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherSundryLiabilitiesCurrent": {
     "auth_ref": [
      "r26",
      "r130"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details": {
       "order": 0.0,
       "parentTag": "us-gaap_OtherAccruedLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Obligations not otherwise itemized or categorized in the footnotes to the financial statements that are due within one year or operating cycle, if longer, from the balance sheet date.",
        "label": "us-gaap_OtherSundryLiabilitiesCurrent",
        "terseLabel": "Other"
       }
      }
     },
     "localname": "OtherSundryLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfFinancingCosts": {
     "auth_ref": [
      "r48"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for loan and debt issuance costs.",
        "label": "us-gaap_PaymentsOfFinancingCosts",
        "negatedLabel": "Payment of offering costs"
       }
      }
     },
     "localname": "PaymentsOfFinancingCosts",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PerformanceSharesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement awarded for meeting performance target.",
        "label": "Performance Shares [Member]"
       }
      }
     },
     "localname": "PerformanceSharesMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r170",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PolicyTextBlockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_PolicyTextBlockAbstract",
        "terseLabel": "Accounting Policies"
       }
      }
     },
     "localname": "PolicyTextBlockAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfCommonStock": {
     "auth_ref": [
      "r47"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the additional capital contribution to the entity.",
        "label": "Proceeds from the sale of common stock, net of issuance costs",
        "terseLabel": "Proceeds from Issuance of Common Stock"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfCommonStock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleOfPropertyPlantAndEquipment": {
     "auth_ref": [
      "r46"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 0.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow from the sale of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale.",
        "label": "Cash received from sale of property and equipment"
       }
      }
     },
     "localname": "ProceedsFromSaleOfPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromWarrantExercises": {
     "auth_ref": [
      "r47"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from holders exercising their stock warrants.",
        "label": "us-gaap_ProceedsFromWarrantExercises",
        "terseLabel": "Proceeds from Warrant Exercises"
       }
      }
     },
     "localname": "ProceedsFromWarrantExercises",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r10",
      "r11",
      "r121",
      "r274",
      "r294",
      "r300"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r22",
      "r121",
      "r314",
      "r315"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentUsefulLife": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Useful life of long lived, physical assets used in the normal conduct of business and not intended for resale, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Examples include, but not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.",
        "label": "us-gaap_PropertyPlantAndEquipmentUsefulLife",
        "terseLabel": "Property, Plant and Equipment, Useful Life (Year)"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentUsefulLife",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r209",
      "r283",
      "r318"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and Development Expense [Member]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r209"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ResearchAndDevelopmentInProcess": {
     "auth_ref": [],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of purchased research and development assets that are acquired in a business combination have no alternative future use and are therefore written off in the period of acquisition.",
        "label": "Abandonment of in-process research and development intangible asset"
       }
      }
     },
     "localname": "ResearchAndDevelopmentInProcess",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RestrictedStockUnitsRSUMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "Restricted Stock Units (RSUs) [Member]"
       }
      }
     },
     "localname": "RestrictedStockUnitsRSUMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r17",
      "r161",
      "r203",
      "r274",
      "r298",
      "r311",
      "r312"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r0",
      "r66",
      "r67",
      "r68",
      "r70",
      "r76",
      "r78",
      "r115",
      "r200",
      "r201",
      "r202",
      "r231",
      "r232",
      "r251",
      "r308",
      "r310"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings [Member]"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r87"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r222"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r215"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r169",
      "r196",
      "r205"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock": {
     "auth_ref": [
      "r176"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the number and weighted-average grant date fair value for restricted stock units that were outstanding at the beginning and end of the year, and the number of restricted stock units that were granted, vested, or forfeited during the year.",
        "label": "Share-based Payment Arrangement, Restricted Stock Unit, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationRestrictedStockUnitsAwardActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r176",
      "r186",
      "r188"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Payment Arrangement, Option, Activity [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r190"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock": {
     "auth_ref": [
      "r162",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.",
        "label": "Schedule of Stockholders' Equity Note, Warrants or Rights [Table Text Block]"
       }
      }
     },
     "localname": "ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensation",
        "verboseLabel": "Stock-based compensation expense"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r171"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period (Year)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of grants made during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r184"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value at grant date for nonvested equity-based awards issued during the period on other than stock (or unit) option plans (for example, phantom stock or unit plan, stock or unit appreciation rights plan, performance target plan).",
        "label": "Granted, Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
        "periodEndLabel": "Unvested, shares (in shares)",
        "periodStartLabel": "Unvested, shares (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r183"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or unit weighted-average fair value of nonvested award under share-based payment arrangement. Excludes share and unit options.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
        "periodEndLabel": "Unvested, Weighted-average grant date fair value (in dollars per share)",
        "periodStartLabel": "Unvested, Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of equity-based payment instruments, excluding stock (or unit) options, that vested during the reporting period.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
        "negatedLabel": "Vested, shars (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r185"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average fair value as of grant date pertaining to an equity-based award plan other than a stock (or unit) option plan for which the grantee gained the right during the reporting period, by satisfying service and performance requirements, to receive or retain shares or units, other instruments, or cash in accordance with the terms of the arrangement.",
        "label": "Vested, Weighted-average grant date fair value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate": {
     "auth_ref": [
      "r193"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated dividend rate (a percentage of the share price) to be paid (expected dividends) to holders of the underlying shares over the option's term.",
        "label": "Dividend yield"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The estimated measure of the percentage by which a share price is expected to fluctuate during a period. Volatility also may be defined as a probability-weighted measure of the dispersion of returns about the mean. The volatility of a share price is the standard deviation of the continuously compounded rates of return on the share over a specified period. That is the same as the standard deviation of the differences in the natural logarithms of the stock prices plus dividends, if any, over the period.",
        "label": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r194"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Risk-free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of additional shares authorized for issuance under share-based payment arrangement.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Additional Shares Authorized (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Number of Shares Available for Grant (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares into which fully or partially vested stock options outstanding as of the balance sheet date can be currently converted under the option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
        "terseLabel": "Exercisable (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted-average price as of the balance sheet date at which grantees can acquire the shares reserved for issuance on vested portions of options outstanding and currently exercisable under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
        "terseLabel": "Exercisable, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod": {
     "auth_ref": [
      "r182"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options or other stock instruments for which the right to exercise has lapsed under the terms of the plan agreements.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
        "negatedLabel": "Expired (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExpirationsInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r181"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
        "negatedLabel": "Forfeited (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Granted (in shares)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r187"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r199"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Options outstanding, aggregate intrinsic value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r178",
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Options outstanding, number (in shares)",
        "periodEndLabel": "Options outstanding, number (in shares)",
        "periodStartLabel": "Options outstanding, number (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
        "periodEndLabel": "Options outstanding, weighted-average exercise price (in dollars per share)",
        "periodStartLabel": "Options outstanding, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": {
     "auth_ref": [
      "r168",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Award under share-based payment arrangement.",
        "label": "Award Type [Domain]"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options of the plan that expired.",
        "label": "Expired, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExpirationsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Forfeited, weighted-average exercise price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Granted, weighted-average exercise price (in dollars per share)",
        "terseLabel": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r170",
      "r174"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Payment Arrangement [Policy Text Block]"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod": {
     "auth_ref": [
      "r172"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period from grant date that an equity-based award expires, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Expiration Period (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r191",
      "r204"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Expected term (Year)",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r199"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for vested portions of options outstanding and currently exercisable or convertible, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
        "terseLabel": "Exercisable, weighted-average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
        "terseLabel": "Options outstanding, weighted-average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r189"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Vested and expected to vest, weighted-average remaining contractual life (Year)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r175"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SharesIssuedPricePerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "us-gaap_SharesIssuedPricePerShare",
        "terseLabel": "Shares Issued, Price Per Share (in dollars per share)"
       }
      }
     },
     "localname": "SharesIssuedPricePerShare",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.",
        "label": "us-gaap_SharesOutstanding",
        "periodEndLabel": "Balance (in shares)",
        "periodStartLabel": "Balance (in shares)"
       }
      }
     },
     "localname": "SharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares used to settle grantee's tax withholding obligation for award under share-based payment arrangement.",
        "label": "us-gaap_SharesPaidForTaxWithholdingForShareBasedCompensation",
        "terseLabel": "Share-based Payment Arrangement, Shares Withheld for Tax Withholding Obligation (in shares)"
       }
      }
     },
     "localname": "SharesPaidForTaxWithholdingForShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r57",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StateAndLocalJurisdictionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Designated tax department of a state or local government entitled to levy and collect income taxes from the entity.",
        "label": "State and Local Jurisdiction [Member]"
       }
      }
     },
     "localname": "StateAndLocalJurisdictionMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r0",
      "r30",
      "r38",
      "r39",
      "r40",
      "r66",
      "r67",
      "r68",
      "r70",
      "r76",
      "r78",
      "r91",
      "r115",
      "r159",
      "r161",
      "r200",
      "r201",
      "r202",
      "r231",
      "r232",
      "r251",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r308",
      "r309",
      "r310",
      "r328"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Cash Flows [Abstract]"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Financial Position [Abstract]"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of Stockholders' Equity [Abstract]"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r66",
      "r67",
      "r68",
      "r91",
      "r284"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-parentheticals",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-cash-flows-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-",
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-operations-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-1-organization-and-description-of-business",
      "http://www.diffusionpharma.com/20211231/role/statement-note-2-liquidity",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-summary-of-accrued-expenses-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-",
      "http://www.diffusionpharma.com/20211231/role/statement-note-5-commitments-and-contingencies-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-warrants-outstanding-to-acquire-shares-of-its-common-stock-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-fair-value-assumptions-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-rsu-stockbased-payment-awards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stock-option-activity-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-stockbased-compensation-expense-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-deferred-tax-assets-and-liabilities-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-details-textual",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-operating-loss-carryforwards-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-reconciliation-of-income-tax-rate-details",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r29",
      "r144",
      "r159",
      "r160",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of the conversion of convertible securities.",
        "label": "Issuance of common stock upon exercise of warrants (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r14",
      "r15",
      "r159",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "us-gaap_StockIssuedDuringPeriodSharesNewIssues",
        "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross": {
     "auth_ref": [
      "r159",
      "r161"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.",
        "label": "Vesting of restricted stock units (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r14",
      "r15",
      "r159",
      "r161",
      "r180"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised",
        "terseLabel": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities": {
     "auth_ref": [
      "r30",
      "r159",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The gross value of stock issued during the period upon the conversion of convertible securities.",
        "label": "Issuance of common stock upon exercise of warrants"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueConversionOfConvertibleSecurities",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross": {
     "auth_ref": [
      "r14",
      "r15",
      "r159",
      "r161"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate value of stock related to Restricted Stock Awards issued during the period.",
        "label": "Vesting of restricted stock units"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAwardGross",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r15",
      "r18",
      "r19",
      "r59",
      "r113",
      "r114",
      "r257",
      "r274"
     ],
     "calculation": {
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "us-gaap_StockholdersEquity",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-balance-sheets-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest": {
     "auth_ref": [
      "r0",
      "r1",
      "r39",
      "r59",
      "r66",
      "r67",
      "r68",
      "r70",
      "r76",
      "r114",
      "r115",
      "r161",
      "r200",
      "r201",
      "r202",
      "r231",
      "r232",
      "r244",
      "r245",
      "r250",
      "r251",
      "r257",
      "r259",
      "r260",
      "r264",
      "r309",
      "r310",
      "r328"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of stockholders' equity (deficit), net of receivables from officers, directors, owners, and affiliates of the entity, attributable to both the parent and noncontrolling interests. Amount excludes temporary equity. Alternate caption for the concept is permanent equity.",
        "label": "us-gaap_StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
        "periodEndLabel": "Balance",
        "periodStartLabel": "Balance"
       }
      }
     },
     "localname": "StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-consolidated-statements-of-changes-in-stockholders-equity-"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityNoteDisclosureTextBlock": {
     "auth_ref": [
      "r58",
      "r145",
      "r148",
      "r149",
      "r150",
      "r151",
      "r152",
      "r153",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r161",
      "r163"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for shareholders' equity comprised of portions attributable to the parent entity and noncontrolling interest, including other comprehensive income. Includes, but is not limited to, balances of common stock, preferred stock, additional paid-in capital, other capital and retained earnings, accumulated balance for each classification of other comprehensive income and amount of comprehensive income.",
        "label": "Stockholders' Equity Note Disclosure [Text Block]"
       }
      }
     },
     "localname": "StockholdersEquityNoteDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SubsequentEventMember": {
     "auth_ref": [
      "r265",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event [Member]"
       }
      }
     },
     "localname": "SubsequentEventMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsequentEventTypeAxis": {
     "auth_ref": [
      "r265",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Axis]"
       }
      }
     },
     "localname": "SubsequentEventTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTypeDomain": {
     "auth_ref": [
      "r265",
      "r275"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.",
        "label": "Subsequent Event Type [Domain]"
       }
      }
     },
     "localname": "SubsequentEventTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-details-textual"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SummaryOfOperatingLossCarryforwardsTextBlock": {
     "auth_ref": [
      "r226"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of pertinent information, such as tax authority, amounts, and expiration dates, of net operating loss carryforwards, including an assessment of the likelihood of utilization.",
        "label": "Summary of Operating Loss Carryforwards [Table Text Block]"
       }
      }
     },
     "localname": "SummaryOfOperatingLossCarryforwardsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_TableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "us-gaap_TableTextBlock",
        "terseLabel": "Notes Tables"
       }
      }
     },
     "localname": "TableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-4-accrued-expenses-and-other-current-liabilities-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-7-stockbased-compensation-tables",
      "http://www.diffusionpharma.com/20211231/role/statement-note-8-income-taxes-tables"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r93",
      "r94",
      "r96",
      "r97",
      "r98",
      "r99",
      "r100"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-significant-accounting-policies-policies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_WarrantMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrant [Member]"
       }
      }
     },
     "localname": "WarrantMember",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-3-basis-of-presentation-and-summary-of-significant-accounting-policies-outstanding-dilutive-securities-details"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_WarrantsAndRightsOutstandingTerm": {
     "auth_ref": [
      "r254"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "us-gaap_WarrantsAndRightsOutstandingTerm",
        "terseLabel": "Warrants and Rights Outstanding, Term (Year)"
       }
      }
     },
     "localname": "WarrantsAndRightsOutstandingTerm",
     "nsuri": "http://fasb.org/us-gaap/2021-01-31",
     "presentation": [
      "http://www.diffusionpharma.com/20211231/role/statement-note-6-stockholders-equity-and-common-stock-warrants-details-textual"
     ],
     "xbrltype": "durationItemType"
    }
   },
   "unitCount": 8
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "105",
   "URI": "http://asc.fasb.org/extlink&oid=124434974&loc=SL124442142-165695"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "275",
   "URI": "http://asc.fasb.org/topic&trid=2134479"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8736-108599"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8906-108599"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8924-108599"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "http://asc.fasb.org/extlink&oid=123359005&loc=d3e8933-108599"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=124259787&loc=d3e4647-111522"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "http://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "http://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "http://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=121556970&loc=d3e13816-109267"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16323-109275"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "350",
   "URI": "http://asc.fasb.org/extlink&oid=66006027&loc=d3e16373-109275"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "http://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "http://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "http://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "http://asc.fasb.org/topic&trid=2144648"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=121557415&loc=d3e14326-108349"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "450",
   "URI": "http://asc.fasb.org/extlink&oid=27011672&loc=d3e149975-122751"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "http://asc.fasb.org/topic&trid=2127136"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=99376301&loc=d3e1243-112600"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442526-122756"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=124359900&loc=SL124442552-122756"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(e)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "http://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496158-112644"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496171-112644"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496180-112644"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=SL123496189-112644"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21463-112644"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=123467817&loc=d3e21475-112644"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "50",
   "Topic": "505",
   "URI": "http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "http://asc.fasb.org/topic&trid=2208762"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "http://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=123468992&loc=d3e4534-113899"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5047-113901"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a),(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b),(f)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(3)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(4)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)-(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=120381028&loc=d3e5070-113901"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "http://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)(2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=121322162&loc=SL121327923-165333"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11149-113907"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "http://asc.fasb.org/extlink&oid=122142933&loc=d3e11178-113907"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "http://asc.fasb.org/topic&trid=2228938"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.1)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31917-109318"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123427490&loc=d3e31931-109318"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32672-109319"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.13(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.17)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123459177&loc=SL121830611-158277"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.7)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.1)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.2)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=123586238&loc=d3e38679-109324"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "http://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "http://asc.fasb.org/topic&trid=2144680"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568447-111683"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123454820&loc=SL4568740-111683"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4I",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "http://asc.fasb.org/extlink&oid=120409616&loc=SL4590271-111686"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "http://asc.fasb.org/extlink&oid=123482062&loc=SL123482106-238011"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bbb)(2)",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=123874694&loc=d3e19207-110258"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "http://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "http://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "http://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "http://asc.fasb.org/extlink&oid=123408670&loc=SL77918686-209980"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "850",
   "URI": "http://asc.fasb.org/extlink&oid=6457730&loc=d3e39599-107864"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "http://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "http://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.25)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "http://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "http://asc.fasb.org/extlink&oid=123353855&loc=SL119991595-234733"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "http://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "http://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "20",
   "Topic": "940",
   "URI": "http://asc.fasb.org/extlink&oid=123384075&loc=d3e41242-110953"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03.17)",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120398452&loc=d3e534808-122878"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-30)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(15))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "http://asc.fasb.org/extlink&oid=123345438&loc=d3e61044-112788"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03.(a),19)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400017&loc=d3e572229-122910"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(8))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(9))",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124504033&loc=SL117819544-158441"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.9)",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "http://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "http://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99779-112916"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "http://asc.fasb.org/extlink&oid=120429125&loc=d3e99893-112916"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "http://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "http://asc.fasb.org/extlink&oid=123360121&loc=d3e27327-108691"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756"
  },
  "r319": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226024-175313"
  },
  "r320": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r321": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r322": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310"
  },
  "r323": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f"
  },
  "r324": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f"
  },
  "r325": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1"
  },
  "r326": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r327": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226049-175313"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=99393222&loc=SL20226052-175313"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669619-108580"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124509347&loc=SL7669625-108580"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(10))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "http://asc.fasb.org/extlink&oid=123367319&loc=SL114868664-224227"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3179-108585"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3255-108585"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3291-108585"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3521-108585"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6801-107765"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3536-108585"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3602-108585"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123570139&loc=d3e3044-108585"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=d3e4273-108586"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "http://asc.fasb.org/extlink&oid=123431023&loc=SL98516268-108586"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=123372394&loc=d3e18726-107790"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(e)(1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6911-107765"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(1)(Note 1))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(iii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(2)(ii))",
   "Topic": "235",
   "URI": "http://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "http://asc.fasb.org/topic&trid=2122369"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e6935-107765"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "http://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1448-109256"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=124098289&loc=d3e7018-107765"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1377-109256"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1252-109256"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=SL5780133-109256"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125511455&loc=d3e1337-109256"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e3842-109258"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "http://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "http://asc.fasb.org/extlink&oid=125512782&loc=d3e4984-109258"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "http://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "http://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592"
  }
 },
 "version": "2.1"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>64
<FILENAME>0001437749-22-006737-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001437749-22-006737-xbrl.zip
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M^KNHE'HJ@V,^ 55&QNQ0.ZOSP"=U1AY4L5UNA/J<Y[C4,#U34T3SW:P>F+%
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MCSW,Z&ON'FP&1>MJ80M5<QO\E3<S#C!;*\#IAVS5)0.8M("3JW=<,">ZI*-
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M<X#'6^11[:!;HJ^AP0W"5>?P+!UO3-NMI_"E1)N5'E-NZ\3"JERQ4&W@YGM
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M/8YJ'[]1K4"GBF+0LC84 ?(QYQ%CSM(UOF\Q9WNQ5V!]25V/"[JP*XQ/<ZY
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MULUBEV<>G5KO9DD/J.$88+_YN2H@5)=FRX.DR:'0T!V0BO"^\/M>[W %SA]
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M KJ8&"#CO!G_/;K0F1'. ;Y^=/ 8C=EOZ "-#C,S2 1]#H[HT#7 BR=6XQY
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MSPP5+WO?']G>=]="[FMTSK'C^]\IQT[\CGZIL)O0WC=RB0>W/AOKYDJ"_B2
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M0I"G:&\23<$1>0C2I+_DNB)EN(X6^EX672T0.P5D^&G3_I;=H_I@V4+2U#)
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M0'?#,Q"I<.+9GK)]^O V9G.IM+63CUSR:33@N"!9E,5;31;D;@O- >PVW.@
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MXC-MG-$&:51C+7R,+;SAI1ISN -%N."GURC*.G=T=HARL^0C^R6RC2/&."D
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M<*U[,&UA"VU#:ZMITT1T2L:1D30,6TCF"S@-]5-;>#]%9;S@9\36[R9:1V-
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M?O.7P_!J!;31^!H)1"9D#RBL1+=AH$I>WRT.MJ\?&&#)@:=-&Q-TC^K]!HG
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M+,1G$@.QHFJU@M9>/,IRM=]3LLBC,[H0:5\1/8U^'(%C X\TN2E3P7]^K#=
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M@-J,1$!K"(=0E(?P.=8Q.(+)MAG2.S")1<'><),O/WKK^)O/9,$2LB6O'#_
MEP2&C\8^R(*<@8*##J[E#&YJ(/!F74-;!%5_;S1JY2CIW7"7BB-6T=JDEW.U
M0:LH:BG]+UJ;O:S7ZZ DKJ(,ELK& 5.<+DNGJX&9P=N?]HU@"L_:&-T*SRB9
MW?DTXEJY*W;(5BNN!V'!GTL6@<28RJYQS5',SGAKI3Q;0HIC -W/9-! 15*J
MF(NRO<DY*'=/34NC*^H"1&<_"9; /QV1.Q*Q6WY/R%DN5!]GIG1FRJ;^MF)^
MQ=D;G;W1V1N=<['*N5C.&]@"BGJZK-&MW=_VN2/)-1O:N*4%4Y<J%EMB'+0
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M.ON<*"57QXMG6 U05+P.>*G:_$S5W2C2"*$Z&TT'_(7$)/$CGO<C7,&USX-
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MP%B!Z45!C/&GK)[P_^/7"/SR?U!+ P04    " "G@G)42'E;>G)) @!Y;Q0
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M('@Y_@;&JL(PG4D/MOD?+SK\>29]WWQFWL8_/W[(AK$/$CL#&9KY*"W@1CA
M-E^8<1*B&9P.>IFS>%:,9V/G_\*JBGO;SA+!O#R4R3<!XN<76KX/KS(\$V"@
M(/GUJ%_1BE8O+;U)T*N$.RSQWW_E<?9^873\94O0URV1PM:-RA+Q1Y95C\L\
M#E9-.)0K-.F^N)D6>U$$)N>IFL5)]D)0RE &"@P\"I2)W6$<AT,9AC&\_>J6
M) M\L/FZN_E^F6QQN9?&_I9V'-BF=W3TM?=%G Y.CD_/Q<E7,*][1^?B_%B
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MR?%I#X%4/OTA3@?[@]/!47]@DLD<9^L=WN&.[7[N?#@&$^)Q<',<S)S*5SX
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M\JW><QY\.?: GGIJV%&+(,03TM/:80Z@'Y\+WL-Y 9YO0UZIDQLCT;3_1O@
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MG#F,"C-7J'/S2@<';$F<$O0HRRQ*SL$4=,+SM17S;@*>QK]$$\)T6#:0K_!
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M!F#():JSXJLSTB?2YWH94T#I1KB6K*@-$""HZKK3=2IC%KS0)= K/2L#X4G
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M.(.X[2:U,EB!365-[4@<9)R1S6+B)BTW9SX\O3;]>+;% 1!@&,+NYL *H%V
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MFQ#-0DF]CEE[+@*0@09^L6D]5*U2?,?9:.9,TAD%QE%F4].YCGH44"Z%SI3
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M[9K<-K)LT??[*QB.>^)($:AJ2;:[[7'?CBC+LJT9NZ4CJ=OW%23!*HQ @ .
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M4@?W ?F$M%RGQ2G=0A8,J>S2#56^/((\<YXT)M?=$V=NL/AY.H6B6$9'+V&
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MT!SB44 FD[> E3VS2?1Y[&U70UR;WSJ72,*'3;7:-^!!<-\); P[6/1-Q!,
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MB90X/F8G2%GPQ+4*!IS./W*_J:NKN?)68G\6#K>F*M?3O'S!R7B#+F@30+]
MW!(8IL3J3"ANV1&']NL?^>&KL1QHHE:+9<\0_-^B*<>'YB[*Y*ZSR;5L#9VO
M%=P$P5Q/U"W.%RG3$:]ML#V;79BW-R/Z8U=*!SV1* S](BA]:M DN2#)\,FN
M7C4HCP-YM2)I5"<_D*CYWE1)3!-\FWT+]6O:,-2U\J8<8L_)(S/RMM7VEH5&
M&^P_]^'VCQX\?,B/%]9T\!L@>1T^?%2HWD%PJYJ#\X>.C8CPLS33P5DUSS7L
MRNN*,X400B E7B9'$A2H'R5KN=ZGN;9I?GBV<2K1A)D_0SDX3VB)O5+3 EG=
M4K4&P(")]/7[VP^GVMB=:V-_/M7&/IK:V&]X[CS=<&^W% \YX^C%UFG )PGA
M/:;!$MJ0(7/GW)3H2]5\-U0R)F>3^9-#U'2G^-D981?NJB-)N;1,G\92+&ST
M7 HMD<X !@V@?DMP)+U4\I0'*W&2>&-65=/R$Q=H9$JLP$1J,M(<9E7WJ_W6
M1'>LS2K HH)8C3'Q'JFC7K!:?H:X]2S/B\\ A).2IX.X&)"NS."7A7VL7?A,
MGH?C?%;R0<!=AS-'''YM4+$*Y[\H $3Q('BGG"\,LWL0A8-S8\> 4F$E33[$
ML)B2?(0*(D"9I.JEQ0">]MC[\!_[[_IKQ*]#'1A 4-8-(2(H@;%7)3DVHG1(
M#XB6'A62)JJ8O*&B!^"M0A>-JBITPVZS.0,?#[PST9>PIY_ X</?)(<")>:8
M]L;[= \8=LB.>A%06FKZML\7S^9WAEP?&?%ETZU>3VH8DI*BZR8/XE<WVJ3$
MIY#$CJL8BUL:7+QUE[XCP]AF;ZQ@QNT&7-/HU17.0-RPCYGS&'C1)2,F,V%"
M5&NIW$C"3G)K"N1>=3M'QCS^7FY9:&+7T$^6G-I]'Q;Y7*]#J7VY7R_[KEQ[
MP/8QKS)<%WE/+=' ?7;"HW<PBNF:(&=X;S'ND_-_G+/U95XD:\\ RHJ@ /I^
M#DS.<;#T9_F(2(_UW[0)R#KI D*S$?4[T?SD8\H;O7*UJG*Q(7'ML0^^HG:"
MX2/8EPZ A)!V*I&);.KKC@P8^;5:XY(3?5N%T]DPXM(:]GSQ4J0'6)DK_H9,
M1P*9<,/T.ZV&+6!JP5SV2J6IYW2@HUO#RE+SC A4)7P^&H]L(34ET=9K:*'O
MVQ"WA@==XW<D,#28(;)[A;!Z_DE8U8^[[7923; 4DZ)KID(-J4M6#P+9YC3\
M.E7/)F"!)"-\G5Q'427WS"9=+)#!9^3,8 NGO.MHY"&&M:Z0$VP[+YK-]ZC.
M(%U:L>S XJ(]V(UGA5T3.I 'GVJ/X^DRGL>D9NK0WS+VGAL@S:[W:4\86N'1
MY=ME(HU,3 \!3\6=R&(-RS]DC@C*K\)5*ZSBX5V6<=(=JY :3Q1-\R+P]1;?
M$LYL5F;Q?9RI.*F$!LMU<KJIKH:H 84<)KEDVQWK38;CAQ9OE)X*VR2<^ZM8
MAJ^BAH8(J^4PHU@KMV6ZGI\QB#"$H:/Q3Y<;*9'W_!!L_&])04C4A=FOS#;(
MW-HM?O9Z=*4!!^D0U,1FW[@,&^BGLPOL:6QN N4U)%:]2>87SQJ1-+I]'[8T
M_2%LYUU7MZ,=:9;V/X2!OZZXG<2."(,KUV1/7"5409/^).GU1# C/,T &4CJ
MW%6KG7OZXX]WNVLR>/J56:E\/,&$'.U@DM9\5!^$ZRYV $0:9;3;<^];-6IO
MK^!"[2<ZSEE!%PZVCHFH7RP7*2-BKY:)E;P&#5DJLTKV*$S4G@$0%(VB=!*C
MV? \%.]A>NGC%51U:B%V18448IFE(]7O,WQ+!$(JDLI)BM"B* HE\&GGFN3Y
MDFX@5D$RL1C/^56R)I_3P6.(;XZ>7,5_D):>?3<&(+T#-_$$Z&&SE^B_RNJ;
M\PX2AXSVVC)LW==*_1U%U[C.6AA%SR%<O!&96N!LMTM5I>9$CU.PC2@?[K+Y
MLSQ62D>UM%RCA5)%>W$1_8KTMC]!6'AA=.<5P"(+'<@#V<PT+U!!F:KR4O]"
MYVFHU11?00-1U!?GYC=Q\)VP/:)Y^W5X/_-!@4#-\4X&LBC68-+R?-K'M,4.
M+UMK!C@>[8]YVFEWV6E/*.U4^\1TV@TIV0'81D-E#GAZAG',L X1S[J:KF$*
M*KJ6.MY2$#'D%I?N)7=.<XP(7@1(2E]B9@<\2(^K<LD:J?E1,"7Z8#3ZXOCB
M2QW3XHA'A93,VU;_NN.*) MT80^8Z)L'R!565K2X!>ELW_JTG]0B3VRZ#Z5B
M^)=3Q?"CJ1C^C!3?6_.<+\BK?!XV?DF.[>(;J=U9 PG)=OZS"WYC,)F2]?Q0
MDIZ_90VU%=S(XZ[ECH8FL;KVGD)Y0STJ\IS#-<\GZT1RC#5X0@ZP<SM[+5I2
M=<J?"4L'+8XX!8N2")T#N5;;.NUF'074Z#B1/M9LX6,QB( [E*Y4GIF'W-P^
MU"'/T"I;*0ZU</$E*_BKH'J;U5(,3Z[CE(]5^F5^"*;^0J<;'^D"E-?I3X+Q
M$%0S%VCL8G5R\N*X;:&5Q>>94Y,2I$5^/JF*2QUYT0FXTH7<QQ82GC&X%.U
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M(IT]XZQI:)9Z=7@PPC.A.^=P)9+7K^L6@@+3!C(4U*TJ!FE!X8@QL2 OI*'
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M'MTN+/OR,K8NX-7&5,ZVHFY!U]V8] >(<0U)I;:N@0_A:9)UGCSE']/HH7T
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M('KWB@H1I@J1@5=C%XQD:ZG0$+Y!7WE<7 43$BYQJ*MF/:@"0_"=8BY%VB:
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MCDG%ZDCG"&>N!;!;':^%'Z\K"P9Q^C[WU +X"FUTL=/=[[M6*F"\NL^^*PG
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MCW!J2;7A(31WMG*P5)%:UTOOS0(+B!AO+R.H%&48S7\JN!'-J\2=?@F'@%G
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MF;TT(,! ]>!.@!>Z3)=C=NS'YGMS\WT9I.(<82NU"DUMHDR+4GR,?K24NUM
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M:P/3Y9YA;P:MS;>$W$.D8FUM[&%-KJX_HJIA^%5J18.Y66_(HD*%P:(24?;
M84'OM<@E'OR4JA":&1A0CZ#OT@S5T=T3RV'DW:GB$/F[KI"/[:'#LAZ'H)O
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MI10*!VV(ZXO+<XP3)T^"X)WG0^H%A :2>3\)J"#3G&LJ"5(D;O<$F4C=3B"
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M?)KRDWE&_2)V"'-ZA7VZ481R\(G?P1O"*W6E=-Z:+9%AIYFN=+!\0BOR*QB
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MG7J]]A==X6F'43]1<"MS^@&6Z/Q2UY4B7!XR$6TV_[7&;EM]\3=\S,?PC:R
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MQM&V0?I?0HQ9^)E8X46UW2<'K(XP08A5"2%)SPG_*0QZSJGN<K_D+G<Z!-A
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MS@-'&2M+>\XY%2?>4J,*5P<=(00*E2+J<N)C+^EG\*=S,._!%O MV%>%*!'
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M\BJ)[Q)O(!<K+#L?Z>9O_-.9%:S0O%:>'HY)+A1#E*@GIHQ+J3;?)[.#P75
M(WC<3-EE1B74KT^40V/5TW7('G&RT2!^+6!7;F'F7_8M.T 54-[F';ZS".X[
M,I^Q":WOW#[&8J;QM7I+E(N3#J#= (Z%(B6'T&>T/-TLG&"/"K&]AT./O1/Z
MRU$?:<+]@)_(%(GP_).@*\'(O1F&S\+ &OKL_&3GY/SXDH>F%A6F:<+F9T5W
M&RORND"-63XQ!5I,3_J?W)W94'U2$T;*ST/]-@W0ZB@.5>F72K^\!?W"SA\<
MU#.;Y^M*\7Q=@2/>@VLUGD;#"*2"8$Q\O[FZO73ND(]M#-O!^0YJC:HLB'/X
MRB,CX"+>=>IUMW[0=MM(7*NJR*0,X$LXC)&M^A9YDA&/ (FSXM!/G3]#0@H(
M!K$R"ZB4P_/#V+83;M&'8!*W'GP?@PBZ&I+?A@(]0YZ-U,2EQ ,J@'Y66$?H
M]TBSX;A$"$YCHNO#1@C!-_K8S(?U#HH/MXR?#Z'8^$?[#;K6*TG)'DY&)LCM
MF:D0^>"F.WUPV'7)'DUF1TVYG,=-WHM0&QJUYGZEUBJU]A;4VAE>\'C4 X06
M2+.=&P8O_0HR0N&68T()G6@XE7HN"A$F\$M ;!1#ZW.8-4B=38RM9!(AEN=]
MV&.<8^((R@)"07$PZ('5C\[)B#YJ["H,N8Q#K>RL%6K%E1BT6%+8J.VDM-Q;
M!YN\G( .ANAN--_E%0H(%T&AS. )JV*L" C!M>R/)23O*']R<C@7$G='J>J!
M\*UX!%Q]>,,J_*G,OO E0,G)#NQ$A\=DF""QPZ$JSK 3]W8XSJ"'8- "%7\T
MP4VNSU"C"^L\>U C-%<TN[69]N2 Q:JW9MM <:TF",?T/^">ZPH<8W")H18G
M H;0:-04C@;L?S=!B(%Z'6P@^#P&\S/RI4'K>IFG"G@0 J#P 22YH5H>%$5*
M.6DJ'G%S4Z\7(+) %O?!=E,X Y(ZB$'U!B <@O,AO_2?(EC<KA,07D JDDQ0
M!P8H98BJ]3[N2K*.:RNSQU@NG13<8%0K8?00]QFK6WG:))971R?\#[#Z$!':
MTTG$400J/"!P_-^_?%/6*]7Z"VX[L1TA'#&!I 14X<^HP3!-$\C79+:[SA_Q
M(X)<NPJ)P;/ Q:S%59-6V<+R=[P/PL3 F^#!)&AD3F>F^!PB"8/K*+KKC?H.
MUL_L8GT66,D>V@((ML8\V?C )X:*BQ^5D%"BE*EY!W"Z25GC7L B=9^8TQTS
MFR!6* B(+0>"25R>B)R!&DAWX7C84@,KA!3#*O.A@,;9_%?$TK$5QY%@0X8$
M]YE.O2!$NS5KE\,N\EG<*8I4N/A 'WMR@I_#OA"*TD107XUP6ZL2L4TI$6M7
M)6)OL41LTR[*G.> #H;O*^!W!+W" 4!]@1*Z\X:I0FY"]80)W7[@WX&_34"/
MRN[B8A+.V<BW36;7<)@C2DY7$.L)]1*N)M2E%'_!=#3J^;L1,X%H;CD)6>#S
M;7-NR.DE,@J9=T_H\P)BF$05RA,?CXAS!<SX[R63CYNNKA;PFBPWRC77O;J:
M]*.S6-.8Z _95Z&N=L'7Q^ZC3I ]HDU"+T:(2W++Z6L^LF\!EPDYB/2R)Q=-
M!G=F++>47"I!?@BV>?$FIY0Y=AME9)Z"2F#3E\"2.'DO-09/:!K<@PKA:+O$
MPWTK=*ZI[&45^!Z_/;[4EPX(#1MB*&2\WB7I S)R"@%_\'6],"(XMM)TACLA
MXU 2I7>Y[=4G\H.PX+73=W2&@L^" #S!(O2?%I-J*$\0S)1KT"LS"'V_']AC
M%'E:8,B$2\FS>+@#4ACH$C"%"_:(1F^4W:?,8H3FCLP"L>8J/V,Z=[00_^'@
MB?B<QI(%JUBK N;AD1_8XA69M:W%430 "X]J8.!C6,LS,2TN)%?L-QH_$DX^
M[#\I#ZON:$%Y<SC'B9#Q!+DXM>CHH9=F=%) @<)T4Y="TN;6N./B/K+PRU4S
MXWU>_NOL1,Z1(>3)^1*3="0I4CS&R!SE=,&!0EJOA&SS=-S-<LO\+/FMNMRT
MK\%U1ZHPDHF9L )1[S=MJRZ"O.F&<A4Z1_Y#F"*F,M.1X4 ,O(=A^@13MQY_
M(J7M[H >AKW#?R+;*KE:W/P,:YJBCV57;U)Y! H1?>8/V;<;VK=;W#=5B8&?
M[ 3L\Y+[$JK&5N5VT+S[X0]X_GT<DV"DHRX^E(O9DK%DC>7=T=Z+])64;$C.
MP01-%&PFZ6@K?!IBM*=^Z/@C83:W:EO1^0+QKP(BTP9$\+K5MWQT%W.M'TF+
MG%GL(,=#>85-E4Y#"Q"+#A]"%?^V3(!,W7(XQG-"IS9YTETZ( ,I?UTB/9JZ
MYW+L8U]/CIP>:$7T4+0"E0/(L7O495K-)J,["LC ,_4K"'JLF8V?>#V*3WOR
M4F#&93$X/F;J!HR@%_8M<'68SJ[."<!2@SH(R.I@N$<=H\0UHN ]XK .LW"
MP7<RF>!P@#2,>J"EV"@G;-=4\6)Q+(FU+8_EC[WN/7AR.V!@T,_TRJK:DZ,W
M/I9#_\C?1G9@A3513(\:11Q\M@.LUC5""LZV>.V(2'FLQQFE'*OPD _/\\F
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M4W2&J?MTW ""*_V2OC>V)-J"ZPD,W$YN 5QJ*QA%"M@@%]? IHR ND)A'KU
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M"/LL-?R")@A*(='Q)4EU# A!<FT I;$[ ^\@6(T!XB+!L_I/INXVOSZ\;JZ
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M@E G- [H$><.!2>*,6@^2CPBX<B=EP[R&;$UEB)-4>Y9UL3EL?"IT1 5":L
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MR\I/L?#FI74Q:HC_,<$D_ 3^JK"&@=>]5X\;7TMNC<<D.L8 J(;^^^[-KC0
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MN<?6<Y+R%D[]@ \75G/ITCC,-3QX?2Z G(Q6\4I6^.70P2N:]]7QNV,RC!K
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M^N'O?_/#!_Y7:93@KX49_O4W,T.:8"Y&("$"GMZO^8D-GWE*<1FF>(8ETMT
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MX/SR^LN7'P_7MS?:W9_]^^_]BZL?C]<7_6\/VO7-!<B)P7[EQ/()W]P^7CW
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MRB]XSMKZ:;N^3[&S)]JO.&P['-8XO$8_:@YKM%MZO5XV#BN/+UMV,WN6B5K
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ME[$68ZF0?(IEDR%Z2"'2$'!OK D(XMH>!UP#@"AG<9F!PUXEN!"BTR7/E8(
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M2>(RK&=YV4I7(#B9X[V@6SFS18UP#YACLV<6J/1(T@$,'4$BAL^3I+P(^\_
ML<0X]=1<!\0G&S)\)PR8,P13Z\GS*0VJIOWIO<#@8)<;88Q5_S23]F1C*%WF
M2J'Y;5.S$3B=**0V!H2&Y04!74EA]Q6\2J?<!CQ ? ,,TR%B].MHPI(:8D)?
M<3CZP'/X#9F \I^ > "> @KD/0=4ABATTT64)@37G!Y/^@%(*Z4&)A==IG,#
M0ET<+D69WU#=>5A6*.['9P'WQ;R+3T''QT0.OY!.$AZXU6@$(VT(\BZ!Z7^[
MB=_4DG;D.6!E!%=_178XO0%J6);SW2YMSG<G(^=;7>/?-+Y*D?Q-K@U]KOW3
MP RA\.TG@1>Z'4EMS2VP%YHN)8ON;"-#?">==A*%GYT>SCO'2,^G\$A\('D8
MJ)>X_6"CPS\D^X=R?(#2\RZQ.PLNL9NQI( _F]U_/42#P 8SP9\^& Z['1(M
M4&?KNVC@V*:<R#5&00)PVF^'/S!$] )S%XU$"_:YII%Y=\1+2E:ZHVXO? @X
M6?IHS33I5DOOM+MZNS6/]: %] !4 ;P?%Y%\0"2?Q"AH/: @,3B!R^9[+>UM
M PU8<X1&(OBZ9NRKQ-_-O>#M9$-N[7#_?SQ<RBZO<Z= O^#'<(=K2;ZX5GYZ
MK=Z<K\='!X7ONPB?X<1QF^*SF"%D\@^,)(N?O3+?M /*Y1Y&CB,]D"A9NCS0
M MIQES2O0)DHW[FET.FC=R?(IA^G]O%?8W7(AQ2-=%.[?A(P\W<K\BUC"L1=
MG[5,3N!]3;0OXMX5)TXE@Y#O-(_DK2M[N/4DB@>>P,=X0L<"*P\F_#(@F E%
M+>6$K%2'?0FEC*P)<:<18*]D9 ETD&Z'7"O2,]?*RVXU<A*S=='-R^+=(F&7
M8YKFZ39CC,KP[%GL)44!6>[V)6FJJ7"%$0H_!JQ>C',(!V_-0Y_U4ZA'%_D[
MF/K*6#S^#"MRG])P W'J+\+02M$GSW(S5&K*3\4ZRP(5DE1R@=?%MT-ATMWZ
M]W@Y352B$(,T^*[=BSBZ\D_PDH OY"[@D,J9RYTHIM4R)P%\"C\%NHU;CEX8
MCL.LSU,Y'?'%=:N"]$ZWJ?>:9WG:+J7IU!/D0D$]O_BPN,OE)O*7J[LE;'V6
M#1%SF%/*T7V94[D22R5E&'\8'U!C7;W8[#9R-:.(;5/N-#(!8K5+AD7Q?V*_
MGHQL"RS2W^4V-S^<#T'8_?$;?O=<Y%<-0781]\G DBT$V?$&=S;W;^K'X]^4
MJGLH!1XQ)VX3=T8.,JM8C#G;>HGP/\U.C&S'B9'P9ZN18RV ^(#)X%=7$^J[
M=%4:#?VT":[*6;.P\,YT09;)Y"Q<]ZWLV%Z=BUP)BON2LD:7[4F63[QM@MJ;
MF=FHUUH+S<PY*S//L.2W^3%7B@OU'".SB(VY2 IDF)<YMF+>:6:YU?((%UL=
M\T<H57Z)#;[V&4J->1"A(N:>4N?"^V>#]:U6J*U^B'%^B#K>WX*-S<AL_.@M
M'FA9;,/6UDW#WCLQ#5>^]TLB+PY>E6')Y9*6T3DVT,P%M*#WA,R---"'@1>O
MSY0O1X5H=(V,X]U1OI\@)S*,$A@%+PJIN37/N^ /V,B'[F8#\RYC*YJC>+_,
MDA%K4++K4!+9Z$5^6C[RM)O5Q%,WR\O=<!_+(9# D,@31V0*4&M,2URA)A@U
M<@>%CDD1-GV+[EEE:E$2GLS=Z&8Q,VU[>T[AVP4;#ESG/BD!W MU(S:S;^NU
MA7J $CZY,IC5[2*/*;W5 X;R0AZ'I:NGPZ^1A!SRF<E 45A@.+_ GH $L0,N
MU+83L>MFP2\N/S%0 G$,B(Q"D,)=_.6QBYZY^R84-L^XC[']Q,VI>/OQS,7)
M48:(/>9Y/%@XN9;<RD80W-Z)E$6(M9N=#(<H;56I&PL.D.VL @+6%I!6/"80
MUSBN4.*(?4P7&1? F=Z3"]:/1?EW0!H6.&I8VNQ:2\\XJSI\7F3FX/!?T@,O
MQ?/04Q7G(B7@ZCYJY\-YLY;!'-)%!<'BLZ$C<Y'2&N8)A!1P2\"-*/!B60I6
M(Y9G!$XFV"%4V B9R@[F]A'SZ'"C?2LIP$B C7 *"#%-N524(D@/36</69N?
MOD@-%(LS?9X%R:_2,*!!"5\&@GB8,DE,E2,BRX6G@D8^UL9+63.)R-N/!U$N
M8@=&())E+=N)8(55E>O^JEQ;595K5>5:5;E65:Y5E>N>JEQ7CA0M "HM'AZ]
MEC:)=,JDH;O%H'=WTZ#W73\='?T7%9@R'^L)IC=@#]+W_[SXIV&[+R0("2KZ
MV[>+$GMBS?9J?EA29I**B,N@W8K^U:9AZRT>26E<L5Y6)F;:%:-;IQ?<9KHN
M0/N<.HP(="YQ1C&;)*E(JOU_O)'L(DD."U+7WW'^@G"],?&3/1M.% -C,Y[P
M3\85 32FXI2JBZ?(@5GBRK\92/)*EJ(*-7H"52B=0<$=7)%" 2]Y3#'0./)V
M8/KV0!3QP$SZ#Q=Y#^DVVAP%.Q>)2V(E(5PAQ9WL9U$V_2>SGNA"EN"@@$5E
MR?85L&$X12J3M37P:Y"A+ZZHJL"/9!E]O(1M3EILLE^LO#"(!O\6&'P87/,&
MO-7%E$K[@R CPF9YA08>(I1@@H?@V')@DW+6;*/@HD^[]>04[  =],@."%U-
MZ<O!;^M$W0INL4'U:=/"^P"N/W6VX"Y^L24JT*88B0A"/^)@Z@BHB&B-6 R.
M,101,(.]<*:$M"U0Q^=W=LP8C^<07*,M^1-#6I( U2?Q_5U.-H*0L7B8 J02
MKE%R>&!Z$XR;FHRG1:N[AS+D=0[(.JD<0](6]T(8(J+BLP&+90D7#*"\0+P1
M/C8_(WL(1\:8O*PKB2;:LSSN!\MJ67>#[I8A7D>&):!09!ES3);JG2J*"9,C
MVBZN#/G]D/[(:7M1\&S#*D!1P2\2FN;J 6>MO^RJP$YF5:#V!Y<](K@!G/^(
MK[,#+PI%]N8";#GU7K-.9HH@ZYG=@>9#.I_ 6F>.@ZT"@!S(LL77HMD0OC[_
M@_<+*M#];MV9S^P /C*[+=[Z8\IH5+OU2[I'TNX>U<AXDNGA5KN(4;HTZ+J%
MF:S;1C*UA#5*$9?-:[G,E3NABESN!PS.;Q/YQ2U_8?WOZCS7V+/=$MCF$XKI
ML'44=-@K)1W>2P"".$*2)L>239>';^*HPW&QSGZI4\ZG\TOQQKOE.N\K;%$E
MP)N,4&GSQC>6&@)NJY_M\>C]O9U1L6:Z%TNB+^"0G:E]AQY@"C##/IJ[=&)H
M8X++.F2^3U?T.(X7%_9D\/6B]I.;'%HVP^[_247ZEFY32N0U*CUK9)=JDB>2
M$P:73D<_# WT3QX]?N;]B^3$[^2!D]^RP3V$8D>M%]GNU5MZ=U'WTYW2PI+&
MIX>DP_9N5YD3"5!C"MES.]WEW+(4$_8;SF&2K(;T>V&2<MP,M5JU5F'N:>]?
MO&U":@=A]H-9B>4R_Q:?VW?J*H9X?.+LMF41MMMD#%86X<XMPNYL)TJ)ZDJ?
MI2[T*E.P%*9@5NUQ<2W'T\TSH"#$N>.Q;P&D8V-CL*$WNEB6.0_V4B8-\;;,
MP0PB7V)Q=?9,B_^B(!D-\MUVL>M826VQ1K.6D3)5'CLZ1ZF?Y-EA.W9'<HDM
M*Q5L7\3&6]R5E=C:*Q!;94F7T9).K*YF:\NV=!5=W;TM/6-#\]3E1D^!1:I,
MYL.9S,W-HJ?9FH/RBQN]-&;B82WF%N+6->;+-,ND"=ZYQ=S,1O/;&2D>C<&\
MB@E3V<M%[.5F%EC GDBMU.9RI]9H=,_FL2'*)"8K@WEIZ)DW((C+OX&X3ZLH
M]+%;SFK3I\I\+HGYO*.(LSQK/.HR&-#-1DMO5_D'5?[!FOD'S>Q6%/OADW*8
M5IE@9U4&0F4&[M(,W('E5\5,]V[Y*89\9?F5Q/)K[2)P"AI-GG59++\66'ZM
MUCP"=)E4067YE=?R:VV6>;H9GY3%\NOTNH63=2K;K[+]-K;]JM#?FS( 8[RO
MRO8KA>VW7M1O)QU -C;P%K7X*).\KPR\$AMXZX7VWDKWE,J*JZRXG=<0M:L8
MWILQX1:BM58VW2%MNM/UXGF)&I/G&K<OX*=ZT%O;!?"T95("E6E77M/N=+W8
MW>H\40X+;P%\<&7A51;>KBP\):=KZT9>%:?;NY$G>\;C<3;>;K"N,%)7N>R_
MPM/.4XGKA?Y^(-KP"\$WQS=;\W=:DGQP2*5+<QFN@1MZ!RMHFF>',"8%1JIZ
M<)6%^38LS/6"A[MAIW)8H8U:L[)!*QMT?S:H:K1TJD!C#FSU6[+96F#\6%Z$
MN)9'9;0MGG>.FFGG!/<.8T]U]-->3S_M'.3>==:>:JUD3VV9X?: XIUHRW45
MV XI/C',RCNY#7;N:*F%J_!5%LUUY6^BB<-OU)A"ML],-=$H0[N6G U*;4E>
MZY8E75HR6[M\V$(7ZX;H8ITC\>NMC,;46:U*LH4_M:;.E/P!X7TS:\UDF^PR
MNB2NQ/CHO--7SO).=[0\Z=-8_)3 '[*]-==ZJC=;"]HCQLM]84G3>5@U-9;V
M/9,QB]KC&!-X]0J#4A/Z/$>RGM6(/'=#E$;D4M7?B4>GNI#SN06KMR%O8QOR
MYL(VY#5M>^W<\S:FD]VAO1%W:-\-(YP$S,3->0'S+6!N:F=:V EL"TQPMJ.E
M;9$)&CV]4>_H[?KI:EP OA1V45=X(9?ZNZONQ,ZIO_/AO%O+8'U)_54/^+WU
M@#^M>L!7/>"K'O#9/?&J'O"9/> +-&/?^RK4G<WRJ Y#E<A77&PD(B-AE<V[
M)U[:@>EX0>2SVR&VG&1N0-V&[OG5\X47A '9-9\-,![NC"FV-UW00_$LLX?B
MKEM+-YKQ"2[64F<UX4D/Y/X.SNFZYH36I:E++T\7ZHTV*:9X\I:S2=[.V[-F
M7;0UENU[[QS#+5F;[MW$&6;[Q6:UB,4&P:MN'EK<S[8%<T4CW'9-GP'UQ4WA
MP=Q%[PNL<='"%9L8^\_"9L><$,,U&7[59[S!,#/,4:Y+)]%M&]R38W]%V(G>
MR_-[VEG6_KP@^1<NZ 9D"5V9\D5>NRAW[6>&G^$.S%V"WD4S'A)X/_@;XPGD
MSZ,7&@X)F^!*-$+^XODXUCW?B%NW#_^%%3G M7;B-IPT"_H-S0_GIQENPR^X
MYW@"(<Y ::";V5<YW9I!Z<%KQ+^QQV-FV3RN,/'!K:;/"_O>=%:1Z[  6U7C
MO^ #8PPV;0AD &/8DXAG!@VF\1RE^,(78SL,&9M9P=\"L*D-W\*W+?" S=#S
M@YK6-TVPM&%^SE3/I8M>!ETT$[J0?Q:GBW\]1(, 2!(^NWJ&?SQ.)_Q7,^\7
MRTQ)M)2Z&WWT-)\8:JW/TSE%U@<GV;HAMKL=]BW>]5W28#\*1YX/XF/M"%7]
M#'SSL_G:;$EAY)D;EI6D> F.%Z0D9& 1_J: 3;/&2:</QG<0@6@0S\D;86Q,
M^8\&3.E/8L;9#M0-GN;V1/4$*)U(<0Y(<1JX@V#L@# #8XYZJ'.^H'[E\ $\
M/P3;))1][>;?H7-%>XGW*I\@P]B<E,E="2A2XZ'8TT(@$1Z[H^?B/F$?=YP(
M!O,F/C(=SH:+1A/F2*\,(G(2G_%ZP$ <QQR[JB@'OCEXCW @'J*@'*;MY$&1
MKB7!=\-[@N.>#=LQN-C_BM2V9AB\6]=[&<5TBF!/R7!#/I;T[# *04DEZI9K
MVO5HY"MSF6\X*%EQ ,$4VLA %M?^P-:]<D2,:)[8KR<C&^0!.##B_-H?SD,&
M5A=^]5S[-6<*C3I-X"./]N*AX[I)WP.A$P]ANCSQ!ID!L 'A"!24[8(&<QPR
M[#7O&19;9&)G,+&1SUB1J;64F07[C\UEFXZSQG51<S'30EQR5\7-1:&'00"B
M,)+B3PA24U7A[!7_9GA62#=#SW&\%Q2N\@,3Q-R31UU$@9I!?.*!4[:IP>4J
M_$L<Z!#(CO$6LMSNQ!$G%'0.X &6C6-9OQ\B8KJ9Z_J /0,C!PS'J_'$\::,
M/8#NM$VV0!K!'IKTU^WP'D[@R475SJ/OY.9F.[7=3*=6^X/N7V7$:VB[C_@Z
M.QJW6M@U33[UR>LG$.',P3[?)I  R4)\+=(LZ#6/E>*?YW^("^*E256+TYR6
M<D:A._+51XF;F7>*-S-?SL7K)VKO)[[V2?;U_M_XE@X=;&U)__%=S4)U1(JW
M%E]^#%E9UFD**)@,6&*Z;;Y+ND4)O5]*J4YN:R=7+R6/%TOXW4 2R NMLWI>
M)O6Z)F*QTB\,:A$$ YKF%GMFCC=!FVVE@JZU9=[: V9WP]@@GW>M)R[V>;NS
MW:@7!3#!U_7&[$&:RM^$=4C>L#R;OFM=)B=SQ:WOK-*.6>-46)O,RC9&Q4CK
M=IT[U>NGZ_?G7&O#MTQ%[Y LLW(&Y[-HCI@L.Z?Z6>^ 9+G5BN:-S,S#*!01
M;2)]8EACV[6#$!W_Y]7 7P[ N_NK^-VE]9;'_,4R:G.97QPO\'X_=;@E8?^S
MTY;>;*Q?<;*>>7F4JNKMDWM6OO2*NJ[DY([ EJWBM;1[(O>R^%>'4H&/_ )_
M25R][.IP@S+%?9N\VRB@[,YVLU^KO&*7S-[MG>G-SOI09ZLS^VI%DQ7M'HYV
M5RX3V;==UNKHC;W:945H]ZBJ&?=_59S<^/)[QB :P^_@@0%=W^(1/F.:@8(0
M93A..O?FJ*]TLQF!(ZSPY?7%'M#%:_;=;:^ZNZWNP/9RDW(C4W?3URE[G8/@
MB^HJ[A@)Z)]4TL:O_@]$/P8(&^.)'7 &LDA5FR#FU0$G,@%>IF3!F4R,BILJ
M;CH:;O+9V+!=0@@]V!S4-%3''AYR.WZU79Z ^K%BZJ-DZO[3D\^>P-TY(!%=
M SG;;F";!YS#/PPG8N\[;:?=/%S:SF?#H;H (YRIOJF7/*R\9,#>(7(BNO/E
M*8U>,>2\M6M.A)^D@.QQ[VW-#K;UGMX\ZU3)..LFXQR$[GJ%Z"X'LG>+U">-
MU3ZW&%.XOVO>3;9K9[N\F5P/S/%0H:D,4VDM&ML*1N&!-^$=;^6[SP[#@DIT
MB2LC935ET<S*)RX.!+<MC?%5 -'SBK6OB."V;K.%7JNA-S;HW/4F;98R4EZQ
ME.$M62S!2@2X?:NE7NM41LM;T+3E'.4HM[(L@9=#&2T"!7:[1LM*,=L#9_GN
M2.T4GMRO>>II,_#?;1E&1",<WT JIS4-H[-Y/.5=)L9ED^''RD1:Q41:)_UN
M9R92!BENWTYJG#9K[5(8[Y5Z+]DFO..M?._A'>5::@['OXKYK*I66EDMG?9D
MSVSI8JJI-T_K>C.C-<"[#O.4_6H*Z:L Y1WKU51WA?Z3[]%T62^)Y["V2\7<
MA9D["XZS4(70%IDZSF&B1*(UE4NWI]<[Z[=K/C36P]$'QJK;O'59<+/>9B6\
MS>LVVOK9(7FQHKQBE+=.$[DCOLWK[K+F].@-O:,)K)1SE*/<RO<>H_KB^4-F
M;]ULJ>[SMG.?URK6^677II&@DLAG&][GG39[^MGI7L,-.[_3JVA]*P!5K:QF
M-@>SQ3(H?@?7AK767GV$?5;&5:9%.4<YRJU\[Z&E6[6EV?QM8F/'QEMK'PIM
M,=13&33:6D!4I\W%K9Z.Y,JRI7>:';W9;!U43^V& "LRWQ*9YW0T>P/WH^W:
MZ5Y3N_9#EX<([VZ\,QG7LC%E;H)QAK0U6$Y^@Y7)[UX"?EQX,>K&(_/'S0\I
M!CI-T2.V=_O=BGR$QL#K^79S%H"O1/<(*[7[/>3@<P2X6J/B?&+DXGB9:=RL
M-TZSC>.M;$ %QK^L<H%T 2$-5E;T\9@7G<-9T0K););XUSBMZ^WF7A/_WI05
MO0,,XU+3_-FA36J%\G>1<M@^[!U 95*7W*1>3'Z+3.I&VJ3NYIK4]5YE4E<F
M]<%-ZJ,/3/^#!8AUCNVML)&'*8#/J:MY96(?C;G1SJJMV9.)S4FH[UI7@H >
M/7RKBE^7A/K?F>7=SBKVV:OEO9PAJAAW99#OVR!?F2J+V>GM9A7ZKNST/=GI
M1]+;:+659YOOZ_<Y>A%LK FX?.T)RQ(TRPB9-C1L7WO&&C7-&VIJ:R/-0%D1
M\"_#CU^,0/OOQ6KVK+/7;+]-"B_HPTM8_1=8_ ;U>9G5%^0YY>W367V?8"KE
MV*?.?)A< YU K;> 0*EC@,: <BTM1^C$SJ>:D[;XZ^"ATE?RAN0>+'X)CRW_
MBW4QG,\"U)?V,W.F-0T9+*2&F&E6$OW!R'&&91W?:OD77YC/\LDY"QMHU;:2
MVS%E)!G'Y-J(Z;53D%Y/VL36\]0*<MPAH;B,N[/2^U?M5%BR[9C/:);;H<\P
M0][&K*P>L@4>:JCK((B8=4DLQ==(WPW4SG72A5I4UD!V*2S\!3S,@+FI5;<^
MG-]X\XN6+$T\(=LHQ:QMN%/D>^3P"<TIT"8P)[3WK9K6#P_ Z^);,"68\#+]
MW<W)^?H74=?C=,*H:_35>.)X4\:4_2[2*3K^&?.?P:_-UETWGLM%)CTRH%[#
MZN<77A#>>.'_,GB,Z3VY8#=9:]%UH]98S.9PD)'KQP](-S@V80IJ4\A(S#@F
MD'!DA-H+#*4-F*:, B<@FB-K'JA8S8A-LQ-IFG'2@><+2EC92RQ^5'LZ'"&$
M/%^\A=]+>8QGW;QDJ48B?F*#GC1H3;M,Z]055&H<O=8U8A$< M>!/"SMW3Q6
M*59D/',4L!&T2E?L;C#',^4N@F]UVWHSHP0>:58N3/0#3[5(!4X(1R >M73G
M.>2Q7'E4K%_URIM\S/7>(+,RA%;<2$_7@FCP;U#'\L8&V8.?".PM$CFN*!B*
MS4:'#Y2W/;3A"\HA:B:P"ZS J&GJ/L2R"[XGU=S,N0N7T0Y(ZOG(CB3H\-LX
MG3&)S("+&"GK<#AFF",4OO ESP5=-6+N[".0&"R;4Q2L%;8&C@3F[7L#RO^"
MU< @-GNFD^*&N>3I>#;+FM;3*!,8\Y7FZDSS2;28[;L=[;EB^^K53+P<5;BA
M:,73%0>>)A*2"@O.-_]LT0C_#885;X%U!=IE,37B"?&XY:+'O8QL(#\RZW*6
MZ'HAMZ>6S:Z8J3>[4;E/Y@_F8C63;M&Z4RT-UR*#%"S09]N+ F>J?BI_I-@P
MX<B#-\2.>;[]9+N& [^:72M_#O T;'#M$+VOV:OI1!:37:8M^UGVF+[[^N7Q
M/K=IG])T6K:I3HTP&I[XWDO\T>QGV%1:N_MZ\^/[\M: <_&\15'LY&EY5--I
M<PJ0$_L-9A:O0'F1^GL4)S'<];]>G7R^O^K_STG_R^/5_>^:X;P8TT!>L&&4
MT66I#?JDC4A]_:XUL=.\R''XKSK])RO]07ST0?LM\VS^O,P^&XSO;N=D'F\O
MOMGNSP_G<C\U3C[I34O_4R$HE;C24__\/]EMR^>CZ.(=GV\<O/7A?.U=R%I^
M[K*+$(7Z9W:H>HYI=4ZR.DIQ>[@P4)]QCX"+*A@AG^6* H(BKXVC)O_?A1^K
M8?$>+W<=G%]>?_GRX^'Z]D:[^[-__[U_<?7C\?JB_^U!N[ZYJ,5-'TLTXYO;
MQZL'.&WMXO;FX?;;]67_\>I2^W)]T[^YN.Y_TQX>X8WO5S>/#P5FO\MC3G/5
MGAZ_;+WK)DVM?^NR\)*%"?MOQDNRT>P!HAC;+BC<*)"N[6<'1.W)@SGRP#K6
MOGL6<[AQ._3 (GRAT%,01&,U.!4%1QER_EU<)^[?JMCP)MX<,2MRV.TPVSM4
MXY(8B>5N97)HCVA:/<)#/X.)_U/$1IKU3J>#ET4,+/H)Z@L_8E(#_D'WG5(5
M#&V7ALA64ZO9(VEZKF,2AX9Z)I@8)I 3.:SX6J1[T&MN1."?YW^("]FE"91;
M:%![5O]E2] *6G)EO;@A=*L,#:'E3+LYO7FWK)H^R9[(G)=WVQ(Y[R2JH]WE
MT=8/=K1E2;E.RY6#]6(2.==@"6B_VCS^$GS<*P9M>XT!UX.0$0]LE2C-;MT+
ME+4O;>/[6<4BB%/RYM/KVGF7)?6"R76KGW F#NLF9WZ,$+EK;%MF8MT2HIS/
M%RA*E/^Z1VJC[WRW77L<C0]+K&<YQ-JNM1H%R76'\F&S',<Y@M@XQW$_M&&\
M'IXV>ML09*4#O=\:ID(9K)%[._AY,O09 [8 ?L$:,-\(6<F-D3R9FU4@TLG*
MR%S?,%@L@^/KO;MHB_?\66R'!_<%SNU:'-L]G%I\-7C2+'@WV") R[FKP5^.
M7DIO&W6^D]6]?#L4E);41TE!\RDCBRBHL@DSJ:M8A_)W*9_JM?G4\DH^S5%0
M5L+:+BS)(Z2@P\JG*O:5$?MZ]AP@#<<.IV_-TEPKI['4DEP>VC_B,UN?$YO-
M6J>2YLNE>;$6$L<DS;=*1>V, I[*XEQ)3F45ZQRWQ;E-"FNT*JNS@)PZ:[PY
MJW.K<NKTH'*JBG,FEN>E_6Q;S+6TJ<V<U1IG;1/58</;A-4Q'%:]EMTFRL3L
M%6VF!,F*?&REP&)ODD*2UGIR DM1YV%\%@F)'=Q&;?6&=ZL (!5K'I8ULUS9
M]95[Q9IOB#6/"9MGC8PZY2%JLJS(_<:$.OO\G@4A+!"C643KV@\@;XV73<,F
MG!?(T7\?X$2R1--&3 >L+8OWC:?'__KA_N''AX]8H^:R%V>J,8>85\>2I1/V
MRLP(T2>T,8F10$(P##S8:7QAV3Y\W_-%53[AF-JN%MBON@9/.AG#>D8PK.T&
MH>$X5.6K#1A,G"H&-\X?2PB!Z #)(( 5"9?FT0XQ;?S:M5 6189#O[D4<\[)
MSUA'%M(__L'+@GF%<KH.OY==AT\[!/Y*=XYYZ9- ,X:AJ/%-T$"4\@=1K9"J
M@3 TV ,L>6!_P:)Y :+X#E#-3Q:*K\:5XDJ%/O=M>Y^PLG,,4Y!U%+QBF HN
MX ?T_!H]1I8[ILJ279@#G(R!ROC$L5V&A=+PC;A>.5VEO/]:Q]TQZ\)2&LFY
MG#.3^A)>; #Z$WX)H\.)XQF#\ZM6D.).J^75$TYYHJ;T]UT5Z"Q=3*;DV4L)
MB,J>66* ,Z78RIP:D$95 U+87-]PE+@BH%F&BH"]EP%P7&80G^E:@+W.@5AC
MU[4(%?GLXN@DX,D!J4?@*!UP!IEUGS@7;7\$7645)+'=SX9#>!]@_/_=<"/#
MGVH[:5VP=ZSKYFXPU_.C/MT,D+CL4$^NX[,ST*NKOR(PIJ[!F?,C\N5N$?WN
M<62XHOXVAC#;I =!H]W2Z_6]XJN7'TH]:\Z+^@4<AGA[6R?>74#S%B?AW>'U
MM@]'VF6YESR4OOK*\0<KY;0R?W?7JN,HJ9Y*0PFNJ:; ANM6:NH(*#<K4V9K
ME'L0);4G9/FSYM%JJC?2*NZ/()HLV 'X_2<,K9\(*+E&$_S 9 H(C_9KX^,?
MO\$(V8YQ>:1&X9#+081+X=G]FB>$UBIB*ZGZ3$/@KZD^.WJK?=@F6CRT\_%@
M?+'5ADA%B'];]?.9!+Y6-EFIM6R:S'>F9=OS^,"[:WI(6$&5DYBK>I4F;7OH
MREK6!JS[4J=KM9W$K@8%^VF45(=N)53:/&OKISO5HEF-)X_1,=U%7]9R<TA[
MZQSR1N.Q9V7CGZUD>&Z6>@FDM9GGF9- RR%K/Z9Z2&"_@A%S<AO#]-:J[]U<
M_ =WAHTM=AZ-UW_B-#T'3Q3>R";Z]<BPH]=/,_H=4N<1RKM,I>.%'KR6N72A
M\:HYMC&@BBF$*_9,F_+&J D$?D-V*^&I?@&C50>8J;D$7+@F((B3(,(><WV+
MY>QM+[4ME<66D[JG]CV1'2$*=S7IK55>O(T\URVV/UFM5_9IYFWNTF9_O;7*
M9(]YIQK=[)VRW>RF(@DG'Q<:>>)14>-/WJ$EW>NP'!W]"K-UM[XE?V0+%%JN
M1H"YW8^6-P)<U.QOIL.?-M?AKXRU!8?K MBMYP';-FN-N;[QH@V@U+Y9AN=^
M<O6Q*PMO.I,TG$D:K6R>6W[M M4QL.TN[<!TO"#R%R2*-S,3Q7=M"\4=2G)D
M5[<FJM$&<N\&YQI?EP8+8T%YZJ&JKE4%*@0*=JWJ5%VKJJY55=>JJFO5EKI6
MK>M)KU>>NEI+J_W.K5P[=<F&S/?1Z3->,;S#P.%##TO&?&PF>[;&#:Y2;6DM
M>P@#,-=D6'L;OC#1_G5HNX9KVH8#:P0/A^H)3</WIW3O-09!+AZ$S\41*0ZU
M8 *\I19S#=Y? WZ!6-848V+P>#-$\U,XI_ >;PJJSLR@MN^R/X<G^V#6M-V&
M@38EWO+,Z0&^;P]M$PMDT)$"[8T'F"[O_1OV09LG)SR;(0.M#\1@<\,Q1,,1
M#>K YNW7^3AQW>JRFM-2=Q*3+ 76<9]VH.]:WQ)JSBD7;57EHJ4L1$+]/4_8
M6RH*JTH1TU5X&1D1547I\1_CSIN451F^JLBZ8:'F34#GTMV<XP4!-[] &0LD
MFW*G&96\(JU7;RR.R>>'T.?,@UMY3-_@E"[40UK[MK?5TL^:\X#,[[IZI/PD
MU5Q<Y'A@DFKIW<ZIWNC.)Q$<2\G&T>>-/B@MIU-W6267Y"4LVNK56UL3WGBW
M(]X3U_.I'#77^LQ<-K3#(/M"#B_<UKS/USNG#;W5GH>S?M=2OI3DEG5_OYY@
M/R"YM<\:>K,YWW'E6#3 T9OTM_YD9+C:I1\]:280 ($M5;)_56;,25W.9D9K
M.'0S3"PZ#3R,"WX6:QKKIV=ZKW5 KJKHIB#==%85XCNEFS8J_^X!E?][M\>_
M,5"N26KTP3H/[+[P<_W1EX"5+V]GTZN?;4=:TVG)2YCI(I;[#_,]RPA&<]R6
M-&59D]WVC)]?B6PBGAS(L^T3SY((2E=O]8Y77!^]\7QA3.P0UOH?@B<W_/ D
MFE 6,,\V\# ON[*F5V>Q+&"V->2S<CSHH^*5.=7JK>FL-O73>DOO-0\(AE91
M4#$*:M2W(Z2W3$%U_:S>TSNM7<(G5!9V/DB1X42\6L/ M""$@BVYA'[[4$.]
MQO;N/>/S[<OC71.GH(Z7G7KO=*^ 8J4#_*FH$ZAS>U>HVZ+.QJG>JW?TSNE>
MK^/SJ?.].P.9R7Q'&;_9(D]O-<Q3;%JK1H,:V[NWO6$++\+*$@5:!UVKTCL[
MTSMY=+F]"]X<NEQV0=MM=/7&V2Y3=,J!]S9#)X=Y^=Y5Z&Q*O%*NLZN\^#5'
M^2,N7*9YO=7!WN%FO?< R;4;&NZ3C;5!1VW$EOT2LI%U];^JV:E4@'WU/ MA
M1_JNE1PA5_^SKU>U4;4 %O7_/IQ45Y8ECH;G1C"R+KQ7-26W2VM+HF]ZL]G2
M.V?=_0;*JT@&/?4>:9*@C@*A!(Y4![RS0$969L)*UZ8*BQ,-W Y_!)R/CT9E
M5/&-4L4W<K523O^U7=%KV?)I=AI2/WI?9'$PH%)'I5='S:P<C)4<G!CH3N'S
M2A%5BFC;BJB9E7ZPDGNT"J4N]7PZ3;V^WSYF^[[874 KJ^!H;$:5F_UZE7F^
MG36]=V,$P2^L+(-DM3*-,F 4O.U&(KUF5L+.!J'5 ]H<JU^?5NUNRD2EN69'
M5N+)!E'9]0R.T].6WNVU#FINM.;-C0U[R>P)''HSG"N)E+@ 2/NT31-1&WA8
M'CPN!V'9]4(.L3PRGED:J9X@,44=OV80RN*AFBUX?K%>"Q+DJ\;[+61V,D%L
MSI#Y+ BIY&;"7,/A^**FZ4<<4A1_D+L71@(_B?N2X$G*+A:U<F"1[YO<1H:E
MW=Q^2X-\:2KT)NXY8;&JFS:)_(F'X*O&(7IB%&KHP;'CB!B'Z:89QX@2&HWA
M =/;X6*$IFQHT-,*&G1^ >6 !@46'! P,O)?ZBA_KR!"-Q""%43H.SO&"B)T
MKZ+K"S<,CBXD4C+8QF9>=ZXXVMR/PI$'!LV4MW*"-\'",R\0!]^?%NF\M6U(
MQV9+/SUMZO73JD;ZR.@M"\"J7GIZ:[3U>J.EM[I[3A2KXN(JABCX3267]V7$
M*&CF)  O8CG::^S\X &!_3WR[<"R:>!#"?M61^\T*[30\A-;3@;P41 ;2OKZ
MF=[K'!" O(I,SX<*)SX[R8VS-;H\SN8NZ1V@#=@3;QML4V?@Y:V^^;@8C02%
M-"H6DJQIU[GC:C?>LVSTV^B)1K]*-R(<TV?4JPK?!9K%[WK#N.UY%,*S7702
M-7@=.:%8BZ&9(\-]8OA=[\5E?C"R)SJPD"5ZHD]\[]D.@)XI-'^-[JT+J[EG
MS\R-\/D6TQX89^R\*&FWF01  QMHP?#%=B1/J&$G^R#U3 >^&JI]E_C59>]3
MH,D^[:&G1:&-8#BBD_/2(X5?>,-A %\;1F'DRQ.AQR?]N@:PY;!90P=[;H7Q
M)[@--[?? MY15ST#WG2+AA_ MS%6J<R-XOE\[V4+*%H<X2[P1ZNW"#ZVG3:T
MQ;*SVSO+:.N=%96-Y>$=K#4?6&@>".*.^1C4,)X22(B39D$)64=LH?DVW+]H
MS_-H-W)/LIIJ%;\6BH-DG$,&S#2P6$",'<%S_-"P7: :_I;MPV8CD!(_A:KG
MZMYZKIY5/5>KGJM5S]6JY^J6>J[N\)B+M%7=^N/+U1*S3S:):X(IP_5V.AU!
M)"UHPB!"NRX*/7^:T0J3NIF2%9AJCPDJ7IA:##^A8;!E)M[<&/A>1H_50+/I
MA[R39G",-^1Q'\TK:NUJ/[/8Z;V'5=ZG-CVGF6:[NC$OZXTYGN,,]U17Y=55
M>76,U55Y.2].Q%7YK&)/E+I?7:RL!7?1[&X2L)$V0Q%+H1^*0WR0AY;Z\NJ1
MG.:'\V:C-A_*V2WLQ2\5@:U&8+T, JLG!#:?Q%\16'55+J[*4=[K/'8^U*0.
M$/*_DO:K,V.KOB]IG[H0C;^G%-X4YL+6A_/3VI[[LU52?E7":NQ+RK\-PGKO
M]KQHI6DEK30K<;X&US4WOFTMPG)S'1/%_>M:+%>O[3D%JI+EJU)5:Q-9?ABJ
M:M9V";M=F>D+!?D%S]2QW:S\B=UA3ZT4^2P;(-4RCMX/1E5N#F3K=%^. B>@
M:W>5_B\K28;3VOH%^YN>1#:5%E9(%4N4B27:^W)Q=LT2C6YM_:YZ.V6)]^X6
M_3$X?_1"PTFR31=>,97'B"V.\%(*V+OU &A:G=TIQ L8UW8CX I1">"Y:X4S
M$BRE1FVO15Z+0&I*['F]#Z+-RL;>DLK: ='6:WLMA5U"M5NI8%DC'6%!'4FO
M>#W+ADIJ8<I=9IY>&@5G:#L$,Y1DUK$P\MU IL_]J#W4X@2\?RMU4I1]AQ/R
MHD#48*@?!ZEBA*3>8O-T-Z!>%TCZ?YGA?TA5,O1D1<[,88=>L6(;7/T41L4D
MPK$!Z_?@2;S4)!K\F^HW/(V]PI&YHMP"K+J,.A'&&Z3S*&D\F#*&SYYM..H(
M^-&1E1U67#:01:S[R47<8GXW)_9-RQ!R<MWW4X0@<^8[W>()Y(>M+]BPO&#%
M'9\K+DC5%BS=+.6O@Z3=XY+XU)-Y*W/B>:])PNE<+NILKFH6N\RGN(I=X'I*
MIM@N]*#  4FJ8>;UZEES)>]G=K^62@AP<*X?K[YKO5K:L5DX(2,*O1U/Z.+/
M_LW7*ZQ)T/HWE]KE]4/_Z_T5S_+7_GG]^*?6O[BX_7'SV,<W;F_DR^N;K_2#
MI#H ?GKQ[?;AQ_U5UNJX12%H-CDNU;38DV#>L:DB2EYO0!K5\I^YGY5M_2D5
M)RN<W"\3*]_>/-[??GL@OKR[O[VXN@1F?'AWW$B;<97<R'A#[=(.3# GL;(8
M73??<[A=>>=[)K/@[4"M:#KDTO=<1H1^!5AS8XU[%>8G*]DI4]VI2;Q3_)L6
M#,X,K$&/_/0W/7!U?.7[O"S;\+&2&-U=K"0&V]^E9]!GMLO=93PLG_T5V3[_
MS@!^PJ<#KP=3+8H]*9]-/#\40[\P\KP0+18< ZQ.3XKEKUY%-7T?W 4[B NY
M=3Y!<##@SX!@,0GP%1? !\</7NQP))X8PK%HX)K8G@4NV@1\^*&=%$8]7%TD
M;ID?.<)MP66!\W:Y=$_1:<1B-OY(+PJ52G1]X8]*L)^&:4;CR*&",'+4O/$X
M<D%2A_R12!U Q<83U8?I8IWHW>$G$Q]>VQ/PAMDK,R,,LR .@&W"T_A:Y>=)
ML9GX7,?IP7D$B$D _\85X[ 2R6 8N=QWUJG.'X%;833*JO3X'2T=J3.E> R'
M-O#9D^$+1 :Q:PD[E$*9[UDZ_),13@,2.M*DX6HL%JLJ)$40P0GPD#V=&Q(Q
MQZHP4&W#"4I!O$MZX) "3 ;L7.!N^<CE4DW[U4"&&A*4*G!%BM#OB:,;+4.(
MR=8GK='^E7VD,1IM:^;MCS7M,R%_1!//Y3RE[MN&*\45D+"P:&A=@#'0VE'\
M\C^YJ(+O@N4DY13)/V1TO>BFO,"/DQU=2\[8;BQ=4*I86Q+.JFQ.GJT*::IH
M/:B$J@3/NH+G=D,6L3R80"CP7SBQ+J)X4".VQ-")W\2>M8A8](Q [W!H&O-]
MCS\67PU]([(P9(FZ^FFT$C>I2ILN.BTD8 /TF"%::4>^A%\QS)'-GI$N.#**
M1V%/V C4:O(Q6C -0C;68<6PL2$L11L!D;U@3 E%!8/O<]+GH55D*A-$N7RX
MYSI3908Z[9PQ"#PG"M7YQ.@ZR2RDL.$S(!MOS,*:]B7RT0C4!7X,+IB6,S-E
M;0P$D0+T&1KRN/#WC$:$G8/]-7GU>>@C6 PNW^7 2C$Z/XP?[SN-.^"_@"4B
M/_D,1("087PS32\(P3C[G$:DH6 VGGIB@)&59#C.S.P#VG&6\C/B&:@;O&@O
MU2%M^$@8C;:+P% FWUVB-!!*0^Q-$!NDW.:6T/O/N O,A8T.J5I?@C8M6 KI
M#B$W#=X0A,_GWY'U)*KXW5@XG8R-GTB N* !'E#DA%.Y_?"C 0SRT_)>7+YF
M#Z2MKRDH/P9:9!,@;,Y!\+^Q#>O[R8!]+,O&2<$^3/7TUN'9V3X(;F1 5")#
M01#L%7[-#\2%?UHV['"$6%Y$9CX=+S!_X-$F("_RT>"D9G<?NV1PTB1N#R+3
M9%Q?)6R'A$7W,9;VY!DP.:Z\\.0F7@AS0Z$C(*M@ 7P]02DD]A9\Z.^Q6D3O
M6#HX\$&@W9,:QIX9,0"9<*RU6[ XM"^Q2.;?A,U\IQ[V;<J^X&9.,$'!A.(>
M0>E8@%$7.Q@AQ2%CX1T7@F+1:PLL HY1EU92&EIVBNKSY3Z3W0'4/.*.O5W
MK#T!LW486[/\54W[L:9]?P'<,X0G2:5]JRAM_EE"';>Q]9[>)F2FR.0VVXR,
M76CD%]XA;4#6N<>M1Q"Q8_;B^3\)2= ^GR7H/WZSD_9<_.,G4J/:E_B7OZ+U
M_Q&_R24YN=<"B0YD;\A(%C[@L7L$6GCK/QFN #F+U>@CR%+KQ9CR7P4!W8M^
M3N::X4>DMTQQ"U;<D1>@F<3.YQY%NNN*1'#8MW"K[E$7W:/VJGO4MWB/NBMM
MW@<Q%' S,%;?7.Y<@Z"?,%);\,D36%AD,M]%H)5,T!0FHFRBE/AB^^-WJL8?
MD^@);ZZ&7I(TID%'&<KN^O'N<B&<[*Z?[.Z$[ZZ1[.X0=E<)!106WF!)(Y+I
MAP"6YS!?D>K"1_A P:U%)@%: 5JC.3AI2GI0C82/.D+B!A%L(=K6$EBVU^U]
ME5^_]"SK!'2A^Q-_H&/\V"!3G8TG(:A7;ZQ&:4A7B00>G&.BP90(.M] #)@H
MVPHJ=>7]?"NF>%)I5-G;2V^T@/C0G@&?SXRW;35SB%M0Z,M2+"[R93QPZ&%H
M0P.3W,= "Y*AE8%U2[\?P1RP51PL"SQ<S2#S"J,O&'(*DI#+%!STGQ@0#+WY
M[^NKS;P4]%ZE'.PRY>!SB5(.;A__O+K7KF^^W-Y_[S]>W]Z\CV2#E0'P#Y$-
M5#E."QRGLWKE.%6.TYJ0B)G R7?]^T?M^OKZ "97I1H3U=BHET@U7E[?7UT\
MWMX_Z-K5_W=U\>/Q^A]7VNV7+]<75_<\1>_B]O[N]K[_>*5]O?W'U3WFT;Z3
MU-GEH*.Y>W-\"YXC5[3B,<"M%KD>VD];K;@YVV=;KXCJEM]GCL')#T+/_(GN
M$?E>;DC>44!XX^ VX63$10 /WM\8@67\I5T8$QLKA[\;_D^FYJL%T_$ W"69
MW7CYY<M-+4Y@[ =)OH6(UW^#9Z&OQZ]&1( C\R'\<ONS9_@6>7J&Y4UPFJ*A
MB?:$+II+]XW4Z ?[W*C9)>)JD3[@X.TRK&$N,Q5W=%)SQW) JIF;"W6Z]L'+
MQ;NPK\G>?HULBSFV6R2#]QWL6U%NFZ?;);O+$TXFU*;G962;HS@C  U8R8[7
M[C,##O:U>TJW\-Q WIQE#A^(:**(E)KQ=U[8(+ Q8R+47EY>:I8]'$9X'389
M&;#R&LB*FM8'<?'$<W.]B6WB2BR?DL9DO&?)DC!*^?M1F6MDK:V@BA:8<0OM
MHD8W->=,"VK&]D/3+_7C7>YDL]YL?LHS[S(FMTVP]-1\. OA#W0*M'N!'=?R
M_A7!!(:89(@\,#?E(A9=12EOAE+N62@N/G1^ 4,)62*)S:<<)&[43#S'-J<5
MN;QO<GE@3J(7+: <$S1J)43>.55P=8.*AKD!B8N*(BJ*L#2'&19O$EO1P_NF
MAV\>UF-B K34&61@S%5/5*KDG1-*K$IX:FI%#^^<'A8E;"?)QA6%O&\*X1)#
MED_RA/8Q8Q@JKZ1'11MSM)%(CHH\WCEY)&HE8$$@RUV\*,3*S"J\49$)G\^E
M( 3*<.70JAJS(K,R/RKB./_.30VJ!G MNL8;3&?<7-=S3RII4A$,#Z%C,3=I
M&VWB&"Y6TE8D\;Y)HJ\@L:C -83I0=124<C[IA#*6<%*,D(5TT+?< ,.Q%Z1
MQCLGC?[ =NQPR@''*;W/L)[MH+(TWCUE7,1P8JA,"!BCLD(KVA"TX0X=V^3@
M5%3"R8*0# Y)(JFLWXI<WC>YQ"$0Q<TEH"H7$:YDN!UIB9+D1YZ#%_^?D* J
MRGG7E,-#\"1A1!\D4D1)/C5!Y]EA!&+&KNY[WSNY"# )$"0)AB:"'4P2CWA
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MWZ_ \DE.RV=!# =10SN=]61)=I38EIZDI.]YWXID440, @P&R>I??_=052B
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M=_?%1W\#U9L?_2CCY%IZ_Q8I+CB#75HO;M$J05T'_J[Z&P?378!,5.1E1BE
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MKU*KC[3ZDMQBED![4O6U>O0D"W>7=Y&,!G&**JT9&9;FW? RM_$.HZQS>1N
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M4Z.RZ&F);\I]]%&2U>XR Z*+3;GPN*[R(4B5EGRJY<'/<\Q*YS**TKL0-*=
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M3)7&(0A8K<DWPR0J$B\*O+R2G6:C_8PM;8 .?!%C>5];[0<OO[73>,Z./-B
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M9CI$8@JBR*\278&@,\$%X[CD22+@<@+5,PM3<=;,N4C"!-XG!C&[^%@[FH1
M_?EG?/80M@?KCU0,#7Q[8C;\68WK>-WR^E)A4*K3ENBG&MZVL%&E1E.ZC^,5
M\QK%/K1IVJ3D9N@3EYWR7"."O(<MWOT91R=D,/CT"7$<Q@$R'6V'L1(\!P+
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MX.!%>O9AM=/FZIM+.: ^9:>'W1T'U$T#JNN'M%'@;.TU_;W.ZKNQ.* ^X1I
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MZ3A$?Z6(WGZ5B)Z-I">B*!<AXWP089=([#_0BZ,\A74,8P".3&Z"OO0&>0+
MYI<FDQ  A2AR)T7B]>Z\.$^\2(SA5DC3Q2#F ."T?&N&>4*=6^^Y/>@F]M[C
M.KQRH]7@%WU]&N[^;,C]Z;R>^W.%^#^.<Z#JZ2B^C>#6P)T(4FPIFX\C+Y'#
M4/;5[;I.8'AO(#+I#460>#<BS/%>> *>2[,DZ&<2MQGWO\)-"#)/8&MN6,9
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MA)0=O]OJE$9&^G3U$:1,4Y'KUSA$@@W4ZM.G(T4DD/IT=_W.[N[+P<S>H6K
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MQ(H]Y@?>L>RSL:C#$D:+A5ZSJ-L$F]AA]Z@)#()^)Y995#/ ^RZA3WAC,*Q
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M2$[^!8Y@":2P"8T@L129A-B$GB-A0ZEMCN.(8XR610 SHT,>8;.%/8Q7Q!$
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M[5IM<QHY$OX<_XI>7VW6K@+S8GN3!4P5L7&62F)3F-3M?KK2S&@853321-*
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MCQ^6VE""?B:WX0.MJ-'/YKJ=FO_]W_\ 4$L#!!0    ( *>"<E27&-1M\P0
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M41ED)   +L4   T   !E>%\S-#@W,3<N:'1M[5U[4]Q&MO][\RGZ>O=FH6K
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M-%*B7=FEGXQ]"#T!@_T9%756OE@]@2E)JT&3B&7E2!IDW06V#%<)%7_'Q/V
M=W;<@%^B35 "!WJC@>FT2 <Y;</VUT^?\&*) C@D.?.[IUWO$,?YI[8-B*?
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M8G.^.5(GF<6X#U()1TG<X$"\R^#,[ECLYR,!:6,ZQ9-YC# @[^-+%@D8+#N
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MQ*8LL>#8V2J9Z&RABA5@U?;NYF-J GYYDF:9F6E"O+&'?9DV.B(0B4=K&O2
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MG0_#S7>,XRCW;:CU<&6OOZ0WY*13=NAJ0N285[G>J%/IC@/JL2>_U&MI;8?
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MVVN?-GW'I/^(V;R[CPT#'H3M?2!<]+\.N(T'!MQ> -R8D>WU!3Q=E7G'#)W
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M&]HH6MN$ZD:4H<>I1^/=^"(U7Q'*5I-FX4C9=%3>I;)CR4[/\9XT6NVRZ@W
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MN3V^(-:92; TJ@IG!%2H8#CPQN_,M%9? _QXNZ\N@TY!#[ZB!" TB]OCG__
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M7?2Z[S^H6]ZC O@#0\F/GS^<UXO\^/\!4$L#!!0    ( *>"<E3_2=0A;0,
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MGUBJ(Y<W]17X7N$@RY0U+\TT_G,OZ=ELI)2?VCR:4\ 4<,3J@2'N&8+!N#V
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M_ D*$$!<;6(ZX+[!12CN67K;:'"'P3L[3)A#'6#=(3.<"R*KSU>!01/=LHY
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MY*BHZ;YSN9:M,B82MPNOTQ-T^([Z?WQ:&/?^S*>GG][#8(<W?E'QH_AM!+O
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M6LH@\==DC8SN2\_G%[=+BWZ03;(J7EM,Y->^$;CK59LX5+R0,MZZ[0&,K/H
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M&Q6+9 -=EG4EIQ.RJY-S;SMON!*F_(V$35>VBRH) >RCH6,V1_4/LG>^D?C
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M'F]$_MH\K\N#7-G'M^X;#%\/!Z5U(KIWMZT)L)Y])_7^Z=^N_QME+R\/<+M
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M'=T0BW=-45JV@EKN/<-O; 7+(0JW>B.Q$K!/M&E&/J.$-?*\F%9;@BN0565
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MD2Y.JG2./>M>@'-92>F(8']26TA7],$9DW'3%4C_GP^RJ>?_ %!+ P04
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MB!%"8 &!82%V9H;2I\^X2+-]@A ;.X0A#P* NV?H96M[4X>=H2Q,C*1#H4;
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M@&G@)[ "; #;4,K#QL#%(,"PAP'&(,^@S*#!H,.@SV#"<(+!CN$,PWD&'X9
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M)^_O4U#>_^49*Q3CN#BY1'EY1?^_G+%B&"R8&/C^?L:J1&]E@& MP/;W4U2
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M/A*KTVLY1QV?_J:=LG* R"[/P2M^52\R+6$;6PN>/)QDV[16>,?//_S(_<X
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MR,A<%#5@?W._S"65X</KEJIEW.)Y@K^_^]J^.X<9P]XBS*MD0O88OBJ1%.J
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M_42AI.PFPC"]I?V1 3;<7H?9"9L^P6EMY%JN.88;C/7,WG&3-.V8^+*@WV[
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MI14IS#V4F@T]J3-JJI;=E\S=(OT;A,C:M]YHN6..B_R!-N^]@]Z/?4&D%,3
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MQ!+V1WK"YR-CT9U<;;7!W2D%KK$7"([X@IQB1[V<4S:&FNO/RX&+$5H%;X\
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M.H-N[A@#(Z_3P\6X-[+?KHMQU2_Y<]#PW\_?"S*M>3=MZ-(9\KSW.V/:6-2
M_GEV4QY"X& Q(,XB"E8 ;Y=_HS*(3I HN98&9]*;TSA@1P.J&K84[05C]A>O
MF72_PH<Z9[0L,Z%:]JZ8YOO?&>,>8MQ:RBH=!(,EL1CQM6AH?>S48!&P, 1T
MSAC@^Y&%&TA&A/,U,(\RX4E*F 1[[IJU/C;;\+PWPN1H#SIW'_@LFJX>9A=$
M AUT5%5YX_PO>#Q4C&L2X\HN"0*MM&MZ,S X-Q/YVP=# 6\]39V=K#FEB.5>
M"L#I\(,/YJZ7[JYFV3>G+=PK4BN8*7(99E^ M/^^(_&-&&?6O7L&2YV[J+M]
MB*NY-"VC-L1PKOS[?62AUG#_F]_H X"MKL<RJQ8V_?]Q_T^.6XR[?:7!Y42D
MR\P)8Q$-3J+3);9T%%6-T$-57"56S)B9G!'%$L'N2Q'70#-$!6#:OS= +S"&
M2_01)%*,(\G."$LH%.TQ,2XW!K:<Q0./0OE^)\4XD @.&HO09QZL5B$P_@=F
M?C5+VGYBIM\),7H9"ZMKQ;CB/OX<2A&:@XTTW+P@#;/KF07N M*H#4V\-C3
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M@G)4DS2L[IB@  "5J   "0   '1S8S R+FIP9[2Z!5B4X;8P^M$M(BDU2(B
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M8 '8 O: "^ !^ )!0#CP!'@)1 /O@ 0@!8 #.4 A4 94 G5 ,_ 5Z )Z@>_
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MY9=_ZY_HIU0NY,F@Y+2X 6W^F9(3!0;!D!BC%S@$*B%O[\ V1^Q!T_=#JX:
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M0':L?9"LTW&HA7+-NG3!NBA_4OZ"LLP7[&^%A>E5HTH;:FH:GWQJ?"'X9&U
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MAI5YB"G7C;48NP E^(25X>%*5:.WF.7J3PI0T_3S0__\'WC@Z=?.$\&.?;
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M>W\\T!<-V2]5?*$3^:P&#SS&S?Q9\@#G8 5.;%55\M>UK3E3&K3% S7G1#)
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M_UE2:2;J7F"%E-((\+8_,;A[KXK=]!@W?ZK0EE5]5_CD]*!)0="?=',T*YI
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M\\LR;+"D'((LX.]DR# ![=#NAMB+_ZP/GVO"FW4C$V ^^ "Y<9\%TDU, /+
M(I;C'Q .Q]-'OBTL9[91EIF UG/@2'LEUEU >!?Z)Q.@.#9]AGI_0FJXL"GG
MBY^;H'IQQW9T)Z[X9GQ\[D$P!4E(YGAW[+-&+JT5Y;K=&^SG'::PC&DW;0S^
M>.GF/1.)&R:_3?Q7LG9Z'FD][[YWY4)"78Z-!3%,:\S=RY?WNM%25#1=<WE-
M#OC/X2J*DRR,'U0'_2KO5]//W4]<6 2<MO^XP(C"T7R8 #],Q[I\B\K]WT-D
MQ>V= 8HH-AQ.:H1JD>G&C)!A]1E7/Y=Z+L61%L*I$G=QW8N"3VM-=G1ECB5
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M@U/H>OTOO)_.5#X/5CQ3N&Q0S1?7B9BB6MKFR'TL$JRMO2:[)'HN*$S3!F*
MBB(P G\D'4SN1 VJ, &('ZX1[44_G^E3;#,#!-[)]S[E,BJQO=JH.X/:4:T
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M-FS<E$I;&RB1R@==*U90?&_*AW)QIG=[+^S1+429 'TRNJ23UFV]S"[SAV-
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MEH.]_8O:LOBS9Q#!3_^H^U?]_$O!: *,J>A3_U'GF@L S?<!0'CZ'W52CP&
M"]RWIJ%_6H_@@;[<" D).*N@$!X>?MK3'7GZ0*!_+_^O'?X'Y9^>=_I@NK^+
M1^*"^W674)\0B0.Y(?U]_$.#)((#7)#N$O+_48G_UP/_-1^G+-VONP>Y^X$C
M;$$M\_3S +?;S\TSQ-/?3\+3[[_:Q/_EL/]0_M)KL/"54P%^Q&F >X@?H%_[
M!##P'0+HG8K %LC?]^TBJRUP</+LH#__TOL_!?*?9Z5#'UR"/3W^C-.WM)9
MA@:%_=7V)QQE!"-Q+H ?$ '$ 4E %HRAE0!UX!R@"Q@ I@ <L 8< &< "=P
M?($@(!RX"=P&XH D(!5X!.0!Q4 Y\!2H!>J!9N -\ [H!3X"GX$Q8 ;X!OP
M5H -8 ?8!T,V9@@'A \B H%"I"%R$"6(!D0'8@"Y"+&$.$"N03P@?I!0R$W(
M74@2)!V2!RF!/(6\A+1"WD$^0+Y IB +$!QD$T*BHZ=CI^.G.T)WG$Z!3H-.
MC\Z,SIKN*IT'72!=%-T]NA2Z'+I2NN=T373OZ#[2C=%]HUNAVZ8'Z _1"](?
MI9>GUZ#7IX?37Z&_3A]$'TN?2)]%7TI?2]]&WT<_0O^-?I5^CX&)@8]!@D&>
MX1R#,8,- Y(AD"&6(9DAC^$)0Q-#-\,(PP+#!@.5D8-1C%&.\2RC":,]HP=C
M.&,<8Q9C)6,C8P_C&.,/QATF)B9!)ADF=29C)@<F+Z9HIF2F0J8ZIK=,7YBP
M3-O,S,PBS'+,VLQP9A?F$.8XYESFY\P8YF'F'\Q$ED,L4!8E%D.6*RQ^+'=8
MLEB>L72P#+/\9-EGY6:59CW+"F=U8XUD1;.6L[:Q#K'^8-UGXV&38=-FLV;S
M8KO-EL-6R];#-LNV=>C0H6.'- ]9'/(\=.M0SJ$7A]X?6CBTQ\[+?I)=G]V)
M/90]A;V*_2W[%/L6!P?'<0Y=CBL<(1PI'$\YNCCF.(B<?)RG.4TXW3A1G/F<
M39S#G+^Y6+FDN?2XG+FBN+*X&KB&N%:Y6;F/<^MSNW#'<N=SMW)/<&_S\/$H
M\L!Y?'F2>9[Q?.#YQ<O,>YS7@->-]QYO&6\7+Y:/GD^23Y\/R7>7KYROA^\'
M/Q._#+\)OQ=_$G\-_R#_A@"O@(J K4"$0+Y N\ W07K!XX(F@CZ":,%ZP7%!
MDM 1(3TA=Z$$H5JA8:%=X</"NL+NPHG"=<)CPB01"1$#$6^1-)%FD:^B#*(G
M12U$PT6+1'M$5P_S'SYW&'DX\7#]X6DQ.K&38I9BT6)E8I_$MH^('S$Z$G D
M]TC7D55Q07%=<2_Q3/$.<1R4#ZH#]81F0C'090D!"3T)'XD<B6Z)C:-B1XV/
MAAXM.3IX=/^8S#&;8W>.U1W[*LDFJ2%Y73)3LE-R0PHJ92YU4ZI::EJ:55I#
M^H9TMG2?].YQF>-VQ^./-Q__)2,L8R(3)5,M,RO+(0N3#90ME1T]P71"XX3W
MB<(3GT_2G50]>>-D_LDA.3HY-3E/N4*Y+Z<83VF>\CM5>FI"GEU>3SY,OEI^
MX;3@Z8NG[YQN/OU;04KABD*:0I\"]8SJ&9\SY6=F%'D5317O*+8I;BJ=5$(J
MY2N-*G,H&RJCE%N4\2IR*NXJ12J3JGRJYJKQJIVJ%#5UM2"U6C6<NI3Z-?4"
M]0D-?HW+&LD:[S49-<]KHC3?:.Z=53L;<K;^[/HY^7/>YYZ=^Z4EH^6N5:Z%
MU3ZF[:)=HOU-1T+GFLYCG6^PHS 76"EL45=2UTVW4O>GW@D]+[WG>K_/GSD?
M=+[Q_*[^6?T8_;<7Z"\874B\,&C :V!CD&<P9WC,T,.PVG##2-4HVNBM,:.Q
MF7&:\83)$1.DR5.3#5-UTQC3;C-V,RNS/+/%BR<O!EUL,Z<S-S7/,)^])'W)
M[U(S'(";P#/@7R_+7 Z\_-J"R>*R1;[%DJ6BY4W+/BL^*X35,ZL=Z_/6:.L9
M&UF;4)M.6RY;)]NGMKMV%^S2[;[9*]C'V']T$'7P=&BYPGS%]DKEE6U' \='
MCC^<5)WBG,:ORER-N/K!6=39Q[D=P85P031<8[QF=^W9-;(+W*749=O5Q+7
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MA'KXSL7V^BP%PNN^DN?AV"223M9C*<U8;<3ZT:XN&L"W;' 5L=>W(EBOD5_
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M?E6)[7976AV ,QC3T8#<9NP!%+\H77U+2RMP<9<**X0N@/=U_OR[\C@6,V.
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MFU/8?%?\)O6X9E0E\^\?VRB[^RD<6KVRN7U="Z#<P<"N56_ZP@_/$\11NC"
ME_F^LG*#"MUY?9E*"V@=GF(GE]S-M>B.R<(/"6+4&E76?$MO6%#\K5N<I;_2
M,R9.*\U#LI9-]<5IP)#,ZG6MK>\%@T7T/7AMK7,TH J<?U@+83?6B0V+*Q:\
M$> N=CD;NTRM(X>N=EB2^UH[/C=RJ4<^^RK9X%FHLB\;SQ-@>TO*M"LZVEV.
M[\-'=!<NX.=.D.J1.(:RJA'2Q3*H$)I<O-$W1IWJZA%#_(Y1*-JI<ET0S?E1
M7$<QA79EQ./ZNL2ALZ[4TYQ<"[W)#5N?KJQGUY*['YYD"TZKJ.JTN@9\%WK
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M56>-Q'[[U 9S.;]4I9I8)=.ZIUUK,<^GL6.#1@^@56,*O[KVP(7%@S;AXW)
M\&(O(]J JJU$%0'A&8;4[MD^]ZC"WA/S^/>2XI[CQR!2D<?K9LFBBAJ>]D?5
M([M%Z7)ZA]2E;L=$-^U[?I0QJ$D1%OLR;Z/PNXQ:@28A[/:^4,MCJ\S3>7.?
M32- 183BY^U*XA&1@_NVXTQE)Z5L<:*.CI[XFV<<IRL_LNN.WSY!;5!70R5L
ME:]>#=-<5,P:UFF%^SN;%,^9H@87R2C-MVN<'T60N)]$,JKGZ/7Q]8'R+&[3
MS[C!V8=MA6U^'*S$<%6JGV;#IX"A"7&H*.R''$6E9#L6EK3W"A>MT>L:J1U$
M0H$PYHN9E&4/6W%].$RAV&DI= //KJ7\)K:N#QL_0H;KH7V'CE<\3)*[HR:^
MOTO]5.=8]5[)2"I&%P(^M7TA7>H$Q[, ^"4'SOZW> GN\"-HQ&O5KZ]%6 V#
MQ6"$;(HD-7P+5!K'0O!D[%;_KI*O:C <O215\LO <'][+3]E?$WVQRJ1&(M>
M .'A_  -N(E%ONO2'-K#NKT<%?YP2I<AWC_XLD[>Z2X-JPN15!GBP=LP$<F;
MU6DP=!F>&BX$'9&XI*DX5QGOTGYBYI>XR -C,LH[0;*U>0JQ=9^N./O*8+>=
M':J*(BIFK/_+YR Q\NS19Z;Q:P9ZAORX2>)=TLO+Y,8VU;:<4=6KZ*.??X<?
M;B:;"7 V/S#M\=:?P, ?BS6(13Q40\;SG=A\92D]&]C7\Q"QZV_YF/]H$ZP.
M]/UN^&[6*="7S:,,NM9R##7453%8B@(YFF3F](C1_J9A([WO6^*MQX]Q^2F?
M\>[LI8K@R>NH(YE13YZ^GG=Y(6[_?=3EK*+RISW+@#9\91"F+_+C-@/IZ#(9
M54F..7TS"@$>&T(9H>;2NGE'XN9)/M;OM^\;Q>MO#12A+8J/].L.,8]0[ Z]
M4@D87=1(J)6I=*:Z[P5_RKMHFT<.M]VJIG-_52%[-M07AX^IF_'YT%/:RY64
M?*$7M7P73T1O4+A8[TY1PN)/Q>599$J3^>IVYW^C:I;/+PM=CCPSY5UT%9-A
MT= N9GNXDFAZR]ST=Z3?? ,-8/RH%&K_TJ-+X^<M=#RU:CN$!I1C$LZ><%\3
M,8,7&/*"7C:8H@ &/95(G1M;OY_6=?,N25F7WK>NNZ!Z&;*O\NEF\,@OPE@5
M;V9]5(0;03MWE1"RIX>Y!*L"+82@8J<MD6N*WF5AKCC%LZS\HY*+<W'?_M .
MXDM4K 0W[J3NDD9V9O(-^-6F&N^M6A>7T0@EQ;YE4!\(&+39D;@Q#&B/DZC:
M4HY]DOK[V.[Z"62[[-DC'4>VGHQZ-BH/%W\RNP/$PO*)A):<AL7,99VG*"&*
M- A@*->UE7K3SYB>3<&BN+JT5F3I+L1*4_>2;S&,TX#;1&HX(5N%+4;R?$F3
M:]AL^)X5N:#@Y<,V!S*JS]+E(ZB*Y.AXBK(J.>E*;%"D>=2(1=)&7?RIQXE>
MJ67P+SXL82=IP+]Z?;,UK[*\1-W#&L*L'P0DWV%KL"VX;Z;0'=L5N*_Y4--A
MDU*\+DG-WIN_6#B'9F;P05MC>-!;J$%J-D$JW63YE7+.X>1>339-;4C";5?1
MPM?0']M*Q][-@+'$>D>1, WH0]W%?0NJ$DZS)+E%H*"$NGCRI^*AFS\]?*,]
MN"/J*LZ_RE%6D+Q\9%>'&>N':I3IHQIZ]];O5!^.A8V@N*HH*Y/PJ<<*$_)U
M56#T-KI #;E^+[%OP-)0*F[A>V))VKU/FG(/!XR/L,SO.13RK2Z]/?P=!4V
MDV9YLBN^1^^04<-*-.#<\)/X@8IQF,,T_&+IN*[>0^>'YF\7I4IH "(]MJ\K
M3.M[$!@;[-?"?@8Z+D;&:L,(\00D8:/:R2&R&RY5&?93:%V3-'J=DMHO]^&C
MX:J.0E.N6"[Q(0UX28[1>4)"55 0]E@UYM<4T-YG9M" CS.]^?!1U7,/#4I;
M&CF$QB>S! 5_9^9MD"4^!BN-'V* H_-?S=I8Y*M%';GPX!N]_Z^#]S.H,B@V
M>ZLE I70-\IY# +=#D(-9.-!N__,#$<-Y^/9JJ$!N&)#.>/8B@I/V8]5GA7W
M#=KU/')J&+)][+4VF[O)+763V%Q*L3.,(6487#1E8L.,!,-?#!4-8CZ"_T@&
M!0C]"CH7G2=W[LOW[=S4?HK +A1J*2(_9/:>,Y2@ 3TH+D+,:2&>Y/"#_['D
MQ6G-77>^Q9'R]GJEDX.R\-S!V_ 84$W)\X0/%^H$SC-18B5.AHG/7/_(Q7X,
M' +C<:!'P?H6$</VS3R[6IZC;"FCJT%S VO)&H^1.N$'3KN+JO,EGS5M)AL[
MA*<(R#VP7%(I"[[<5:4_C^_?#^\<9QD\ -]8(@E)>-EU;V.CV [$*3TT0-PA
M^F27ER2BP92/'.F?-S<RP'(M3C9&D82)QQ._^:0^-@$?+UZ>*M?_W5#V9)2/
M^L[3E8(7";F; 6^5SIT8N9OX>03E UC??_$=<0,U*/2^/A;A+:UG0;)ITH:U
M)$6-U&WY30[>O+@)?T"%3>G<>:_Z5[[A_$P_7#<9Q07"@NYL?KZ&S>E%&76K
ME(JKS\RC-JN"^J@B]>?5P?B?A'GVR;!_Y?*73\_?WH>MT0#VUQR]MBC0X71T
M"'[2O<,*<A=/0?.& T6',XOXND6517^SY4VTK,UZV#R.<XK$9@AK*1,^Q>KD
MHNJQ0<K8Y%*D0J7^&)$<9;.499=6/I7TTO.L;?DH81=7:.3EI6I?WWU[OP.#
M0T%39(1,DJ#QG6=1=I2?VTZ.#YD(U^1:'U.UMPX[3@,  P,R%<6%Q1\GVWOG
MPM!]A*R$"S>0_"4PMSOFNH_W0GWZ>J:%SWBFR/J? !4&3U8DH\XJC_0[7!B<
M%2SRS)M5M#]RS%M#)B4<,=]"=Z&:J[[O&JI_H#;[E :6I?@R>L0Y10&'&H8-
MAURMF,K0Y"Q5/J,H=O"NDI F[C7^(WUNQ!"+F_:<D?*">6:_+>S@2UUC[6-G
M)57DXZG9^*[.D=5=C]N:'C#K(8I47[MQ)Z6FO:ERJFYD^<7B=C&ASBK]^/DZ
MRDGQO>\/8XQWC^=S%3=Y13L']]Z\Z+%"]:_"4_M/M!?Z%*4GV-M,/B01-*)/
M]<$=*L250>1&;)?]D-ROZMTH-R5>5'XO[O%E<T_G6W;R._&.J6DB49(*=EPC
M1++1WH#H16&\81DUGS1/R.8U">6^5QTJ-4I_J0R%FBCP<[IY& 3%9-1+T+UD
M9&F! ERTH'H1WABFJ 0P"HN2VW[<M62/,'X&*\/CJ,^0F=R033*J@P9<!&&$
M=(P,&;>9]L#&G"SC2Z*G-OO4V;KT!7X?RTL@8/2W1)Y.5O_G%]ZZ*\V^GN57
M+]7TC''1_P[CKXK9,/XLW<!^H1)"#B 5N5P1-]7U_<AK$"NH50W_7D=6X-I^
ML>(?#CJZ<IVZJKV,_&&+-C(*08Q!+5&W[IBF"O(&FD+O9Q[U0[#535&1]OE[
MF+%]^^^\95U#<8C?L(I?!%0'NHHHNAD0,-N$WI^3[2.B:JCY2>2"25$0'V9_
M/'+AS"J&U4+>2ZB;:SL2U=O:V7>ZP5N&@D;MKR]FCY$1/;\&LKWI4>WSI/D>
MA1W8.JRL9SLHFN.$C$'*O'6:^U&!:_"X.P7])T?MUD+A/Z@^OVG 5*PD<:%X
M7UR&/PU$< :0VMZ=.C:#R.V7HJ\8K1.?VG%T/_)3B<R=H?@O?9LL[B-9*9",
MB*AV:O3I\@,HODAMYN4T][=*9UF(CH_X<O<.5[=7-V ?*'/M$Z9_%I6]J$ZD
M0JO(Z[]0'W04K$M6D#'SZ$4"ZAQ%G=!17!$M;[OA.5"9.SLM$OORUZTW'.]T
M[Q@^T9J49PM"F0NMHG1\7JMK]"AW:V"^1J%P4-PEY^*?!@6*W1GZP:! U(:J
M2!TR97A&]XBN4:ZODHI1B71O3'E,Z_:?%^^(Q0H217:"WZMJ0N)AN_.$8@)J
MN*E7E4T&O[*-:J4!9R-H0/[;;G_YHFGJXBBJK3QBP/C)HO&RVEJ^(OI$-J?R
M=A3F4S%V#X,K/*'R)<X2N3@ONLJJ%9VR=,L_>\C8F$F\ UH'XI/GE[T#//LW
MXJIL95P:9:-V/A+V% VOH7@'#[()?1M/EB^EZBZ_9\795"'\VNNU,1F"W PN
M!R^RBA>WD0G6?HY4V.!5,<L<"RY]3!,!9TK1O!]OIGS/MXL5)00&\*B!(&3K
M%AE5<&NL-8XH]&UV&\9A.*JZ4>OUVI0!/AQ13<1 ?ZIX04IFLWK=D'IZEJQ!
M<J8V3U#-JH''07_+EW!8!D_]\/1&LEWLM=^7>C&1[R0@Y7SM=_;EJ $ENN37
MXW V.QNOEY1GCCTC+DT&#SOB_JB^Y6N!5SE\O2^;N\,J^VY::F).*[B'M>5A
MN-;%1CK6KO@8?Q"!IN-Y^6.,9F*+U];O]$?TAWJKT  [_:N_SA5CU-M\+]EW
M"Q]D5%*@*RC%2:14]Q6UXSE5,H^?S'*5TP QW(:7JF5/CW)S. $%Q2_1\3"&
MI+-,C)YCF-POI)"5Q2,OG5'J'T Q;U!UZD@&KSZWG93CMVIY9 *)LG.-1<KU
MW!6O=Y8E!% 0Z"T,3JV]Q[%$H,7#U92P1R3^B,FG"SVNN_$ 'T"%X8X[:/JW
MUP@E9@B3GA'HI<E-R"?'4>T/:$#0N&(WIS#)1D#;2_#9YA3_:NSZK]80%4W5
M."ON;\Q$T%^L&*0-L$!Z% CS8*RB<'IXC/GLYKZ64<H"IA+^JO'SB(MP%><)
M*@R*NZ)Q'X^/LHWQ)$IN/+_F/[FV5:'LF/1JLR_N@I,D OVKE1= =U^.JIC*
M3SBT$[ZV.U*'X,FY^GHZWB85'G\W'@<ZI&$2,F$A.8!'+!Y+F:C"4>] *I65
M3CWL81J;N_M+@ ;<=_H"/UJ(,#P>/I2-)<_OG/0Q,'9^M&ZZEB89DS>@C'F?
M5SRH<,(NF&0HB<6N!ITT(R $_F#,__17&Y,W(.P0.WS[_0G7VUZ>5I]\]7<P
M8^_=5 \'O4+,Q1>EPQ^>Y"2'/3D'W;8+GU\D!O-_GO'%S-& "A*U>(&:!>.[
M/Y<'VMX-5%4\\U9VWW;ZU6M/"\IO\]\Z&=$8'3@+)<XL+$ZF#<6A=U##@6BN
M+]2G76^_/"M+L>NOH X14;.HUU21-Y,.7K&I%>7/C%>1-<8KK=B/J.W@HB,)
M3XXP;]>!* GV&TG>31)U^']:^?)P*-_PW[&UV,E.AI ]+421$=FS9HDPA:PA
M2I:8L>^,7<F2[%0B0F(JH[$F^Q*&&4N69 P:8Y;SSO?\?K_K+-]SG>M<U_G'
M'ZYWWN=Y[^=^[OOSN9_/<W.\A2"P)+@8="+L[L?=)HF+G]?5N:473QM)</=8
MG'-R=YVG3H%W'Y5+!)$?(ZKQ%/"O:]-GVRG((1(2A_ES9NU%'U9-D3FMO_9C
MHDDF!Y="'>_QW5:N9<IKG6V*&&0X<:R'#/V#K"N4]313R74<D4JXPHZ]A(]:
M[]=E' ^45N%*.D<#W7= 8D)5?,D/*7 \>$LB _Z3_,?Z5G7;HH\.+PLH=@<1
MFZ=O,<,JBD!UE1)4E*8/(E </%-4S6XJ 4'-]N_I3"5'BCD!]MN@@C<?4O>>
MLBAU5Q-L(J !61NPJ;.44N*DVM!![M<K[(GRAI0_1QCBG]HK#+D1-! .B;_5
MMT\#780.]J);@A_5.[W?G@ 5]WB]#("*_5(5L<J.L";)$/?A;)7C1JA"$IU3
MU^@Q9'#O9)J6-L%^J&+<EIQF/;?ZU@.-UCLC#($$@4#!XZ?N3K*_7WJVF&MG
M?/R,2+-4#?[E[T+<S*4AN6(@M?(!^*X!?:I8ZY54YP/L,?ZL]>N.X ?US?B[
MN*4^S0O4>VX9]J)UU*:TOXT*+(9$V'"R=(Y9XD"53TMD[:D37UE*^5S#J)"Z
MA*Z/;'[ZJOLLFMN<OBV%+Z( 'T_.\&;@:ZRJ9 4ICO_=7$!.;:V67%Q:H9<K
M(K7,A4N.8!#P&ES-\YC4B\<-J/!]C-1-HPTZJII!$N)+$.3ZWU[?Y*DK1:=H
M((.=4EQV7S>LQ/BYX/M?-V./_U.&]=T/\_(*5>-*6!C_K+\5&PG.)Z"E6^V9
MN9J^#UKX#7? 42^4XFZV7SZ!=Q#+UW%SD)=A#?GS0RR?5P5FRLB R99\2[0X
M*NNUOZL=O*$5A*NY4%"=2>>RX.T[*_F5'V@@Q%\,_F1>Y8:3U<FE,Y;[ZY@/
M <V%C45IC[28GQ)A--"F>K><9H;7I,F/TSWZ!FB_;T\TEA+/74)(D(!P@BH*
M2_ZF:Z5%3PP'+O%9WQKKK:-^9![?/"+8)^HIW;Y_P68>+7Z._^W</9S)I2WS
M>S[2DM7<;X57J"J?/<6]GIH^CBFOO_4;S'W)^=77\T;9&I54&@@/.9!+ YW(
M]._BC;>)8:WEK^7[3:CRWZ$^1@D]1%. #(4@%.Y^XQ63K2N>4WEZ/G\I%=QL
M-,=['!I96TAY(KP1%%NTL\."KHY*XA$O73I4"\IZ;:!1^SF]P*UUGGRQ,R*P
M&YR8AD(#:0:Q-^;'H[9CLNP282GRQL<P'=X@28T@%&=>9J&![N"I)5"+^L-/
M%[PR&P&HW%9&@=9OX'1-A>PDC21"15:5RH&D1[Z%T!B9L9#X4@*[P4I]>&B*
M/,I*)1Z)V9(N_+OHZ?KF9>2=T;<ORSR\^G2N$J#)WM1>]F/JK4\]A'<&!?/Q
M?#B=)Q(V("X).<VI+(^ *'C6LTSU;7K5?)A>;280-5[M%0$&WX;7@T^-43U_
M=+IX41SN(<;SI/)&C!P+#7Q\8"([_A!!\M5E?(S1GY^4/V0+L3;X6+,/\_VT
MA9'R'@H4A:SL42J"6K#U0U:\OHYD/YXJ<QE3CB1Q$8["VJZ*M8RM44-P%/7Q
M7]_2F/9#'I/A@M7XKY^7<NR2KX4V?U$T8Y24:6>L>X,:JT9%*=9 ?!%'RFKA
M71 $L0'U23O51]=G\NH$Y>^D0>%=)79O,3:K_LKKHN^#?"@-NW#?7 =./2"L
M_<5TT\]MX= 0'!$^#^=J2"O!+IAZ+PCG*AJ^KT)QRER>+HVO11]TH<%_1&66
M(6+2 %/]2$7LMX4V&7?&4R%CX6WE^X$D6!>DZH)C]D7&*\>W?=ND@E#I4=:W
MP;O(%Z,HD17B&O4%L1,^V4<1",Q:(5(1)*@39 -[5O/#*F-I(DP_@09B$[<5
M7[&GJE,->A->Z?P>I('0P.: )1N;^R $"89'T\"PE60XWS/G;\A@58(Q.C/K
M>;ROY<F:!I?G[>B?5Y-PB_S=Q'\.B%!]:^9!9I/ GB+NXNK>I45H58CF;;-.
M=D9<>W_Q6F=-G,9US!$<<_%2-";Q"0UD@KB1OX(28=B&E;*C3S=(G?Z^]AV*
M^ M9NR1<;F>P<7DV_:/1J.FIJX5,2WM_, U.#89OND^"><]&V--/QB$8X]>>
M8# :1TG)#3K6YCT)F0]HC8RZIOCS0ARQ2?@$"8Y%BFF7+MXV7PEN)5O0-9A-
M-Y"B!Y4B+V.GWA@?1XGUJM6<Z=12_B1UMCN;<5O#-?=;PB>=.9XI_Z.I\VK<
M/'E,?3W](%4^.8W]!:0G<45SUS?R!0VD80$]M'><HK0LE.ZE<RJ01/\Y6#7Y
MQ>1[7K7,X(VW>2*JAAS8\A%VU^>2X7[R4+N$\,D@^*2T_^6?%YOZ)7BX"$CP
M9$!1E'@I&H(FV6AYBZ(&]U6ZEL?>SEM$TT"0V7X<&Z+T"(.2H0B<D?A& Z72
M53":Y)7)!KX'3/(>4I6*DR4+PEJ\3!@@RFINW,_0E0TD%N#PWY['.:;&7F_U
M^\@5$/!@MIN;'P(8YX\@VS/0&EU6FCAZ3G[4*_EX,%CIU\.##"UBW885&%$-
MV&50O@UW%Q*.BAUSTVN\!J]R_]6A:*41>R50UQ _19$EFSKMGT^K?Z,N?:]W
M[9W)#QX3'L*?J7,37IPWRP7TUA-'@'D4)7DD)PHYB_>??'DV*O@MKG%P\.,#
MH2@AM!#$AKY7*REGA=Z;0^TKJ! QY2&1;U*9?3;W[%BO*UH;8#O.5\\\^/K;
M67XL.@<Q!GQLA57E.+%*+R'-QO.)0N1YL7<;\H7I_K<TJ%N!)M >2@  M&N'
M5H98E)0]BM:"') >G7_?*!9&FN?L8I>O7Z2*JU36F";^P\:MG[,15'2C/STR
M4^Q89DL$_K2,QR@ZDY]H^I$O?KP1S_^%&R7_*>X' W(I>XF?7F7G];(OI9=C
MOR//9!404ONO UNDXHSJ$27C1HQ0+\\023F:LP?Z;T(Z @VDYC7L5B.,M?;S
MGV[RL[6O.9=8]1M_L90X 5.*^(IDHOS%3<B&E ^CQ4_M&U)*L9"M4-@S?;FF
M]KUS9XKE3-[=34?5JI9+,OVVM>BAMI+9%9\R ;'^2 X(?:B^HM!RPQH:*!G@
M,.4:="T)M01<G1@=UMH?7EW0(MC2GFSW?3G\@R!CI4Q2/BC!)?MLOPYE#=)R
M%#;M'20V3?P"'IUU02S10.JIB90<=D>Y03]EW#X<P//F-% U#73:6)6H]K/X
MFN>'<5M7K>D>?1G64F,OQD:8*?CK )X,WD;.XGHQ>&(:$M@$XI3YJ3$\=8":
M14TCAN:Y-1*DS<Y4E0G6?6HWM$1U1*TAOJPWUML?V%-%GR5ODR.16\@47[=B
MF'8#>H(&XC9=%=4<T-Q5\316\;32RE;TZS>)"HNULZ)V+X90FE$A(3 (L'F-
M,0U0]!A%91[>F#@FUP.JNGJ!73 ]E-';Y)2.;XM-BPTX'L9'O9D+HJ^TU#GP
M*@F"$)4$ UL&L0;_&./PUN>AXV<_*=GQ9P\#G4>YK_)8P]1PZ((9RAIA9?:A
MDM$N.1S)0VT@./NW6AXOIT!P))>& R4G(_[IAIFRG_X5(D_A0^WPTZ((7 $
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M&,!8+R[(9B3BJ-?(8$,"_.6$5@2PWO7X#6PI9S;6($Y2VOXM%:/_<$ U:8D
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M1^5+@-#1=@W;$[-UGY#WM5426;59=[QS#/T"N=00D_KIPF&\2>51I^T/-!O
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MU6K9XTV,@CZ%M:?((1L6"@%L=M'6$202F50VBH9B7K8K_T3AO\> XU\H(&8
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M= C@@*]LY]395"83A.Z6X%X*QB@]T+?8E82<$R* 7Y,((%:OZZ=W];3ZEK=
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M^!6'W1MK@/;@&P6;KP[T)^@W9/51@G87S-LO$/Q('X;<&\387PK$_GQTL?%
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M%.T>[\)WW37\MQNN)V'>5//S2+?.#$J0^],BKCAS8<8QN;K*LV3K;$O2?*Z
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M4/A%,%CZ\9?P2\,5Q[*Z-?&/-PXIAE?P=,_,Q<^X&'3+JSZ,3_$'OKS<T1F
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MB%2(U(FTB6X0F1!9$=TA<B7R(@H@"B%Z3A1)%$OTGBB#*)^HE*B6Z#M1!]$
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M74#W\*4A#V"@G9G\U?>6*VF)6]0T#>!;7R3K(_7OKS\QR1JFWLD]4>4E.<9
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M-6N.8A*RQU][LOSD6JT)M7D3/9VA^.-)</B!S7PS#(["@>?CJA?0D/U(H8&
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M+@_5?'L_"+22FR ),=M-2CW>J>U75!&H=^;^:"#Q<GZUK<)+T@,9*>_GW-P
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M1E?8ESNJK8E0N\(6]#]OTRVY -A8*GFHMLG[1MH\'Y.00<:32K]W=YOYU%\
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MIW]P+_4?7ZI]_1]02P$"% ,4    " "G@G)4$]'2<W,-   >EP  $0
M        @ $     9&9F;BTR,#(Q,3(S,2YX<V102P$"% ,4    " "G@G)4
MMI\3;N<)   5@   %0              @ &B#0  9&9F;BTR,#(Q,3(S,5]C
M86PN>&UL4$L! A0#%     @ IX)R5+N4<V&)+@  G=X# !4
M ( !O!<  &1F9FXM,C R,3$R,S%?9&5F+GAM;%!+ 0(4 Q0    ( *>"<E3.
M'S6CLD8  )/G P 5              "  7A&  !D9F9N+3(P,C$Q,C,Q7VQA
M8BYX;6Q02P$"% ,4    " "G@G)4.FJTQ@\Q  #Y/00 %0
M@ %=C0  9&9F;BTR,#(Q,3(S,5]P<F4N>&UL4$L! A0#%     @ IX)R5$AY
M6WIR20( >6\4 !0              ( !G[X  &1F9FXR,#(Q,3(S,5\Q,&LN
M:'1M4$L! A0#%     @ IX)R5#N$$DKJ!P  ("@   T              ( !
M0P@# &5X7S,T-C0W."YH=&U02P$"% ,4    " "G@G)4TV?C/=0'   &*
M#0              @ %8$ , 97A?,S0V-#<Y+FAT;5!+ 0(4 Q0    ( *>"
M<E27&-1M\P0  $P8   -              "  5<8 P!E>%\S-#8T.# N:'1M
M4$L! A0#%     @ IX)R5/XS41ED)   +L4   T              ( !=1T#
M &5X7S,T.#<Q-RYH=&U02P$"% ,4    " "G@G)42+#/!NLA  "9T   #0
M            @ $$0@, 97A?,S0X-S$X+FAT;5!+ 0(4 Q0    ( *>"<E3_
M2=0A;0,  +$8   -              "  1ID P!E>%\S-#@W,3DN:'1M4$L!
M A0#%     @ IX)R5!^17B#N @  TP@   T              ( !LF<# &5X
M7S,T.#DU,2YH=&U02P$"% ,4    " "G@G)4@R)1LU1B   :9@  "
M        @ '+:@, ;&]G;RYJ<&=02P$"% ,4    " "G@G)43Y57PX]D  "U
M=   "0              @ %%S0, ='-C,#$N:G!G4$L! A0#%     @ IX)R
M5),TK.Z8H   E:@   D              ( !^S$$ '1S8S R+FIP9U!+ 0(4
M Q0    ( *>"<E0X464076H  $)T   )              "  ;K2! !T<V,P
M,RYJ<&=02P$"% ,4    " "G@G)4WEQ V)95  #;70  "0
M@ $^/04 ='-C,#0N:G!G4$L! A0#%     @ IX)R5!8VQE]]2P  ME8   D
M             ( !^Y(% '1S8S U+FIP9U!+!08     $P 3 ',$  "?W@4
"   !

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
